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Abstract 
Mendelian mitochondrial disease presents vast clinical and genetic heterogeneity, which 
provides challenges in attaining genetic diagnoses for affected patients. With approximately 
1,200 proteins encoded by the nuclear genome that tightly coordinate mitochondrial function, 
targeted screening of a subset of genes provides a low diagnostic yield. Clinicians and 
researchers have increasingly turned to whole exome sequencing (WES), a targeted next-
generation sequencing technology for the identification of all variants in the exons (coding 
regions) of all known genes for variant discovery and prioritisation, constituting 
approximately 1% of the human genome.  
WES was utilised to provide genetic diagnoses in two patients cohorts with clinically well-
defined, genetically undetermined mitochondrial disease: (i) adult-onset progressive external 
ophthalmoplegia (PEO) (n=19), a mitochondrial DNA (mtDNA) maintenance disorder 
characterised by extraocular paresis and skeletal muscle restricted multiple mtDNA deletions, 
with broad phenotypes ranging from indolent PEO and fatal multisystem PEO-plus; (ii) early-
onset mitochondrial respiratory chain complex (RC) deficiency (n=20), typically affecting 
patients in the first decade of life and are associated with heterogeneous phenotypes. 
Pathogenic mtDNA mutations were previously excluded in all patients. Adult-onset PEO with 
multiple mtDNA deletions patients were recruited following negative genetic testing of 
commonly associated nuclear genes, while early-onset RC deficiency patients were negative 
genetic testing in a small selection of nuclear genes. 
Using custom variant filtering strategies for each cohort, confirmed diagnoses were attained in 
10% of adult-onset PEO with multiple mtDNA deletions patients and 35% of early-onset RC 
deficiency patients. This was comprised of known mitochondrial disease associated genes in 
both cohorts (AARS2, EARS2, MRPS22, PDHA1, SCO1, TK2, TRMU, TWNK), while novel 
candidate genes involved in mitochondrial translation, mtDNA replication, nucleotide 
metabolism and mitochondrial dynamics were also proposed. The pathological mechanism of 
a novel heterozygous GMPR1 variant was characterised as a potential new candidate gene 
associated with late-onset PEO due to impaired nucleotide balance for mtDNA maintenance. 
GTPBP3 was identified as a novel locus causing defective tRNA modification with multiple 
RC deficiency and the clinical, molecular and genetic features of AARS2, EARS2 and YARS2 
mutations were expanded. Finally, this research highlights the potential significance of de 
novo and somatic mosaic variants in WES variant discovery and prioritisation. 
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Chapter 1. Introduction 
1.1 Overview 
Here, an overview of mitochondria functions and mitochondrial disease is discussed, which 
provides the backdrop to all studies in this thesis. Unless stated, this overview relates only to 
mammalian mitochondria. Additional pertinent background is also discussed in relevant 
chapters, which are indicated.   
1.2 Mitochondria 
Mitochondria are dynamic, intracellular double-membrane organelles found in almost all 
eukaryotic cells and are involved in a wide array of roles for maintaining cellular homeostasis. 
Derived from the Greek Latin ‘mitos’ for ‘thread’ and ‘chondrion’ meaning ‘small grain’, the 
major function of mitochondria is the production of adenosine triphosphate (ATP) by 
oxidative phosphorylation (OXPHOS) (Hatefi, 1985). Nonetheless, mitochondria are also 
critical for regulating calcium (Ca2+) homeostasis, apoptosis (Wang and Youle, 2009), iron-
sulphur (Fe-S) cluster biogenesis (Rouault, 2012) and the tricarboxylic acid (TCA) cycle 
(Akram, 2014). Intriguingly, the mitochondrion is the only organelle other than the nucleus to 
possess its own genome (mtDNA), which encodes essential OXPHOS proteins, ribosomal 
RNAs (rRNAs) and transfer RNAs (tRNAs) for mitochondrial function. However, the vast 
majority of mitochondrial proteins, approximately 1,200 (Lopez et al., 2000; Calvo et al., 
2006), are now encoded by the nuclear genome with only 13 proteins encoded by mtDNA 
remaining (Anderson et al., 1981). 
1.2.1 Origins and Evolution of Mitochondria 
Alternative theories have been proposed to explain the origins of mitochondria in eukaryotic 
cells (Martin et al., 2015). The most widely accepted model is endosymbiotic theory in which 
mitochondria are believed to originate from free-living Eubacteria; the host cell received ATP 
and the Eubacterium benefited from a metabolite rich environment. Margulis (1971) was first 
to propose that mitochondria originated from Eubacteria incorporated into primitive 
eukaryotic cells in an independent endosymbiosis event that followed the formation of the 
nucleus from an Archaebacterium, with these two successive events referred to as the ‘serial 
endosymbiosis’ theory. Martin and Muller (1998) proposed an alternative hypothesis in which 
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both the nucleus and mitochondria were formed from the acquisition of a hydrogen-dependent 
Eubacteria by a hydrogen generating Archaebacterium, known as the ‘hydrogen hypothesis’. 
Nonetheless, both theories propose that endosymbiosis took place and that the majority of 
genes were transferred from the Eubacterium to the host genome. These theories are 
supported by the shared characteristics between the mitochondrion and the primitive 
Eubacterium, particularly the evolutionary conservation between bacterial and mitochondrial 
respiratory chain (RC) complexes (Gray et al., 1999). 
1.2.2 Structure 
Mitochondria are frequently depicted as autonomous ovoid or rod structures in textbooks and 
educational material. Indeed, the first electron micrograph (EM) images of the mitochondrion 
showed an ovoid structure measuring 1-2µm in length and 0.5-1µm in diameter, comprising a 
folded inner membrane with ridges, termed ‘cristae’, enclosed in an outer membrane (Palade, 
1952) (Figure 1.1A). 
The mitochondrion is comprised of five compartments; the outer mitochondrial membrane 
(OMM), the intermembrane space, the inner mitochondrial membrane (IMM), the matrix and 
cristae; highly folded invaginations of the IMM (Figure 1.1B).  
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The OMM is a highly porous membrane enclosing the organelle that contains membrane 
protein families that allow mitochondria to exchange molecules between the cytosol and 
communicate with the cellular environment. Voltage-dependent anion channels (VDACs) are 
highly abundant in the OMM with approximately 10,000 channels per mitochondrion, which 
allow small molecules up to 10 kilodaltons (kDa) to enter and exit the intermembrane space 
(Bayrhuber et al., 2008; Shoshan-Barmatz et al., 2010).  
The IMM is composed of two distinct layers connected at cristae junctions by tubular 
structures; the inner boundary membrane (IBM) and the cristae membrane (CM) (Frey and 
Mannella, 2000). Due to the substantial surface area of folded cristae invaginations, the CM is 
enriched in the multi-subunit OXPHOS enzyme complexes for ATP generation. In contrast to 
the OMM, the IMM is permeable only to NH3, H2O, O2 and CO2 due to a protein rich lipid 
bilayer, thus separating the intermembrane space from the matrix. Hence, the import of small 
Figure 1.1 Mitochondrial Structure. (A) Electron micrograph (EM) image of two skeletal 
muscle mitochondria with aligned cristae. (B) Schematic of the mitochondrion showing key 
structures and compartments. Scale bar - 500 nanometers (nm). EM figure courtesy of Amy 
Vincent (unpublished). 
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molecules and proteins to the matrix requires transporter proteins. The translocase of the outer 
membrane (TOM) and sorting and assembly machinery (SAM) complexes allow the import of 
nuclear encoded mitochondrial proteins across the OMM (Hill et al., 1998; Wiedemann et al., 
2003). Translocase of the inner membrane (TIM) forms a supercomplex with TOM to allow 
import of proteins with specific N-terminal mitochondrial targeting sequences (MTSs) (Bauer 
et al., 2000), which are cleaved and processed further in the matrix (Hawlitschek et al., 1988; 
Pfanner et al., 1988). The IMM also contains additional transporter proteins for exchange of 
ATP, ADP and ions between the cytosol and matrix, including the abundant ADP/ATP carrier 
also referred to as adenosine nucleotide translocator 1 (ANT1) (Klingenberg, 2008). 
The majority of mitochondrial processes occur in the mitochondrial matrix. It contains 
multiple copies of the mitochondrial genome and the essential machinery for mtDNA 
transcription, replication and translation of mitochondrial RC complex subunits, mt-tRNAs 
and rRNAs. The matrix is also the site of the TCA cycle, Fe-S cluster biogenesis and β-
oxidation of fatty acids. Due to the alkali pH of 7.9 in the matrix, a transmembrane 
electrochemical gradient is generated that powers ATP synthesis (Llopis et al., 1998).   
1.2.3 Dynamics 
Advances in imaging techniques have revealed that mitochondria form a dynamic network 
maintained by the continual processes of mitochondrial fusion, fission and turnover that 
regulate mitochondrial homeostasis, communication with the cytosol, morphology and 
content exchange between mitochondria (Chen and Chan, 2009) (Figure 1.2). 
Figure 1.2 Mitochondrial Dynamic Network. Tetramethylrhodamine Methyl Ester 
(TMRM) staining and confocal microscopy imaging depicting the mitochondrial network in a 
single fibroblast cell (unpublished). Scale bar - 10µm. 
   
5 
 Fusion 
Mitochondrial fusion is dependent on the large dynamin-related GTPases mitofusin 1 
(MFN1), mitofusin 2 (MFN2) and optic atrophy protein 1 (OPA1), allowing mixing of 
mitochondria content (Figure 1.3). MFN1/2 are surface exposed proteins in the OMM that 
interact with between mitofusins of adjacent mitochondria via a heptad repeat region (HR2), 
which acts as a tether to fuse together mitochondria (Chen et al., 2003; Koshiba et al., 2004). 
OPA1 is present in IMM on the side of the intermembrane space and in partnership with 
MFN1 (Cipolat et al., 2004), coordinating fusion of the IMM (Olichon et al., 2002; Ishihara et 
al., 2006).  
 Fission 
Mitochondrial fission is dependent on dynamin-related protein 1 (Drp1), a predominantly 
cytosolic protein recruited to the OMM where it oligomerises into spirals around the 
mitochondrion, constricting and separating it into two organelles (Figure 1.4) (Ingerman et 
al., 2005; Elgass et al., 2013). Recruitment of Drp1 to the OMM is mediated by Fis1 in yeast 
(Okamoto and Shaw, 2005). However, knockout of Fis1 in mammalians prevents 
mitochondrial fission but does not alter recruitment of Drp1 to the OMM, suggesting that it 
has a minor role in mammalian mitochondrial fission (Lee et al., 2004). Drp1 also interacts 
with mitochondrial fission factor (MFF), mitochondrial dynamics protein of 49 kDa (MID49) 
Figure 1.3 Mitochondrial Fusion. OPA1 coordinates fusion of the IMM. MFN1/2 interact 
with mitofusins of adjacent mitochondria via a HR2 as a tether for fusion. This allows mixing 
of mitochondrial contents (red and green). 
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and 51 kDa (MID51) (Loson et al., 2013), which may be more essential for Drp1 recruitment 
in mammalians than in yeast. A recently characterised component of fission, septin 2 (SEPT2) 
(Pagliuso et al., 2016), is discussed in 4.5.5.2. 
1.3 Mitochondrial Respiration and the Electron Transport Chain (ETC) 
1.3.1 TCA Cycle and Initiation of ATP Production 
The major role of mitochondria is the production of ATP via OXPHOS (Hatefi, 1985). This is 
initiated in the cytosol by the conversion of glucose to pyruvate in the final step of glycolysis. 
Glycolysis is summarised in the following equation: 
Glucose + 2NAD+ + 2ADP + 2Pi
                
→     2Pyruvate + 2NADH + 2H+ + 2ATP + 2H2O 
Pyruvate is the main provider of carbon for the TCA cycle; a closed-loop cycle and key driver 
of cellular respiration. Pyruvate is transported from the intermembrane space to the matrix 
through the mitochondrial pyruvate carrier (MPC) (Bricker et al., 2012). Next, pyruvate is 
irreversibly converted to acetyl Co-enzyme A (CoA), known as pyruvate decarboxylation, by 
the pyruvate dehydrogenase complex (PDHc) (Patel and Korotchkina, 2006). Pyruvate 
decarboxylation is summarised in the following equation: 
Pyruvate + CoA + NAD+
                
→     Acetyl CoA + CO2+ NADH + H
+ 
Figure 1.4 Mitochondrial Fission. Drp1 is recruited to the OMM where it oligomerises into 
spirals around the mitochondrion to constrict and separate it into two organelles. Recruitment 
is potentially mediated by MFF, MID49, MID51 or Fis1. 
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Acetyl CoA, NAD+ and FAD are the major substrates for the TCA cycle (Figure 1.5) (Akram, 
2014). Overall through eight intermediate redox reactions, acetyl CoA is oxidised to generate 
CoA, while NAD+ and FAD are reduced to NADH and FADH2. One cycle also generates one 
molecule of either ATP or guanosine triphosphate (GTP). The overall TCA cycle reaction is 
summarised in the following equation:  
Acetyl CoA + 3NAD+ + FAD + ADP + Pi +2H2O  
                
→    CoA + 3NADH + 2H+ + FADH2 + ATP + 2CO2 
The end stage of cellular respiration is OXPHOS for the generation of ATP, performed by 
four multi-subunit RC enzyme complexes (I-IV) and ATP synthase (V) that comprise the 
electron transport chain (ETC) (Figure 1.11). Despite producing only one ATP or GTP 
Figure 1.5 TCA Cycle. Schematic of the eight intermediate redox reactions for the 
conversion of Acetyl CoA to CoA. One molecule of GTP (red) or ATP is generated by 
transfer of an inorganic phosphate from succinyl-CoA to either GDP or ADP. Despite the 
generation of one GTP or ATP molecule, the NADH and FADH2 molecules produced are 
essential electron carriers for the ETC. 
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molecule, the TCA cycle is also indirectly involved in ATP production via the ETC, since 
generated NADH and FADH2 are critical electron carriers that donate electrons to complex I 
and II, which are then transferred to complex III and IV. Protons and H+ released from the 
matrix into the intermembrane space create an electrochemical gradient, driving the 
conversion of ADP and Pi to ATP.  
1.3.2 Complex I – NADH: Ubiquinone Reductase 
Complex I (NADH: ubiquinone reductase) is the first and largest enzyme of the ETC at 
approximately 1.1 megadaltons (MDa), comprising 45 subunits; seven mtDNA encoded and 
38 nuclear encoded (Figure 1.6) (Sazanov, 2015; Zhu et al., 2016). Of these, 14 core subunits 
are evolutionarily conserved between bacteria and humans, which are considered essential yet 
sufficient for complex I enzyme activity (Hirst, 2011; Vinothkumar et al., 2014), meaning 
that human mitochondria contain 31 supernumerary nuclear encoded structural subunits. The 
significance and characterisation of these 31 structural subunits was recently examined by 
Stroud et al. (2016), which demonstrated that 25 subunits were indispensable for assembly of 
functional complex I and one subunit, NDUFAB1, was required for cell viability. Complex I 
is also comprised of nine essential co-factors; eight Fe-S clusters and one flavin 
mononucleotide (FMN) for electron transport (Zhu et al., 2016).  
Complex I has an L-shaped conformation with a hydrophilic matrix arm and a hydrophobic 
membrane arm imbedded in the IMM, which are composed of three modules (N, Q, P) with 
independent functions. The N-module is located at the periphery of the matrix arm and is 
where NADH is oxidised to NAD+, releasing two electrons that are donated to FMN. The Q-
module is also located in the matrix arm, containing a chain of eight Fe-S clusters that pass 
one electron at a time to reduce ubiquinone (Q) to ubiquinol (QH2), which is transferred to 
complex III. The P-module is located in the membrane arm and is required for the pumping of 
four hydrogen protons from the matrix across the IMM to the intermembrane space to create a 
membrane potential (ΔΨm) necessary to drive ATP synthesis by complex V. The complex I 
reaction is summarised in the following equation: 
 NADH + Q + 5Hmatrix
+
                
→     NAD+ + QH2+ 4Hims
+  
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Assembly of complex I is a complex, phased process. Current models (Vogel et al., 2007b; 
McKenzie and Ryan, 2010) suggest that intermediate modules of approximately 400-500 kDa 
are formed in the early-stages of assembly, composed of the core NDUFS2, NDUFS3 and the 
ND (mtDNA encoded) subunits of the P- and Q-modules. This is expanded further with the 
addition of the remaining structural subunits, with the N-module formed in the late-stages of 
assembly. Precise assembly of complex I is highly dependent on an increasing number of 
assembly factors (Heide et al., 2012; Guarani et al., 2014). This includes the mitochondrial 
complex I assembly (MCIA) complex, which is comprised of assembly factors NDUFAF1, 
ACAD9, ECSIT, TMEM126B and TIMMDC1 (Vogel et al., 2005; Vogel et al., 2007a; 
Nouws et al., 2010; Heide et al., 2012; Guarani et al., 2014). 
Complex I deficiency is one of the most frequent biochemical manifestations in mitochondrial 
disease, with isolated deficiency occurring due to mutations of mtDNA or nuclear encoded 
structural subunits, assembly factors or in combination with deficiency of other mitochondrial 
proteins (Loeffen et al., 2000). Isolated complex I deficiency is particularly common in early-
onset mitochondrial disease, affecting approximately 30% of patients (Kirby et al., 1999). The 
clinically heterogeneous phenotypes are reflected in the increasing number of nuclear encoded 
Figure 1.6 Complex I - NADH: Ubiquinone Reductase. Schematic of the complex I 
structure. This shows the passing of two electrons from the reduction of NADH donated to 
FMN, which are then passed along a chain of eight Fe-S clusters (brown circles) to reduce Q 
to QH2. The N-, Q- and P-modules are distinguished by dashed-lines. 
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structural subunits and assembly factor defects that are now associated with the pathology of 
complex I deficiency. The most frequent presentation is Leigh syndrome, characterised by 
bilateral symmetrical hyperintensities of the brainstem and basal ganglia on brain MRI, 
whereby isolated complex I defects account for approximately 35% of all Leigh syndrome 
patients (Fassone and Rahman, 2012). Isolated complex I defects are also associated with 
mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) (Liolitsa et 
al., 2003), Leber hereditary optic neuropathy (LHON) (Yu-Wai-Man et al., 2003), 
leukoencephalopathy (Ferreira et al., 2011b) and neonatal lactic acidosis (Spiegel et al., 
2009). Multiple OXPHOS deficiencies that include complex I are predominantly due to 
nuclear gene defects of mtDNA maintenance, mitochondrial protein synthesis, cofactors of 
OXPHOS, dynamics and metabolism (Mayr et al., 2015). However, isolated complex I 
defects have also been noted in patients with mutations of these additional nuclear encoded 
genes (Fassone and Rahman, 2012).     
1.3.3 Complex II – Succinate Dehydrogenase 
Uniquely, complex II (succinate dehydrogenase) is a heterotetrameric enzyme comprised of 
four nuclear encoded subunits only (Figure 1.7) (Cecchini, 2003). Complex II is also the only 
membrane-bound enzyme required for the TCA cycle, oxidising succinate to fumarate 
(Figure 1.5), in addition to participating in the ETC. 
Of the four nuclear encoded subunits, hydrophilic 70kDa SDHA and 30kDa SDHB catalytic 
subunits are located in the matrix, while the hydrophobic SDHC and SDHD subunits ensure 
that complex II is attached to the IMM. SDHA contains a covalently attached FAD co-
enzyme that is reduced to FADH2 following the oxidation of succinate to fumarate. SDHB 
contains three Fe-S clusters (2Fe-2S, 3Fe-3S, 3Fe-4S), along which two electrons from flavin 
are transferred to reduce Q to QH2. There is also a haem b group, although it is not clear if 
this participates in the ETC (Cecchini, 2003). Unlike the other ETC reactions, there is no 
transfer of protons across the IMM. The complex II reaction is summarised in the following 
equation: 
Succinate + Q
                
→     Fumarate + QH2 
   
11 
Although the role of the haem b group in the mammalian complex II is unclear, studies of 
Escherichia coli suggest a critical role in complex II assembly. In this bacterial model (Lenaz 
and Genova, 2010), haem b group binds to SdhD (SDHD in human nomenclature), which 
then links it to SdhC (SDHC) and finally provides a link to a complex II SdhA-SdhB (SDHA-
SDHB) intermediate module. In humans, two nuclear encoded assembly factors (SDHAF1, 
SDHAF2) have been identified, but the precise roles in assembly are unclear (Ghezzi and 
Zeviani, 2012). 
Mutations of the nuclear encoded complex II structural subunits and assembly factors have 
been predominantly associated with autosomal dominant hereditary paraganglioma–
pheochromocytomas syndromes, which are tumours of the neuroendocrine tissues or adrenal 
medulla (Hoekstra and Bayley, 2013). Mitochondrial disease characterised biochemically by 
isolated complex II deficiency is rare (Hoekstra and Bayley, 2013), due to recessive mutations 
of SDHA, SDHB, SDHD and SDHAF1 causing variable phenotypes including 
leukoencephalopathy and hypertrophic cardiomyopathy (HCM) (Ghezzi et al., 2009; Alston 
et al., 2012; Alston et al., 2015). SDHC and SDHAF2 are not currently associated with 
isolated complex II deficiency.         
Figure 1.7 Complex II – Succinate Dehydrogenase. Schematic of complex II showing the 
passing of electrons from flavin along a chain of three Fe-S clusters (brown circles) for the 
reduction of Q to QH2. Electrons are donated to FAD following oxidation of succinate to 
fumarate. However, it is unclear if the haem b group (yellow circle) participates in the ETC. 
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1.3.4 Complex III – Ubiquinol: Cytochrome c Reductase 
Complex III (ubiquinol: cytochrome c reductase) is a homodimeric enzyme composed of 11 
subunits; 10 nuclear encoded and one mtDNA encoded (cytochrome b) (Figure 1.8). It 
contains a catalytic core that comprises the cytochrome b subunit with two haem groups, 
cytochrome c1 with one haem group and an Fe-S cluster referred to as the ‘Rieske Fe-S 
cluster’ (Xia et al., 1997).  
The process of electron transfer with complex III is referred to as the ‘Q Cycle’ (Mitchell, 
1975). QH2 from complex I binds to the Q0 site to donate two electrons. One electron is 
passed through the Rieske Fe-S cluster and cytochrome c1 where it next reduces one 
cytochrome c (CytC) molecule, which is released from complex III and two hydrogen protons 
are pumped from the matrix to the intermembrane space. Simultaneously, the second donated 
electron is cycled through the two haem groups of cytochrome b, where it reduces Q to a 
semi-ubiquinone (Q-) at a Q0 site. Binding of another QH2 at the Q1 site results in the release 
of two more electrons; one electron again reduces one CytC molecule that is released, while 
the second electron passes through the cytochrome b haem groups to reduce Q- further to Q. 
Hence, two cycles of CytC reduction are necessary, which results in the release of four 
hydrogen protons from the intermembrane space to the matrix and the uptake of two protons 
Figure 1.8 Complex III - Ubiquinol: Cytochrome c Reductase. Schematic of complex III 
showing the transfer of electrons in the process called the ‘Q Cycle’. Overall, four electrons 
are required for the reduction of two cytochrome c (CytC) (grey circle) molecules and the 
pumping of four hydrogen protons from the matrix to the intermembrane space. The Rieske 
Fe-S cluster (green circle), cytochrome c1 (blue circle), haem groups (orange circles) and Q0 
and Q1 sites (small blue circles) are shown. 
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from the matrix. The complex III reaction is summarised in the following equation: 
 2QH2 + Q + 2Cytcoxidised + 2Hmatrix
+  
                
→     2Q + QH2 + 2Cytcreduced + 4Hims
+  
Isolated complex III deficiency is a rare form of early-onset mitochondrial disease and has 
been associated with mutations of both structural subunits and assembly factors including 
BCS1L and TTC19 (Bénit et al., 2009; Tucker et al., 2013; Ardissone et al., 2015a; Dallabona 
et al., 2016). Mutations of mtDNA encoded MT-CYB have been predominantly associated 
with exercise intolerance (Andreu et al., 1998), but also multisystem disorders including 
encephalopathy, lactic acidosis, leukoencephalopathy and neurodegeneration (Bénit et al., 
2009; Tucker et al., 2013; Ardissone et al., 2015a; Dallabona et al., 2016). 
1.3.5 Complex IV – Cytochrome c Oxidase 
Complex IV (cytochrome c oxidase, COX) is the final holoenzyme of the ETC and is a dimer 
composed of 14 subunits; three essential core mtDNA encoded (MT-COI, MT-COII, MT-
COIII) and 11 nuclear encoded (Figure 1.9) (Tsukihara et al., 1996). Initially thought to 
comprise 13 subunits, NDUFA4 was recently identified at the 14th subunit of human COX but 
not complex I (Balsa et al., 2012), which has been supported by the identification of patients 
with NDUFA4 mutations and isolated COX deficiency (Pitceathly et al., 2013).  
COX is comprised of two haem groups (a and a3) and two copper binding sites (CuA and CuB). 
Together, three mtDNA encoded subunits constitute the catalytic core. MT-COI and MT-
COII are catalytic subunits with highly conserved domains containing copper binding sites, 
whereas MT-COIII is the core structural subunit. MT-COI contains both haem groups and the 
copper binding site CuA, while MT-COII contains the copper binding site CuB. COX is 
essential for the reduction of O2 to H2O, requiring a total of eight hydrogen protons and four 
electrons donated from four reduced CytC molecules (Tsukihara et al., 1996; Faxen et al., 
2005). 
The formation of H2O and the pumping of four hydrogen protons from the matrix to the 
intermembrane space occurs in two stages each requiring two electrons (Faxen et al., 2005). 
Firstly, two electrons are passed sequentially across the electron acceptor CuA and haema 
group from two molecules of reduced CytC, which are re-oxidised. At the catalytic binuclear 
site, one electron reduces haema3 and the second electron reduces CuB, establishing a peroxide 
bridge with O2 between the haema3 and CuB sites. Secondly, a further two electrons are 
donated from two additional reduced CytC molecules, with the electrons passed through the 
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CuA site and haema group to the catalytic binuclear site. Two hydrogen protons each bind to 
the CuB site and haema3 group, breaking the peroxide bridge and reducing the two oxygen 
atoms to release two H2O molecules, while the CuB site and haema3 group return to their initial 
oxidised states. Simultaneously, four hydrogen protons are pumped across the IMM from the 
matrix to the intermembrane space. The complex IV reaction is summarised in the following 
equation: 
4Cytc
reduced
 + 8H+ + O2
                
→     4Cytc
oxidised
 + 2H2O + 4Hims
+  
There are over 20 nuclear encoded ancillary factors currently known to be essential for COX 
structural assembly and biogenesis, which includes maturation of mtDNA-encoded subunits, 
and metalation of the copper and haem sites (Kadenbach and Hüttemann, 2015). Most 
recently, COA6 was identified as a copper chaperone for MT-COII maturation (Stroud et al., 
2015). COX assembly occurs in four sequential steps forming intermediate subcomplexes 
(Nijtmans et al., 1998; Fontanesi et al., 2006; Ghezzi and Zeviani, 2012). Synthesised MT-
COI is imbedded in the IMM (S1), followed by incorporation of COX4 and COX5A (S2), 
MT-COIII, COX5b, COX8 and small nuclear encoded subunits (S3), and finally all remaining 
Figure 1.9 Complex IV – Cytochrome c Oxidase (COX). Schematic of COX showing the 
passing of four electrons through CuA and haema group to the CuB-haema3 catalytic binuclear 
site. Together with four hydrogen protons pumped from the matrix to the intermembrane 
space and four hydrogen protons binding to the binuclear site, a total of two H2O molecules 
are generated. 
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subunits to complete assembly. Insertion of the haem groups and copper binding sites also 
occur during formation of the intermediate subcomplexes.  
Isolated COX deficiency is a common form of mitochondrial disease that predominantly 
manifests in severe early-onset phenotypes, due to mutations of the three mtDNA encoded 
subunits or several of the nuclear encoded structural subunits or COX assembly factors 
(DiMauro et al., 2012). The most common phenotype is Leigh Syndrome, which has been 
especially associated with recessive mutations of the COX biogenesis factor SURF1 (Zhu et 
al., 1998). Mutations of nuclear encoded COX assembly or biogenesis factors comprise a 
significant proportion of patients with isolated COX deficiency when compared to COX 
structural subunits, suggesting that mutations of structural subunits are predominantly 
incompatible with life (DiMauro et al., 2012). Nonetheless, mutations of mtDNA-encoded 
COX subunits are rare, causing mild and broad late-onset phenotypes (Horváth et al., 2005). 
Mutations of mt-tRNAs, nuclear encoded mitochondrial protein synthesis or other 
mitochondrial proteins have been associated with isolated COX deficiency, including 
LRPPRC (Oláhová et al., 2015), APOPT1 (Melchionda et al., 2014) and mt-tRNAGlu (Horvath 
et al., 2009). Similar to complex I, COX deficiency with deficiencies other enzymes of the 
OXPHOS system is common due to nuclear encoded mutations, typically involving combined 
deficiencies of complexes I and IV, or complexes I, III and IV (Mayr et al., 2015).  
1.3.6 Complex V – ATP Synthase 
Complex V (ATP synthase) is a ~600kDa dimeric enzyme composed of two regions; a 
soluble catalytic F1 region located in the matrix and an F0 region bound within the IMM 
(Figure 1.10) (Jonckheere et al., 2012). The F1 section comprises the central stalk and is 
composed of three copies each of α and β subunits forming a hexamer ring, plus one γ, δ and ε 
subunits. The F0 section comprises a ring composed of approximately eight c subunits, plus 
one a, b, d, A6L and F6 subunits, of which the b, d and F6 subunits compose a peripheral stalk. 
Some of the structural subunits have multiple isoforms encoded by different nuclear genes, 
such as the α (ATP5A1, ATP5A2) and β (ATPAF1, ATP5B) subunits. 
ATP synthase catalyses the reversible synthesis of ATP from ADP and inorganic phosphate 
(Pi) in the F1 section, driven by the ΔΨm generated by the ETC. A high ΔΨm between 150 and 
180 mV under normal conditions is favourable to ATP synthesis (Campanella et al., 2009). 
The ΔΨm provides energy that causes rotation of the c ring around the central stalk and 
rotation of the γ, δ and ε subunits in the F1 section. Hydrogen protons are driven through the 
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F0 section past the a subunit to the c ring of the F0 section. It is the rotation of the γ subunit 
that permits the synthesis of ATP, in a mechanism known as ‘binding change’ (Boyer, 1975). 
Rotation causes alternating conformational changes to the nucleotide binding sites of the three 
catalytic β subunits, which are either ‘open’, ‘loose’ or ‘tight’ for ADP and Pi binding. 
Through rotation of the γ subunit and the conformation switches, the ADP and Pi molecules 
are brought ‘tight’ together to synthesise ATP.  
Assembly of the ATP synthase monomer has been well characterised in yeast (Wagner et al., 
2010; Rak et al., 2011), although assembly is known to occur in step-wise stages in both yeast 
and mammalian mitochondria (Ruhle and Leister, 2015). The F0 and F1 sections are assembled 
independently followed by linkage, with the assistance of assembly factors ATP11 and 
ATP12 in mammalians. It is also known that a and A6L are the last two subunits to be 
incorporated to the assembled monomer (Wittig et al., 2010).    
Figure 1.10 Complex V – ATP Synthase. Schematic of complex V showing the structural 
subunits that comprise the F0 and F1 sections. ‘Rotary catalysis’ of the γ subunit causes 
conformational changes of the β subunit – ‘open’, ‘loose’ and ‘tight’ – that permits the 
synthesis of ATP from ADP and Pi. 
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Isolated complex V defects are a rare form of mitochondrial disease. Nonetheless, mutations 
of the mtDNA encoded subunit MT-ATP6 are a common cause of Leigh syndrome (Lake et 
al., 2016), which includes the recurrent m.8993T>G mutation (Santorelli et al., 1993). Less 
common MT-ATP6 phenotypes include motor neuron syndrome (Brum et al., 2014) and 
adult-onset spinocerebellar ataxia (Pfeffer et al., 2012). Mutations in the second mtDNA 
encoded structural subunit MT-ATP8 have also been described (Jonckheere et al., 2008), as 
have mutations in the nuclear encoded structural subunits α (ATP5A1) (Jonckheere et al., 
2013) and ε (ATP5E) (Mayr et al., 2010), and two assembly factors (ATP12, TMEM70) (De 
Meirleir et al., 2004; Cizkova et al., 2008). 
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Figure 1.11 Electron Transport Chain (ETC) Multi-Subunit Complexes. The multi-subunit complexes that comprise the ETC are located within 
the IMM. The dashed red line denotes the pathways of electrons once entered the ETC. The numbers below each complex show the number of mtDNA 
and nuclear encoded subunits. CytC – cytochrome c; Q – ubiquinone; QH2 – ubiquinol. 
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1.3.7 Supercomplexes (SC) 
The ETC is frequently depicted as free-moving, isolated RC enzyme complexes that are 
linked together by the electrons carriers Q and CytC, known as the ‘fluid model’ (Figure 
1.11) (Hackenbrock et al., 1986). On the contrary, structural analyses suggest that the RC 
enzymes are dynamic, forming ‘supercomplexes’ (SCs) together with free-moving isolated 
RC enzymes in the IMM, known as the ‘plasticity model’ (Acin-Perez and Enriquez, 2014). 
This includes a so-called ‘respirasome’ (I+III+IV) and two SCs (I+III; III+IV), together with 
the free-moving isolated RC enzymes. Complex II does not form SCs with other RC enzymes, 
while active ATP synthase remains in a dimer structure. Evidence for SCs has been provided 
by blue-native polyacrylamide gel electrophoresis, emphasised by the identification of the 
respirasome comprising complex I, III and approximately four units of complex IV (Schagger 
and Pfeiffer, 2000). Electron cryo-microscopy has also been pivotal, used to establish the 
structure of the respirasome (Althoff et al., 2011). In fact, complex I has been shown to be 
unstable in the absence of complex III or IV (Acin-Perez et al., 2004; Diaz et al., 2006; 
Vempati et al., 2009). Loss of several complex I structural subunits also disrupts formation of 
complex I SCs (Stroud et al., 2016). However, the precise roles of SCs have not been 
elucidated, although Lapuente-Brun et al. (2013) demonstrated the presence of two distinct 
pools of Q for electron supply in the I+III SC; one derived from the oxidation of NADH and 
the second from FADH2. Furthermore, the assembly and binding of the individual complexes 
to form the SCs is not fully understood. Cardiolipins that compose a high proportion of the 
IMM membrane are thought to have a crucial role in SC assembly, as demonstrated for 
assembly of complexes III+IV in yeast (Bazan et al., 2013). Most recently, in silico modelling 
of complex III+IV from bovine heart mitochondria suggested that cardiolipin uses binding 
sites on the surface of both RC enzymes to guide and assemble the complexes (Arnarez et al., 
2016). 
1.4 Mitochondrial Functions    
1.4.1 Generation of Reactive Oxidative Species (ROS) 
Approximately 1-5% of O2 consumed during OXPHOS is converted into reactive oxidative 
species (ROS), mainly at complexes I and III, that induce oxidative stress in mitochondria, 
including super oxide anions (O2-
.), hydrogen peroxide (H2O2) and hydroxyl radicals (.OH) 
(Orrenius, 2007). Mitochondria have several antioxidant enzymes that catalyse the removal of 
ROS such as superoxide dimutase 1 (SOD1) (Barber et al., 2006), glutathione peroxidase 1 
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(GPx1) (Handy et al., 2009) and catalases (Chelikani et al., 2004). Despite this, 
approximately 1% of ROS eludes enzymatic removal (Shoshan-Barmatz et al., 2010). 
Mitochondria are highly susceptible to oxidative stress due to ROS, particularly mtDNA due 
to its close proximity to the ETC. ROS are also capable of damaging lipids of the 
mitochondrial membranes, oxidising macromolecules and releasing CytC plus additional pro-
apoptotic proteins to the cytosol (Ott et al., 2007). In spite of their toxicity, ROS are also 
involved in intracellular signalling pathways including apoptosis, differentiation and cell 
growth (Ott et al., 2007). 
1.4.2 Fe-S Cluster Biogenesis 
Fe-S clusters are abundant inorganic co-factors that are essential for a wide range of cellular 
processes (Rouault, 2012). Fe-S clusters and the machinery for biogenesis are conserved in 
almost all organisms, highlighting their crucial role for even the most primitive of life. 
Mammalian Fe-S clusters are typically present in rhombic (Fe2S2) or cubic (Fe4S4) structures 
that are normally non-covalently bound to cysteine or less frequently to histidine protein 
residues (Beilschmidt and Puccio, 2014). Fe-S clusters are essential components of the 
OXPHOS system for accepting and donating electrons, particularly in complexes I, II and III 
(Stehling et al., 2009). Indeed, electron transfer in complex I is dependent on a chain of eight 
Fe-S clusters (Sazanov, 2015). Fe-S clusters are also involved in the bindings of substrates for 
mitochondrial enzymatic reactions, notably to aconitase for the conversion of citrate to 
isocitrate, plus succinate dehydrogenase for the conversion of succinate to fumarate, with both 
reactions occurring in the TCA cycle (Figure 1.5) (Akram, 2014). 
Fe-S biogenesis begins with the transport of reduced iron (Fe2+) into the matrix by mitoferrins 
(Paradkar et al., 2009). Cysteine desulfurase (NFS1) and its co-factor pyridoxal phosphate 
supply sulphur from cysteine, while iron-sulphur cluster assembly enzyme (ISCU) provides a 
backbone structure upon which the cluster can be synthesised from the reduced Fe2+ and 
inorganic sulphur (Lill, 2009; Rouault, 2012). Stability of NFS1 is also dependent upon on 
LYRM4 (ISD11) (Shi et al., 2009). In bacteria, the basic machinery for Fe-S cluster 
biogenesis are encoded by a single Isc operon (Zheng et al., 1998). However, following 
formation it is not yet fully understood how clusters are exported to the cytosol or how 
clusters are targeted and are incorporated into proteins (Rouault, 2012; Beilschmidt and 
Puccio, 2014).   
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1.4.3 Ca2+ Homeostasis 
Mitochondria are important Ca2+ storage vessels essential for the intracellular homeostasis of 
Ca2+  (Newmeyer and Ferguson-Miller, 2003), channelling Ca2+ to and from the cytosol and 
endoplasmic reticulum (ER) (De Vos et al., 2012), ATP production (Jouaville et al., 1999) 
and apoptosis (Giorgi et al., 2012). Ca2+ is also vital in the TCA cycle for activation of 
pyruvate dehydrogenase, isocitrate dehydrogenase and α-ketoglutarate (Denton, 2009). Thus, 
it is through control of the TCA cycle that Ca2+ regulates ATP production to meet the 
intracellular needs (Jouaville et al., 1999).   
Ca2+ is imported across the OMM into the intermembrane space via VDAC (Bayrhuber et al., 
2008; Shoshan-Barmatz et al., 2010). Ca2+ is predominantly transported via a highly selective 
mitochondrial Ca2+ uniporter (MCU) located in the IMM, which is driven by the proton 
gradient but is independent of ATP synthesis or transport of other ions (Kirichok et al., 2004). 
Additional IMM Ca2+ transporters for uptake and release have also been proposed, principally 
Na+/Ca2+ and H+/Ca2+ exchange channel proteins, which may include leucine zipper-EF-hand 
containing transmembrane protein 1 (LETM1) (Shao et al., 2016). 
1.4.4 Apoptosis 
Apoptosis, also known as programmed cell death, is a controlled biochemical process 
essential for maintaining the cell population and the degradation of damaged cells. Apoptosis 
can be induced by damage from ROS, UV damage or starvation, which triggers CytC release 
from the matrix to the cytosol (Liu et al., 1996; Ott et al., 2007; Wang and Youle, 2009). Key 
to the release of CytC from mitochondria and activation of apoptosis pathways are the Bcl-2 
proteins Bak and Bax (Cory and Adams, 2002). Under healthy conditions, Bax is localised to 
the cytosol, whereas Bak is associated with mitochondria. When cells are damaged, Bax 
translocates from the cytosol to the OMM (Hsu et al., 1997; Wolter et al., 1997), forming 
oligomers (Antonsson et al., 2001) and interacts with another Bcl-2 protein, tBid, to induce 
permealisation of the membrane (Lovell et al., 2008). Simultaneously, Bak continues to 
associate with mitochondria, but undergoes conformational changes to form oligomers 
(Griffiths et al., 1999). The release of CytC from the matrix to the cytosol is critical to 
activation of the caspases, which are essential protease enzymes for controlled degradation of 
proteins during apoptosis (McIlwain et al., 2013). 
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1.5 The Mitochondrial Genome 
1.5.1 Structure and Organisation 
Uniquely, the mitochondrion is the only organelle of eukaryotic cells except for the nucleus to 
have its own genome. Human mitochondrial DNA (mtDNA) is a compact, circular ~16,569 
basepair (bp) double-stranded DNA molecule with 2-10 copies present in each mitochondrion 
(Figure 1.12), thus it is a multi-copy number genome in eukaryote cells. Initially sequenced 
by Anderson et al. (1981), the human mitochondrial genome sequence was revised by 
Andrews et al. (1999) and is referred to as the Revised Cambridge Reference Sequence 
(rCRS). The current GenBank accession number is NC_012920.  
Throughout the evolution of mitochondria, almost all genes from the ancient Eubacterium 
have been lost or transferred to the nuclear genome. Hence, human mtDNA now has only 37 
genes, encoding 13 proteins that comprise essential core subunits of complex I, III, IV and V. 
Also encoded are 22 mitochondrial transfer RNAs (mt-tRNAs) and two ribosomal RNAs 
Figure 1.12 Human Mitochondrial Genome. Schematic representation of the human 
mitochondrial genome showing the H- and L-strands. Protein coding (blue), rRNA (yellow) 
and mt-tRNA (orange) genes are noted. ‘Term’ denotes the terminator of the short HSP1 
transcript. Arrows show the direction of transcription. OH and OL denote the origins of H-
strand and L-strand replication. Adopted from Suzuki et al. (2011). 
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(rRNAs) (12S and 16S) for mitochondrial protein synthesis. Since all remaining 
mitochondrial proteins are encoded in the nucleus and imported, mitochondria are therefore 
dependent upon the close genetic coordination between the nuclear and mitochondrial 
genomes.  
The double-stranded mitochondrial genome comprises an outer guanine-rich heavy (H-) 
strand and a cysteine-rich inner light- (L-) strand (Anderson et al., 1981). Unlike the nuclear 
genome, there are no introns within mtDNA genes, nor are there intergenic regions between 
each of the encoded genes. The major exception of the human mtDNA is a 1.1kb triple-
stranded displacement loop (D-loop) (Kasamatsu et al., 1971). This contains the origin of H-
strand replication (OH), one H-strand promoter (HSP1), the L-strand promoter (LSP), binding 
sites for mitochondrial transcription factor A (TFAM) and three conserved sequence blocks 
(CSB1, CSB2, CSB3). A second H-strand promoter (HSP2) is located near the 5’ end of the 
MT-RNR1 gene, while the origin of L-strand replication (OL) is located between the MT-TC 
and MT-TN genes (Montoya et al., 1982). 
Unlike the nuclear genome which is organised in regular nucleosomal array structures 
(Kornberg, 1974), mtDNA is packaged throughout the mitochondrial network in compact, 
spherical nucleoprotein complexes called the ‘nucleoids’ containing one or more copies of 
mtDNA (Garrido et al., 2003; Bogenhagen, 2012). There are a number of proteins associating 
with the nucleoids that are involved in mitochondrial transcription, replication and translation. 
A central component of mammalian nucleoids is TFAM (Garrido et al., 2003; Wang and 
Bogenhagen, 2006; Kaufman et al., 2007). Also co-localising with the nucleoids are Lon 
protease 1 (LONP1) (Lu et al., 2007), DNA polymerase gamma subunit 1 (POLG1, POLγA) 
(Bogenhagen et al., 2008), the mitochondrial RNA polymerase (POLRMT) (Bogenhagen et 
al., 2008), the twinkle helicase (TWNK) (Garrido et al., 2003; Rajala et al., 2014) and 
mitochondrial single-stranded binding protein (mt-SSB) (Wang and Bogenhagen, 2006; 
Bogenhagen et al., 2008; Rajala et al., 2014). 
1.5.2 Maternal Inheritance 
In contrast to nuclear DNA, the mammalian mitochondrial genome is strictly inherited 
through the maternal lineage (Hutchison et al., 1974; Giles et al., 1980). However, there is 
one apparent instance, a male patient who harboured a pathogenic 2-bp deletion in MT-ND2, 
where mtDNA was apparently inherited paternally (Schwartz and Vissing, 2002). The 
mechanisms for elimination of the paternal mtDNA in mammalians are not fully understood 
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(Sato and Sato, 2013). Currently, the prevailing hypothesis is that mammalian paternal 
mitochondria are tagged for ubiquitin-mediated degradation and are eliminated before the 
four-cell stage (Sutovsky et al., 1999).  
1.5.3 mtDNA Haplogroups 
The mitochondrial genome has a mutation rate approximately 10- to 17-fold faster than the 
nuclear genome (Brown et al., 1979), due to the close proximity of the nucleoids to the ROS 
generated from ETC. As a consequence, a significant proportion of neutral or benign human 
mtDNA variants that have occurred sporadically. Since mtDNA is maternally inherited, these 
polymorphisms can be grouped and subject to phylogenetic analysis, allowing the tracking of 
human migration out of Sub-Saharan Africa (Kivisild, 2015). Thus, these mtDNA 
‘haplogroups’ have been assigned alphabetical labels to denote different geographical 
populations (Torroni et al., 1993; Torroni et al., 1994). 
1.5.4 Mitochondrial Transcription 
Transcription of the mitochondrial genome occurs bi-directionally and is initiated at the three 
promoter regions, two H-strand promoters (HSP1, HSP2) and one L-strand promoter (LSP). 
Transcription from the HSP2 and LSP promoters produce near-genome length polycistronic 
transcripts, covering almost all of the coding regions on the L-strand and H-strand. On the 
other hand, the HSP1 promoter generates a short polycistronic transcript that encompasses the 
two rRNAs (12S and 16S) and two mt-tRNA (mt-tRNAPhe and mt-tRNAVal). 
In vitro studies have shown that three proteins are essential for the initiation of transcription, 
forming the mitochondrial transcription initiation complex; POLRMT, TFAM and 
mitochondrial transcription factor B2 (TFB2M) (Falkenberg et al., 2002; Shi et al., 2012; 
Yakubovskaya et al., 2014). A second transcription factor, TFB1M, was also initially thought 
to participate in transcription (Falkenberg et al., 2002; McCulloch and Shadel, 2003), but this 
is no longer the case (Metodiev et al., 2009). Transcription of mtDNA is performed by a 
single-subunit of POLRMT, which is unable to transcribe nuclear DNA (Kuhl et al., 2014). 
POLRMT contains an N-terminal extension (NTE) with an unclear role in transcription, 
although it could act as a transcription repressor (Gustafsson et al., 2016). 
Initiation of transcription (Figure 1.13) begins with the binding of TFAM approximately 10-
15bp upstream of the promoter site, which introduces a 180OC bend in mtDNA (Gaspari et 
al., 2004; Shi et al., 2012). This conformational change allows TFAM to coordinate the 
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recruitment of POLRMT, which binds to the promoter region, upstream bases and TFAM. 
POLRMT itself undergoes a change in conformation, which allows TFB2M binding to the 
pre-initiation complex, thus generating the fully assembled initiation complex that 
encompasses the promoter region (Yakubovskaya et al., 2014). An additional protein, 
mitochondrial transcription elongation factor (TEFM) has been shown to interact with 
POLRMT for transcribing longer sections of RNA and is indispensable for transcription 
(Minczuk et al., 2011). However, it is not clear whether TEFM is a putative second subunit of 
POLRMT or if it is an elongation accessory subunit (Gustafsson et al., 2016). 
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Figure 1.13 Mitochondrial Transcription Initiation. Transcription is initiated by binding of TFAM upstream of the promoter region, which induces 
a 180O bend in mtDNA (1). This facilitates binding of POLRMT to mtDNA and TFAM (2). POLRMT undergoes a conformational change (3) to allow 
binding of TFB2M to generate the fully assembled transcription initiation complex. Adopted from Gustafsson et al. (2016).   
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Mitochondrial transcription termination factor 1 (MTERF1) is the responsible protein for 
termination from all three transcription promoters (Kruse et al., 1989; Fernandez‐Silva et al., 
1997). However, only the HSP1 termination site has been functionally characterised; 
MTERF1 binds to 28bp region that is located downstream of the 16S rRNA gene (Kruse et 
al., 1989). However, knockout of Mterf1 in mice did not show a phenotype or altered rRNA 
or messenger RNA (mRNA) levels, suggesting that it is dispensable for transcription of rRNA 
through the HSP1 promoter region (Terzioglu et al., 2013). 
Two additional MTERF proteins have also been identified in mammalians; MTERF2 and 
MTERF3 (Roberti et al., 2009). MTERF2 is poorly characterised but has been shown to co-
localise with the nucleoids, which suggests a role in mtDNA expression (Pellegrini et al., 
2009). On the other hand, MTERF3 has been demonstrated as a repressor of transcription, 
since heart-specific knockout in mice caused significant up-regulation in transcription (Park et 
al., 2007).  
1.5.5 Mitochondrial Genome Replication 
 Replication Machinery 
Unlike the nuclear genome, the mammalian mitochondrial genome is not coupled to the cell 
cycle and hence, there is constant replication and turnover of mtDNA (Bogenhagen and 
Clayton, 1977). Mitochondrial genome replication is dependent on the replisome, comprising 
POLG1 (POLγA) and POLG2 (POLγB) that together compose the only known replicative 
mitochondrial DNA polymerase (POLG), TWNK for unwinding of the dsDNA and mt-SSB 
for stabilisation of ssDNA, plus POLRMT that likely synthesises the RNA primers needed for 
replication (Figure 1.14) (Falkenberg et al., 2007; Wanrooij et al., 2008; Fuste et al., 2010; 
Gustafsson et al., 2016). 
 Models of Replication 
Despite characterisation of mtDNA replication machinery, the precise mechanism(s) are still 
debated (Figure 1.15). Currently, there are two prevailing models proposed; strand-
displacement (asynchronous) and strand-coupled (synchronous) replication (Holt and Reyes, 
2012; McKinney and Oliveira, 2013). 
In the strand-displacement model, replication is initiated at the OH (leading-strand) and 
continues ‘unidirectionally’ until the OL (lagging-strand) is exposed by the underwinding of 
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DNA by TWNK, which initiates replication of the lagging-strand (Kasamatsu and Vinograd, 
1973; Tapper and Clayton, 1981; Clayton, 1982). 
In the strand-coupled model, replication is ‘bi-directional’ with initiated at the OH and at 
multiple initiation sites for lagging-strand synthesis, revealed during unwinding of the DNA, 
until replication is terminated at the OH (Holt et al., 2000). This model proposes the existence 
of Okazaki fragments as replication intermediates, but its presence in mitochondria have not 
yet been proved (Wanrooij and Falkenberg, 2010; McKinney and Oliveira, 2013). 
A third controversial model similar to the strand-coupled hypothesis has been proposed, 
referred to as the Ribonucleotide Incorporated ThroughOut the Lagging Strand (RITOLS) 
model (Yang et al., 2002; Yasukawa et al., 2006). This model proposes that leading- and 
lagging-strand synthesis occur simultaneously but in the presence of ribonucleotides that are 
incorporated into the synthesised lagging-strand and mature into DNA probably following 
exposure of the OL.         
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Figure 1.14 Mitochondrial Replication Machinery. Mitochondrial genome replication is shown in a 5’ to 3’ direction. Replication is dependent on 
the replisome comprising POLγA (dark blue), POLγB (light blue), twinkle (purple), mt-SSB (green) and POLRMT (orange). Based on Wanrooij and 
Falkenberg (2010). 
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Figure 1.15 Models of Mitochondrial Genome Replication. The current models of mitochondrial genome replication; strand-displacement 
(asynchronous), RITOLS and strand-coupled (synchronous). Adopted from McKinney and Oliveira (2013). 
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1.5.6 mtDNA Maintenance and Repair 
Initially thought to have a reduced capacity for DNA repair (Clayton et al., 1974; Miyaki et 
al., 1977), mitochondria are now known to possess several complex mechanisms for mtDNA 
maintenance, involving the coordination of a wide array of repair enzymes that are often 
shared with the nuclear genome and distinguished by a MTS (Kazak et al., 2012; Alexeyev et 
al., 2013). Repair mechanisms of mtDNA are extensively reviewed by Kazak et al. (2012) 
and Alexeyev et al. (2013).  
Base excision repair (BER) is the most well-characterised and perhaps the main repair 
mechanism in mitochondria (Kazak et al., 2012), which involves repair of damaged 
nucleotide base(s) (Svilar et al., 2011). Since mitochondrial BER proteins are localised at the 
IMM, BER only occurs when mtDNA is associated with the membrane (Stuart et al., 2005). 
This first requires recognition and removal of damaged base(s) by either monofunctional 
(uracil DNA glycosylase 1 – UNG1; MutY DNA glycosylase – MUTYH) or bifunctional (8-
oxoguanine-DNA glycosylase 1 – OGG1; Nth-like DNA glycosylase 1 – NTHL1; Nei-like 
DNA glycosylase 1 and 2 – NEIL1, NEIL2) DNA glycosylases. This generates an abasic site 
that is typically removed by apurinic/apyrimidinic endonuclease 1 (APE1) (Chattopadhyay et 
al., 2006). However, gaps introduced by the bifunctional glycosylases NEIL1/2 are processed 
by polynucleotide kinase/phosphatase (PNKP) (Jilani et al., 1999). Single-strand breaks are 
then repaired by either long-patch or short-batch BER. Short-batch BER occurs when a 3’-OH 
group is generated at one end of the break, with single nucleotide insertion and synthesis 
performed by POLG (Van Goethem et al., 2001), together with a 5’-phosphate. On the other 
hand, when 5’-ends are cannot be ligated, long-batch BER occurs. POLG mediated-
displacement synthesis with two or more nucleotides creates a single-strand DNA flap. Short 
flaps of eight nucleotides or less are cleaved by flap exonuclease 1 (FEN1) (Kalifa et al., 
2009). On the other hand, the ATP dependent helicase/nuclease DNA2 is required to generate 
a ‘stub’ on the end of longer flaps (Duxin et al., 2009), which can then be cleaved by FEN1. 
Following both short- and long-batch BER, the ends are ligated by the only known 
mammalian mitochondrial DNA ligase, LIG3 (Simsek et al., 2011).  
Mitochondria also possess single-strand break repair (SSBR) for when mitochondrial 
topoisomerase I (TOP1mt) fails to re-join DNA ends during replication (Zhang et al., 2001), 
ROS or from BER. SSBR involves the several of the same steps and enzymes as BER and is 
often considered a subpathway of BER (Kazak et al., 2012). Two important enzymes 
involved in mitochondrial SSBR are aprataxin (APTX) and tyrosyl-DNA-phosphodiesterase 1 
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(TDP1) (Meagher and Lightowlers, 2014). APTX cleaves a 5’ adenosine monophosphate 
(AMP) from a lesion created from abortive ligation, so a further attempt at ligation can 
proceed (Sykora et al., 2011). When TOP1mt collides with DNA and RNA polymerases, it 
can remain covalently attached to DNA (Zhang et al., 2001). Following degradation of 
TOP1mt, a 3’ phosphotyrosine bond that remains is removed by TDP1 to leave a 3’ phosphate 
that can undergo further processing for ligation (Das et al., 2010).  
It is critical that the nuclear genome possesses double-strand break repair (DSBR) 
mechanisms, but since mtDNA is a multi-copy genome it is not as equally crucial to repair 
(Kazak et al., 2012). Two key pathways of DSBR are homologous recombination - requiring 
a template sequence to exchange nucleotide sequences to repair end breaks- and non-
homologous end joining that simply requires the ligation of breaks. There is some evidence 
that mammalian mtDNA undergoes homologous recombination and non-homologous end 
joining to repair double-strand breaks (Coffey et al., 1999; D'Aurelio et al., 2004; Bacman et 
al., 2009). However, this evidence suggests that DSBR is an uncommon or minor repair 
mechanism in mammalian mitochondria (Alexeyev et al., 2013).  
Mitochondria could also possess a mismatch repair mechanism to prevent misincorporation 
and proofreading errors of nucleotides by POLG (Alexeyev et al., 2013). Although mismatch 
repair mechanisms of the nuclear genome are well characterised (Li, 2008), it is not yet clear 
in mitochondria although Y-box binding protein 1 (YBX1) has been shown to recgonise and 
have base mismatch repair activity in mitochondria (de Souza-Pinto et al., 2009).  
Mitochondrial genome replication is also dependent upon a balanced supply of all four 
deoxynucleotide triphosphates (dNTPs), derived from cytosolic and mitochondrial salvage 
pathways (Pica-Mattoccia and Attardi, 1972; Saada, 2009). Incorporation of damaged dNTPs 
represent a significant source of mismatch errors (Pursell et al., 2008). Supply of dNTPs for 
mtDNA maintenance is detailed in Chapter 5.  
1.5.7 mt-tRNA and mRNA Processing 
Following transcription, synthesised polycistronic transcripts undergo processing based 
largely upon the position and folding of the mt-tRNAs. These are excised by tRNA 
ribonuclease (RNase) Z (ELAC2) that has 3’-end cleavage activity (Brzezniak et al., 2011) 
and mitochondrial ribonuclease P (RNase P) comprising three subunits that has 5’-end 
cleavage activity (MRPP1, MRPP2, MRPP3) (Holzmann et al., 2008). This releases the 
mRNA and mt-tRNA transcripts for additional processing and modification. 
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Following mt-tRNA modification, a –CAA sequence is added to the end of the 3’-acceptor 
stem (Nagaike et al., 2001), which allows aminoacylation (charging) of the cognate mt-
tRNAs with their specific amino acid, catalysed by the corresponding mitochondrial amino-
acyl tRNA synthetase (mt-aaRS). Aminoacylation of the mt-tRNAs by the mt-aaRS is 
outlined in detail throughout Chapter 7.    
At the same time or after cleavage of the mt-tRNAs, all rRNA and mRNA transcripts are 
polyadenylated by the mitochondrial poly(A) polymerase (MTPAP) to introduce a poly(A) or 
oligo(A) extension (Slomovic et al., 2005; Bratic et al., 2016). This completes the UAA stop 
codon in seven mRNA transcripts and may stabilise some mRNAs (Ojala et al., 1981; Smits 
et al., 2010). In mammalian mitochondria, UAA or UAG are the two conventional stop 
codons for mRNA transcripts (Suzuki et al., 2011). However, human MT-COI and MT-ND6 
possess AGA and AGR stop codons, which requires the mitoribosome to promote a -1 
frameshift at these codons to allow termination with the conventional UAG codon (Temperley 
et al., 2010).    
1.5.8 Post-Transcriptional mt-tRNA Modification 
Post-transcriptional modification of mt-tRNAs at the anti-codon stem wobble-base, the first 
base of the anti-codon, is essential for the decoding, stability, folding and interaction between 
mt-tRNA and mRNA since mammalian mitochondria have a different decoding system to the 
universal code (Suzuki et al., 2011). Hence, nucleoside modification at the wobble-base is 
critical for decoding the mRNA. 
Elucidating the number of mt-tRNA modifications has been historically challenging due to 
the difficulties in isolating and mass spectrometry analysis of individual mt-tRNAs. 
Furthermore, not all modification enzymes have been characterised to date, although they are 
evolutionarily inferred. Most recently, Van Haute et al. (2016) demonstrated for the first time 
that NSUN3 was required for methylation (m5C) and formylation (f5C) in position 5 of the 
U34 wobble-base in mt-tRNAMet. The f5C modification of mt-tRNAMet had been predicted in 
humans since it is evolutionary conserved (Moriya et al., 1994; Bilbille et al., 2011), whereas 
the m5C modification was previously unknown. Nonetheless, compared with cytosolic 
tRNAs, mammalian mt-tRNAs have fewer modifications at the wobble-base (Suzuki et al., 
2011). 
Modification of the U34 wobble-base and three factors involved (MTU1, GTPBP3, MTO1) 
are discussed in 6.5.1.2.  
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1.5.9 Mitochondrial Translation 
After post-transcriptional processing, there are nine monocistronic and two dicistronic mRNA 
transcripts that are translated into proteins via three phases; initiation, elongation and 
termination (Figure 1.16). This is outlined in detail by Mai et al. (2016) and (Ott et al., 2016).  
 Initiation 
First, the mitoribosome is dissociated into its two subunits; the large 39S subunit (comprising 
50 subunits and 16S rRNA) and the small 28S subunit (comprising 30 subunits and 12S 
rRNA) (Amunts et al., 2015; Greber et al., 2015). mRNA is recruited to the 28S subunit, 
which is bound to initiation factor IF3mt to prevent re-association of the mitoribosome. Met-
tRNAMet is formylated by mitochondrial methionyl-tRNA formyltransferase (mt-FMT) to 
generate an fMet-tRNAMet species (Takeuchi et al., 2001). Since mtDNA encodes only one 
tRNAMet, fMet-tRNAMet is used for translation initiation and non-formylated Met-tRNAMet is 
required for elongation. fMet-tRNAMet is recruited by GTP-bound IF2mt to the P-site of the 
28S subunit. Correct codon:anti-codon binding causes IF3mt to be released and hydrolysis of 
the GTP-bound IF2mt, allowing re-association of the mitoribosome subunits.  
 Elongation 
Elongation of the polypeptide requires the delivery of complex comprising an aminoacylated 
mt-tRNA by the mitochondrial elongation factor Tu (mt-EFTu) and GTP. Correct codon:anti-
codon binding causes GTP hydrolysis and the release of mt-ETFu. The mt-EFTu:GTP 
complex is restored by mitochondrial translation factor Ts (TSFM) (Schwartzbach and 
Spremulli, 1989). After the release of mt-EFTu, a peptide bond is formed at the peptidyl 
transferase centre (PTC) of the 39S subunit. This leaves an uncharged mt-tRNA occupying 
the P-site and a dipeptidyl mt-tRNA at the A-site. A third mitochondrial elongation factor, G1 
(mt-EFG1), initiates a conformational change in the mitoribosome structure that causes 
translocation of the uncharged mt-tRNA to the E-site and its release from the mitoribosome, 
then translocation of the dipeptidyl mt-tRNA across three nucleotides from the A-site to the 
P-site.  
 Termination 
Elongation of the polypeptide continues until a stop codon – either UAA or UAG - at the A-
site is reached, for which a mt-tRNA is unable to bind. The stop-codon is recognised by 
mitochondrial release factor 1a (mt-RF1a), which hydrolyses the ester bond between the mt-
   
35 
tRNA in the P-site and the last amino acid of the synthesised polypeptide, thus releasing the 
polypeptide from 39S subunit (Soleimanpour-Lichaei et al., 2007). Following release of the 
polypeptide, dissociation of the mitoribosome and release of the uncharged mt-tRNA and 
mRNA occurs through two mitoribosome recycling factors; mitochondrial release factor 1 
(mt-RRF1) and mitochondrial elongation factor G2 (mt-EFG2) (Rorbach et al., 2008). 
Despite the nomenclature, the function of mt-EFG2 is restricted to mitoribosome recycling 
and not elongation (Tsuboi et al., 2009). 
 
36 
  
    
Figure 1.16 Mitochondrial Translation. Schematic showing the initiation, elongation and 
termination stages of mitochondrial translation. mt-EFG1 – mitochondrial elongation factor 
G1; mt-EFG2 – mitochondrial elongation factor G2; mt-EFTu – mitochondrial elongation 
factor Tu; mt-RF1a – mitochondrial release factor 1a; mt-RRF1 – mitochondrial ribosomal 
recycling factor 1; PTC – peptidyl transferase centre; TSFM – mitochondrial elongation factor 
Ts. Based on Mai et al. (2016) and Ott et al. (2016). 
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1.6 Mitochondrial Disease 
Mitochondrial disease encompasses a common group of clinically heterogeneous metabolic 
disorders, defined as dysfunction of the OXPHOS system due to mitochondrial genome or 
nuclear gene defects (Lightowlers et al., 2015; Alston et al., 2017). Mitochondrial 
abnormalities have also been associated with the normal process of mammalian ageing, which 
is largely based around the ‘free radical theory’ in which ROS causes mtDNA mutations 
(Harman, 1956). However, the role of mitochondria in ageing is still debated and is likely due 
to multiple processes (Payne and Chinnery, 2015). Mitochondrial dysfunction has also been 
associated with other Mendelian and age-related disorders that include Alzheimer’s disease 
(Coskun et al., 2012), Parkinson’s disease (McCoy and Cookson, 2012), amyotrophic lateral 
sclerosis (ALS) (Cozzolino and Carrì, 2012), myofibrillar myopathy (Vincent et al., 2016) 
and cardiac disease (Rosca and Hoppel, 2013). 
1.6.1 Primary mtDNA Disease 
Primary mitochondrial DNA diseases arise predominantly due to mtDNA mutations or single, 
large-scale mtDNA deletions. It is estimated that 1 in 200 individuals harbour a heteroplasmic 
pathogenic mtDNA point mutation (Chinnery et al., 2012), while the minimum point 
prevalence of adults manifesting primary mitochondrial disease is estimated at 1 in 5000, with 
1 in 9,346 individuals estimated to be at risk of developing mtDNA disease (Gorman et al., 
2015b).    
 Point Mutations and Indels 
mtDNA point mutations including small insertions or deletions (indels) are predominantly 
inherited through the maternal lineage, while the prevalence of de novo mtDNA mutations, 
usually manifesting in severe early-onset mitochondrial disease has been estimated at 24.6% 
(Sallevelt et al., 2016). Pathogenic mutations of all mtDNA genes have been reported and are 
curated in the human mitochondrial genome database MITOMAP (Lott et al., 2013; Lott, 
2016). 
LHON is the most common mtDNA disease (Gorman et al., 2015b), with m.3460G>A (MT-
ND1), m.11778G>A (MT-ND4) and m.14484T>C (MT-ND6) mutations in complex I subunit 
genes comprising over 90% of LHON patients (Yu-Wai-Man et al., 2003). These mutations 
principally manifest as visual failure in young adults due to degeneration of the retinal 
ganglion cell layer and typically sporadic or homoplasmic (Yu-Wai-Man et al., 2003). 
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However, there is incomplete penetrance of LHON mutations since only 40% of males and 
10% of females are manifest disease symptoms despite being homoplasmic for a mutation.   
Despite comprising a small proportion of the mitochondrial genome, point mutations of the 
mt-tRNAs have emerged as an important cause of mitochondrial disease (Yarham et al., 
2010). This includes the most common mtDNA mutation, m.3243A>G mutation occurring in 
MT-TL1 (mt-tRNALeu(UUR)). Initially associated with MELAS (Goto et al., 1990b), the 
m.3243A>G mutation is associated with variable, overlapping syndromes that also include 
maternally inherited deafness and diabetes (MIDD) and progressive external ophthalmoplegia 
(PEO) (Nesbitt et al., 2013).   
 Single Large-scale mtDNA Deletions 
Single large-scale mtDNA deletions are the most common primary mtDNA re-arrangement 
associated with mitochondrial disease. They are typically sporadic in comparison to mtDNA 
point mutations (Chinnery et al., 2004), with an estimated minimum prevalence of 1.5 in 
100,000 (Gorman et al., 2015b). The clinical manifestations of a large-scale deletion are 
categorised into three classic syndromes, though these are now recognised as an overlapping 
continuum of syndromes (Mancuso et al., 2015); Kearn-Sayre syndrome (KSS) (Kearns and 
Sayre, 1958; Kearns, 1965), Pearson’s syndrome (Pearson et al., 1979; McShane et al., 1991) 
and PEO to PEO-plus phenotypes (Moraes et al., 1989). PEO is a frequent manifestation in all 
three classic syndromes due to single large-scale mtDNA deletions and is discussed further in 
Chapter 3. 
Deletion size is variable but approximately one-third of patients harbour a ‘common deletion’ 
of 4,977kb (Schon et al., 1989). However, it is debated whether the size or location of the 
mtDNA deletion correlates with the clinical phenotypes (Aure et al., 2007; Yamashita et al., 
2008; Lopez-Gallardo et al., 2009). 
 Secondary multiple mtDNA deletions 
Secondary multiple mtDNA deletions of varying size and position occur predominantly due to 
mutations of nuclear gene encoding mtDNA transcription, replication and maintenance 
machinery (Kaukonen et al., 2000; Spelbrink et al., 2001; Van Goethem et al., 2001). mtDNA 
deletions have been also been shown to accumulate in post-mitotic tissue during the process 
of healthy ageing (Kraytsberg et al., 2006; Yu-Wai-Man et al., 2010b). Disorders of mtDNA 
maintenance are discussed in 1.6.2.1. 
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 Heteroplasmy and the Threshold Effect 
Since mtDNA is a multi-copy genome in eukaryotes, two or more populations of mtDNA 
harbouring a single causative mutation or large-scale rearrangements can arise. The 
phenomenon of mixed mtDNA populations is referred to as heteroplasmy (Stewart and 
Chinnery, 2015). Conversely, homoplasmy refers to a population of mtDNA that are identical.  
Some rare causative mtDNA mutations are homoplasmic, but most causative mutations are 
heteroplasmic (Lightowlers et al., 2015). Most heteroplasmic mutations occur at low levels 
and do not manifest mitochondrial disease. Thus, there is a critical threshold in which a 
minimum proportion of mutant mtDNA is necessary before biochemical and clinical features 
are exhibited, referred to as the ‘threshold effect’ (Figure 1.17) (Rossignol et al., 2003; 
Stewart and Chinnery, 2015). This threshold is variable depending on the mtDNA mutation, 
the type of mutation and the tissues harbouring mutant mtDNA.  
Figure 1.17 Heteroplasmy and the Threshold Effect. Schematic demonstrating a critical 
threshold of approximately 70%. The minimum proportion of mutant mtDNA must reach this 
threshold before biochemical and clinical features manifest. Wild-type mtDNA are shown in 
green. Mutant mtDNA are shown in red. 
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 Clonal Expansion 
The accumulation of somatic mtDNA mutations or mtDNA deletions over time in post-
mitotic tissue is known as ‘clonal expansion’. The mechanism continues to be debated, 
although there are currently three principal hypotheses. 
The first hypothesis, termed ‘survival of the smallest’, proposes a replicative advantage for 
mtDNA with larger deletions (Wallace, 1989). This hypothesis suggests that smaller mtDNA 
replicate faster than wild-type mtDNA, leading to an accumulation of deleted molecules over 
time. Although this hypothesis has been studied extensively (Diaz et al., 2002; Fukui and 
Moraes, 2009), it fails to provide an explanation for the accumulation of point mutations since 
these do not confer a replicative advantage. More recently, Campbell et al. (2014a) 
demonstrated no replicative advantage for larger deleted mtDNA molecules in skeletal muscle 
compared to wild-type mtDNA. 
The second hypothesis, termed ‘survival of the slowest’, proposes that pathogenic mtDNA 
mutations reduces the respiratory capacity of the mitochondrion, leading to lower levels of 
ROS, slower replication and slow accumulation of mtDNA damage (De Grey, 1997). Wild-
type mtDNA respire normally, which generates higher levels ROS and faster accumulation of 
mtDNA damage. Therefore, there is a selective advantage for slow replicating mtDNA 
molecules. However, this hypothesis only provides an explanation for when respiratory 
capacity has been already affected. Furthermore, it also suggests that mitotic tissue should 
accumulate a greater proportion of mtDNA deletions than post-mitotic tissue, given that 
replicative turnover is higher. 
The third hypothesis, termed ‘random genetic drift’, was developed through mathematical 
modelling and proposes that relaxed replication alone without any replicative advantage can 
lead to clonal expansion of mtDNA deletions throughout human life (Elson et al., 2001). 
Further modelling showed that this could apply to point mutations in normal human ageing 
and tumours (Coller et al., 2001; Poovathingal et al., 2009). However, the predicted levels of 
clonal expansion were not observed in aged human substantia nigra neurons (Bender et al., 
2006; Reeve et al., 2008).  
1.6.2 Mendelian Mitochondrial Disease 
The nuclear genome is estimated to encode for 1,500 proteins that are required for the 
coordination of mitochondrial processes (Lopez et al., 2000; Calvo et al., 2006). Therefore, a 
mutation of any one of these nuclear genes could cause mitochondrial disease. The minimum 
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point prevalence of nuclear mutations in diagnosed adults with mitochondrial disease is 2.9 in 
100,000, which is approximately one-third the prevalence mtDNA mutations (Gorman et al., 
2015b). Thus, a nuclear aetiology accounts for a significant proportion of mitochondrial 
disease patients.  
Nuclear mitochondrial disease obeys Mendelian inheritance, thus causative mutations can be 
dominant (heterozygous), recessive (compound heterozygous or homozygous), X-linked 
(hemizygous) or occur de novo. Reflecting the vast mitochondrial proteome and pathways 
involved, Mendelian mitochondrial disease manifests in broad phenotypic and genetic 
diversity. There are approximately 245 nuclear genes currently associated with Mendelian 
mitochondrial disease (Figure 1.18) (Mayr et al., 2015). However, this catalogue of nuclear 
defects continues to expand due to advances in DNA sequencing technologies. 
This thesis focuses on two Mendelian mitochondrial disorders characterised by extreme 
clinical and genetic heterogeneity; (i) adult-onset Mendelian mitochondrial PEO with mtDNA 
instability and (ii) early-onset mitochondrial RC deficiency. These Mendelian disorders are 
outlined in detail throughout Chapter 3, Chapter 4 and Chapter 6.  
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Figure 1.18 Genes Associated with Mitochondrial OXPHOS Defects. All mtDNA and nuclear genes associated with mitochondrial disease 
(n=281). Genes in green are associated with multiple RC deficiencies. Bold genes indicate those reported in human disease since publication of the 
Mayr et al. (2015) review. Figure courtesy of Charlotte Alston and amended from (Mayr et al., 2015).   
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 Disorders of mtDNA Maintenance 
Quantitative and qualitative defects of mtDNA maintenance have been recognised as an 
important syndromes in early- and adult-onset Mendelian mitochondrial disease (El-Hattab 
and Scaglia, 2013; Ahmed et al., 2015). Disorders of mtDNA maintenance can be classified 
into two broad groups with overlapping features; (i) autosomal recessive mtDNA depletion 
syndrome, characterised by a severe reduction in mtDNA copy number and (ii) late-onset 
mtDNA instability, characterised by multiple mtDNA deletions in post-mitotic tissues due to 
dominant or recessive mutations. These disorders are overwhelming associated with 
mutations in nuclear genes encoding mtDNA transcription, replication or maintenance 
machinery, nucleotide metabolism enzymes and nucleotide transporters (Figure 1.19) 
(Sommerville et al., 2014). 
Adult-onset Mendelian PEO with secondary, clonally expanded skeletal-muscle restricted 
multiple mtDNA deletions fits into this latter category and is discussed in Chapter 3.  
 Early-Onset Mitochondrial RC Disease 
With an estimated minimum prevalence of 1 in 5000 live births (Skladal et al., 2003), early-
onset RC disorders are amongst the most common metabolic disorders; this is discussed 
further in Chapter 6.  
Figure 1.19 Defects of mtDNA Maintenance. Schematic showing the major proteins 
associated with mtDNA maintenance disorders. Adopted and amended from Sommerville et 
al. (2014).   
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1.6.3 Diagnostic Algorithm in Mitochondrial Disease 
The diagnosis of mitochondrial disease requires a multidisciplinary approach that combines 
clinical characteristics, histopathological, biochemical and genetic investigations, for which a 
diagnostic algorithm has been devised (Figure 1.20) (McFarland et al., 2010). 
Despite the vast clinical heterogeneity of mitochondrial diseases, precedent exists for which 
targeted mtDNA or nuclear gene screening can be performed based on clinical features alone. 
For example, visual failure in a young adult may prompt targeted sequencing of the three 
LHON mtDNA mutations (Yu-Wai-Man et al., 2003), while the classic MELAS phenotype 
evokes screening for the common m.3243A>G mutation (Nesbitt et al., 2013).   
Nonetheless, paramount to the diagnosis of mitochondrial disease for almost all patients is the 
requirement for clinically affected tissue samples, which is often skeletal muscle but can also 
include liver, brain or cardiac tissue if available. Available tissue can be subject to 
histopathological and biochemical analyses to direct the future diagnostic actions. 
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Figure 1.20 Current Diagnostic Algorithm for Investigating Mitochondrial Disease. Despite the increasing number of mtDNA and nuclear gene 
mutations associated with mitochondrial disease and advances in investigative tools and techniques, the diagnostic algorithm for the investigation of 
mitochondrial disease published in 2010 still holds true. Adopted from McFarland et al. (2010). 
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 Histopathology 
Two common stains used are haematoxylin and eosin (H&E) and modified Gomori trichrome. 
H&E is a general stain for observing muscle fibre morphological abnormalities (Figure 
1.21A). Modified Gomori trichrome stain is used to detect the presence of ‘ragged red fibres’ 
(Gomori, 1950; Engel and Cunningham, 1963), characterised by the abnormal 
subsarcolemmal accumulation of mitochondria, which indicates mitochondrial proliferation. 
The standard histochemical assay used is sequential cytochrome c oxidase/succinate 
dehydrogenase (COX-SDH) histochemistry (Figure 1.21A) (Old and Johnson, 1989; Sciacco 
and Bonilla, 1996), which can visualise RC activities for complex IV and II. Global or mosaic 
patterns of COX-deficiency can be visualised by the presence of blue fibres, which can occur 
due to mtDNA defects or nuclear mutations. A mosaic pattern of COX-deficiency is typically 
associated with mtDNA mutations, often due to heteroplasmy and the multi-copy nature of 
mtDNA. However, COX-deficient fibres are also noted in other neuromuscular diseases and 
can be observed as part of the normal ageing process (Greaves et al., 2011; Vincent et al., 
2016).   
The disadvantage of sequential COX-SDH histochemistry is that it does accommodate 
activities of the other RC complexes, particularly complex I which is the one of the most 
commonly affected enzymes of the OXPHOS system (Loeffen et al., 2000). Recently, a novel 
quadruple immunofluorescence assay has been developed for the quantification of complex I 
and IV abundance in individual skeletal muscle fibres using monoclonal antibodies for 
NDUFB8 and MT-COI, together with VDAC1/porin as a mitochondrial mass marker and 
laminin as a marker of myofibre boundaries (Figure 1.21B) (Rocha et al., 2015). It has been 
demonstrated as accurate and reproducible in a large proportion of muscle fibres from range 
mitochondrial disease patients with mtDNA and nuclear genetic defects, thus showing 
promise in aiding the diagnostic process. 
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Figure 1.21 Histopathological Techniques in the Diagnosis of Mitochondrial Disease. Panel demonstrating sections of (A) current standard 
histopathology techniques in skeletal muscle from a patient harbouring a single large-scale mtDNA deletion, which show ragged red fibres and COX-
deficient fibres; (i) H&E and (ii) modified Gomori trichrome stain, (iii) COX, (iv) SDH and (v) sequential (merged) COX-SDH reactions. Panel 
demonstrating sections from the same patient subjected to the novel quadruple immunofluorescence assay for the quantification of complex I and IV 
protein abundance; (i) laminin is used as a marker of myofibre boundaries, quantification of (ii) NDUFB8 (complex I), (iii) MT-COI (complex IV) and 
(iv) VDAC1/porin, plus (v) a merged image. Adopted and amended from Alston et al. (2017).   
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  Biochemistry 
In vitro spectrophotometric biochemical assays for measuring the activity of each individual 
RC complex in muscle relative to activity of the matrix enzyme citrate synthase in frozen 
muscle is an essential diagnostic method, particularly in suspected early-onset mitochondrial 
disorders (Kirby et al., 2007). However, assays require a significant quantity of muscle 
(>50mg) and complex V cannot be reliably measured in frozen muscle.  
 Genetic and Molecular Studies 
Genetic investigations and the order of sequenced mutations or genes is dependent upon the 
clinical, histochemical and biochemical findings. Rapid whole mitochondrial genome 
sequencing using next generation sequencing (NGS) that can also accurately measure 
heteroplasmy may be considered in a significant proportion of patients following exclusion of 
common mtDNA mutations (Tang et al., 2013). Targeted Sanger sequencing of a subset of 
known causative nuclear genes is also routinely performed following exclusion of mtDNA 
mutations. This includes mutational screening of nuclear genes involved mtDNA maintenance 
or mitochondrial translation in patients with multiple RC deficiency in affected tissues, or RC 
enzyme complex subunits and assembly factors for patients with isolated RC deficiency. 
Segregation studies are also integral to confirming maternal inheritance of a causative 
mtDNA mutation and the carrier status of unaffected and affected relatives of the proband. 
This is not always feasible however, especially in late-onset patients where access to DNA 
from parents or relatives is frequently a challenge. 
Regarding mtDNA maintenance disorders, quantitative real-time PCR of muscle DNA is used 
to determine relative mtDNA copy number (Dimmock et al., 2010; Venegas and Halberg, 
2012). Single large-scale mtDNA deletion and multiple mtDNA deletions are typically 
detected by long range PCR or occasionally be Southern blotting (Figure 3.1C and D). The 
presence of multiple mtDNA deletions, depletion or both would allow a mutational screening 
of a subset of known causative nuclear genes associated with mtDNA maintenance disorders. 
(El-Hattab and Scaglia, 2013; Ahmed et al., 2015). 
1.7 Applications of DNA Sequencing and the Emergence of Next Generation Sequencing 
(NGS) Technologies 
The advance of human society has been greatly enriched by the ability to sequence the genetic 
code, comprising of just four dNTPs, that dictates the vast diversity of all life on Earth. The 
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power of DNA sequencing has led to landmark discoveries and outcomes, including the 
discovery of non-coding RNAs (Eddy, 2001), estimation of evolutionary trees (Felsenstein, 
1981) and of course, sequencing of the mitochondrial genome (Anderson et al., 1981). 
1.7.1 First-Generation Sequencing   
Many of the first seminal discoveries to date have relied upon ‘first-generation’ DNA 
sequencing methodologies. The earliest such methodologies were largely chemical based, 
including Maxam and Gilbert sequencing, which used four chemical cleavage reactions 
(Maxam and Gilbert, 1977). However Sanger sequencing, also known as chain-termination 
sequencing, was adopted over the Maxam and Gilbert methodology and continues to be used 
today. Developed by the Nobel Laureate Frederick Sanger almost four decades ago (Sanger et 
al., 1977b), the initial Sanger sequencing protocol was essentially a modified PCR reaction 
that relied upon a DNA polymerase, DNA primers, dNTPs and modified di-dNTPs (ddNTPs) 
for termination of DNA synthesis and a single-stranded DNA (ssDNA) template. The ssDNA 
was fragmented into short single-stranded DNA (ssDNA) of varying lengths and added to 
four reaction mixtures comprising each of the dNTPs and ddNTPs. These short ssDNA 
fragments were amplified and terminated with radio-labelled ddNTPs, with each of the four 
reaction mixtures then separated by length through a polyacrylamide radiograph gel. This gel 
was then visualised by x-ray, with dark bands in the gel representing each base. Thus, the 
nucleotide sequence was manually read from the top to bottom. Sanger sequencing was 
enhanced by the development of automation technologies, which instead relied upon 
fluorescently labelled ddNTPs that were excited with a laser and the emitted colour recorded, 
corresponding to one of the four bases. Using this chain-termination chemistry the first full 
genome, bacteriophage phi X174, was sequenced (Sanger et al., 1977a).  
Sequencing continued to be enhanced over the following decades thanks to the development 
of PCR for amplification of short DNA fragments, thermal cyclers and discoveries of heat-
resistant polymerases including Taq from Thermus aquaticus (Saiki et al., 1985; Smith et al., 
1986; Saiki et al., 1988). This also included development of the first automated sequencer, the 
ABI 370 by Applied Biosystems, allowing all four necessary reactions to be contained within 
a single mixture (Prober et al., 1987). Computer processing power and storage capabilities 
also increased dramatically throughout the 1980s and 90s. For the curation of millions of 
DNA sequences generated, the GenBank database was established in 1982 as an open-access, 
publically available source of nucleotide and amino acid sequences (Benson et al., 2013). 
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Updated every 2 months, GenBank grows exponentially with each release (Benson et al., 
2013). 
Despite continued improvements, Sanger sequencing was only able to sequence short DNA 
reads. For sequencing of larger DNA regions such as whole chromosomes or genomes, high-
throughput methods including shotgun de novo sequencing was developed. This initially 
involved randomly fragmenting DNA into short reads by sonification, cloning the fragments 
into a plasmid vector and transformation into a host organism including E. coli, which then 
incorporated Sanger sequencing of the short reads (Shendure and Ji, 2008). The first genome 
to be sequenced using this strategy was the cauliflower mosaic virus (Gardner et al., 1981). 
Following the advent of PCR (Saiki et al., 1985; Saiki et al., 1988), fragmented DNA could 
be amplified with paired primers flanking the target. This became known as pairwise-end 
reading and allowed for more accurate alignment with the DNA fragment. This approach was 
utilised to sequence the first free-living organism, Haemophilus influenza (Fleischmann et al., 
1995). 
Shotgun sequencing was also the strategy of choice for sequencing of the human genome 
throughout the 1990s and early 2000s. Initiated by the international collaborative Human 
Genome Project (HGP) in 1990, this kick-started a race between the publically-funded HGP 
and private-funded Celera Corporation founded by Craig Venter. The outcome was the 
publication of the draft human genome in 2001 (Lander et al., 2001; Venter et al., 2001), 
followed by the declaration of completion in 2003 and publication in 2004 (Human Genome 
Sequencing, 2004; Schmutz et al., 2004). Key findings were that the human genome 
contained far less protein-coding genes than anticipated, ranging from 19,000 to 23,000, and 
the prevalence of large segmental duplications that constituted the remaining gaps. Expected 
to herald a new era in precision medicine, over a decade on from publication of the draft 
sequence the legacy of the first human genome sequencing efforts continue to be debated 
(Lander, 2011). 
1.7.2 Second-Generation Sequencing  
Although the first complete human genome was sequenced ahead of time and under-budget, 
the sequencing cost in 2001 was estimated at approximately $100 million (Figure 1.22) 
(Wetterstrand, 2016). It became clear that novel technologies were essential for rapid high-
throughput sequencing with significant reductions in production costs. While revolutionary, 
Shotgun sequencing was not fit for purpose, but served as the precursor for all next-generation 
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sequencing (NGS) technologies used today. These new technologies were termed ‘second-
generation’ DNA methodologies (Shendure and Ji, 2008). Although it is necessary for DNA 
fragments to be shorter in length (50-150bp) than for Sanger sequencing, single or paired-end 
reads can be rapidly quantified compared with the previous shotgun approach. 
The first commercially available NGS platform was 454 Pyrosequencing from Life Sciences 
(now Roche) (Roche, 2016), also known as ‘sequencing by synthesis’ (Rothberg and Leamon, 
2008). 454 Pyrosequencing was based on emulsion PCR, a common genomic library 
preparation tool still used today, in which denatured ssDNA are compartmentalised in water 
droplets on beads in a water-in-oil emulsion (Kanagal-Shamanna, 2016). Performed on a 
microtiter plate (Margulies et al., 2005), incorporation of one complementary dNTP at a time 
released pyrophosphate that emitted a unique wavelength detectable by the sequencer, 
allowing automated reading of a wavelength trace generated (Rothberg and Leamon, 2008). 
This platform was used to sequence the second human genome, of James Watson, more 
rapidly and at a much reduced cost compared to Shotgun sequencing (Wheeler et al., 2008). 
This ‘sequence-by-synthesis’ approach is similar to that of Illumina NGS platforms (also 
referred to as Solexa platforms) used today. In contrast to 454 Pyrosequencing, Illumina 
platforms use ‘bridge amplification’ for library preparation (Adessi et al., 2000; Fedurco et 
al., 2006). DNA fragments are flanked by adaptors ligated to each end and denature to form 
ssDNA. These are added to a ‘flow cell’ with corresponding fixed adaptors that bind to one 
end of the ssDNA fragments. Fragments are elongated by PCR with the terminus adaptors 
‘bridging’ (binding) to their corresponding fixed adaptor. Strands are denatured and further 
Figure 1.22 Cost Per Genome Since 2001. The cost of sequencing one human genome has 
fallen dramatically since 2001 and does not follow Moore’s Law. Adopted from Wetterstrand 
(2016). 
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cycles proceed to generate clusters of DNA for sequencing. Fragments undergo single-base 
extension with chemically-cleavable fluorescent-labelled dNTPs with distinct emissions that 
can be imaged (Turcatti et al., 2008). Cleavage of the modified dNTPs allows further single-
base extensions and imaging to occur to determine the nucleotide sequences. Currently, the 
most popular Illumina NGS genetic analysers used are the HiSeq and MiSeq systems 
(Illumina, 2016). 
ThermoFisher Scientific and Applied Biosystems market a third NGS platform, referred to as 
‘Sequencing by Oligo Ligation and Detection’ (SOLiD) (Life Technologies, 2016). Library 
preparation previously used emulsion PCR, similar to that of 454 Pyrosequencing. More 
recently, the SOLiD platform switched to ‘Wildfire technology’ with amplification using a 
flowchip with fixed adaptors for hybridisation of DNA fragments and pair-wise amplification 
(Ma et al., 2013). Moreover, the SOLiD platform uses a DNA ligase instead of a DNA 
polymerase for amplification, with the fluorescence emitted from repeated cycles of ligation 
and extension that can be read to determine the fragment sequences (Shendure and Ji, 2008).  
The advent of second-generation sequencing has seen the cost of sequencing one human 
genome fall dramatically over the past 15 years, with the current cost estimated at just over 
$1000 (Wetterstrand, 2016). Moore’s Law states that the number of transistors per square inch 
on an integrated circuit doubles approximately every 2 years and hence, computing power is 
increased (Moore, 1998). Therefore the technological costs decrease, although there is 
expected to be a physical limitation to Moore’s Law that could soon be reached. The cost of 
genome sequencing has significantly outpaced the cost predicted by Moore’s Law since early 
2008 when second-generation sequencing began to reach the fore-front of genomics (Figure 
1.22). Nonetheless, the sequencing cost per human genome is still economically unviable for 
many public-funded research institutes and groups, who seek other cost-effective alternatives. 
1.7.3 Whole Exome Sequencing (WES) 
One of the NGS platforms developed in the mid-2000s provided such opportunities as a cost-
effective, targeted tool of coding variation only, termed ‘whole exome sequencing’ (WES).  
Since it has been estimated that protein-coding changes in the coding regions (exons) of the 
account for 85% for human Mendelian disorders, the potential use of WES in the diagnosis of 
Mendelian disease has been widely recognised (Choi et al., 2009; Ng et al., 2010; Bamshad et 
al., 2011). The first diagnoses attained by WES were a novel homozygous SLC26A3 missense 
mutation in a patient with a differential diagnosis of Bartter Syndrome (Choi et al., 2009) and 
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an X-linked XIAP missense mutation in a young patient who presented with inflammatory 
bowel disease (Worthey et al., 2011). Identification of the causative XIAP mutation was 
seminal in guiding therapeutic strategies, in this case an allogeneic hematopoietic progenitor 
cell transplant that greatly improved quality of life for the patient (Worthey et al., 2011).  
Aside from costs, WES has been an attractive tool in Mendelian disease diagnosis compared 
with whole genome sequencing (WGS) or virtual targeted gene panel approaches (Figure 
1.23). 
The basic workflow for WES is described by Bamshad et al. (2011) and is performed using 
hybridisation exome-capture kits, which include the TruSeq and Nextera Rapid Exome 
Capture kits used in this thesis (Illumina, 2016). Genomic DNA is fragmented to create a 
shotgun library. Fragments are flanked with adapters and subjected to aqueous-phase 
hybridisation capture, in which fragments enriched with exons are hybridised to biotinylated 
DNA baits in the presence of blocking oligonucleotides. Hybridised fragments are recovered 
by streptavidin-based pulldown. These fragments are then amplified using bridge 
amplification for library preparation and ‘sequencing by synthesis’ using the Illumina HiSeq 
or MiSeq genetic analysers. These hybridisation-based exome capture kits require a relatively 
substantial quantity of genomic DNA for exome sequencing, approximately 2-3µg (Rykalina 
et al., 2014).  
Figure 1.23 Comparison of WGS, WES and Targeted Gene Panel Approaches. A 
schematic comparing WGS, WES and targeted gene panel approaches to the diagnosis of 
Mendelian disease. Individual boxes represent one exon. Blue, green and red exon(s) 
represent distinct genes. Grey and dashed boxes represent introns.     
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Since it has been estimated that protein-coding changes in the coding regions (exons) of the 
genome account for 85% for human Mendelian disorders, the potential use of WES in the 
diagnosis of Mendelian disease has been widely recognised (Choi et al., 2009; Ng et al., 
2010; Bamshad et al., 2011). The first diagnoses attained were a novel homozygous SLC26A3 
missense mutation in a patient with a differential diagnosis of Bartter Syndrome (Choi et al., 
2009) and an X-linked XIAP missense mutation in a young patient who presented with 
inflammatory bowel disease (Worthey et al., 2011). Identification of the causative XIAP 
mutation was seminal in guiding therapeutic strategies, in this case an allogeneic 
hematopoietic progenitor cell transplant that greatly improved quality of life for the patient 
(Worthey et al., 2011). 
Although WES has been demonstrated as an effective diagnostic and research tool, there has 
been continued challenges regarding the assessment of identified variants. The identification 
of ‘variants of unknown significance’ (VUS), defined as a non-informative variants that could 
be associated with human pathology but lack additional evidence, such as segregation studies 
or functional validation, to confirm pathogenicity. Similarly, the identification of all protein-
coding changes raises ethical concerns regarding ‘incidental’ or ‘secondary’ findings. Such 
findings are typically unrelated to the primary genetic investigations but could be variants 
associated with increased risk of developing certain cancers, including in BRCA1 or BRCA2 
genes (Levy-Lahad and Friedman, 2007), or drug metabolism (Yu et al., 2014). Guidance and 
opinion on the return of genetic findings to patients including secondary findings continue to 
be fiercely debated (Bennette et al., 2013; Yu et al., 2014; Roche and Berg, 2015), including 
whether such findings are clinically relevant to the primary investigations, medically 
actionable or if additional family members could also be at risk. Ultimately, the definition of 
secondary findings and the actions taken by the clinicians are likely to be determined on a 
‘case-by-case’ basis.  
WES also provides some technical challenges in identifying potentially pathogenic mutations. 
WES is dependent on PCR-amplification steps to create a shotgun library from fragmented 
DNA that aims to provide adequate coverage of the genome (Bamshad et al., 2011). 
However, this can often lead to poor or uneven coverage, especially in GC-rich regions and 
because read lengths are typically short (Kozarewa et al., 2009; Veal et al., 2012). Short read 
lengths and poor or uneven coverage can also prevent the detection of large genomic 
rearrangements, expanded or triplet repeats, which are often implicated in neurological 
diseases (Orr et al., 1993; Campuzano et al., 1996; Walker, 2007). 
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Nonetheless, WES has emerged as a cost-effective targeted NGS tool with the potential to 
transform the diagnostic algorithm for mitochondrial disorders. The use of WES in the 
diagnosis of adult-onset mtDNA maintenance disorders and early-onset RC disease is 
discussed in Chapter 4 and Chapter 6.  
1.8 Aims and Objectives 
Over the past decade, NGS sequencing technologies have rapidly become part of the 
clinicians and researchers toolkit in the diagnosis and investigation of human disease. 
Mendelian mitochondrial disease is no exception, providing diagnoses for a significant 
proportion of patients while also identifying novel genes associated with this complex 
disease. Owing to the broad phenotypic and genetic heterogeneity of adult-onset PEO with 
multiple mtDNA deletions and early-onset RC disease, many patients remain without a 
genetic diagnosis following routine diagnostic investigations. Hence, NGS technologies 
including WES offer new opportunities to elucidate the genetic aetiology. This thesis seeks to 
take advantage of WES in a diagnostic and research orientated approach to mitochondrial 
diseases, specific to adult-onset Mendelian PEO with multiple mtDNA deletions and early-
onset RC deficiency. 
First, the clinical, molecular and genetic characteristic of all published patients with adult-
onset Mendelian PEO and mtDNA instability will be systematically reviewed. The 
phenotypic spectrum of this mitochondrial disorder is poorly characterised and has not been 
previously reviewed. Such a systematic review of all known nuclear gene defects aims 
delineate the reported phenotypes and to identify genotype-phenotype correlations, where 
possible. 
Secondly, the findings from this systematic review will be used to develop a custom variant 
filtering strategy for WES analysis and will be applied to a cohort of patients with clinically 
well-defined, genetically undetermined Mendelian PEO with multiple mtDNA deletions. The 
systematic review findings will help direct the category of gene variants that will be filtered 
for and will assist in the prioritisation of candidates. 
Simultaneously, a second custom WES filtering strategy for patients with early-onset RC 
deficiency will be developed and applied to a cohort of undiagnosed patients. It is anticipated 
that this filtering strategy will differ from that used for the first cohort, but should nonetheless 
be effective in prioritising the causative variants. 
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For all causative or putative causative variants, Sanger sequencing will be performed to 
provide confirmation of variants identified. Critically, segregation studies of unaffected and 
affected family members will also be performed, where possible, to confirm carrier status. 
This will be especially pertinent for parents and families with affected children, for which 
confirmation of the causative variants could inform future reproductive options. 
Finally, known and novel candidate gene variants identified from both patient cohorts will be 
characterised, depending on the availability of patient tissue for study. This includes skeletal 
muscle, fibroblasts (skin cells) using techniques to investigate the effect on mitochondrial 
physiology and function. Where possible, in vitro and in silico tools plus models will be 
incorporated to complement laboratory studies. 
Overall, this thesis aims to demonstrate the use of WES in the diagnosis and investigation of 
mitochondrial diseases with extreme clinical and genetic heterogeneity, with the use of 
appropriate filtering and prioritisation strategies.
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
ABI 3130xl Genetic Analyser Applied Biosystems 
Analogue Tube Roller, SRT6 Stuart 
Autoclave Astell 
Balance, AR3130 Ohaus 
Benchtop Centrifuge 5417R (Refrigerated)  Eppendorf 
Benchtop Centrifuge 5418 Eppendorf 
Benchtop Centrifuge 5804 Eppendorf 
Benchtop Centrifuge U-32 Boeco 
BH-EN-2004 Class II Microbiological Safety 
Cabinet 
Faster 
Biopipette 8 Channel Pipette, 1-10µl Labnet 
Cellometer Auto 1000 Nexcelom Bioscience 
ChemiDoc MP Imaging System Bio-Rad 
CO2 Cell Culture Incubator, MCO-18AIC Panasonic 
Dry Heat Block Techne 
GeneAmp PCR System 9700 Applied Biosystems 
Leica DM IL LED Microscope Leica 
Magnetic Stirrer, RCT Basic IKA 
Magnetic Stirring Bars Camlab 
Microcentrifuge, Technicomini Griffin Education 
Mini Electrophoresis Blotting System Hoefer 
Mini-Protean Tetra Cell System Bio-Rad 
Mini Trans-Blot Cell System Bio-Rad 
NanoDrop Spectrophotometer, ND-1000 Thermo Scientific 
NANOpureII Water Purification System Barnstead 
Nikon A1R Resonant Scanning Confocal System Nikon Instruments 
Orbital Shaker SSL1 Stuart 
PCR UV Cabinet Bioair Instruments 
PerfectBlue Maxi Gel System M PEQLAB 
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Pestle and Mortar CoorsTek 
pH Meter 3510 Jenway 
Pipette Controller StarLab 
Power Supply, 250 Volts Cleaver Scientific 
SpectraMax M5e Multimode Plate Reader Molecular Devices 
StepOnePlus™ Real-Time PCR System Applied Biosystems 
Stirrer, Ceramic Plate U151 Stuart 
Ultra-Turrax Homogeniser, T25 IKA 
Ultra-Turrax Homogeniser, T8 IKA 
Vacusafe Aspiration System Integra 
Veriti 96 Well Thermal Cycler Applied Biosystems 
Vortex Genie 2 Scientific Industries 
Vortex IR  StarLab 
2.1.2 Consumables 
-Dish, 35mm, High, ibiTreat iBidi 
24-Well PCR Plate, Non-Skirted, Elevated Wells StarLab 
8-Strip PCR Caps, Domed StarLab 
90mm Petri Dish, Sterile Thermo Scientific 
96-Well PCR Plate, Semi-Skirted, Clear 4titutde 
96-Well PCR Plate, Semi-Skirted with Raised 
Rim 
StarLab 
Advanced Polyolefin StarSeal, X-Clear StarLab 
Aluminium Foil Terinex 
Aluminium StarSeal StarLab 
Autoclave tape Fisher Scientific 
Cellstar Falcon Tubes (15ml, 50ml) Greiner Bio-One 
Cellstar Aspirating Pipette, 2ml  Greiner Bio-One 
Cellstar Disposable Pipettes (5ml, 10ml, 25ml)  Greiner Bio-One 
Cellstar Tissue Culture Flasks (25cm2, 75cm2) Greiner Bio-One 
Chromatography Paper, 3mm Whatman 
CryoPure Tubes Sarstedt 
DNeasy Blood and Tissue Kit Qiagen 
FrameStar Break-A-Way 96 wells, Clear Tubes, 4titutde 
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Blue Frame 
Gloves StarLab 
Immun-Blot PVDF Membrane Bio-Rad 
MicroAmp® Fast Optical 96-Well Reaction Plate 
with Barcode, 0.1ml 
Applied Biosystems 
Microfuge Tubes (0.6ml, 1.5ml, 2ml) StarLab 
Nunc Cryotube Vials Thermo-Scientific 
Parafilm, Pre-Cut M 
Pasteur Pipette, 3ml StarLab 
Performa® DTR V3 96-Well Short Plate Kit EdgeBio 
Sarogold Pro Food Wrap Sarogold 
Scalpel Swan-Morton 
Stericup-GP, 0.22µm, Polyethersulfone, 500ml, 
Radio Sterilised 
Merick-Millipore 
Syringe Filter Unit, 0.22µm, Polyethersulfone, 
33mm, Gamma Sterilised 
Millex 
Syringes Without Filters, 1ml BD Plastipak 
2.1.3 Solutions 
Ammonium Persulphate (APS), (w/v) 10% 1g APS 
Dissolve in 10ml ddH2O 
Bromophenol Blue, 1% (w/v) 100mg Bromophenol Blue 
Dissolve in 10ml ddH2O 
Cell Lysate Buffer 500µl 1M Tris-HCl, pH 7.5 
600µl 2M NaCl2 
20µl 1M MgCl2 
100µl Triton X-100 
1X EDTA protease inhibitor cocktail 
tablet 
Top-up to 10ml with ddH2O 
Aliquot and store at -20OC 
Before use, add 1µl 100mM PMSF per 
100µl cell lysate buffer 
Dithiothreitol (DTT), 1M 0.308g DTT  
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Dissolve in 2ml ddH2O 
DNA Loading Buffer 0.25% (w/v) Bromophenol Blue 
0.25% (w/v) Xylene Cyanol 
30% (v/v) Glycerol 
Electrophoresis Buffer 900ml ddH2O 
100ml TAE, 1X 
Laemmli Buffer, 4X 4ml 50% (v/v) Glycerol  
0.8g SDS 
5ml 0.5M Tris-HCl, pH 6.8 
0.25% (w/v) Bromophenol Blue 
0.25% (w/v) Xylene Cyanol 
Make up to 10ml  
Aliquot and store at room temperature 
Before use, add 1µl 1M DTT per 
100µl Laemmli buffer (4X) 
Laemmli Buffer, 5X 4ml 1.5M Tris-HCl, pH 6.8 
1ml 1% Bromophenol Blue 
10ml Glycerol 
2.0g SDS 
5ml β-Mercaptoethanol 
Aliquot and store at -20OC 
Magnesium Chloride (MgCl2), 1M 0.203g MgCl2 
Dissolve in 1L ddH2O 
Phenylmethylsulphonyl Fluoride (PMSF), 100mM 192mg PMSF 
Dissolve in 10ml Isopropanol 
Phosphate Buffered Saline (PBS), 1X, pH 7.4 1X PBS tablet 
Dissolve in 200ml 
Ponceau S Staining Solution 1g Ponceau S 
50ml Acetic Acid 
Make up to 1L with ddH2O  
Protease Buffer 10ml RIPA Buffer 
1X EDTA protease inhibitor cocktail 
tablet 
100µl PMSF 
Radioimmunoprecipitation Assay (RIPA) Buffer 250µl 10% SDS 
   
61 
 
0.125g Sodium Deoxycholate 
250µl 100% Igepal 
375µl Triton-X 100 
16.47µl β-Mercaptoethanol 
Make up to 25ml in 1X PBS 
Running Buffer (Western Blot), 10X 30g Trisma Base 
144g Glycine 
10g SDS 
Make up to 1L with ddH2O 
Sodium Dodecyl Sulphate (SDS), (w/v) 10 % 1g SDS 
Make up to 10ml with ddH2O 
Tris-Acetate-EDTA (TAE) Buffer, 10X 48.4g Trisma Base 
11.42ml Glacial Acetic Acid 
20ml 500mM EDTA pH 8.0 
Make up to 1L with ddH2O 
Tris-Acetate-EDTA (TAE) Buffer, 1X 100ml 10X TAE 
Make up to 1L with ddH2O 
Tris-Buffered Saline and Tween-20 (TBST), 5X, 
pH 7.6 
60.5g Trisma Base 
45g NaCl 
2.5ml Tween-20 
Make up to 800ml with ddH2O 
Adjust to pH 7.6 with concentrated 
HCl 
Top-up to 1L  
Transfer Buffer (Western Blot), 10X 30.3g Trisma Base 
144g Glycine 
Dissolve in 1L ddH2O 
Tris-HCl, 0.5M, pH 6.8 6.06g Trisma Base 
Make up to 100ml with ddH2O 
Adjust to pH 6.8 with concentrated 
HCl 
Tris-HCl, 1M, pH 7.5 12.13g Trisma Base 
Make up to 100ml with ddH2O 
Adjust to pH 7.5 with concentrated 
HCl 
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Tris-HCl, 1.5M, pH 6.8 18.18g Trisma Base 
Make up to 100ml with ddH2O 
Adjust to pH 6.8 with concentrated 
HCl 
Tris-HCl, 3.75M, pH 8.5 45.45g Trisma Base 
Make up to 100ml with ddH2O 
Adjust to pH 8.5 with concentrated 
HCl 
2.1.4 Chemicals and Reagents 
Ethanol, 100%  Fisher Chemical 
Liquid Nitrogen BOC 
Methanol, 100% Fisher Chemical 
2.1.5 Polymerase Chain Reaction (PCR) Reagents 
Colorless GoTaq Flexi Buffer, 5X Promega 
Colorless GoTaq Reaction Buffer, 5X Promega 
Deoxyribonucleotide Triphosphate (dNTP) Mix, 
2mM 
Bioline 
dNTP Mixture, 2.5mM TaKaRa 
GoTaq G2 DNA Polymerase, 5U µl-1 Promega 
GoTaq G2 Hot Start Polymerase, 5U µl-1 Promega 
MgCl2 Solution, 25mM Promega 
PrimeSTAR GXL DNA Polymerase, 1.25U µl-1 TaKaRa 
PrimeSTAR GXL Buffer, 5X TaKaRa 
2.1.6 Sanger Sequencing Reagents 
BigDye Terminator v3.1 Cycle Sequencing Kit Applied Biosystems 
Exonuclease I, 20U µl-1 Thermo Scientific 
Thermosensitive Alkaline Phosphatase (TSAP) Promega 
2.1.7 Tissue Culture Reagents 
Dialysed Foetal Bovine Serum (DBS) Sigma-Aldrich 
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Dulbecco's Modified Eagle Medium (DMEM) Gibco 
Dulbecco's Phosphate-Buffered Saline (DPBS) Gibco 
Ethidium Bromide, 10mg ml-1 Sigma-Aldrich 
Foetal Bovine Serum (FBS) Gibco 
Gentamicin, 50mg ml-1 Gibco 
GlutaMAX Supplement, 100X Gibco 
L-Glutamine, 2mM Gibco 
Minimum Essential Medium (MEM) Gibco 
MEM Non-essential Amino Acid Solution (100X) Sigma-Aldrich 
MEM Vitamin Solution, 100X Gibco 
Penicillin and Streptomycin Solution Gibco 
PBS, 1X Gibco 
Picogreen  Life Technologies 
Skeletal Muscle Cell Growth Medium (SMGM) PromoCell 
Sodium Pyruvate, 100mM Gibco 
Tetramethylrhodamine Methyl Ester (TMRM), 
25mg 
Invitrogen 
TrypLE Express Enzyme (1X), Phenol Red Gibco 
Uridine Sigma-Aldrich 
2.1.8 Gel Electrophoresis Reagents 
Agarose (Molecular Grade) Bioline 
1Kb DNA Ladder, 0.1µg µl-1 Promega 
SYBR Safe DNA Gel Stain, 10,000X Invitrogen 
2.1.9 SDS-Page and Western Blot Reagents 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Acrylamide/Bis-acrylamide, 30%, 29:1 NBS Biologicals 
Benzonase Nuclease, Purity >90% Merck Millipore 
Clarity Western ECL Substrate Bio-Rad 
Glycine Sigma-Aldrich 
Marvel Dried Skimmed Milk Powder Marvel 
Polysorbate 20 (Tween 20) Acros Organics 
Ponceau S Sigma-Aldrich 
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SuperSignal West Pico Chemiluminescent 
Substrate 
Thermo Scientific 
Trisma Base Sigma-Aldrich 
2.1.10 Molecular Reagents 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
Pierce Bovine Serum Albumin Standard, 2mg ml-1 Thermo Scientific 
Protein Assay Dye Reagent Concentrate Bio-Rad 
Spectra Multicolor Broad Range Protein Ladder  Thermo Scientific 
2.1.11 Software 
Alamut Interactive Biosoftware 
Discovery Studio Visualiser (Version 4.1) Accelrys Software Incorporated 
FinchTV (Version 1.4.0) Geospiza Incorporated 
Foundation Data Collection (Version 3.0) Applied Biosystems 
IBS: Illustrator for Biological Sequences (Version 
1.01) 
The CUCKOO Workgroup 
ImageJ (Version 1.48) Open Source 
Image Lab (Version 4.0.1) Bio-Rad 
Mutation Surveyor SoftGenetics 
NIS-Elements Viewer (Version 4.2) Nikon 
Prism 5 (Version 5.02) GraphPad Software Incorporated 
SeaView (Version 4.5.3) Manolo Gouy  
Laboratoire de Biometrie et Biologie 
Evolutive 
CNRS / Universite Lyon I 
StepOne Sofware (Version 2.1) Applied Biosystems 
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2.2 Patients 
2.2.1 Recruitment of Patients 
Patients were recruited via the NHS Highly Specialised Service for Rare Mitochondrial 
Disorders and the NHS Highly Specialised Mitochondrial Diagnostic Service in Newcastle 
upon Tyne (NHS Highly Specialised Service for Rare Mitochondrial Disorders, 2016). The 
research undertaken was approved by the NHS Research Ethics Committee (REC) under 
references 16NE/0267 and 8061. Patient and control tissue samples were obtained from the 
Diagnostic laboratory via a tissue and DNA request form. 
2.2.2 Ethical Guidelines 
All procedures were approved and performed under the ethical guidelines of the NHS Highly 
Specialised Mitochondrial Diagnostic Service and with the Helsinki Declaration of 1975, as 
revised in 2000. Informed consent had been previously obtained from patient and/or guardians 
for research purposes.  
2.2.3 Diagnostic Investigations 
Unless stated, all recruited patients underwent clinical, histochemical, molecular and genetic 
investigations performed by the NHS Highly Specialised Mitochondrial Diagnostic Service. 
Whole mitochondrial genome sequencing was performed to exclude mtDNA mutations. 
MtDNA rearrangements were determined in skeletal muscle DNA by one or more of long-
range PCR, quantitative real time PCR or Southern blot assays. Analysis of the muscle 
mitochondrial respiratory chain complex activities were performed for early-onset patients 
(Kirby et al., 2007). Muscle histochemical studies performed were sequential COX-SDH and 
Gomori trichrome staining (Taylor et al., 2004), if tissue was available. Targeted nuclear-
encoded gene screening was performed in several patients to exclude variants commonly 
associated with Mendelian mitochondrial disease. 
2.2.4 Control Tissue 
Appropriate age-matched control fibroblast, myoblast cell lines and muscle tissue were made 
available from the NHS Highly Specialised Mitochondrial Diagnostic Service for research 
purposes. This comprised of four paediatric and three adult fibroblast cell lines, two adult 
myoblast cell lines, two paediatric muscle and two adult muscle blocks. 
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2.3 Whole Exome Sequencing 
2.3.1 Exome Capture and Enrichment 
Forty patients with clinically well-defined, undiagnosed mitochondrial disease who 
underwent WES between July 2011 and April 2016 were analysed for this project. All 
genomic DNA for WES was prepared by the Highly Specialised Newcastle upon Tyne 
Mitochondrial Diagnostic Laboratory. Patient blood or muscle genomic DNA was isolated 
using the DNeasy Blood and Tissue kit (Qiagen). Patients 1-34 were sequenced externally by 
AROS Applied Biotechnology A/S (AROS, 2016) and patients 35-40 were sequenced in-
house. For each patient, 2-3µg of genomic DNA was prepared and sent externally or 
internally for WES. Genomic DNA was fragmented and exome enriched by either Illumina 
TruSeq 62Mb (15 patients), Illumina TruSeq Rapid Exome 45Mb (six patients), Nextera 
Rapid Exome Capture 37Mb (14 patients) or Agilent Sure Select Human All Exon V5 50Mb 
(five patients) capture kits and sequenced using either the Illumina HiSeq 2000 or Illumina 
GAIIx in 100 base pair (bp) reads. The final outputs were raw sequence reads in FASTQ 
format, comprising the nucleotide sequence and the quality score (Cock et al., 2010).  
2.3.2  In-House WES Analysis Pipeline 
The WES analysis pipeline was developed and run in-house by bioinformaticians (Helen 
Griffin, Wei Wei, Yaobo Xu, Konstantinos Douroudis) based at the Centre for Life, Institute 
of Genetic Medicine, Newcastle University. The in-house pipeline was run using Linux 
command line with a series of Bash Shell scripts that automated necessary tools or software 
commands. This was able to run simultaneous exomes using one initial Shell script with the 
file names and corresponding sample identification numbers. Samples were run together in 
batches with approximately 2 days to complete the analyses. FastUniq was used to remove 
duplicate reads (Xu et al., 2012), which identified duplicates by comparing adjacent paired 
reads and by sequence comparison. Raw sequence reads were aligned to the human reference 
genome sequence (UCSC hg19) using the Burrows-Wheeler Alignment (BWA) tool (Li and 
Durbin, 2009) and alignments were generated in Sequence Alignment/Map (SAM) format.  
The Genome Analysis Toolkit (GATK) was used for variant annotation of single nucleotide 
variants (SNVs), short insertions or deletions (INDELs) and genotyping (Van der Auwera et 
al., 2013). SAM files were converted to the equivalent Binary Alignment/Map (BAM) format. 
Variant annotation generated a Variant Call Format (VCF) file for each patient comprising of 
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fixed fields; chromosome, (genomic) position, identifier, reference base(s), alternate base(s), 
quality score, filter status and additional information. Missing values were expressed as ‘.’.  
The quality score was based on a phred-scaled likelihood that the alternate base(s) was called 
correctly (Ewing and Green, 1998; Ewing et al., 1998). Quality scores (𝑄) for each base were 
logarithmically related to the probability (𝑝) that the base(s) were called incorrectly: 
𝑄 =  −10 × log10(𝑝) 
For example, a quality score of 40 is equivalent to a 1 in 10,000 probability that a base(s) was 
called incorrectly and hence, the base call accuracy would be 99.99%.  
The filter status was expressed as ‘PASS’ if the variant had passed all variant quality score 
filters or as a semi-colon separated list of all failed filters. For purposes of identifying variants 
associated with Mendelian disease, variants that did not pass the quality filters were excluded 
from analysis. For each exome in each genomic position the additional information field 
comprised of genotype fields in the following format; genotype (GT), unfiltered allele depth 
(AD), filtered read depth (DP), genotype quality (GQ) and likelihood of the called genotype 
(PL). GQ and PL values were based upon the Phred-scaled quality scores for each base. The 
most likely GT was expressed as two allele values separated by ‘/’. The first allele value 
represented the human genome sequence and the second allele variant represented the 
alternative (patient) sequence at that position. Since human cells are diploid, heterozygous 
variants were called as ‘0/1’ and homozygous as ‘1/1’. AD was expressed as the total number 
of unfiltered reads at each position that supported the reported allele value. For example, 
’34,37’ represented 34 reads with the reference position and 37 reads with the alternate 
position. On the other hand, DP expressed the total number of reads that passed quality score 
filtering to support the reported allele value. PL was represented by three values, which 
expressed the normalised phred-scaled likelihoods of each possible genotype at a given 
position; 0/0 (variant absent), 0/1 and 1/1. The most likely genotype was assigned a 
normalised PL value of 0 on the phred scale. GQ expressed the genotype quality as a phred-
scaled confidence score based upon the PL values. This was calculated as the difference 
between the second most likely genotype PL value and the most likely PL value. For 
differences between PL values that were greater than 99, then the GQ value was capped at 99. 
This indicated the highest quality genotype value for the most likely genotype as given by the 
PL field. 
The full specifications for the SAM/BAM and VCF data formats are available at Samtools at 
GitHub (samtools, 2016).  
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Functional annotation of called variants stored VCF files was performed using Annovar 
(Wang et al., 2010). Gene annotation determined whether called variants occurred in genes, if 
these were affecting coding or non-coding regions, the affected exons and the specific amino 
acids affected. Reference systems used for gene annotation were RefSeq (O'Leary et al., 
2016), UCSC Genes (Rosenbloom et al., 2015) and Ensembl Genes, using the latest system 
versions from Annovar. Next, called variants were annotated with allele frequency data from 
external exome databases and protein effect prediction scores from several in silico tool 
databases for SNVs. Allele frequency data assigned to called variants were derived from 
Exome Aggregation Consortium (ExAC) (Lek et al., 2016), National Heart, Lung and Blood 
Institute Exome Sequencing Project (NHLBI ESP), 1000 Genomes Project (February 2012 
data release) (The Genomes Project, 2015) and Complete Genomics (Drmanac et al., 2010). 
The in silico protein prediction tool databases assigned to called SNVs were SIFT, PolyPhen 
2, LRT, Mutation Taster, Mutation Assessor, FATHMM, RadialSVM, LR, GERP++, PhyloP 
and SiPhy.  
The final output was a Microsoft Excel Open XML format spreadsheet (.xlsx) file generated 
by a Perl script that concatenated the fields from variant and functional annotation into single 
columns each, with called variants each represented by one row. Called variants were also 
annotated with additional allele frequency data from up to 378 in-house exomes that had 
previously been analysed by the WES pipeline. Both Microsoft Excel .xlsx and VCF files for 
each patient were made available for purposes of variant analysis. 
2.3.3 WES Variant Analysis for Mendelian Mitochondrial Disease 
VCF and .xlsx files generated by the in-house WES analysis pipeline required additional, 
extensive investigations for the prioritisation of potentially pathogenic variants associated 
with Mendelian mitochondrial disease. Analysis of variants discovered and annotated by the 
in-house WES pipeline was performed by filtering of the fixed fields provided in the .xlsx 
file. On-target variants with a minor allele frequency (MAF) greater than or equal to 0.01, 
corresponding to a frequency of 1% or greater in external databases were excluded. The 
external databases used were Exome Aggregation Consortium (ExAC), National Heart, Lung 
and Blood Institute Exome Sequencing Project (NHLBI ESP), 1000 Genomes Project (The 
Genomes Project, 2015), Complete Genomics and in-house exomes. Variants were restricted 
to exonic (coding) or splice-site variants. Although functional annotation of called variants by 
Annovar assigned several in silico protein effect predictions tool databases, only PolyPhen 2 
(Adzhubei et al., 2013), SIFT (Sim et al., 2012) and Align-GVGD (Tavtigian et al., 2006) 
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were considered in the analysis of variants of interest. Insertions, deletions, splice-site and 
truncating variants were immediately considered as damaging to either protein function or 
structure. Possible effects on pre-mRNA splicing were predicted using the Human Splicing 
Finder v.3.0 (Desmet et al., 2009). Variants of interest were analysed using the mutation 
analysis software Alamut (Interactive Biosoftware), which incorporated gene transcripts, 
MAFs, in silico protein effect prediction tools and amino acid conservation across species.  
The filtering and analysis strategy of variants differed between the adult-onset PEO with 
multiple mtDNA deletions cohort and the early-onset mitochondrial respiratory chain 
complex deficiency cohort, by taking the possible mode of inheritance and GO-Terms of 
nuclear-encoded genes into consideration. Briefly, the filtering of variants for early-onset 
respiratory chain complex deficiency patients prioritised the identification of recessive 
(homozygous or compound heterozygous) variants in nuclear-encoded genes encoding 
mitochondrial-targeted proteins, with additional prioritisation of genes associated with 
mitochondrial translation. On the other hand, the strategy for the adult-onset PEO with 
multiple mtDNA deletions cohort prioritised nuclear-encoded genes associated with DNA 
maintenance, repair and replication with both dominant (heterozygous) and recessive 
(homozygous or compound heterozygous) inheritance considered. Full outlines of the WES 
analysis and filtering strategies employed are described in Chapter 4 and Chapter 6. 
2.3.4 Copy Number Variants (CNVs) 
Copy number variations (CNVs) were predicted using ExomeDepth (Plagnol et al., 2012), 
which uses an algorithm to compare the ratios of each exon read depth counts of a patient 
between approximately 10 control samples as a reference, while reducing technical variability 
between samples. Deletions and duplications were determined by quantifying the read depth 
ratio between the patient sample (reads observed) and the control samples (reads expected). 
For example, a hemizygous deletion gives a ratio of 1:2 (patient:controls) to equal 0.5. 
Conversely, a duplication gives a ratio of 3:2 to equal 1.5. 
CNV outputs were generated using a Perl script that provided the start and end genomic 
positions of the CNVs, the type of CNV (deletion or duplication), the number of exons 
affected, the CNV length (bp), chromosome, reads expected, reads observed, gene 
abbreviation(s) and exon(s), full gene name(s) and Online Mendelian Inheritance in Man 
(OMIM) gene-phenotype relationship if applicable. The Bayes Factor for each CNV was also 
given, which computed the likelihood of the CNV presence by assessing read depth, 
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chromosome, genomic coordinates and the type of CNV. The minimum, maximum and 
average observations of each CNV from in-house exomes were also given. Common CNVs 
detected by Conrad et al. (2010) were annotated. Known, pathogenic CNVs from the ClinVar 
archive were also annotated (Landrum et al., 2016). CNVs were constrained to those observed 
in a minimum of zero to three in-house exomes. Hence, only novel, rare or known pathogenic 
CNVs were considered. Filtering and prioritisation of CNVs employed the same GO-Terms 
that were applied to the respective WES patient cohorts. 
2.3.5 Primers 
Primers used for molecular and genetic studies were made available from the Mitochondrial 
Diagnostic Service, colleagues from the Wellcome Trust Centre for Mitochondrial Research 
or were custom-designed. All full list of all primers used is provided in Appendix A.   
2.3.6 Custom Primer Design 
Whole exons or exonic regions harbouring putative pathogenic variants were selected and 
flanked by 200 bps upstream (5’) and downstream (3’). Custom-designed forward and reverse 
primers were designed using Primer3 (Resnick, 1996). SNPCheck3 (NGRL, 2016) was used 
to identify single nucleotide polymorphisms (SNPs) in the primer binding sites. Final designs 
were flanked by universal M13-derived forward (5’-TGTAAAACGACGGCCAGT-3’) and 
reverse (5’-CAGGAAACAGCTATGACC-3’) primers and ordered from Integrated DNA 
Technologies. Unless stated, all primers were aliquoted in 10µM stocks containing both the 
forward and reverse primers.     
2.3.7 Polymerase Chain Reaction (PCR) 
PCRs were all prepared in ice on the laboratory bench. Amplification was performed using 
either the GeneAmp PCR System 9700 or the Veriti 96 Well Thermal Cycler. For each run a 
no template control was also performed.  
Standard PCR amplification was performed in a total of 25µl comprising 13.8µl NANOpure 
water, 5.0µl 5X Colourless GoTaq G2 Reaction Buffer, 2.5µl 2mM dNTPs, 0.2µl GoTaq G2 
DNA Polymerase, 2.5µl 10µM (forward and reverse) primers and 1µl DNA at a concentration 
at least 5ng µl-1. Unless stated, the standard PCR protocol was one cycle of 94OC for 1 minute 
then 30 cycles of 94OC for 1 minute, 60OC for 1 minute and 72OC for 1 minute. The final 
extension step was 72OC for 10 minutes.   
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Hot Start PCR amplification was performed in a total of 25µl comprising 10.0µl nuclease-free 
water, 5.0µl 5X Colorless GoTaq Flexi Buffer, 2.5µl 2mM dNTPs, 2.0µl 25mM MgCl2, 0.5µl 
GoTaq G2 Hot Start Polymerase, 4.0µl 10µM (forward and reverse) primers and 1.0µl DNA. 
Unless stated the Hot Start PCR protocol was one cycle of 94OC for 4 minutes, then 30 cycles 
of 94OC for 45 seconds, 60OC for 45 seconds and 72OC for 1 minute. The final extension step 
was 72OC for 10 minutes. 
2.3.8 Gradient PCR for Primer Optimisation 
For all forward and reverse primers, 60OC was the standard annealing temperature for 
standard PCR and Hot Start PCR amplification. For primers where amplification failed to 
occur at 60OC, a gradient PCR was performed using the Veriti 96 Well Thermal Cycler with 
annealing temperatures tested at 56OC, 58OC, 60OC, 62OC and 64OC. Additionally, PCRs 
were tested at all temperatures with and without the addition of 2.0µl DMSO to each reaction. 
2.3.9 Long Range PCR 
Long range PCR primers were designed by Georgia Campbell, with optimisation also done by 
Georgia Campbell and Amy Vincent. Amplification was performed to investigate the 
presence of single large-scale mtDNA deletions or multiple mtDNA deletions. Diagnostic 
long range PCR was also performed using extracted muscle DNA. Extracted DNA samples 
were run in triplicate using the PrimeSTAR GXL DNA Polymerase kit (TaKaRa). Two pairs 
of forward and reverse primers for amplification of the whole mitochondrial genome were 
used on all samples (Table 2.1), together with control blood homogenate DNA, two 
additional control DNAs and a no template control. PCRs were prepared in ice on the 
laboratory bench. Each amplification was performed in a total of 50µl comprising 32µl 
nuclease-free water, 10µl 5X PrimeSTAR GXL buffer, 4.0µl 2.5µM dNTPs, 1.0µl forward 
primer, 1.0µl reverse primer, 1.0µl PrimeSTAR GXL DNA polymerase and 1.0µl stock DNA. 
The PCR block was pre-heated to 94OC. The long range PCR protocol was 35 cycles of 98OC 
for 10 seconds and 68OC for 11 minutes. Products were visualised using a 0.7% agarose gel. 
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Primer Sequence Fragment Size (bp) Amplified Region 
719/16422 
F-gttcaccctctaaatcaccacgatcaaaag 
R-tattgatttcacggaggatggtggtcaag 
15704 ChrM:719-16422 
122/16309 
F-cagtatctgtctttgattcctgcctcatc 
R-ctatgtactgttaagggtgggtaggtttg  
16188 ChrM:122-16309 
Table 2.1 Long Range PCR Primers. Forward and reverse primers for long range PCR 
amplification of mtDNA. 
2.3.10 Quantitative Real Time PCR for mtDNA Quantification 
The quantitative real time PCR protocol and primers were optimised by Ilaria Dalla Rosa for 
mtDNA copy number quantification. Fibroblast DNA was extracted using the DNeasy Blood 
and Tissue Kit (Qiagen) according to the manufacturer’s protocol and quantified using the 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). All tested samples were run in 
triplicate on 96-well reaction plates, with each plate also run in triplicate. Master mixes and 
samples were prepared in ice on the laboratory bench and plates prepared in the PCR UV 
cabinet. Each amplification was performed in a total of 25.0µl comprising 12.5µl Power 
SYBR Green PCR Master Mix (Applied Biosystems), 1.25µl forward primer, 1.25µl reverse 
primer, 5.0µl nuclease-free water and 5.0µl DNA at a concentration of 5.0ng µl-1, loaded in 
MicroAmp® Fast Optical 96-Well Reaction Plates and centrifuged at 1600rpm for 2 minutes. 
The real time PCR programme was 50OC for 2 minutes, 95OC for 5 minutes, then 40 cycles of 
95OC for 5 seconds and 60OC for 1 minute. MtDNA was amplified with forward and reverse 
primers specific for human MT-COII gene as the target gene, with forward and reverse 
primers for human APP encoding amyloid-β precursor protein used as a nuclear-encoded 
reference gene (Table 2.2). MT-COII primer stocks were prepared at a concentration of 
10µM, whereas APP primer stocks were at a concentration of 30µM. 
Primer Sequence Amplified Region 
MT-COII 
F-cgtctgaactatcctgcccg 
R-tggtaagggagggatcgttg 
ChrM:7774-7874 
APP 
F-tttttgtgtgctctcccaggtct 
R-tggtcactggttggttggc 
Chr21:27462334-27462407 
Table 2.2 Quantitative Real Time PCR Primers. Human MT-COII and APP forward and 
reverse primers for mtDNA quantification by real time PCR. 
Quantification of mtDNA was calculated using the 2-∆∆Ct method (Schmittgen and Livak, 
2008). As this was a comparative methodology for mtDNA quantification, a control sample 
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was always used alongside the untested patient samples. Cycle threshold (ct) values for APP 
and MT-COII used were the average of the three triplicates. This reflected the number of 
cycles required for exponential amplification and for fluorescent signal to cross the threshold 
value to exceed background levels. The average ct values were used in the following 
calculations: 
∆Ct(control) = Ct(MT‐COII)  −  Ct(APP) 
∆Ct(untested) = Ct(MT‐COII) ‐ Ct(APP) 
∆∆Ct = ∆Ct (control) ‐ ∆Ct (untested) 
Therefore, the relative expression fold change was calculated as 2-∆∆Ct. Ct values for MT-COII 
were higher when mtDNA was depleted because more amplification is required to reach 
exponentiation. Relative mtDNA quantities were expressed as fold changes relative to one 
control. Student’s t test was performed for statistical comparison between controls and patient 
samples.   
2.3.11 Gel Electrophoresis 
Unless stated, PCR products were visualised using a 1% agarose gel. Gels were prepared by 
heating 1.0g agarose and 100ml 1X TAE in a microwave until the agarose had fully 
dissolved. After cooling, 3.0µl of SYBR Safe DNA Gel Stain was swirled into the gel 
mixture. The gel mixture was poured and left to set for 30 minutes. For each PCR product, 
5.0µl was mixed with 1.0µl DNA loading buffer and loaded into the agarose gel. In each row 
used, 3.0µl of 1Kb DNA ladder was loaded. Unless specified, products were run using a 
benchtop power supply at 120 volts (v) for 40 minutes. Products were visualised using the 
ChemiDoc MP Imaging System using the SYBR Safe protocol, according to the manufacturer 
guidelines.     
2.3.12 Sanger Sequencing 
Prior to Sanger sequencing, the PCR products were cleaned-up. On ice, 5µl of PCR product 
and 1.5µl ExoSAP-IT was added to a 96-well PCR plate in duplicate for sequencing with 
forward and reverse universal primers, capped with a rubber seal and mixed by pulse 
centrifuge. The ExoSAP-IT PCR clean-up programme was 37OC for 15 minutes and 80OC for 
15 minutes. ExoSAP-IT enzyme removes unbound dNTPs and residual PCR primers that may 
interfere with sequencing.  
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For 20µl of cycling, a reaction mixture comprising 7µl nuclease-free water, 3µl 5X BigDye 
v.3.1 sequencing buffer, 2µl BigDye v.3.1. ready reaction mix and 1µl universal forward or 
reverse primer was added to each PCR-ExoSAP-IT mixture, capped with a rubber seal and 
mixed by pulse centrifuge. The cycle sequencing programme was 96OC for 1 minute, then 35 
cycles of 96OC for 10 seconds, 50OC for 5 seconds and 60OC for 4 minutes. 
The final step of PCR product clean-up was filtration through the Performa DTR V3 96-well 
plate, a gel filtration plate for the removal of unincorporated BigDye v.3.1. terminator dye, 
dNTPs and additional low molecular weight material. The Performa DTR 96-well plate was 
placed onto a clean 96-well PCR plate and centrifuged at 2,300rpm for 3 minutes to remove 
excess eluate. The total volume of PCR products for sequencing were added to the centre of 
each well in the Performa DTR 96-well plate, which was then placed on top of a clean 96-
well PCR plate and centrifuged at 2,300rpm for 5 minutes. The eluted products in the 96-well 
PCR were retained and sequenced using the ABI 3130xl Genetic Analyser. Sequencing 
programmes were setup using the Foundation Data Collection (Applied Biosystems) software. 
Completed DNA sequencing from the ABI 3130xl Genetic Analyser was generated into .ab1 
files for each amplification, comprising of the raw DNA base sequence and electropherogram. 
Mutation Surveyor (SoftGenetics) or FinchTV (Geospiza) software was used to analyse the 
sequencing files and figure preparation. 
2.4 Tissue Culture 
2.4.1 Cell Culturing 
All cells were incubated in a CO2 Cell Culture Incubator at 37
OC with 5% CO2. Cell culturing 
techniques were performed in a Class II Microbiological Safety Cabinet (Faster) using aseptic 
technique and sterile or autoclaved equipment. Unless stated, all cells were grown in T75 
tissue culture flasks (Greiner Bio-One). 
Cultured fibroblasts were grown in MEM with 10% FBS, 1% MEM vitamins, 1% non-
essential amino acids, 50U ml-1 penicillin, 50µg ml-1 streptomycin, 1mM sodium pyruvate 
solution, 25mg ml-1 uridine solution and 2mM L-glutamine. Cultured myoblasts were grown 
in SMGM with 10% FBS, 1% GlutaMAX supplement and 50µg ml-1 liquid gentamycin. 
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2.4.2 Subculturing of Fibroblasts 
Fibroblast cells were passaged at approximately 90% confluency. Fibroblast MEM was 
aspirated since this inhibits activity of the trypsin, rinsed with 2ml TrypLE Express Enzyme 
(Gibco) to ensure full coverage of cells and incubated at 37OC for 5 minutes. Cells were 
quenched with 4ml fresh MEM, transferred to a 50ml falcon tube, centrifuged at 1,200rpm for 
4 minutes to obtain a pellet and the supernatant aspirated. Pellets were suspended in 1ml fresh 
MEM, which was divided equally into T75 tissue culture flasks with 15ml fresh MEM and 
incubated. 
2.4.3 Subculturing of Myoblasts 
Myoblasts were passaged at approximately 60% confluency to prevent differentiation in 
myotubes. SMGM was aspirated, myoblasts were washed with 5ml sterile PBS then aspirated, 
rinsed with 2ml TrypLE Express Enzyme (Gibco) and incubated at 37OC for 6 minutes. Cells 
were quenched with 4ml fresh SMGM, divided equally into T75 tissue culture flasks with 
15ml fresh SMGM and incubated. 
2.4.4 Harvesting of Cells 
Both cultured fibroblasts and myoblasts were prepared for harvesting using the steps 
described in 2.4.2, until a pellet was obtained in a 50ml falcon tube. Pellets were re-suspended 
in 1ml MEM or SMGM and transferred to a clean 1.5ml eppendorf tube. After further 
centrifugation at 1,200rpm for 4-5 minutes the supernatant was aspirated and the pellet 
rapidly frozen in liquid nitrogen for storage at -80OC.  
2.4.5 Freezing of Cells 
Both cultured fibroblasts and myoblasts were prepared for freezing using the steps described 
in 2.4.2, until a pellet was obtained in a 50ml falcon tube. Fibroblast pellets were carefully 
resuspended dropwise in 500µl fibroblast freezing medium containing 90% FBS and 10% 
DMSO. Myoblast pellets were carefully resuspended dropwise in 1ml myoblast freezing 
medium containing 70% DMEM, 20% FBS and 10% DMSO. Resuspended cells were stored 
for 24 hours at -80OC, then transferred for long term storage in liquid nitrogen stores.      
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2.4.6 Generation and Harvesting of Quiescent Fibroblasts 
Quiescent (non-dividing) fibroblasts were generated to repress the cytosolic nucleotide 
salvage pathway and constrain mitochondria dNTP supply to the mitochondrial nucleotide 
salvage pathway (Dalla Rosa et al., 2016). Once fibroblast cells were confluent in T75 tissue 
culture flasks, MEM was aspirated and replaced with MEM that contained 0.1% DBS, instead 
of 10% FBS as described in 2.4.1. Fibroblasts were incubated in quiescent MEM for between 
10 and 14 days, with quiescent MEM replenished every 3-4 days. 
Quiescent fibroblasts were harvested by aspirating the quiescent MEM, washing the cells with 
4ml PBS, rinsing the cells with 2ml TrypLE Express Enzyme and incubating for 5 minutes. 
Cells were quenched with 500µl FBS, 4ml PBS, transferred to a 50ml falcon tube, centrifuged 
at 1,200rpm for 5 minutes to obtain a pellet and the supernatant aspirated. Pellets were 
resuspsended in 500µl PBS and transferred to a clean 1.5ml eppendorf tube. After further 
centrifugation at 1,200rpm for 5 minutes the supernatant was aspirated and the pellet rapidly 
frozen in liquid nitrogen for storage at -80OC. 
2.5 Western Blotting 
2.5.1 Whole Cell Lysis 
Lysis of fibroblast or myoblast pellets was performed on ice. The cell lysate buffer comprised 
50mM Tris-HCl, 130mM NaCl, 2mM MgCl2, 1% NP-40 (v/v) and 1X EDTA-protease 
inhibitor cocktail tablet. Cell lysate buffer was prepared in 10ml stocks and stored at -20OC in 
200µl aliquots. Immediately before use, 1mM PMSF was added to the lysate buffer. 
Dependent on the pellet size, 50-100µl cell lysate buffer was added to each pellet and mixed 
by pipetting. All samples were vortexed thoroughly for 30 seconds, then centrifuged at 4OC, 
2,300rpm for 2 minutes. After centrifuging, the supernatant was transferred to a clean 1.5ml 
eppendorf tube then rapidly frozen in liquid nitrogen for storage at -80oC.  
2.5.2 Muscle Homogenisation 
Frozen skeletal muscle was homogenised for western blot studies using a protease buffer 
prepared from RIPA buffer. Liquid nitrogen was added to a pestle and mortar for rapid 
cooling, then 10-20mg frozen control or patient muscle was added to the mortar. Using the 
pestle, the muscle was crushed to obtain a powder with further liquid nitrogen added to cool 
the muscle, pestle and mortar. Once a fine powder was attained, 0.5-1ml protease buffer was 
added to the tissue. Once frozen, the tissue continued to be crushed until the protease buffer 
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and tissue were thawed in a homogenate, then pipetted into a clean 1.5ml eppendorf tube. The 
homogenate was vortexed for 15 seconds then placed on ice for 5 seconds. This was repeated 
a further four times, then placed on ice for 45 minutes. Next, the homogenate was 
homogenised using the either the T25 or T8 Ultra-Turrax homogeniser (IKA) or for 5 
seconds, placed on ice for 15 seconds, then repeated. The homogenate was returned to a clean 
1.5ml eppendorf tube and centrifuged in a chilled centrifuge at 4OC, 11,500rpm for 10 
minutes. After centrifuging, the supernatant was transferred to a clean 1.5ml eppendorf tube 
and rapidly frozen in liquid nitrogen for storage at -80OC. 
2.5.3 Bradford Assay 
Protein quantification was performed using a Bradford assay with bovine serum albumin 
(BSA) to produce a standard curve. BSA stocks were prepared at 1mg ml-1 and stored at -
20OC. The standard curve was prepared in duplicate with BSA calibration points at 0, 2, 5, 10, 
15 and 20mg ml-1. Protein samples of unknown concentrations were prepared at 1µl and 2µl 
dilutions; no duplicates were made. All tubes were vortexed after addition of all the reagents 
and left at room temperature for 5 minutes. Once the BSA calibration points and protein 
samples for quantification were prepared, 200µl were aliquoted using reverse pipetting into a 
96-well plate. Each protein sample for quantification was aliquoted twice. Plates were then 
read at 595nm using the SpectraMax M5e Multimode Plate Reader (Molecular Devices). 
2.5.4 SDS-Page Sample Preparation 
Fibroblast, myoblast and muscle lysates were prepared for western blot loading using 4x or 5x 
laemmli sample buffer. Hence, the ratio of lysate to sample buffer was 3:1 or 4:1. Prepared 
samples were heated at 37OC on a dry heat block for 30 minutes. After heating, 0.5µl 
benzonase nuclease (Merck Millipore) was added to each sample to degrade residual nucleic 
acid. Samples were flicked to mix and kept on the laboratory bench at room temperature for a 
further 15 minutes.  
2.5.5 SDS-Page 
Polyacrylamide gels were handcast and electrophoresis performed using the Mini-Protean 
Tetra Cell system (BioRad) or the Mini Electrophoresis Blotting System (Hoefer). Either 10% 
or 12% polyacrylamide gels were used, depending on the molecular weight of the proteins of 
interest (Table 2.3). Once the resolving gel was poured, isopropanol was added on top to 
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produce an even edge until polymerisation. After the isopropanol was washed away, the 
3.75% stacking gel was poured on top. 
 
10% Resolving 
Gel 
12% Resolving 
Gel 
3.75% Stacking 
Gel 
Acrylamide/Bis-acrylamide, 30%, 29:1 1.667ml 2ml 0.625ml 
3.75M Tris-HCl, pH 8.5 0.5ml 0.5ml / 
0.5M Tris-HCl, pH 6.8 / / 1.25ml 
dH2O 2.726ml 2.395ml 3.02ml 
10% SDS 50µl 50µl 50µl 
TEMED 5µl 5µl 5µl 
10% APS 50µl 50µl 50µl 
Table 2.3 Polyacrylamide Gel Casting Reagents and Volumes. List of reagents and 
volumes for casting a 10% or 12% resolving gel and the 3.75% stacking gel. 
SDS-page electrophoresis was performed in 1X running buffer (25mM Tris, 192mM glycine, 
0.1% SDS) with 25-50µg protein per sample as prepared in 2.5.4, plus 10µl Spectra 
Multicolor Broad Range Protein Ladder (Thermo Scientific). Electrophoresis was run at a 
constant 150V using the Bio-Rad Mini-Protean Tetra Cell System or 120V using the Hoefer 
Mini Electrophoresis Blotting System until the sample buffer dye reached the bottom of the 
polyacrylamide gel.    
2.5.6 Wet Electroblotting Transfer and Blocking 
The transfer of proteins from the SDS-page gel to a polyvinylidine fluoride (PVDF) 
membrane (Bio-Rad) was performed using wet electroblotting transfer with the Mini Trans-
Blot Cell System (Bio-Rad). The SDS-page gel was removed from the gel running system and 
placed in 1X transfer buffer (25mM Tris, 192mM glycine). The PVDF membrane 
(8.5x5.5cm) was activated in 100% methanol for 30 seconds and rinsed in distilled water. A 
cassette was assembled with the gel and membrane between four cut-pieces (8.5x5.5cm) 3mm 
thick chromatography paper (Whatman) and two sponges. This was placed in the transfer tank 
filled with 1X transfer buffer, a magnetic stirring bar and an ice pack. Wet transfer was 
performed at 100V for 60 minutes, at 4OC on a magnetic stirrer to keep the transfer buffer 
cool. Following transfer, membranes were blocked in 5% powdered milk (Marvel) in 1X 
TBST for 1 hour at room temperature to prevent non-specific binding of antibodies. 
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2.5.7 Ponceau S Staining 
Ponceau S staining solution was used for qualitative visualisation of protein loading on PVDF 
membranes. Following wet electroblotting transfer, membranes were incubated with Ponceau 
S solution for 2 minutes at room temperature and rinsed in dH2O until background staining 
was removed. After visualisation, membranes were further rinsed in dH2O until all staining 
solution was removed.      
2.5.8 Primary and Secondary Antibodies 
Membranes were probed with primary antibodies diluted in 5% powdered milk in 1X TBST 
(Table 2.4); either overnight at 4OC or for 2 hours at room temperature. Anti-alpha Tubulin, 
anti-β-actin, anti-GAPDH and anti-Vinculin were used as loading controls. 
Antibody Dilution Predicted (Observed) 
Size, kDa 
Host 
Species 
Clonality 
Anti-AK2 (ab37594, Abcam) 1:1000 26 Rabbit Polyclonal 
Anti-AK3 (ab119058, Abcam) 1:1000 26 Mouse Monoclonal 
Anti-alpha Tubulin (ab7291, Abcam) 1:10000 50 Mouse Monoclonal 
Anti-ATP5B (ab14730, Abcam) 1:2000 52 Mouse Monoclonal 
Anti-beta Actin (A5316, Sigma) 1:10000 42 Mouse Monoclonal 
Anti-GAPDH (ab8245, Abcam) 1:10000 40 (36) Mouse Monoclonal 
Anti-GMPR1 (ab118751, Abcam) 1:1000 37 Rabbit Polyclonal 
Anti-GMPR1 (SAB1101144, Sigma) 1:1000 37 (40-42) Rabbit Polyclonal 
Anti-LONP1 (15440-1-AP, 
Proteintech) 
1:1000 100 Rabbit Polyclonal 
Anti-MRPL12 (Affinity purified in 
Lightowler laboratory) 
1:500 19 Rabbit  
Anti-MTCOI (ab14705, Abcam) 1:1000 57 (40) Mouse Monoclonal 
Anti-MTCOII (ab110258, Abcam) 1:1000 26 Mouse Monoclonal 
Anti-mtAlaRS/AARS2 (ab197367, 
Abcam) 
1:1000 107 Rabbit Polyclonal 
Anti-mtGluRS/EARS2 (HPA043633, 
Sigma) 
1:1000 60 Rabbit Polyclonal 
Anti-mtTyrRS/YARS2 (AP7838a, 
Abgent) 
1:500 60 Rabbit Polyclonal 
Anti-mtRNA Polymerase/POLRMT 
(ab32988, Abcam) 
1:250 139 (140) Rabbit Polyclonal 
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Antibody Dilution Predicted (Observed) 
Size, kDa 
Host 
Species 
Clonality 
Anti-MT-TFA/TFAM (ab119684, 
Abcam) 
1:1000 29 (25) Mouse Monoclonal 
Anti-NDUFB8 (ab110242, Abcam) 1:1000 22 Mouse Monoclonal 
Anti-p53R2 (ab8105, Abcam) 1:5000 41 (39) Rabbit Polyclonal 
Anti-R1 (sc-22786, Santa Cruz) 1:1000 94 Rabbit Polyclonal 
Anti-R2 (sc-10846, Santa Cruz) 1:1000 45 Goat Polyclonal 
Anti-RMDN3/PTPIP51 
(HPA009975, Sigma) 
1:500 62 Rabbit Polyclonal 
Anti-SDHA (ab14715, Abcam) 1:1000 70 Mouse Monoclonal 
Anti-SLC25A33/PNC1 (ab97820, 
Abcam) 
1:1000 35 Rabbit Polyclonal 
Anti-SLC25A36/PNC2 (ab154559, 
Abcam) 
1:1000 34 Rabbit Polyclonal 
Anti-SLC29A1/ENT1 (LS-C96639, 
Lifespan Biosciences) 
1:1000 50 Rabbit Polyclonal 
Anti-TK1 (H00007083-M02, 
Abnova) 
1:500 26 Mouse Monoclonal 
Anti-TK2 (Liya Wang) 1:1000 26 Rabbit Polyclonal 
Anti-UQCRC2 (ab14745, Abcam) 1:1000 48 Mouse Monoclonal 
Anti-VDAC1/Porin (ab14734, 
Abcam) 
1:10000 39 (37) Mouse Monoclonal 
Anti-Vinculin/VCL (ab18058, 
Abcam) 
1:2000 130 Mouse Monoclonal 
Table 2.4 Primary Antibodies. List of primary antibodies used for western blotting.  
Membranes incubated overnight at 4OC were transferred to room temperature for a further 20 
minutes of incubation to enhance the signal. Next, membranes were washed five times at 5 
minutes in 1X TBST, then probed with horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Dako) diluted in 5% powdered milk in 1X TBST (Table 2.5) for 1 hour at room 
temperature. 
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Antibody Dilution Host Species Clonality 
Anti-Goat Secondary (P0449, Dako) 1:3000 Rabbit Polyclonal 
Anti-Mouse Secondary (P0260, Dako) 1:2000 Rabbit Polyclonal 
Anti-Rabbit Secondary (P0399, Dako) 1:3000 Swine Polyclonal 
Table 2.5 Secondary Antibodies. List of HRP-conjugated secondary antibodies used for 
immunodetection. 
After secondary antibody incubation, membranes were washed a further five times for 5 
minutes in 1X TBST. Detection of secondary antibodies was performed using either Clarity 
Western ECL Substrate (Bio-Rad) or SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific). A 1:1 ratio of the luminol/enhancer reagent and stable peroxide solution 
were mixed, added to the membrane surface with the protein side up and incubated in 
darkness for 5 minutes. Fluorescence was measured using the ChemiDoc MP Imaging System 
(Bio-Rad) and analysed using the Image Lab (Bio-Rad) software. 
2.6 Live Cell Imaging 
2.6.1 Fluorescent Dyes 
TMRM (Invitrogen) sequestered by mitochondria was used for visualisation of mitochondrial 
network morphology. PicoGreen (Life Technologies) was used to stain double-stranded DNA 
(dsDNA) for the visualisation of mitochondrial nucleoid morphology.  
2.6.2 Seeding of Fibroblasts 
Passage matched fibroblasts were seeded approximately 24 hours before live cell imaging 
studies. At least two controls and patient fibroblasts were seeded at 50,000 cells ml-1 in 35mm 
glass bottom imaging dishes (iBidi) with 2ml MEM and incubated overnight at 37OC. 
Approximately 50 minutes prior to imaging, the MEM was aspirated and replaced with fresh 
MEM containing 5nmol TMRM or 3µl ml-1 PicoGreen dye.  
2.6.3 Confocal Microscopy 
Live cell imaging of fibroblast cells was performed at The Bio-Imaging Unit (Central 
Campus, Newcastle University) using the Nikon A1R Invert point scanning confocal 
microscope. Imaging was done in an enclosed environmental chamber at 37OC with 5% CO2 
using resonant scanning for fast scanning and an increased frame rate with a 63X oil 
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immersion objective. At least 10 cells from each fibroblast line were captured as a series of Z-
stacks for volume analysis.    
2.6.4 Mitochondrial Network Morphology Analysis 
ImageJ (Open Source) was used to process all live cell images. Z-stacks were processed into a 
single image using a maximum projection method. A kernel filter was applied using 
deconvolution to smooth the image signal. Next, images were binarised to allow the 
automated quantification of mitochondrial morphological features, demonstrated as aspect 
ratio (AR) and form factor (FF). AR reflected the ratio between the major and minor axis, or 
the length-to-width ratio of mitochondria. FF reflected the degree of branching, which was 
calculated using mitochondria perimeter and area as follows: 
𝐹𝐹 =  
𝑃𝑒𝑟𝑖𝑚𝑒𝑡𝑒𝑟2
4𝜋 × 𝐴𝑟𝑒𝑎
 
Average AR and FF for each replicate and fibroblast line were calculated. Student’s t test and 
Dunn’s Multiple Comparison test were performed to compare the median AR and FF between 
control and patient fibroblasts. 
2.7 Bioinformatics Analysis of Protein Sequences and Structures 
2.7.1 Protein Amino Acid Sequencing and Secondary Structure Retrieval 
Full length primary amino acid sequences encoded by genes of interest were retrieved from 
the UCSC Genome Browser in FASTA format (Genome Bioinformatics Group, 2009; 
Rosenbloom et al., 2015). 
Secondary protein structures were retrieved from the RCSB Protein Data Bank in .pdb format 
(Berman et al., 2000; The Protein Data Bank (PDB), 2016).   
2.7.2 Identification and Visualisation of Protein Domains 
Full length amino acid sequences were submitted to InterProScan 5 for identification of 
protein domains (Jones et al., 2014; InterPro, 2016). Graphical representation of proteins 
domains was generated using IBS: Illustrator for Biological Sequences (Liu et al., 2015). 
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2.7.3 Multiple Sequence Alignment (MSA) 
Protein sequences of interest were aligned to infer the evolutionary relationship between 
species or between orthologs. Full length amino acid sequences were arranged in FASTA files 
with a single line description line for each sequence denoted by the greater-than sign (‘>’) and 
one or more lines of the protein sequence. FASTA files were read by SeaView (Manolo 
Gouy, Laboratoire de Biometrie et Biologie Evolutive, CNRS/Universite Lyon I) (Gouy et al., 
2010) and aligned using MUltiple Sequence Comparison by Log-Expectation (MUSCLE) 
(Edgar, 2004b; Edgar, 2004a). 
2.7.4 Secondary Structure Analysis 
Secondary protein structures were analysed using Discovery Studio Visualiser (Accelrys 
Software Incorporated), allowing investigation of intramolecular bonds and mutational 
analysis. To facilitate analysis, water molecules were removed.
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Chapter 3. A Comprehensive Systematic Review of Adult-Onset Mendelian 
Mitochondrial PEO and mtDNA Instability  
This review was published (Sommerville et al., 2014) in Journal of Neuromuscular Diseases 
and has been updated to include newly described genes and patients, plus material from 
Garone et al. (submitted manuscript).    
3.1 Introduction 
Progressive external ophthalmoplegia (PEO) is an adult-onset mitochondrial disorder 
characterised by paresis of the extraocular muscles and drooping of the eyelids (ptosis) 
(Figure 3.1A). Historically, PEO associated with mitochondrial dysfunction has been widely 
described in the literature (Iannaccone et al., 1974; Muller Hocker et al., 1983; Marolda et al., 
1984; Byrne et al., 1985; Turnbull et al., 1985; Cooles et al., 1988; Federico et al., 1988; 
Yamamoto and Nonaka, 1988). Mitochondrial PEO is typically associated with single, large-
scale mtDNA deletions or mtDNA point mutations (Zeviani et al., 1988; Moraes et al., 1989). 
Maternally-inherited or sporadic single, large scale mtDNA deletions can cause Kearns-Sayre 
syndrome (Zeviani et al., 1988; Holt et al., 1989), a mitochondrial cytopathy associated with 
PEO, retinitis pigmentosa, cardiomyopathy and ataxia (Kearns and Sayre, 1958; Kearns, 
1965) or indolent PEO phenotypes (Moraes et al., 1989; Goto et al., 1990a). Single mtDNA 
point mutations of several mtDNA genes with varying adult-onset PEO phenotypes include 
tRNAAla (Spagnolo et al., 2001; Pinos et al., 2011; Filosto et al., 2016), tRNALeu(UUR) 
including the common m.3243A>G mutation (Moraes et al., 1993; Verma et al., 1996; Koga 
et al., 2000; Campos et al., 2001; Nesbitt et al., 2013), tRNALeu(CUN) (Fu et al., 1996; 
Cardaioli et al., 2008), tRNALys (Tiranti et al., 1999), tRNATyr (Raffelsberger et al., 2001; 
Sahashi et al., 2001), tRNAGlu (Alston et al., 2010), tRNAIle (Franceschina et al., 1998; 
Corona et al., 2002; Berardo et al., 2010; Schaller et al., 2011), tRNAPro (Hardy et al., 2016), 
tRNAAsn (Seibel et al., 1994; Ronchi et al., 2012d), tRNAVal (Yan et al., 2010) and 
tRNASer(UCN) (Cardaioli et al., 2007; Souilem et al., 2010). 
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Mutations of nuclear encoded genes essential for maintenance and repair of mtDNA have 
been increasingly recognised as important causes of adult-onset PEO associated with 
secondary, clonally expanded skeletal muscle restricted multiple mtDNA deletions (Zeviani et 
al., 1989). However the phenotypic spectrum is broad, ranging from indolent or isolated PEO 
to fatal multisystem disorders. The most widely recognised nuclear encoded gene associated 
with adult-onset Mendelian PEO is POLG, encoding the catalytic subunit of the only known 
mitochondrial DNA polymerase (Van Goethem et al., 2001). Over the past two decades, 
additional mutated genes have emerged as important causes of mtDNA maintenance 
disorders, including TWNK (formerly known as C10orf2 or Twinkle) (Spelbrink et al., 2001), 
SLC25A4 (also known as ANT1) (Kaukonen et al., 2000) and RRM2B (Tyynismaa et al., 
2009b). Sequential COX-SDH histochemistry of patient skeletal muscle characteristically 
show COX-deficient fibres (Figure 3.1B), while modified Gomori trichrome staining also 
often demonstrates ragged-red fibres. Similar to patients with single large-scale mtDNA 
Figure 3.1 Clinical, Histochemical and Molecular Features of Adult-Onset Mendelian 
PEO and mtDNA Instability (A) Paresis of the extraocular muscles is demonstrated by a 
patient asked to look (i) left, (ii) right, (iii) up and (iv) down. (B) Sequential COX-SDH 
histochemical studies from patients with (i) a homozygous p.Ala467Thr POLG variant; (ii) a 
heterozygous p.Gln458His TWNK variant; (iii) compound heterozygous p.Arg186Gly and 
p.Thr218Ile RRM2B variants; (iv) compound heterozygous p.Asn288* and p.Lys558* SPG7 
variants. (C) Southern blotting of muscle DNA demonstrating typical banding pattern 
associated with multiple mtDNA deletions (lanes 3 and 4), a large scale single deletion (lane 
2) and wild-type (lane 1). (D) Long range PCR of muscle DNA also shows a banding pattern 
typical of multiple mtDNA deletions (lane 3), together with wild-type mtDNA (lane 2) and a 
size marker (lane 1). Adopted from Sommerville et al. (2014).   
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deletions, multiple mtDNA deletions are typically detected by long range PCR or 
occasionally by Southern blotting of muscle DNA, which show a typical multiple banding 
pattern (Figure 3.1C and D).  
Despite the identification of several associated nuclear encoded genes, there remains a poor 
correlation between phenotypes and genotypes. Genetic diagnosis of patients has been 
enhanced by WES and NGS technologies (Garone et al., 2012; Ronchi et al., 2012b; 
Tyynismaa et al., 2012; Kornblum et al., 2013; Ronchi et al., 2013; Pfeffer et al., 2014; 
Wedding et al., 2014; Gorman et al., 2015a; Reyes et al., 2015). Unlike early-onset 
mitochondrial disorders that are overwhelmingly recessively inherited, the prioritisation of 
variants identified by NGS is challenging since both dominant and recessive variants are 
associated with adult-onset Mendelian PEO. Since these disorders are predominantly late-
onset, for identified candidate heterozygous variants it is often impossible to perform 
segregation studies with parental DNA samples; it is unknown whether candidate variants 
were indeed inherited or occurred de novo. Therefore, NGS studies of undiagnosed 
mitochondrial disease has principally focused on early-onset mitochondrial disorders that are 
considered more likely to lead to genetic diagnoses (Taylor et al., 2014; Wortmann et al., 
2015; Pronicka et al., 2016). Clinically, some patients with overlapping phenotypes may have 
different genetic aetiologies, while other patients with different phenotypes may have a 
similar genetic aetiology. Furthermore, muscle histopathology and molecular studies also 
demonstrate variability between patients, sometimes providing inconclusive evidence of 
mitochondrial dysfunction or mtDNA rearrangements. Therefore, approximately half of 
patients with clinically well-defined adult-onset Mendelian PEO remain without a confirmed 
genetic diagnosis following exclusion of known associated nuclear encoded genes. 
3.2 Aims  
This chapter reviews the genotypic and phenotypic heterogeneity of all patients from the 
literature with adult-onset Mendelian PEO and mtDNA instability, classifying all currently 
known nuclear encoded genes. 
3.3 Methods 
3.3.1 Patient Selection 
Published patients were identified using the following inclusion criteria; (1) adult patients, 
defined as 16 years old or older; (2) presenting PEO, which included the use of additional 
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descriptors such as ‘CPEO’, ‘ophthalmoparesis’, ‘ophthalmoplegia’, paresis or restricted 
movement of the extraocular muscles; (3) have evidence of skeletal muscle restricted multiple 
mtDNA deletions, mtDNA depletion or both; (4) have a confirmed genetic diagnosis of 
nuclear aetiology. 
3.3.2 Literature Search Strategy 
Electronic searches were performed for articles published between 1st January 1970 and 8th 
November using three online literature database; Scopus, PubMed and Genetics Abstracts, 
with additional searches performed with UniProt (Appendices B-E). This wide date range 
was selected to allow historic patients who received a genetic diagnosis in later publications 
to be included. Only English-language articles were included and duplicate articles retrieved 
from combined electronic searches were excluded. Patients reported in two or more published 
articles were included once only, with careful consideration taken when analysing articles 
reporting large, undefined patient cohorts. The following keywords were used for searches: 
‘PEO’, ‘CPEO’, ‘ophthalmoplegia’, ‘ophthalmoparesis’, ‘adult’ and ‘adult-onset’. Additional 
electronic searches were performed after 8th November 2013 to expand the initial remit of the 
systematic review.  
Figure 3.2 Flow of Articles Identified Systematically and Manually. Assessment of articles 
identified systematically (1st January 1970 and 8th November 2013) and from additional 
searches. Figure adopted and amended from Sommerville et al. (2014). 
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3.3.3 Data Extraction and Analysis 
Articles were arranged by genes in the order of discovery with regards to involvement in 
adult-onset Mendelian PEO and mtDNA instability. Statistical and meta-analyses were not 
performed due to the vast numbers of patients and the variation in the quality of articles. 
3.4 Results 
3.4.1 Identification and Assessment of Adult-Onset PEO and mtDNA Instability  
A total of 1129 articles were retrieved from the electronic searches using the set search terms. 
Of this, 164 articles described 594 patients who met the inclusion criteria and harboured 
variants of 12 nuclear encoded genes. A large number of patients initially identified were 
excluded, due to symptoms presenting before 16 years of age, an undetermined genetic 
aetiology or a non-mitochondrial aetiology. Additional manual searches after 8th November 
2013 identified a further 73 patients in 24 articles (including one unpublished article) with 
SPG7, AFG3L2, DNM2 and RNASEH1 variants, plus additional patients with variants of 
known genes (Figure 3.2). Five patients were also reported with digenic inheritance of two 
heterozygous mutations associated with PEO. Hence, 16 nuclear encoded genes were 
identified where variants cause adult-onset PEO and mtDNA instability in 667 patients 
(Table 3.1). All mutations are listed in Appendices F, G, I and K. 
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Gene Genotype Effect on mtDNA # Patients # Articles 
POLG AD and AR Multiple deletions and depletion 280 73 
TWNK AD Multiple deletions and depletion 161 39 
OPA1 AD Multiple deletions 53 12 
TYMP AR Multiple deletions and depletion 51 33 
RRM2B AD and AR Multiple deletions and depletion 42 6 
SLC25A4 AD Multiple deletions 39 8 
SPG7 AD and AR Multiple deletions 12 2 
RNASEH1 AR Multiple deletions 12 2 
TK2 AR Multiple deletions 8 4 
MGME1 AR Multiple deletions 3 1 
POLG2 AD Multiple deletions 3 3 
AFG3L2 AD Multiple deletions 2 1 
DGUOK AR Multiple deletions 2 1 
DNA2 AD Multiple deletions 1 1 
MPV17 AR Multiple deletions 1 1 
DNM2 AD Multiple deletions 1 1 
Table 3.1 Nuclear Genes Associated with Adult-onset PEO and mtDNA Instability. All 
16 genes currently associated with adult-onset Mendelian PEO and mtDNA instability and the 
number of affected patients reported. Four patients had digenic variants (variants of two 
genes). AD – autosomal dominant. AR- autosomal recessive. 
3.4.2 TYMP – Thymidine Phosphorylase 
TYMP encodes thymidine phosphorylase, which is essential for the nucleotide salvage 
pathway, converting thymidine (dT) to thymine and deoxyuridine (dU) to uracil. TYMP 
variants cause the multisystem disorder mitochondrial neurogastrointestinal encephalopathy 
(MNGIE), of which PEO is a prominent feature. There were 51/667 (7.6%) patients from 33 
articles that met the review criteria. All patients had recessive variants; either homozygous or 
compound heterozygous. Splice variants were particularly prevalent in comparison to variants 
of other genes associated with PEO and mtDNA instability (Appendix G), which were 
generally missense changes. Hence, patients had depleted TYMP activity that was typically 
below 5% compared to controls. Most patients had mtDNA depletion in the skeletal muscle 
where such analyses were performed, although a small number had multiple mtDNA deletions 
or both (Nishino et al., 1999a; Nishino et al., 2000).  
The most prominent feature of MNGIE was gastrointestinal dysmotility, which varied in 
severity between patients. Some of the common associated symptoms included borborygmi, 
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abdominal pain, diarrhoea, vomiting and early satiety. MNGIE-like phenotypes were 
described in several patients with pathogenic variants of different PEO-associated nuclear 
genes, including a patient with recessive RRM2B variants (Shaibani et al., 2009) and some 
patients with POLG variants (Filosto et al., 2003; Bostan et al., 2012; Tang et al., 2012; 
Woodbridge et al., 2013; Horga et al., 2014), but whom all had normal TYMP activity. 
Additionally, leukoencephalopathy typical of TYMP patients was also absent in these 
additional patients (Van Goethem et al., 2003a). Almost all patients had myopathy, which 
included muscle weakness and atrophy. Patients also frequently had peripheral or sensory 
neuropathies, including absence of deep tendon reflexes. Retinopathy, hearing loss or both 
were also frequently described (Hirano et al., 1994; Hamano et al., 1997; Carrozzo et al., 
1998; Hirano et al., 1998; Nishino et al., 2000; Blazquez et al., 2005; Blondon et al., 2005a; 
Marti et al., 2005; Amiot et al., 2009; Laforce et al., 2009; Massa et al., 2009; Filosto et al., 
2011; Etienne et al., 2012). Three patients also apparently had no gastrointestinal dysmotility 
(Gamez et al., 2002; Giordano et al., 2006; Filosto et al., 2011). However, the distinct and 
progressive MNGIE phenotype observed in all other patients suggest that this may yet to 
present. 
MNGIE is an early-onset mitochondrial disorder with a distinct, progressive phenotype with 
poor prognosis. Typically, patients presented with in the first decade of life or early teens and 
therefore, several were excluded from the review. Onset of symptoms after 30 years of age 
was rare. Despite the characteristic features of MNGIE, there was no correlation between 
TYMP variants and phenotype. 
3.4.3 SLC25A4 – ADP/ATP Translocase 1 
SLC25A4, also known as ANT1, encodes ADP/ATP translocase 1 and is required for the 
exchange of ADP from the cytoplasm with ATP generated by mitochondria (Stepien et al., 
1992). There were 39/667 (5.8%) patients with dominant SLC25A4 variants in eight articles 
who presented indolent or mild PEO phenotypes, with or without ptosis (Kaukonen et al., 
2000; Napoli et al., 2001; Komaki et al., 2002; Deschauer et al., 2005). The majority of 
patients had a heterozygous c.340G>C (p.Ala114Pro) variant. Reduced hearing ability was 
described in several members of an Italian family, while generalised myopathy was described 
in some members of another Italian family (Kaukonen et al., 2000).  
Four patients had striking psychiatric symptoms (Siciliano et al., 2003; Deschauer et al., 
2005; Galassi et al., 2008). This included a late-onset patient with severe depression, 
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insomnia and nocturnal panic attacks, bradykinesia, rigidity, slurred speech, dysphagia, 
dysmetria, bilateral postural-action tremor and absent deep-knee tendon reflexes. This patient 
was found to have heterozygous SLC25A4 c.865G>A (p.Val289Met) and POLG c.1399G>A 
(p.Ala467Thr) variants that may explain the severe phenotype in comparison to other 
SLC25A4 patients. Schizoaffective disorder was described in a female with bilateral ptosis, 
mild limb weakness and retinopathy but who had two affected siblings without psychiatric 
features (Deschauer et al., 2005). Bipolar affective disorder was also described in a mother 
and daughter; the mother had bilateral facial bradykinesia, temporal wasting, ataxic gait, 
peripheral neuropathy and hearing loss, while her daughter had a milder phenotype of 
exercise intolerance (Siciliano et al., 2003). Both shared a heterozygous p.Leu98Pro variant 
that was also found in Italian families with mild PEO phenotypes but without psychiatric 
symptoms. 
Dominant SLC25A4 variants manifest mild but often varied adult-onset PEO phenotypes, 
even in patients harbouring the same variant. A family history of PEO was reported in all 
cases except for one apparently de novo case. Multiple mtDNA deletions were also found in 
muscle from all analysed patients. Recently, the genotype-phenotype correlation has been 
further complicated by the identification of neonatal-onset patients with severe mtDNA 
depletion due to de novo heterozygous SLC25A4 variants (Thompson et al., 2016). Recessive 
SLC25A4 variants have also been associated with mitochondrial myopathy, hypertrophic 
cardiomyopathy (HCM) and mtDNA instability, but without PEO or muscle weakness 
(Palmieri et al., 2005; Echaniz-Laguna et al., 2012; Korver-Keularts et al., 2015).  
SLC25A4 variants continue to be a rare cause of adult-onset PEO and mtDNA instability but 
should be considered in all suspect patients with mild or indolent PEO, particularly those with 
facial weakness.  
3.4.4 POLG – DNA Polymerase Gamma Subunit 1 
POLG encodes the catalytic subunit of the only known DNA polymerase of mitochondria, 
required for the binding and processing of newly synthesised DNA. There were 280/667 
(42.0%) patients from 73 articles that met the review criteria harbouring predominantly 
dominantly inherited, heterozygous POLG variants and a smaller number harbouring 
recessive variants.  
POLG variants were the most frequently reported cause of adult-onset Mendelian PEO and 
mtDNA instability in the literature, presenting a heterogeneous, broad spectrum of 
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overlapping features (Appendix H). Patients typically presented systemic or complex 
phenotypes; indolent PEO with or without ptosis was uncommon. Due to significant numbers 
of patients identified, adult-onset PEO associated with mtDNA instability and POLG variants 
have been categorised by clinical features to assist in diagnosis (Cohen et al., 1993). 
 Autosomal dominant PEO (adPEO) – Patients have phenotypes ranging from indolent 
PEO to PEO-plus, which also frequently include non-systemic features. 
 Autosomal recessive PEO (arPEO) – Similar to adPEO, some patients present non-
systemic features. However, ataxia and MNGIE-like manifestations have also been 
described (Van Goethem et al., 2003a; Tang et al., 2012). 
 Myoclonic epilepsy myopathy and sensory ataxia (MEMSA) – This includes patients who 
present with ataxia usually as the first symptom, epilepsy, proximal or distal myopathies, 
but who do not have ophthalmoparesis. MEMSA was previously classified as 
Spinocerebellar Ataxia with Epilepsy (SCAE). 
 Ataxia Neuropathy Spectrum (ANS) – Approximately 90% of patients within this 
spectrum present with ataxia and neuropathy, while muscle weakness is uncommon. This 
encompasses the previous classifications of Sensory Ataxia Neuropathy Dysarthria and 
Ophthalmoparesis (SANDO) and Mitochondrial Recessive Ataxia Syndrome (MIRAS). 
Sensory or cerebellar ataxia were common features due to POLG variants and were often 
associated with peripheral sensory neuronopathy. However, the true extent of affected patients 
reported in the literature was unclear due to incomplete patient descriptions or non-specific 
terms for neuropathies. POLG-associated muscle weakness was predominantly proximal or 
manifested as exercise intolerance, although a significant number of patients presented distal 
weakness; a rare feature due to variants of other adult-onset PEO associated nuclear-genes.   
Additional, non-syndromic features reported included diabetes mellitus, dysphagia, dysarthria 
and dysphonia. Liver involvement was also uncommon in adults with POLG variants (Neeve 
et al., 2012). Interestingly several female patients had premature ovarian failure (POF) 
(Pagnamenta et al., 2006; Hudson et al., 2007; Blok et al., 2009; Baruffini et al., 2011), 
which appeared to be confined to POLG variants with the exception of one female with a 
pathogenic TWNK variant (Virgilio et al., 2008). Extrapyramidal features were also frequently 
reported. There were 46 patients who had Parkinsonism (Del Bo et al., 2003; Luoma et al., 
2004; Mancuso et al., 2004b; Pagnamenta et al., 2006; Invernizzi et al., 2008; Remes et al., 
2008; Betts-Henderson et al., 2009; Synofzik et al., 2010a; Ferreira et al., 2011a; Milone et 
al., 2011; Gurgel-Giannetti et al., 2012; Dolhun et al., 2013; Mukai et al., 2013; Horga et al., 
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2014; Miguel et al., 2014; Delgado-Alvarado et al., 2015; Martikainen et al., 2016; Mongin et 
al., 2016). Dystonia was less common but may also be suggestive of a POLG associated 
disorder (Paus et al., 2008; Remes et al., 2008; Horga et al., 2014; Rajakulendran et al., 
2016). Dementia was also a common manifestation (Van Goethem et al., 2004; Horvath et al., 
2006b; Komulainen et al., 2010; Martikainen et al., 2010; Tang et al., 2011; Dolhun et al., 
2013; Roos et al., 2013a), as was depression or avoidant personalities (Lamantea et al., 2002; 
Van Goethem et al., 2003a; Luoma et al., 2004; Mancuso et al., 2004a; Kollberg et al., 2005; 
Hudson et al., 2007; Galassi et al., 2008; Schulte et al., 2009; Echaniz-Laguna et al., 2010b; 
Synofzik et al., 2010a; Gurgel-Giannetti et al., 2012; Palin et al., 2012; Dolhun et al., 2013).  
There were 91 POLG variants identified that were associated with adult-onset PEO 
(Appendix I). This comprised of 78 missense changes, six nonsense variants, three frameshift 
variants, two splice-site variants, one in-frame deletion and one stop-loss variant. The most 
commonly occurring variants were c.1399G>A, p.Ala467Thr; c.2243G>C, p.Trp748Ser, 
c.1760C>T, p.Pro587Leu and c.752C>T, p.Thr251Ile, which were associated with recessive 
inheritance. Nonetheless, most variants were reported in small numbers or in single patients 
and were chiefly pathogenic dominant variants. However, there was no correlation between 
variants and phenotypes. Patients with overlapping features who harbour known and novel 
POLG variants continue to be reported, often using previous classifications of SANDO, 
SCAE and MIRAS for diagnosis. Taken together, both dominant and recessive pathogenic 
POLG variants should be screened for in undiagnosed adult-onset PEO patients with 
suspected Mendelian aetiology.  
3.4.5 TWNK – Twinkle 
TWNK (C10orf2 or Twinkle) encodes a DNA helicase that catalyses the ATP-dependent 
unwinding of mtDNA in the 5’ to 3’ direction, co-localising with the mtDNA in the nucleoids 
(Spelbrink et al., 2001; Korhonen et al., 2003). Autosomal dominant TWNK variants 
comprised the second largest group of patients, with 161/667 (24.1%) patients described in 39 
articles. TWNK variants manifested in a broad phenotypic spectrum ranging from indolent 
PEO to a fatal multisystem disorder (Appendices J and K). Features that were particularly 
common included proximal muscle weakness, gait weakness, exercise intolerance and fatigue. 
Additional features included diabetes mellitus, visual loss or impairment and ataxia. One 
patient had also POF (Virgilio et al., 2008), a feature more frequently observed in females 
with pathogenic POLG variants but also in Perrault syndrome due to recessive TWNK variants 
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without ophthalmoparesis or mtDNA instability (Morino et al., 2014; Demain et al., 2016; 
Lerat et al., 2016).  
Three patients were reported harbouring digenic variants that included one pathogenic TWNK 
variant. The first had heterozygous TWNK c.1001G>A (p.Arg334Gln) and POLG c.2542G>A 
(p.Gly848Ser) variants who presented PEO, ptosis, depression and severe dysphagia that led 
to cachexia, dysarthria, generalised myopathy and pyramidal signs (Van Goethem et al., 
2003a). The second patient had heterozygous TWNK c.1142T>C (p.Leu381Pro) and POLG 
c.2831A>G (p.Glu944Gly) variants and presented late-onset PEO, bilateral ptosis, had a short 
stature, dysphagia and reduced deep tendon reflexes (Da Pozzo et al., 2015). The third patient 
had heterozygous TWNK c.1121G>A (p.Arg374Gln) and TYMP c.317G>C (p.Glu106Gly) 
variants leading to a complex, late-onset MNGIE-like phenotype comprising PEO, bilateral 
ptosis, irregular abdominal pain, gastrointestinal dysmotility, fatigue and prominent 
myopathy, without evidence of mtDNA instability (Nakhro et al., 2011). The identification of 
patients with co-existing variants causing adult-onset PEO suggests that digenic inheritance 
may be a rare but important contributor to the pathogenesis.   
The prevalence of psychiatric symptoms was higher in patients with TWNK variants than in 
other adult-onset PEO associated genes. Depression and avoidant personalities were described 
in a cohort of patients (Spelbrink et al., 2001). The prevalence of dementia and Alzheimer’s 
disease was also higher than would be by chance (Spelbrink et al., 2001; Hudson et al., 2005; 
Virgilio et al., 2008; Echaniz-Laguna et al., 2010a). Parkinsonism was described in seven 
patients, including three affected members of the same family (Baloh et al., 2007). A 
deceased patient was also found to have scattered white matter lesions, but did not apparently 
present psychiatric symptoms, Alzheimer’s disease, Parkinsonism or dementia (Martin-
Negrier et al., 2011). 
HCM was described in several patients. This included a patient with right bundle branch 
block (Lewis et al., 2002), a cohort with left ventricular hypertrophy (Fratter et al., 2010) and 
a Chinese family with familial heart disease (Hong et al., 2010). An Arabian family with 
double nucleotide changes (c.1078C>G and c.1079T>G) leading to a heterozygous 
p.Leu360Gly missense change, had congestive cardiac failure together with severe 
hepatopathy and acute encephalopathy (Bohlega et al., 2009). 
Although present in all tested patients, multiple mtDNA deletions were not always prominent 
in the skeletal muscle. One patient also had mtDNA depletion in addition to mtDNA deletions 
(Jeppesen et al., 2008). Although less frequently described, TWNK variants present a broad 
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phenotypic spectrum similar to that of POLG variants, though multisystem disorders are less 
common. With variable and heterogeneous phenotypes, TWNK variants should be considered 
in all suspect adult-onset PEO patients, particularly those with psychiatric symptoms, 
cardiomyopathies or both. 
3.4.6 OPA1 – Optic Atrophy Protein 1 
OPA1 encodes the mitochondrial dynamin-like 120 kDa protein, which is required for 
regulating mitochondrial fusion and morphology (Olichon et al., 2002; Ishihara et al., 2006). 
Reviewing the clinical presentations of patients with pathogenic OPA1 variants revealed a 
distinctive, progressive phenotype that required amendment of the review criteria. Typically, 
OPA1 variants caused optic neuropathy, sometimes with additional visual abnormalities, 
within the first decade of life that progressed to PEO and other mitochondrial disease 
associated symptoms in adult life. Therefore, the review criteria were relaxed to include 
patients that presented before 16 years old. With this amended criteria, 53/667 (7.9%) patients 
in 12 articles with pathogenic heterozygous OPA1 variants were identified. 
Sensorineural hearing loss (SNHL) was the most prominent feature, present in almost all 
patients. Other frequently described features included ataxia, axonal neuropathy, ptosis, 
proximal myopathy and exercise intolerance. A small number of patients also had one or more 
of migraines, diabetes, Parkinsonism, dementia or epilepsy (Yu-Wai-Man et al., 2010a; 
Carelli et al., 2015). One patient who also presented with hypogonadism and macrocytic 
anemia was initially diagnosed with a heterozygous POLG2 variant but was later found to 
have a pathogenic OPA1 variant, which was presumed the most likely genetic aetiology 
(Ferraris et al., 2008). Multiple mtDNA deletions were detected in all patients where such 
analyses were performed. 
OPA1 variants were first described in patients presenting non-syndromic autosomal dominant 
optic atrophy (ADOA), with mitochondrial disease associated features described later (Payne 
et al., 2004), referred to as ADOA-plus. However, the phenotype had been historically 
described in the literature (Treft et al., 1984; Meire et al., 1985). Delineating the genotype-
phenotype correlation between ADOA and ADOA-plus is not currently possible since these 
overlapping phenotypes can be caused by the same variant. For example, the c.1334G>A, 
p.Arg455His variant has been described in 12 patients with optic atrophy, PEO and multiple 
mtDNA deletions, but also in patients with pure ADOA (Shimizu et al., 2003). 
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Phenotypically, patients with OPA1 variants are similar to those with Leber Hereditary Optic 
Neuropathy (LHON) (Yu-Wai-Man et al., 2003).   
OPA1 variants have been extensively studied and described in patients with ADOA-plus, 
which include features such as ophthalmoparesis and hearing loss or with pure ADOA. 
Therefore, targeted OPA1 screening should be performed in all patients that present optic 
atrophy within the first decade of life or adolescence, independent of additional syndromic 
features.  
3.4.7 POLG2 – DNA Polymerase Gamma Subunit 2 
POLG2 encodes the mitochondrial DNA polymerase gamma accessory subunit, which binds 
to single-stranded DNA and is required for mtDNA replication and embryogenesis, as evident 
from mouse models demonstrating a single copy of POLG2 is sufficient to sustain life 
(Humble et al., 2013).  
There were 3/667 (0.4%) patients with heterozygous POLG2 variants reported in three 
articles. The first was a 19 year old female with a heterozygous p.Arg369Gly variant 
presented a multisystem disorder comprising PEO and ptosis with gastrointestinal reflux, 
delayed gastric emptying, apnoea and respiratory insufficiency (Young et al., 2011). She had 
Duchene Muscular Dystrophy (DMD)-like muscle weakness, was easily fatigued and suffered 
from exercise-induced cramps. The second patient was a 55 year old male who also had the 
same POLG2 variant (Craig et al., 2012), for whom a family history of PEO and ptosis was 
reported. He developed ptosis at 30 years of age, followed by the gradual progression of 
ophthalmoparesis, cerebellar ataxia, exercise intolerance, proximal myopathy, absent knee 
jerk response and the inability to walk from heel to toe. The third patient was a 60 year old 
female with a heterozygous c.1352G>A (p.Gly451Glu) variant (Longley et al., 2006), 
presenting progressive PEO and ptosis that was preceded by exercise intolerance and muscle 
pain from the age of 40. Mild facial and limb muscle weakness, glucose intolerance and a 
cardiac conduction defect were also noted. A family history of PEO and ptosis was also 
reported including her similarly affected mother. 
Classification of adult-onset PEO patients with heterozygous POLG2 variants is difficult due 
to small number identified, the broad range of symptoms and the variation in clinical 
progression. This is further complicated by the identification of patients with juvenile-onset 
phenotypes (Young et al., 2011) and the identification of a patient with early-onset mtDNA 
hepatocerebral depletion syndrome associated with a homozygous POLG2 variant (Varma et 
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al., 2016). Nevertheless, proximal muscle was a common feature in all three adult PEO 
patients. Although rare, POLG2 variants should be considered in all adult-onset PEO patients, 
especially those with multisystem phenotypes.    
3.4.8 RRM2B – Ribonucleotide Reductase Subunit M2B 
RRM2B encoding ribonucleoside-diphosphate reductase subunit M2 B (p53R2) is required for 
the supply of deoxynucleotide triphosphates (dNTPs) for nuclear and mtDNA replication 
(Bourdon et al., 2007). 
There were 42/667 (6.3%) patients identified in six articles with pathogenic RRM2B variants, 
resulting in broad phenotypes comparable to those caused by POLG and TWNK variants. In 
total, there were 16 pathogenic RRM2B variants reported. The most common pathogenic 
variant was the c.979C>T (p.Arg327*) nonsense change harboured by 19 patients. This was 
described in a four generation family, including some members who were unaware that they 
were affected with mild PEO, myopathy and exercise intolerance, plus a Hungarian family 
with the proband also presenting with mild gait ataxia and decreased reflexes (Tyynismaa et 
al., 2009b). Among all RRM2B patients, the most frequent features were hearing loss, muscle 
atrophy and exercise intolerance (Fratter et al., 2011; Kato et al., 2011; Takata et al., 2011). 
Almost all patients had dominant RRM2B variants, but two adult patients with recessive 
variants were also reported. The first patient had a homozygous p.Pro33Ser variant and 
presented with PEO, ptosis, hearing loss and had a depressive mood and anxiety (Takata et 
al., 2011). The second patient had compound heterozygous (c.329G>A, p.Arg110His and 
c.362G>A, p.Arg121His) variants and presented PEO, ptosis, nausea, gastrointestinal 
dysmotility, cachexia, dysarthria and hearing loss (Shaibani et al., 2009), which closely 
resembled MNGIE and early-onset RRM2B patient phenotypes (Bourdon et al., 2007). 
Furthermore, this was the only adult-onset RRM2B patient to have mtDNA depletion; at 12% 
compared to age-matched controls. Multiple mtDNA deletions were described in all other 
tested patients.  
Interestingly, a synonymous c.48G>A variant was also identified in three patients (Pitceathly 
et al., 2012). This c.48G>A change was found to occur in the last nucleotide of exon 1 and 
predicted to result in aberrant splicing, which was demonstrated by RNA analysis showing the 
abolition of normal exon 1 and 2 splicing with partial intron retention leading to premature 
translation (Pitceathly et al., 2012). This is currently the only known pathogenic synonymous 
variant in any of the 16 known adult-onset PEO associated genes. 
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RRM2B variants are the fifth most described cause of adult-onset PEO and present a broad 
phenotypic spectrum. Although there was a single patient with a MNGIE-like phenotype, 
multisystem disorders arising from RRM2B variants are considered rare. Targeted RRM2B 
screening is recommended in all adult-onset PEO patients, especially where other systemic 
features such as hearing loss, bulbar involvement and gastrointestinal dysmotility present.  
3.4.9 TK2 – Thymidine Kinase 2 
TK2 encodes thymidine kinase 2, an essential component of the mitochondrial nucleotide 
salvage pathway that generate dNTPs for mtDNA replication. There were 8/667 (1.2%) 
patients identified with recessive TK2 variants; four patients from the literature (Tyynismaa et 
al., 2012; Alston et al., 2013; Camara et al., 2015) and four unpublished patients (Garone et 
al., submitted). TK2-deficiency has been more widely described in early-onset patients with 
mtDNA depletion syndrome, who present a severe phenotype leading to premature death 
(Saada et al., 2001). 
The four published adult patients comprised two affected sisters and two unrelated female 
patients. The affected first sister developed progressive bilateral ptosis at 47 years of age and 
received blepharoplasty at 52. Skin sarcoidosis, progressive leg muscle weakness and mild 
atrophy, scapular winging and difficulty in rising from a squatted position were noted at 49; 
PEO did not develop until 52 years old. Although able to walk unaided at 64, she developed 
dysarthria, dysphagia and died of pancreatitis, associated pneumonia and respiratory 
insufficiency. Her affected sister developed ptosis in her 30s or 40s, which was operated on 
three times (41, 46 and 48 years old). During her 40s she also developed progressive proximal 
arm and leg muscle weakness, but did not seek medical attention until 54 years old. At this 
time PEO and walking difficulties were also noted, but at 59 years old normal eye movements 
and only mild ptosis were seen. She also had scapular winging on both sides, dysphagia 
without facial muscle weakness and respiratory insufficiency. Both sisters were found to have 
compound heterozygous TK2 variants (c.547C>T, p.Arg183Trp and c.562A>G, p.Thr188Ala) 
(Tyynismaa et al., 2012). The third patient was a 74 year old female with hearing loss, mild 
ptosis, subtle PEO, facial weakness, proximal muscle atrophy including scapular winging and 
of the sternocleidomastoids and weak neck flexion and extension. She carried compound 
heterozygous TK2 variants (c.103C>T, p.Gln35* and c.582G>T, p.Lys194Asn) (Alston et al., 
2013). The fourth patient presented with mild PEO, severe ptosis, limb girdle muscle 
weakness, dysphagia, dysarthria and facial diplegia. This patient harboured a homozygous in-
frame c.604_606del (p.Lys202del) deletion (Camara et al., 2015). All four unpublished 
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patients (Garone et al. submitted) presented initially with progressive myopathy, PEO, ptosis 
and with multiple mtDNA deletions. Three patients had dysphagia. Respiratory insufficiency 
also manifested in three patients, of which two required ventilatory support. An unpublished 
patient corresponds to patient 4 (4.4.6), who harboured a homozygous c.323C>T 
(p.Thr108Met) TK2 missense variant identified by WES.   
All eight adult-onset PEO patients with TK2-deficiency presented with a late-onset and 
slowly progressive myopathy, with PEO and ptosis of varying severity while often developing 
scapular winging and respiratory involvement. Although rare, targeted TK2 gene screening 
should be considered in all PEO patients with progressive myopathies and reduced respiratory 
capacity.  
3.4.10 DGUOK – Deoxyguanosine Kinase 
DGUOK encodes deoxyguanosine kinase and is essential for dNTP generation via the 
mitochondrial nucleotide salvage pathway for mtDNA replication (Jullig and Eriksson, 2000), 
similar to TK2. There were only 2/667 (0.3%) patients described with recessive DGUOK 
variants in one article (Ronchi et al., 2012b). 
The first adult patient was a 69 year old female who presented indolent PEO and ptosis at 58 
years old, although a sibling was noted to have exercise intolerance. The second patient was a 
72 year old female who presented with PEO and bilateral ptosis for over 20 years, occasional 
dysphagia for liquids and complained of upper and lower limb girdle muscle weakness with 
leg cramps in later life. Both these patients shared a heterozygous c.462T>A (p.Asn154Lys) 
DGUOK variant. However, the 69 year old female also had a c.605_606del (p.Arg202Tyrfs*) 
frameshift variant, while the 72 year old female had an additional c.130G>A (p.Glu44Lys) 
missense change. These variants had also been previously described in early-onset DGUOK 
patients (Dimmock et al., 2008). Unlike the mtDNA depletion syndrome patients, liver 
function in both adults was normal. 
To date, pathogenic DGUOK variants are predominantly associated with early-onset 
hepatocerebal mtDNA depletion syndrome (Mandel et al., 2001; Dimmock et al., 2008). 
Therefore, DGUOK variants remain a very rare cause of adult-onset PEO. 
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3.4.11 MPV17 – MPV17 Mitochondrial Inner Membrane Protein 
MPV17 encodes a mitochondrial inner membrane protein that has yet to be fully 
characterised, although it is believed to be associated with the mitochondrial nucleotide 
salvage pathway and dNTP balance for mtDNA replication (Spinazzola et al., 2006; Dalla 
Rosa et al., 2016). Currently, only 1/667 (0.1%) patient with adult-onset PEO, multiple 
mtDNA deletions who had recessive MPV17 variants has been reported in one article (Garone 
et al., 2012). MPV17 variants are frequently associated with early-onset hepatocerebal 
mtDNA depletion syndrome (Spinazzola et al., 2006; El-Hattab et al., 2010), which is 
comparable to that caused by DGUOK variants. 
The patient was a 67 year old male born to non-consanguineous parents who developed distal 
limb muscle weakness and numbness at 34 years old, leading to an initial diagnosis of 
Charcot-Marie-Tooth disease following nerve conduction and EMG studies. This progressed 
to proximal limb muscle weakness, exercise intolerance, diabetes, ptosis, ophthalmoparesis, 
hearing loss, severe constipation due to gastrointestinal dysmotility and depression in his 40s. 
At 65 years old, he had Parkinsonism with bradykinesia, bilateral resting tremor and mild 
rigidity. He was also found to have a fatty liver following ultrasonography of the abdomen. 
His mother reportedly had ptosis, while his sister died of unexplained liver failure at 39 years 
old. WES identified three heterozygous MPV17 variants (c.263A>T, p.Lys88Met; c.265A>T, 
p.Met89Leu; and c.428T>G, p.Leu143*). The p.Lys88Met missense change had been 
previously described in patients with early-onset hepatocerebal mtDNA depletion syndrome 
(El-Hattab et al., 2010). 
Ophthalmoparesis and axonal sensory-motor neuropathy preceding liver dysfunction in the 
adult patient was similar to that of some early-onset patients with MPV17 variants, whereas 
Parkinsonism and gastrointestinal dysmotility were additional features. Comparable to 
recessive DGUOK variants, MPV17 variants represent an extremely rare cause of adult-onset 
mitochondrial disease. 
3.4.12 MGME1 – Mitochondrial Genome Maintenance Exonuclease 1 
MGME1 encodes mitochondrial genome maintenance exonuclease 1, which has been 
demonstrated to be the cleavage of single-stranded DNA, processing DNA flap substrates and 
maintaining 7S DNA levels (Kornblum et al., 2013; Szczesny et al., 2013; Uhler et al., 2016). 
Only 3/667 (0.4%) patients from one article harbouring homozygous MGME1 variants were 
included in this review (Kornblum et al., 2013); two Italian brothers with a homozygous 
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c.456G>A (p.Trp152*) nonsense variant and a German female with a homozygous c.698A>G 
(p.Tyr233Cys) missense change. 
The Italian brothers, aged 53 and 42, were born to consanguineous parents and presented with 
mild bilateral ptosis in the third decade of life that progressed to insidious PEO, proximal 
myopathy, generalised muscle wasting and mild kyphosis that developed over time. Both 
were profoundly emaciated and suffered from respiratory insufficiency. The younger sibling 
developed sleep apnoeas and became dependent on continuous positive airway pressure 
(CPAP) at night, followed shortly afterward by the elder sibling who also required CPAP 
occasionally during the day. The German female presented with bilateral ptosis, generalised 
muscle weakness and fatigue at the age of 57. Further examination at 65 years old revealed 
PEO, diplopia, decreased deep tendon reflexes and dyspnea. Similarly to the Italian siblings, 
she developed respiratory insufficiency at 66 years old and began non-invasive ventilation 
with oxygen therapy at 67. Furthermore, she also suffered from chronic renal failure, cardiac 
arrhythmias, depressive episodes and memory lapses.  
Early-onset patients with MGME1 variants were also described, including three siblings who 
shared the same homozygous p.Trp152* variant as the two Italian brothers, with similar 
clinical presentations. Although the phenotype appears to be distinct and progressive, 
MGME1 variants remain extremely rare.  
3.4.13 DNA2 – DNA Replication ATP-Dependent Helicase/Nuclease DNA2 
DNA2 encodes a dual nuclear-mitochondrial helicase required for Okazaki fragment 
processing, nuclear and mtDNA repair, and telomere maintenance (Duxin et al., 2009). Only 
1/667 (0.1%) female patient, who presented at 35 years old, from one article has been 
described with adult-onset PEO, multiple mtDNA deletions and a single heterozygous 
c.2167G>A (p.Val723Ile) DNA2 variant (Ronchi et al., 2013). Clinical examination at 55 
years old showed that she had lower limb weakness, ophthalmoparesis, diplopia and myalgia. 
Three other adult patients presenting progressive myopathy, multiple mtDNA deletions and 
with heterozygous DNA2 variants have also been reported, but did not have extra ocular 
features. Nonetheless, DNA2 variants are considered a rare cause of adult-onset mitochondrial 
disease.    
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3.4.14 SPG7 – Paraplegin 
SPG7 encodes paraplegin, a mitochondrial inner membrane metalloprotease forming an m-
AAA protease holo-oligmer with AFG-3 like protein 2 (Casari et al., 1998). Following the 
initial systematic searches for adult-onset PEO and multiple mtDNA deletion patients, 
Wedding et al. (2014) and Pfeffer et al. (2014) described 12/667 (1.8%) patients identified by 
WES and targeted sequencing, who met the review criteria with dominant and recessive SPG7 
variants. There were 11 patients identified from a cohort of 68 patients with undiagnosed 
adult-onset PEO, indicating that SPG7 variants may be a common genetic cause. Eight 
patients had recessive variants and four had heterozygous variants, including the commonly 
described c.1529C>T (p.Ala510Val) variant. Of these, nine presented with the classical 
spastic paraplegia that had been previously associated with recessive SPG7 variants (Casari et 
al., 1998). Brain MRI revealed cerebellar atrophy in six patients and ataxia was described in 
10 patients, of which one patient was spastic. Only one patient presented isolated PEO. 
Typically, patients with SPG7 variants presented PEO and spastic ataxia or a progressive 
ataxia disorder. With a high frequency of patients reported with spastic paraplegia or 
progressive ataxia, this may direct targeted gene screening of SPG7 in undiagnosed patients.  
3.4.15 AFG3L2 – AFG3-like Protein 2 
AFG3L2 encodes AFG-like protein 2 and is known to associate with paraplegin in the 
mitochondrial inner membrane (Banfi et al., 1999; Di Bella et al., 2010). Pathogenic 
heterozygous AFG3L2 variants have been typically associated with adult-onset 
spinocerebellar ataxia 28 (SCA28). Only 2/667 (0.3%) patients from one article were 
identified following WES and targeted AFG3L2 screening (Gorman et al., 2015a). The first 
patient had an indolent gait and limb ataxia that had begun as a teenager. On clinical 
examination, this had progressed to a broad-ataxic gait with dysmetria and dysarthria. There 
was also a family history of ataxia. The second patient presented with slowly progressive 
ataxia and limb spasticity. Brain MRI revealed marked cerebellar atrophy. However, there 
was no prior family history. Nonetheless, both patients presented late-onset, slowly 
progressive PEO with slurred speech and limb muscle weakness. The first patient had a 
heterozygous c.2011G>T (p.Gly671Trp) variant, while the second patient had a heterozygous 
c.2065T>C (p.Tyr689His) variant. Both variants occurred in the hot-spot for pathogenic 
AFG3L2 variants, lending support to pathogenicity.  
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With only two patients identified, this suggests that pathogenic heterozygous AFG3L2 
variants are a very rare cause of late-onset PEO and multiple mtDNA deletions. Hence, 
targeted AFG3L2 gene screening may be considered for undiagnosed patients presenting late-
onset PEO with ataxia, spasticity or both.  
3.4.16 DNM2 – Dynamin 2 
DNM2 encodes dynamin-2, a widely expressed dynamin belonging to a subfamily of GTP-
binding proteins and is required for a variety of functions including membrane trafficking, 
endocytosis, neuron morphology and growth (Tinelli et al., 2013). Autosomal dominant 
DNM2 variants had been previously been reported as a cause of centronuclear myopathy 
(CNM) (Bitoun et al., 2005), CMT (Zuchner et al., 2005), hereditary spastic paraplegia (HSP) 
(Sambuughin et al., 2015) and a homozygous variant associated with lethal congenital 
contracture syndrome (Koutsopoulos et al., 2013). Mitochondrial abnormalities have also 
been described but are uncommon (Zanoteli et al., 2009; Catteruccia et al., 2013; Gal et al., 
2015).   
To date, 1/667 (0.1%) patient from one article, a 47 year old Hungarian female from a single 
article has been reported with PEO and multiple mtDNA deletions due to a heterozygous 
c.1105C>T (p.Arg369Trp) DNM2 variant (Gal et al., 2015). The p.Arg369Trp variant had 
been previously associated with centronuclear myopathy (Bitoun et al., 2005). The patient 
presented at 32 years old with difficulty tiptoeing, stair climbing, standing from a seated 
position and had frequent ankle sprains, weakness in the hands and generalised muscle 
weakness. On clinical examination at 42 years, she had a long myopathic face, 
ophthalmoparesis mostly affecting the left side, bilateral ptosis, diplopia, moderate atrophy of 
the hand and feet muscles, hammer toe and mild, predominantly distal muscle weakness. She 
also had cardiomyopathy, axonal neuropathy and mild depression. Her mother was also 
affected by ophthalmoparesis and severe cardiac failure but genetic investigation was not 
possible.  
Targeted DNM2 gene screening may be considered in adult patients with mtDNA deletions 
presenting PEO with axonal neuropathy and muscle weakness. However, the presence of 
central nuclei and low-level COX-deficiency in skeletal muscle together with clinical 
investigations, suggest that muscle histochemical studies are more beneficial in leading to the 
diagnosis of DNM2 patients.    
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3.4.17 RNASEH1 – Ribonuclease H1 
RNASEH1 encodes ribonuclease H1, a dual nuclear and mitochondrial endonuclease required 
for the degradation of RNA-DNA hybrids (Cerritelli and Crouch, 1998). Recessive RNASEH1 
variants are the most recent to be associated with adult-onset PEO and multiple mtDNA 
deletions. Currently, 12/667 (1.8%) patients from two articles have been reported (Reyes et 
al., 2015; Akman et al., 2016).  
Most patients presented initially with ptosis and progressive PEO during their twenties, 
although one patient presented at 45 years old, progressing to gait difficulties, ataxia and 
muscle weakness. One patient became wheelchair dependent late in life. Sensorimotor 
neuropathies manifested in several patients, while one presented with a mild motor 
myelinating neuropathy. In late life, three of four affected siblings had respiratory 
impairment. A fourth unrelated patient also had reduced respiratory capacity leading to an 
acute episode requiring a tracheotomy, but only mild respiratory deficit thereafter. One patient 
had HCM, though a second patient also died after a sudden cardiac event. Multiple mtDNA 
deletions were also detected in the skeletal muscle of all tested patients. Furthermore, all 
patients harboured a c.424G>A (p.Val142Ile) variant either homozygous (10 patients) or in 
compound (two patients) with a second variant (c.469C>T, p.Arg157* or c.554C>T, 
p.Ala185Val). 
RNASEH1 variants have only been recently described and therefore only a small number of 
patients are currently known. Nonetheless, all reported patients presented initially with adult-
onset ptosis and progressive PEO, which progresses to a multisystem disorder with 
respiratory involvement. 
3.5 Discussion 
Adult-onset mitochondrial PEO remains predominantly caused by mtDNA point mutations or 
a single, large scale deletion. Sixteen nuclear-encoded genes were identified that are 
associated with adult-onset PEO and mtDNA instability, leading to a broad spectrum of 
clinical features affecting multiple body systems (Table 3.2). There were 667 patients 
described in 188 published articles with confirmed genetic diagnoses (Table 3.1). Twelve 
genes were identified systematically; SPG7, AFG3L2, DNM2 and RNASEH1 variants were 
identified with additional searches, using the initial search terms employed. 
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POLG ++ ++ + + + + - + - 
TWNK ++ + ++ + + + - + - 
OPA1 ++ ++ + - - + - - - 
TYMP ++ ++ + - - ++ - - - 
RRM2B ++ ++ + + - + + - + 
SLC25A4 ++ + + - + - - - - 
SPG7 ++ ++ + - - - - - + 
RNASEH1 ++ ++ - + - - ++ - - 
TK2 ++ + - - - - + - - 
MGME1 ++ - + + - - ++ - + 
POLG2 ++ ++ - - - + + - - 
AFG3L2 ++ ++ - - - - - - - 
DGUOK ++ - - - - ++ - - - 
MPV17 ++ ++ ++ - ++ ++ - - - 
DNA2 ++ - - - - - - - - 
DNM2 ++ ++ ++ ++ - - - - - 
Table 3.2 Body Systems Affected in Adult-Onset PEO and mtDNA Instability Disorders. 
Summary of the body systems affected in adult-onset PEO and mtDNA instability due to 
nuclear-gene defects. NS – nervous system. ‘++’ - frequently involved. ‘+’ - rarely involved. 
‘-‘ – not involved. Adopted and amended from Sommerville et al. (2014). 
3.5.1 Influence of Publications on Systematic Review Quality 
Systematic reviews are greatly influenced by the quality of the papers describing the case 
studies. With 188 papers reporting patients from a period greater than 10 years, there was vast 
variation in the quality of reporting. Several patients identified from the literature were 
initially described without a confirmed genetic diagnosis, particularly before 1999, with 
molecular and genetic analyses of the same patients reported in later articles. For the purpose 
of this review, articles that described patients in the greatest detail were considered of a high 
quality. This included a full case report for each patient; containing the age of onset, age at 
clinical examination, a complete description of the phenotype, and full molecular and genetic 
analyses. This was notable in recent articles, but earlier papers and those describing large 
patient cohorts were poor. Age of onset was a key detail for this review, but was not described 
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in some earlier papers. It was challenging to determine if some patients should be included in 
the review. Ultimately, such patients were included if a dominant aetiology with multiple 
mtDNA deletions were confirmed, which was more likely to suggest onset of symptoms in 
adult-life. Articles reporting ‘juvenile’ patients were excluded, while ‘young adults’ were 
included. Therefore, it was not feasible to perform meta-analyses or statistical comparisons. 
3.5.2 Broad Phenotypic Spectrum of Adult-Onset PEO with Multiple mtDNA Deletions 
Patients with adult-onset PEO and mtDNA instability presented a broad spectrum of clinical 
features ranging from indolent or isolated PEO to fatal multisystem phenotypes. The broadest 
features were observed in patients harbouring POLG and TWNK variants, comprising over 
65% of all described patients in the literature who met the review criteria. It should be noted 
though that the prevalence of mutations in each gene identified from the literature may not be 
representative of the wider population (Gorman et al., 2015b). It was also not uncommon for 
the same pathogenic heterozygous variants of either POLG or TWNK to cause divergent 
phenotypes between patients. Psychiatric features such as depression or psychosis were 
particularly prevalent in patients with POLG and TWNK variants compared to other 
associated genes. POF was also confined to patients with either POLG or TWNK variants 
only. RRM2B variants also showed a diverse phenotypic spectrum, but were uncommon 
compared to POLG and TWNK variants. Nonetheless TWNK, RRM2B and SLC25A4 variants 
were more frequently associated with indolent or mild PEO phenotypes. POLG2 mutations 
were also associated with mild PEO and ptosis, with all patients also presenting proximal 
muscle weakness. Multisystem phenotypes were commonly associated with dominant or 
recessive POLG variants. Sensory ataxia, neuronopathy and Parkinsonism were also 
indicative of POLG variants.   
Though defining the genotype-phenotype correlations remains challenging, it was possible to 
delineate distinct phenotypes due to pathogenic OPA1, TYMP and SPG7 variants. Dominant, 
heterozygous OPA1 mutations caused optic atrophy with varying severity of visual loss in 
childhood, followed by ophthalmoparesis and mitochondrial myopathy in adult-life (Payne et 
al., 2004). Hence, it was vital to provide an exemption of the review criteria for OPA1 to 
allow inclusion this review. Similarly, recessive TYMP variants cause MNGIE with patients 
typically presenting gastrointestinal dysmotility of varying severity, encephalopathy, PEO and 
sensorimotor neuropathy (Nishino et al., 1999a). Unlike other associated nuclear-encoded 
genes, TYMP variants were frequently associated with mtDNA depletion in the skeletal 
muscle; multiple mtDNA deletions were uncommon. For patients with dominant and 
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recessive SPG7 variants, spastic ataxia was the prominent feature, in addition to PEO (Pfeffer 
et al., 2014; Wedding et al., 2014).  
Delineating the genotype-phenotype correlation for the remaining associated nuclear-encoded 
genes was not possible. This was due the inherent lack of patients who met the review criteria 
or because few patients were reported. Nonetheless, discrete features may direct targeted gene 
screening in undiagnosed patients. Respiratory insufficiency and myopathy were prominent in 
patients with recessive TK2, MGME1 or RNASEH1 variants. Also, patients with TK2 and 
MGME1 variants had generalised muscle wasting. However, onset in TK2 patients was 
typically later than those with MGME1 or RNASEH1 variants. Liver involvement in adult-
onset PEO was unmistakably rare, except for adults homozygous for the POLG p.Ala467Thr 
variant (Neeve et al., 2012), one adult patient with recessive DGUOK variants (Ronchi et al., 
2012b) and one adult patient with recessive MPV17 variants (Garone et al., 2012). 
Mendelian adult-onset, mitochondrial PEO was predominantly associated with multiple 
mtDNA deletions in the skeletal muscle. The exception was TYMP, which was generally 
association with mtDNA depletion. POLG variants were also associated with mtDNA 
depletion in adults harbouring recessive variants, particularly the frequently occurring 
p.Ala467Thr, p.Thr251Ile, p.Pro587Leu and p.Trp748Ser variants. Additional patients 
identified with depletion included one with a heterozygous TWNK variant (Jeppesen et al., 
2008) and one with compound heterozygous RRM2B variants that phenocopied MNGIE 
(Shaibani et al., 2009). Furthermore, disturbed mtDNA maintenance was not confirmed in a 
significant number of patients, which may be due to unavailable skeletal muscle for analysis. 
Inheritance of adult-onset Mendelian PEO was overwhelmingly due to autosomal dominant, 
heterozygous variants that were inherited or occurred de novo. POLG, RRM2B, and SPG7 
were associated with both dominant and recessively inherited PEO. TYMP, RNASEH1, TK2, 
MGME1, DGUOK and MPV17 variants were also associated with recessively inherited PEO 
only. Although rare, digenic inheritance of variants in nuclear-encoded genes associated with 
adult-onset PEO and mtDNA maintenance occurred more frequently than would perhaps be 
expected (Van Goethem et al., 2003a; Galassi et al., 2008; Nakhro et al., 2011; Da Pozzo et 
al., 2015), suggesting that it may be an under-recognised pathological mechanism. 
3.5.3 Concluding Remarks  
PEO is the most prominent feature of Mendelian mtDNA maintenance disorders, due to 
defects of nuclear-encoded genes essential for mtDNA integrity. Adult-onset Mendelian PEO 
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with multiple mtDNA deletions has been historically described in the literature (Zeviani et al., 
1989), though it was not until the discovery of TYMP variants using linkage analysis that the 
underlying genetic aetiology began to be deciphered (Nishino et al., 1999a). Although there 
are overlapping clinical features shared between mutations of different nuclear genes, there 
are some discrete features that can direct targeted gene sequencing of undiagnosed patients. 
Nonetheless, the phenotypic spectrum is broad and for several genes there are currently few 
patients reported to allow a complete delineation of phenotypes and progression. As further 
patients are reported in the literature, continued revision of the clinical spectrum of adult-
onset Mendelian PEO and mtDNA instability with further serve both clinicians and patients, 
providing crucial guidance on disease progression, treatment options and the development of 
therapeutic strategies.
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Chapter 4. WES of Adult-Onset PEO with Multiple mtDNA Deletions  
4.1 Introduction 
This chapter contains material from Garone et al. (submitted manuscript). Additional clinical, 
diagnostic and research support are provided from colleagues and external collaborators who 
are appropriately acknowledged. 
4.1.1 Adult-Onset PEO with Multiple mtDNA Deletions 
As discussed in Chapter 3, adult-onset Mendelian PEO with multiple mtDNA deletions 
presents a broad phenotypic spectrum ranging from indolent or isolated PEO to fatal 
multisystem PEO-plus syndromes (Sommerville et al., 2014). However, approximately 50% 
of patients are currently without a diagnosis. Overlapping phenotypes and variable muscle 
biopsy findings are often insufficient to indicate specific genes for targeted mutational 
screening. Also, family history is often negative or there is reduced penetrance between any 
additional affected members. Thus, determining autosomal dominant or recessive inheritance 
has been historically difficult. This is further complicated by patients presenting late in life, 
which limits segregation studies. Consequently, it has been challenging to provide a genetic 
diagnosis for these patients. This is reflected by the identification of only 14 known nuclear 
genes, expanded to 16 nuclear genes during this study (Chapter 3), that have been associated 
with this disorder to date, with roles in mtDNA replication, maintenance and repair. 
4.1.2 Identification of Novel mtDNA Maintenance Disorders using WES and WGS 
Although large-scale studies have primarily focused on early-onset mitochondrial respiratory 
chain deficiency (Lieber et al., 2013; Taylor et al., 2014; Wortmann et al., 2015; Kohda et al., 
2016; Pronicka et al., 2016), WES and WGS have successfully elucidated the genetic 
aetiology of some adult-onset PEO with multiple mtDNA deletions patients due to RRM2B 
(Tyynismaa et al., 2009a), TK2 (Tyynismaa et al., 2012), DGUOK (Ronchi et al., 2012a), 
MPV17 (Garone et al., 2012), MGME1 (Kornblum et al., 2013), DNA2 (Ronchi et al., 2013), 
SPG7 (Pfeffer et al., 2014), AFG3L2 (Gorman et al., 2015a) and RNASEH1 (Reyes et al., 
2015) mutations. Mutations of RRM2B, TK2, DGUOK and MPV17 were previously 
associated with early-onset mtDNA depletion syndrome (Mandel et al., 2001; Saada et al., 
2001; Spinazzola et al., 2006; Bourdon et al., 2007), hence rare or novel variants identified in 
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these genes would have been highly prioritised as potentially causing a late-onset mtDNA 
maintenance disorder. Autosomal recessive mutations of SPG7 encoding the mitochondrial-
AAA metalloprotease paraplegin, were first described in patients presenting with spastic 
paraplegia with additional neurological features that included ophthalmoparesis and ptosis 
with evidence of mitochondrial dysfunction (Casari et al., 1998). Autosomal dominant 
AFG3L2 mutations, encoding the catalytic subunit of the mitochondrial-AAA protease that 
interacts with paraplegia, were first reported in patients with spinocerebellar ataxia 28 
(SCA28) including some patients who additionally had ophthalmoparesis and ptosis (Cagnoli 
et al., 2006; Di Bella et al., 2010). Since (i) both AFG3L2 and SPG7 mutations were known 
to cause ophthalmoparesis, (ii) AFG-like protein 2 and paraplegin interact in the 
mitochondrial membrane and (iii) mitochondrial dysfunction had been noted in muscle 
biopsies of some SPG7 patients (Casari et al., 1998), the identified mutations in these genes 
from patients with adult-onset PEO and multiple mtDNA deletions would have been 
prioritised (Pfeffer et al., 2014; Wedding et al., 2014; Gorman et al., 2015a). MGME1, DNA2 
and RNASEH1 were the only genes that had not been associated with Mendelian human 
disease, prior to the identification of adults with mtDNA instability.  
4.1.3 Challenges of WES Variant Filtering and Prioritisation 
Almost all nuclear genes associated with adult-onset mtDNA maintenance disorders are 
directly involved with mtDNA replication, maintenance, repair or the synthesis and balance of 
nucleotide pools. However, current strategies employed for the filtering and prioritisation of 
mitochondrial disease candidate gene variants are incompatible for adult-onset PEO with 
multiple mtDNA deletions. Unless an autosomal dominant aetiology was anticipated, current 
strategies have focused on early-onset Mendelian mitochondrial disease with expected 
autosomal recessive (compound heterozygous and homozygous) or X-linked inheritance 
(Vasta et al., 2009; Calvo et al., 2012; Vasta et al., 2012; DaRe et al., 2013; Lieber et al., 
2013; Neveling et al., 2013; Taylor et al., 2014; Wortmann et al., 2015; Kohda et al., 2016; 
Legati et al., 2016; Pronicka et al., 2016). As stated in Chapter 3, adult-onset Mendelian 
PEO with multiple mtDNA deletions is predominantly associated with dominant, 
heterozygous variants and less frequently with autosomal recessively inherited variants. 
Secondly, several nuclear genes encode proteins that are not localised to mitochondria. 
Cytosolic enzymes are essential for the synthesis and balance of nucleotides that are imported 
to mitochondria for mtDNA replication, which includes TYMP encoding thymidine 
phosphorylase (Nishino et al., 1999b) and RRM2B encoding p53R2 (Bourdon et al., 2007). 
Although seemingly uncommon, filtering for nuclear genes encoding mitochondrial proteins 
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would exclude genes encoding cytosolic-targeted enzymes. Additionally, DNM2 encodes a 
dynamin-GTPase with its role in mitochondrial function yet to be fully understood. Finally, 
the complete mitochondrial proteome and mtDNA maintenance pathways have yet to be fully 
elucidated. MGME1 is the most prominent example of an essential enzyme for mtDNA 
maintenance that was uncharacterised prior to the identification of patients with multiple 
mtDNA deletions (Kornblum et al., 2013). Previously referred to as C20orf72, Kornblum et 
al. (2013) demonstrated that MGME1 encoded a mitochondrial exonuclease required for the 
cleavage of single-stranded DNA and the processing of DNA flap-substrates. The 
identification of patients allowed additional characterisation into the role of MGME1 in 
mtDNA replication. Nicholls et al. (2014) used MGME1 patient muscle and fibroblasts to 
demonstrate that MGME1 played a role in 5’ end processing of mtDNA, with unusually large 
mtDNA rearrangements in affected patients and that it interacted with POLG at the nucleoids. 
Further efforts to identify mtDNA maintenance genes included a genome-wide RNA 
interference (RNAi) screen in Drosophila melanogaster cells (Fukuoh et al., 2014). However, 
the study of model organisms such as D. melanogaster and Saccharomyces cerevisiae for 
identifying human mtDNA maintenance orthologs is not always appropriate due to 
evolutionary divergent pathways and mechanisms. It is also possible that genes encoding 
known nuclear genome maintenance proteins are dual-localised to nuclear DNA and mtDNA, 
such as DNA2 (Duxin et al., 2009), but to date have not been associated with mtDNA 
maintenance.  
Therefore, there is a need to devise a clear, concise strategy for the discovery and filtering of 
candidate gene variants identified by WES or NGS of adult-onset mtDNA maintenance 
disorders. This filtering strategy would be required to incorporate (i) autosomal dominant 
(heterozygous) and recessive (compound heterozygous or homozygous) inheritance, as patient 
family history may dictate; (ii) the prioritisation of genes encoding mitochondrial, cytosolic 
and nuclear proteins, which (iii) have known or putative roles in the transcription, replication 
or repair of DNA. In this chapter, a custom filtering strategy for the prioritisation of candidate 
gene variants is designed and applied to patients with clinically well-defined, genetically 
undetermined adult-onset PEO with multiple mtDNA deletions.  
4.2 Aims 
This chapter identifies candidate gene variants using a custom filtering strategy for the 
prioritisation of genes and variants in patients with clinically well-defined, genetically 
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undetermined adult-onset PEO with multiple mtDNA deletions, ranging from indolent PEO to 
fatal, PEO-plus multisystem phenotypes.   
4.3 Methods 
4.3.1 Recruitment of Patients 
Patients were clinically examined at the NHS Highly Specialised Service for Rare 
Mitochondrial Disorders, with diagnostic testing performed by the NHS Highly Specialised 
Mitochondrial Diagnostic Service Laboratory in Newcastle upon Tyne. There were 67 
patients (35 male, 31 female) identified with genetically undetermined, clinically well-defined 
adult-onset PEO and multiple mtDNA deletions. Diagnostic investigations were performed as 
described in 2.2.3. 
4.3.2 Targeted RNASEH1 Sanger Sequencing 
In addition to diagnostic genetic analyses, custom forward and reverse primer designs for all 
eight exons of RNASEH1 were designed to exclude pathogenic or likely pathogenic mutations 
in all 67 patients. Sanger sequencing confirmation and analysis were performed as described 
in 2.3. 
4.3.3 WES Selection Criteria 
Of the 67 clinically well-defined, genetically undetermined adult-onset PEO with multiple 
mtDNA deletions patients, 20 unrelated patients (14 male, 6 female) were selected for WES 
(Table 4.2). Patients were selected due to significant clinical, biochemical and molecular 
evidence suggestive of a disorder of mtDNA maintenance. Hence, it was considered highly 
likely that candidate variants in genes required or implicated in mtDNA maintenance would 
be identified. Criteria for selection were: -  
 Clinically well-defined adult-onset PEO; 
 Presence of multiple mtDNA deletions in skeletal muscle detected by at least one 
diagnostic assay (long-range PCR, Southern blotting or quantitative real time PCR 
assays); 
 COX-SDH histochemistry demonstrating ≥5% COX-deficient fibres; 
 Negative results in diagnostic whole mitochondrial genome sequencing; 
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 Negative results in diagnostically targeted nuclear gene screening of common PEO and 
multiple mtDNA deletions associated genes. 
4.3.4 Diagnostic Genetic Analysis of Nuclear Genes 
Diagnostic targeted gene screening of POLG (NM_002693), RRM2B (NM_015713), 
SLC25A4 (NM_001151), TWNK (NM_021830) and POLG2 (NM_007215.3) was performed 
in all 20 patients recruited for WES. TK2 (NM_004614.4) was sequenced for all patients 
except patients 3, 4 and 12. PABPN1 (NM_004643.3) GCN repeat analysis of exon 1 to 
exclude polyalanine tracts was performed for patient 14. 
4.3.5 WES Filtering and Analysis 
Called variants that passed quality score filtering were restricted to exonic (coding) or splice-
site variants, with a minor allele frequency (MAF) equal to or less than 0.01 (1%) of in-house 
exomes or external exome databases. The effect of missense variants on protein function were 
predicted using PolyPhen2, Align-GVGD and SIFT. However, in silico predictions were 
purely advisory and were not used to directly exclude candidates. Splice-site or nonsense loss-
of-function (LOF) variants were also considered. 
To confirm diagnostically targeted genes and RNASEH1 screening results, any filtered 
variants identified of the genes listed in 4.3.4 were examined. Next, any filtered variants 
identified in all other published nuclear genes associated with adult-onset PEO and multiple 
mtDNA deletions were examined; TYMP (NM_001257989), OPA1 (NM_130837), TK2 
(NM_004614), MPV17 (NM_002437), DGUOK (NM_080916), DNA2 (NM_001080449), 
SPG7 (NM_003119) and AFG3L2 (NM_006796). Filtered variants occurring in additional 
nuclear genes associated with mtDNA maintenance disorders were also examined; ABAT 
(NM_020686), DDHD1 (NM_030637), GFER (NM_005262), FBXL4 (NM_001278716), 
MFN2 (NM_001127660), SUCLA2 (NM_003850), SUCLG1 (NM_003849), TFAM 
(NM_003201) and WFS1 (NM_006005). 
Following the exclusion of known nuclear genes associated with mtDNA maintenance 
disorders, variants were filtered using GO-Terms associated with mitochondrial localisation, 
DNA replication and repair. GO-Terms employed allowed the inclusion of nuclear genes 
encoding proteins involved in DNA replication and repair, but that had not necessarily been 
associated with mtDNA maintenance to date. Therefore, nuclear and mtDNA maintenance 
genes were considered. GO-Terms used were the wildcard term ‘mitochondr*’, ‘DNA repair’, 
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‘replication’, ‘transcription’, ‘nucleotide’, ‘purine’, ‘pyrimidine’, ‘exonuclease’, 
‘polymerase’, ‘topoisomerase’, ‘ligase’, ‘helicase’ and ‘nucleoside’. CNVs were also analysed 
using the same employed GO-Terms. 
Lists of genes and called variants were categorised according to gene role and function, 
expected inheritance and association with human disease (if known). Autosomal dominant 
(heterozygous) variants were prioritised for patients with a known family history extending at 
least one generation. For patients with no known family history, both dominant and autosomal 
recessive (homozygous or compound heterozygous) variants were prioritised. 
To assess the potential pathogenicity of called variants, a simplified scoring system was used 
(Table 4.1). Since trios comprising the proband and parental WES datasets were not 
sequenced, segregation of variants was not included in variant prioritisation. The effect of 
missense on protein function were predicted using PolyPhen2, Align-GVGD and SIFT. 
However, in silico predictions were purely advisory and were not used to directly excluded 
candidates using the scoring system. Splice-site or nonsense loss-of-function (LOF) variants 
were also considered but not scored. Due to both autosomal dominant and recessive mutations 
in Mendelian mitochondrial PEO, the scoring system was also purely advisory. 
Mutation(s) Genotype  GO-Terms Mitochondrial Disease 
Gene? 
Sc
ore 
Mitochondr*  Replication/Mainte
nance/Repair Terms  
Y/N  Allele
-1 
Allele-
2 
c.?, 
p.? 
       
Table 4.1 Basic WES Variant Scoring System for Adult-Onset PEO with Multiple 
mtDNA deletions Patients. Genotype – 1 point for a heterozygous variant, 2 points for a 
recessive (homozygous, compound heterozygous) or hemizygous variant(s). Since 
mitochondrial disease was confirmed in biochemical and histopathological studies, 2 points 
were given for mitochondr* hits. ‘Replication/Maintenance/Repair Terms’ denotes any of the 
GO-Terms used for DNA replication and maintenance, with 1 point awarded for each 
matched term. 1 point was given if they gene was previously associated with mitochondrial 
disease. 1 point was given to each known pathogenic variant (compound heterozygous) or 2 
points for a known pathogenic homozygous or hemizygous variant. CNVs were also included 
in analysis. For this patient cohort, the scoring system was purely advisory in guiding 
prioritisation.  
Owing to the scores attained, variants could be classified into categories. Category-1 
comprised the highest level candidates. These variants met the following criteria: 
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 Autosomal dominant (1 point) or autosomal recessive (homozygous, compound 
heterozygous) or hemizygous (2 points), dependent on a known family history. 
 GO-Terms matched ‘mitochondr*’ (2 points) or one or more DNA 
replication/maintenance/repair terms (1 point each). 
 Known causative gene associated with adult-onset Mendelian PEO and multiple 
mtDNA deletions (1 point). 
 One or more previously reported causative mutation(s) (1-2 points).  
Category-2 was comprised of medium prioritised candidates. These variants met the 
following criteria: 
 Autosomal dominant (1 point) or autosomal recessive (homozygous, compound 
heterozygous) or hemizygous (2 points), dependent on a known family history. 
 GO-Terms matched ‘mitochondr*’ (2 points) or one or more DNA 
replication/maintenance/repair terms (1 point each). 
 Known causative gene associated with adult-onset Mendelian PEO and multiple 
mtDNA deletions (1 point) or a different mtDNA maintenance disorder (½ point). 
 One or more previously reported causative mutation(s) (1-2 points).  
Category-3 variants were considered low priority, since any role in mtDNA replication or 
maintenance would be unclear. These variants met the following criteria: 
 Autosomal dominant (1 point) or autosomal recessive (homozygous, compound 
heterozygous) or hemizygous (2 point), dependent on a known family history. 
 GO-Terms matched ‘mitochondr*’ (2 points) or one or more DNA 
replication/maintenance/repair terms (1 point each). 
 No known association with a mtDNA maintenance disorder (0 points). 
Finally, the last category were considered variants of unknown significance (VUS). In this 
instance, no appropriate candidate variants in nuclear genes encoding mitochondrial localised 
proteins were identified. Upon this failure, all dominant VUS were evaluated individually, 
since this was considered the most likely aetiology. All listed VUS in unsolved cases were 
reviewed at least every 2-3 months to ensure up-to-date findings from the literature were 
reflected. 
 Autosomal dominant (1 point). 
 No GO-Terms matched (0 points). 
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 No known association with a mtDNA maintenance disorder or other known human 
pathology (0 points). 
In comparison, the American College of Medical Genetics and Genomics (ACMG) standards 
and guidelines for the interpretation use a set of devised terminology to assess sequence 
variants (Richards et al., 2015). The ACMG standards and guidelines proposed two sets of 
criteria; one for classifying pathogenic or likely pathogenic variants and the second for 
classifying benign or likely benign variants. The criteria using this system were weighted 
upon the evidence available, including in silico scores, segregation of candidate variants, loss-
of-function, allele frequency and if the variant or gene were previously associated with human 
disease. To contrast with this study, the authors of the ACMG standards and guidelines did 
not opt to use a point scoring system, since as quantitative system was viewed as insufficient 
to account for the complexity of human genetic disorders.  
Custom forward and reverse primer design for candidate variants, PCRs, Sanger sequencing 
confirmation and analyses were performed as described in 2.3. If available, primers designed 
within the NHS Highly Specialised Mitochondrial Diagnostic Service Laboratory were used. 
A schematic of WES filtering for adult-onset PEO with multiple mtDNA deletions is given in 
Figure 4.1. 
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Figure 4.1 Adult-Onset PEO with Multiple mtDNA Deletions WES Filtering Strategy. 
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4.3.6 Cell Culture 
Cultured fibroblasts were grown for patient 14 and two appropriate age-matched controls. 
Subculturing, freezing, harvesting and generation of quiescent fibroblasts were performed as 
described in 2.4. 
4.3.7 Western Blotting 
Patient 14 and control fibroblast lysates were prepared and subjected to 12% SDS-page, 
probed with primary and secondary antibodies (Table 2.4, Table 2.5) then detected as 
outlined in 2.5. Membranes were incubated with primary antibodies specific to POLRMT, 
MRPL12 and SDHA. β-Actin was used as a loading control. 
4.3.8 Quantitative Real Time PCR for mtDNA Quantification 
DNA was extracted from proliferating and quiescent fibroblasts of patient 14 and two 
controls. Quantitative real time PCR was performed as outlined in 2.3.10. 
4.3.9 Long Range PCR of Quiescent Fibroblast DNA 
Long-range PCR of quiescent patient 14 and two control fibroblast DNA plus 1:10 control 
blood DNA homogenate was performed as outlined in 2.3.9. 
4.4 Results 
4.4.1 Targeted RNASEH1 Screening 
In anticipation of WES, Sanger sequencing of all eight coding exons of RNASEH1 was 
performed in all referred undiagnosed adult-onset PEO and multiple mtDNA deletion patients 
(n=67) (Appendix L). No non-synonymous variants were identified. A common synonymous 
c.498A>G (p.Pro166Pro) (rs10186193) variant of exon 4 was found in 38 patients, either 
heterozygous or homozygous. Two additional rare synonymous changes were also identified; 
c.474A>G (p.Ala158Ala) (rs61738918) of exon 4 in one patient and c.702A>G 
(p.Ala234Ala) (rs143510329) of exon 7 in two patients. Common intronic variants identified 
were c.409+34C>A (rs75663960) in 40 patients (heterozygous or homozygous), c.245-
118_245-115het_delAGAG (rs151141402) in 20 patients (heterozygous or homozygous), 
c.564+16C>T (rs375447388) in two patients, c.649+13A>G (rs75789502) in two patients and 
c.774+132A>T (rs116083909) in two patients. Two novel deep intronic variants were also 
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identified, c.128+44G>A and c.509+44C>G, in patients 4 and 10 respectively, which were 
confirmed by WES. However in the absence of coding or non-coding variants and with an 
alternative diagnosis reach for patient 4, these were not deemed pathogenic. Therefore, no 
patients with pathogenic or likely pathogenic RNASEH1 variants were identified. 
4.4.2 Clinical and Molecular Features 
After WES was performed and analysis had commenced, further details obtained externally 
for patient 13 showed no clinical, biochemical or molecular evidence of adult-onset PEO with 
multiple mtDNA deletions. Instead, this patient presented hearing-loss only. Therefore, 
patient 13 was omitted from the study and the total number of patients analysed was 19. 
The clinical and molecular features of patients recruited for WES from the undiagnosed 
cohort are summarised in Table 4.2. Almost all patients had PEO (18/19, 94.7%) and all had 
ptosis (19/19, 100%). Over half of patients had myopathy, fatigue or exercise intolerance 
(12/19, 63.2%). Less common features were sensorineural hearing loss (SNHL) (7/19, 
36.8%), dysphagia (6/19, 31.6%), neuropathy (6/19, 31.6%), diplopia (4/19, 21.1%), ataxia 
(4/19, 21.1%), cataracts (3/19, 15.8%), dysarthria (2/19, 10.5%), HCM (2/19, 10.5%), 
respiratory insufficiency (2/19, 10.5%), retinitis pigmentosa (2/19, 10.5%), liver involvement 
(2/19, 10.5%) and diabetes (2/19, 10.5%). Rare features noted in single cases were scapular 
winging, tremor, muscle pain, myalgia and optic neuropathy. Posterior fossa vascular 
malformation and cystinuria were features considered unrelated to the PEO phenotypes. One 
patient presented a MNGIE-like phenotype. Oculopharyngeal-muscular dystrophy (OPMD)-
like phenotype was noted in 3/19 (15.8%) patients, typically associated with GCN-repeat 
tracts or mutations of PABPN1 encoding polyadenylate-binding nuclear protein 1 (Banerjee et 
al., 2013). All patients had skeletal muscle restricted multiple mtDNA deletions confirmed by 
long range PCR. Southern blotting (3/19, 15.8%) and quantitative real time PCR (2/19, 
10.5%) were also used diagnostically. A family history of PEO was reported in only 8/19 
(42.1%) of cases and 3/19 (15.8%) patients were deceased. 
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Patient Sex 
Age of 
Onset 
Family 
History 
Clinical Features Muscle Histopathology 
Evidence of Multiple 
mtDNA Deletions 
1 M n.d. - PEO, bilateral ptosis, mild axonal neuropathy, SHNL COX-deficient fibres + (long-range PCR) 
2† M 40s - PEO, areflexic peripheral neuropathy, emaciated, MNGIE-like 
20% COX-deficient fibres  
9% Ragged-red fibres 
+ (long-range PCR) 
3 M 40s + (AD) PEO, ptosis, OPMD-like, SHNL, diplopia, dysphagia 
COX deficient fibres 
Ragged-red fibres 
+ (long-range PCR, 
Southern blot) 
4 M Mid 50s - 
PEO, bilateral ptosis, myopathy, dysarthria, dysphagia, respiratory 
insufficiency 
25% COX-deficient fibres 
6% Ragged-red fibres 
+ (long-range PCR) 
5 M n.d. + (AD) 
PEO, bilateral ptosis, cataracts, diplopia, proximal muscle (neck) 
weakness, tremor, muscle pain in arms, shoulder and neck, SNHL 
20% COX-deficient fibres 
7% Ragged-red fibres 
+ (long-range PCR) 
6 M n.d. + (AD) 
PEO, bilateral ptosis, OPMD-like, diplopia, dysphagia, facial 
muscle weakness and wasting, SHNL 
35% COX-deficient fibres 
15% Ragged-red fibres 
+ (long-range PCR) 
7 M Late 40s n.d. 
PEO, bilateral ptosis, OPMD-like, facial muscle weakness, bulbar 
involvement 
35% COX-deficient fibres 
13% Ragged-red fibres 
+ (long-range PCR) 
8 F Mid 40s + (AD/AR) 
PEO, ptosis, ataxia, axonal neuropathy, HCM (cardiac conduction 
defect), dysphagia, SHNL, proximal muscle weakness 
10% COX-deficient fibres 
10% Ragged-red fibres 
+ (long-range PCR, 
Southern blot) 
9† M n.d. + (AD/AR) 
Ptosis, proximal muscle weakness, SNHL, diabetes, 
endocrinopathy 
13% COX-deficient fibres + (long-range PCR) 
10 F n.d. - PEO, ptosis 
30% COX-deficient fibres 
10% Ragged-red fibres 
+ (long-range PCR) 
11 F n.d. - PEO, bilateral ptosis, diplopia 
15% COX-deficient fibres 
3% Ragged-red fibres 
+ (long-range PCR) 
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Patient Sex 
Age of 
Onset 
Family 
History 
Clinical Features Muscle Histopathology 
Evidence of Multiple 
mtDNA Deletions 
12† F Mid 40s - 
PEO, ptosis, sensory ataxia, SMAN, bulbar involvement, cataracts, 
dysphagia, proximal and facial muscle weakness, scapular 
winging, myalgia, optic neuropathy, respiratory insufficiency, 
retinitis pigmentosa 
20% COX-deficient fibres 
8% Ragged-red fibres 
+ (long-range PCR, 
Southern blot) 
14 M n.d. - 
PEO, ptosis, ataxia, HCM, cataracts, dysarthria, exercise 
intolerance, facial muscle weakness, myopathy, SMAN, 
neuronopathy  
20% COX-deficient fibres 
Ragged-red fibres 
+ (long-range PCR) 
15 M 20s + (AD) PEO, ptosis 
COX-deficient fibres 
Ragged-red fibres 
+ (long-range PCR, real 
time PCR) 
16 F n.d. - PEO 5% COX-deficient fibres + (long-range PCR) 
17 M n.d. + (AD) PEO, ptosis, mild dysphagia 30% COX-deficient fibres + (long-range PCR) 
18 F n.d. - PEO, ptosis, small posterior fossa vascular malformation 20% COX-deficient fibres + (long-range PCR) 
19 M n.d. - PEO, ptosis, myopathy, fatigue, cystinuria 
18% COX-deficient fibres 
3% Ragged-red fibres 
+ (long-range PCR) 
20 M n.d. - 
PEO, ptosis, ataxia, diabetes, subtle facial muscle weakness, liver 
cirrhosis, proximal muscle weakness, retinitis pigmentosa 
COX-deficient fibres 
+ (long-range PCR , real 
time PCR) 
Table 4.2 Clinical and Molecular Features of the Adult-Onset PEO with Multiple mtDNA Deletions Cohort for WES. Patients with adult-onset 
PEO and multiple mtDNA deletions selected for WES. AD – autosomal dominant; AR – autosomal recessive; HCM – hypertrophic cardiomyopathy; 
MNGIE – mitochondrial neurogastrointestinal encephalopathy; OPMD – oculopharyngeal muscular dystrophy; SMAN – sensory motor axonal 
neuropathy; SNHL – sensorineural hearing loss. † - deceased. ‘+’ – yes; ‘-‘ – no. Patient 11 underwent corrective squint surgery at 60 years old, but no 
additional details are available for onset of PEO (see 5.4.1). Patient 13 presented SHNL only and was omitted from the study. ‘n.a.’ – not applicable; 
‘n.d.’ – not determined. AD/AR denotes cases with possible AD or AR family, such as an affected sibling but with no details on a possible affected 
parent for example.  
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4.4.3 WES Read Coverage and Depth Statistics 
WES read coverage and depth statistics of the adult-onset PEO and multiple mtDNA 
deletions cohort was calculated for 32,947,520 exome consensus coding sequence (CCDS) 
bases (bp) (Appendix M). The mean depth per CCDS bases was 59-fold. The mean 
percentage of CCDS bases at 20-fold coverage was 77.83%.    
4.4.4 WES Analysis 
Using the simplified scoring system devised to advise the prioritisation of candidates, 
causative or likely causative variants and VUS are listed in Table 4.3 with MAF data and in 
silico predictions. Causative (2/19, 10.5%) and likely causative variants associating with 
adult-onset PEO and multiple mtDNA deletions (4/19, 21.1%) were identified in six patients, 
providing a diagnostic yield of 31.6%.  
Causative mutations were identified in two nuclear genes previously associated adult-onset 
mtDNA instability disorders for two patients (4 and 18); somatic TWNK and homozygous 
TK2 missense variants. Both variants were previously reported as pathogenic and were 
confirmed by Sanger sequencing using diagnostic forward and reverse primers. After 
evaluation and confirmation, variants were diagnostically reported. 
Likely causative variants were identified in four patients (3, 5, 11 and 19) in RRM1 
(NM_001033.3), VDAC1 (NM_003374.2), GMPR1 (NM_006877.3) and SEPT2 
(NM_006155). All variants require additional validation including segregation and molecular 
studies to confirm pathogenicity. 
Two patients had digenic inheritance of known pathogenic mutations not associated with a 
mtDNA maintenance disorder, but were nonetheless actionable variants. Patient 1 had a 
known pathogenic heterozygous 1.4Mb deletion in chromosome 17 (chr17:14095307-
15477497) associated with neuropathy. Patient 19 had two known pathogenic mutations of 
SLC3A1 associated with isolated cystinuria.  
In spite of no PEO and multiple mtDNA deletions for patient 13, analysis of known genes 
associated with SNHL revealed a likely causative MYH14 (NM_001145809) mutation.  
VUS were identified in five patients (1, 6, 8, 15 and 17) in ABAT (NM_000663.4), RRM2B, 
TOP3A (NM_004618.3), POLRMT (NM_005035.3) and MGME1. Candidate genes were 
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either not currently associated with human disease or occurred at low MAFs in external 
databases. 
Analysis of 8 patients did not identify causative or likely causative variants (2, 7, 9, 10, 12, 
14, 16 and 20). VUS were listed for these patients (Appendix N) but it was not possible to 
determine the significance due to a lack of information on the function of encoded proteins.  
To attain genetic diagnoses, patient 6, 8, 12 and 15 genomic DNA were prepared and sent for 
WGS to the Human Genome Sequencing Center at the Baylor College of Medicine in 
Houston, Texas. At the time of writing, an RRM2B (rs72554098) missense change and 
POLRMT splice-site variant remain the top prioritised candidates for patients 6 and 15.   
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Patient Clinical Features Gene Mutations Minor Allele Frequency In Silico Predictions 
cDNA Change Amino Acid 
Change 
ExAC  NHLBI 
ESP 
1000G PolyPhen
2 
Align-
GVGD 
SIFT 
Causative Variants 
1 PEO, bilateral ptosis, mild axonal neuropathy, 
SHNL 
1.4Mb Chromosome 17 Deletion including PMP22 (chr17:14095307-15477497), Heterozygous 
4 PEO, bilateral ptosis, myopathy, dysarthria, 
dysphagia, respiratory insufficiency 
TK2 Homozygous 
c.323C>T 
p.Thr108Met 
(rs137854431), 
Homozygous 
0.0000248 Ø Ø 1.000 Class 15 0.03 
18 PEO, ptosis, small posterior fossa vascular 
malformation 
TWNK c.1121G>A/= p.Arg374Gln, 
Heterozygous  
(Somatic 
Mosaic) 
Ø Ø Ø 1.000 Class 35 0.26 
19 PEO, ptosis, myopathy, fatigue, cystinuria SLC3A1 c.1400C>T/= p.Met476Thr 
(rs121912691), 
Heterozygous 
0.002713 0.002076 0.0003993 0.823 Class 65 0.05 
Exon 5-9, 13.98kb Duplication (chr2:44527111-44541090), Heterozygous 
           
Likely Causative Variants 
3 PEO, ptosis, OPMD-like, SHNL, diplopia, 
dysphagia 
RRM1 c.1281C>A/= p.Asn427Lys, 
Heterozygous 
Ø Ø Ø 1.000 Class 65 0.00 
5 PEO, bilateral ptosis, cataracts, diplopia, 
proximal muscle (neck) weakness, tremor, 
VDAC1 c.239C>T/= p.Thr80Ile, 
Heterozygous 
Ø Ø Ø 0.997 Class 15 0.12 
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muscle pain in arms, shoulder and neck, 
SNHL 
11 PEO, bilateral ptosis, diplopia GMPR1 c.547G>C/= p.Gly183Arg, 
Heterozygous 
Ø Ø Ø 1.000 Class 65 0.00 
13 SNHL MYH14 c.5185C>T/= p.Arg1729Trp, 
Heterozygous 
0.0000859 Ø Ø 1.000 Class 65 0.00 
19 PEO, ptosis, myopathy, fatigue, cystinuria SEPT2 c.988C>T/= p.Arg330Cys, 
Heterozygous 
Ø Ø Ø 0.990 Class 65 0.00 
           
Variants of Unknown Significant (VUS) 
1 PEO, bilateral ptosis, mild axonal neuropathy, 
SHNL 
ABAT c.1157C>T/= p.Pro386Leu, 
Heterozygous 
0.0000165 Ø Ø 1.000 Class 65 0.00 
6 PEO, bilateral ptosis, OPMD-like, diplopia, 
dysphagia, facial muscle weakness and 
wasting, SHNL 
RRM2B c.482C>T/= p.Thr161Ile 
(rs72554098), 
Heterozygous 
0.0000082 0.0000769 Ø 0.508 Class 0 0.00 
8 PEO, ptosis, ataxia, axonal neuropathy, HCM 
(cardiac conduction defect), dysphagia, 
SHNL, proximal muscle weakness 
TOP3A c.298A>G p.Met100Val 0.0000580 0.0000769 Ø 0.001 Class 0 0.68 
c.403C>T p.Arg135* 0.0001983 0.0000769 Ø n.a. n.a. n.a. 
15 PEO, ptosis POLRMT c.2641-1G>C/= Splice-Acceptor 
Site, 
Heterozygous 
0.0000163 Ø Ø n.a. n.a. n.a. 
17 PEO, ptosis, mild dysphagia MGME1 c.706C>G/= p.Leu236Val, 
Heterozygous 
Ø Ø Ø 0.978 Class 15 0.13 
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Table 4.3 Pathogenic variants, potential pathogenic variants and VUS identified with possible associations with adult-onset PEO and multiple mtDNA 
deletions. ‘Ø’ denotes that a variant absent from external databases. HCM – hypertrophic cardiomyopathy; OPMD – oculopharyngeal muscular 
dystrophy; SNHL – sensorineural hearing loss. n.a. – not applicable.  
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4.4.5 TK2 – Thymidine Kinase 2 
Patient 4 was a 64 year old male who initially presented with bilateral ptosis in his mid-50s. 
This progressed to PEO, myopathy, dysarthria, dysphagia and respiratory failure requiring 
ventilatory support. Diagnostic long-range PCR confirmed the presence of multiple mtDNA 
deletions in the skeletal muscle. Muscle histopathology revealed 25% COX-deficient fibres 
and 6% ragged-red fibres (Figure 4.2A). Family history was negative for mitochondrial 
myopathy.  
WES analysis identified a homozygous c.323C>T (p.Thr108Met) (rs137854431) variant in 
TK2 (16q21), matching GO-Terms ‘mitochondr*’, ‘pyrimidine’ and ‘replication’. Sanger 
sequencing using diagnostic forward and reverse primers for TK2 exon 5 confirmed the 
variant (Figure 4.2B). The p.Thr108Met variant affected a highly conserved residue in a 
highly conserved region of TK2 (Figure 4.2C) and had been previously identified either 
homozygous or was compound heterozygous with an additional variant in patients with TK2-
deficiency. The p.Thr108Met variant was present in 3/121070 alleles (MAF=0.00002478) in 
ExAC; two non-Finnish Europeans and one Latino, all in heterozygous state. It was absent 
from in-house exomes, NHLBI ESP and 1000 Genomes Project. The parents were not known 
to be consanguineous. 
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4.4.6 TWNK - Twinkle 
Patient 18 was a female who presented late-onset PEO, ptosis and had small posterior fossa 
vascular malformation. Muscle histopathology showed 20% COX-deficient fibres. Long-
range PCR of skeletal muscle detected multiple mtDNA deletions. Family history was 
negative for extraocular paresis.  
WES analysis identified a heterozygous c.1121G>A (p.Arg374Gln) variant in TWNK 
(10q24.31), matching GO-Terms ‘mitochondr*’, ‘replication’, ‘transcription’ and ‘helicase’. 
Suspicions were raised for the identified p.Arg374Gln TWNK variant due to its known 
pathogenicity (Spelbrink et al., 2001) and since all coding exons and intronic regions of 
TWNK had been diagnostically sequenced. Examination of WES coverage at the c.1121 
(Chr10:102749088) site showed 22 reads that passed quality score filtering, with an unfiltered 
AD of 16 reads at the reference (c.1121G) position and 6 reads (27.3%) with the alternate 
(c.1121G>A) base. The PL of the heterozygous alternate base was 0, indicating that 
heterozygosity was the most likely genotype. GQ was also 99, the highest possible phred-
scaled quality score. Examination of the diagnostic electropherogram for TWNK exon 1c with 
Figure 4.2 Histochemical and Genetic Features of Patient 4. (A) Sequential COX-SDH 
histochemistry of patient 4 skeletal muscle demonstrating COX-deficient fibres. (B) Sanger 
sequencing confirmation of the homozygous p.Thr108Met TK2 missense variant. (C) Multiple 
sequence alignment (MSA) of the TK2 Thr108 residue. 
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blood DNA showed that the variant was apparently absent except for a small peak at the 
c.1121 site. Repeated Sanger sequencing with blood (Figure 4.3A) and muscle (Figure 4.3B) 
genomic DNA also showed a small peak at the c.1121 site. Unfortunately, available urine 
DNA failed to amplify. Segregation studies were not possible.  
4.4.7 RRM1 - Ribonucleotide Reductase Subunit M1  
Patient 3 was a 66 year old male who presented an OPMD-like phenotype with PEO, ptosis, 
hearing loss, diplopia and dysphagia. Muscle histopathology showed COX-deficient and 
ragged-red fibres. Multiple mtDNA deletions were confirmed by long-range PCR and 
Southern blotting. Family history was significant; his mother also presented with the same 
phenotype. 
WES analysis for heterozygous variants identified a c.1281C>A (p.Asn427Lys) missense 
change in RRM1 encoding ribonucleotide reductase subunit M1 (R1). RRM1 (11p15.4) 
matched GO-Terms ‘replication’, ‘purine’ and ‘nucleotide’. Sanger sequencing using custom 
forward and reverse primers for RRM1 exon 12 confirmed the variant (Figure 4.4A). 
Segregation studies including of the affected mother were not possible. Asn427 was 
Figure 4.3 Electropherograms of the Somatic Mosaic p.Arg374Gln Variant in Patient 18 
Blood and Muscle DNA. Both electropherograms of patient 18 (A) blood and (B) muscle 
genomic DNA show a small peak at the TWNK c.1121 site for the G>A nucleotide 
substitution. 
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conserved from humans to S. cerevisiae (Figure 4.4B). The Asn427Lys variant was absent 
from in-house exomes and external databases. 
Independent of this WES study, two apparently unrelated patients with childhood-onset PEO 
and multiple mtDNA deletions were identified harbouring a homozygous c.1142G>A 
(p.Arg381His) RRM1 missense change. The p.Arg381His missense change was absent from 
all external exome databases and affected a highly conserved residue in all tested species 
except Danio rerio, D. melanogaster and S. cerevisiae (Figure 4.4B). 
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Figure 4.4 RRM1 Sanger Sequencing Confirmation, Domain Architecture and MSA. (A) Sanger sequencing confirmation of novel p.Asn427Lys 
RRM1 missense variant in patient 3. (B) RRM1 domain architecture showing location of the dominant heterozygous p.Asn427Lys (red) and the 
reported homozygous p.Arg381His missense variant (black). (C) MSA of RRM1 Arg381 and Asn427 residues. ‘……‘ denotes the space between the 
residue where the residues are located. 
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4.4.8 VDAC1 – Voltage Dependent Anion Channel 1 
Patient 5 was a 64 year old male with a history of asthma and migraine since childhood. Upon 
clinical examination, the patient had PEO, ptosis, neck muscle weakness, a tremor, cataracts 
and SNHL. He had features of irritable bowel syndrome and complained of muscle pain in his 
arms, neck and shoulders as well as double vision. Muscle histopathology disclosed 20% 
COX-deficient fibres and 7% ragged-red fibres. Multiple mtDNA deletions were also 
confirmed by diagnostic long-range PCR. His mother, grandmother and sister all had ptosis, 
while his mother also had hearing loss. 
WES analysis of heterozygous variants identified a c.239C>T (p.Thr80Ile) missense change 
in VDAC1 encoding voltage dependent anion channel 1, also known as porin. VDAC1 
(5q31.1) matched the GO-Term ‘mitochondr*’. Sanger sequencing confirmed the variant with 
custom forward and reverse primers for VDAC1 exon 3 (Figure 4.5A). Segregation studies of 
affected and unaffected family members were not possible. The p.Thr80Ile variant was absent 
from in-house exomes and all external exome databases. Analysis of the human VDAC1 
secondary protein structure (PDB ID 2JK4) (Bayrhuber et al., 2008) showed that the Thr80 
residue was located at the edge of a β-strand fold (Figure 4.5B). Thr80 was conserved in all 
tested species except S. cerevisiae, occurring in a highly conserved region of the protein 
(Figure 4.5C).  
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4.4.9 GMPR1 – Guanosine Monophosphate Reductase 1 
Application of the WES strategy for patient 11 identified a novel heterozygous GMPR1 
c.547G>C (p.Gly183Arg) missense change in GMPR1 encoding guanosine monophosphate 
reductase 1. This is investigated in Chapter 5 as a likely novel causative gene associated with 
late-onset PEO and multiple mtDNA deletions. 
4.4.10 SEPT2 – Septin 2 
Patient 19 was a 50 year old male who first presented cystinuria, a disease characterised by 
the build-up of cysteine in urine leading to the formation of stones, which required a partial 
nephrectomy and treatment with penicillamine. This was followed by what was initially 
presumed to be penicillamine-induced myasthenia gravis, manifesting as PEO, ptosis and 
Figure 4.5 Sanger Sequencing Confirmation, VDAC1 Secondary Structure and MSA. 
(A) Sanger sequencing confirmation of the novel p.Thr80Ile VDAC1 missense change. (B) 
Secondary structure of VDAC1 demonstrating the location of the Thr80 residue. (C) MSA of 
the VDAC1 Thr80 residue. VDAC1 secondary structure adopted and amended from PDB ID 
2JK4. 
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fatigue. Serum lactate was also mildly elevated (3.1mmol/L; normal <2.5mmol/L). However, 
withdrawal of penicillamine did not resolve the symptoms and the patient was investigated for 
a possible mitochondrial myopathy. Muscle histopathology disclosed 18% COX-deficient 
fibres and 3% ragged-red fibres. Multiple mtDNA deletions were detected by long-range 
PCR. Family history was negative for ophthalmoparesis or mitochondrial myopathy.  
Application of the WES filtering strategy did not reveal any causative or likely causative 
variants and hence, rare dominant and recessive variants were listed.  
Recently, Pagliuso et al. (2016) demonstrated that septin 2, a cytoskeleton component 
encoded by SEPT2, was essential for Drp1-mediated mitochondrial fission. A cohort-wide 
search for rare or novel SEPT2 variants identified a heterozygous c.988C>T (p.Arg330Cys) 
missense change harboured by patient 19, confirmed with custom forward and reverse primers 
for SEPT2 exon 12 (Figure 4.6A). The GO-Terms for SEPT2 did not match those of the WES 
filtering strategy devised for adult-onset PEO and multiple mtDNA deletions patients. Arg330 
was fully conserved from humans to D. melanogaster, occurring in a highly conserved region 
(Figure 4.6C). The variant was absent from in-house exomes and all external databases. 
Segregation studies were not possible and therefore, the p.Arg330Cys variant was presumed 
de novo or parental germline mosaic.  
Due to the cystinuria presented by this patient, the co-existence of two or more Mendelian 
disorders was considered. To date, isolated cystinuria has been associated with autosomal 
recessive mutations of SLC3A1 (type A) (Calonge et al., 1994) and SLC7A9 (type B) 
(Feliubadalo et al., 1999). WES analysis of SLC3A1 and SLC7A9 genes identified a known 
pathogenic heterozygous c.1400T>C (p.Met467Thr) (rs121912691) SLC3A1 missense 
variant, confirmed with custom forward and reverse primers for SLC3A1 exon 8 (Figure 
4.6B). No pathogenic or likely pathogenic SLC7A9 variants were identified. Analysis of 
CNVs identified an additional known pathogenic 13.98kb SLC3A1 exon 5-9 duplication 
(chr2:44527111-44541090). Unfortunately there was insufficient DNA to perform 
quantitative real time PCR to confirm the presence of the duplication. Therefore, this resolved 
the genetic aetiology of the cystinuria and likely the elevated serum lactate readings.   
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4.4.11 ABAT (VUS) – GABA Transaminase 
Patient 1 was a 72 year old male with gradual progressive bilateral ptosis since his late 40s, 
PEO, a mild axonal neuropathy, mild hearing loss and intermittent difficulty swallowing. 
Muscle histopathology disclosed COX-deficient and ragged-red fibres. Multiple mtDNA 
deletions were detected by diagnostic long-range PCR. Family history was negative. 
WES analysis identified a heterozygous c.1157C>T (p.Pro386Leu) missense variant of ABAT 
encoding the GABA transaminase. ABAT (16p13.2) matched the GO-Term ‘mitochondr*’. 
Sanger sequencing using custom forward and reverse primers for ABAT exon 13 confirmed 
the variant (Figure 4.7A). The missense change was absent from in-house exomes. However, 
it was reported in 2/121064 heterozygous non-Finnish European alleles (MAF=0.00001652) 
in ExAC. Pro386 was fully conserved in all tested species and occurred in a moderately 
conserved region of the protein (Figure 4.7B). 
Analysis of CNVs for patient 1 revealed a known pathogenic 1.4Mb deletion in chromosome 
17 (chr17:14095307-15477497, 17p12). Within this deletion were all coding exons of PMP22 
(peripheral myelin protein 22) and COX10 (cytochrome c oxidase assembly factor 10) exon 6. 
GO-Terms matched were ‘mitochondr*’, ‘polymerase’ and ‘transcription’. Unfortunately 
Figure 4.6 SEPT2 and SLC3A1 Sanger Sequencing Confirmation and SEPT2 MSA. 
Sanger sequencing confirmation of (A) the novel SEPT2 p.Arg330Cys missense change and 
(B) the known pathogenic heterozygous SLC3A1 p.Met467Thr missense change. (C) MSA of 
the SEPT2 Arg330 residue. 
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there was insufficient DNA to confirm the presence of the deletion either by real time PCR or 
array comparative genomic hybridisation (CGH) assays.   
4.4.12 RRM2B (VUS) – Ribonucleotide Reductase Subunit M2B  
Patient 6 was a 76 year old male presenting an OPMD-like phenotype with PEO, bilateral 
ptosis, facial muscle weakness with mild wasting of the facial muscles, dysphagia, 
intermittent diplopia and SNHL. Muscle histopathology showed 35% COX-deficient fibres 
and 15% ragged-red fibres. Diagnostic long-range PCR demonstrated the presence of multiple 
mtDNA deletions. There was a family history of hearing loss but extraocular paresis was 
confined to patient 6.  
WES analysis revealed a heterozygous RRM2B missense change, c.482C>T (p.Thr161Ile), 
that had previously been catalogued (rs72554098) and had been excluded diagnostically as a 
causative variant. RRM2B (8q22.3) matched GO-Terms ‘DNA repair’, ‘nucleoside’ and 
‘replication’. The missense change was absent from in-house exomes and the 1000 Genomes 
Project, but was reported in 1/121346 non-Finnish European allele (MAF=0.000008241) in 
ExAC and in 1/13006 (MAF=0.00007689) in the NHLBI ESP, both in heterozygous state. 
The Thr161 residue was fully conserved, occurring in a highly conserved region of the protein 
Figure 4.7 ABAT Sanger Sequencing Confirmation and ABAT MSA. (A) Sanger 
sequencing confirmation of the heterozygous p.Pro386Leu ABAT missense change. (B) MSA 
of the ABAT Pro386 residue. 
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(Figure 4.8A). In the absence of additional candidate variants, p.Thr161Ile was classified as a 
VUS. 
Further analysis of rare annotated disease-causing variants identified a heterozygous 
c.1150G>T (p.Gly384Cys) (rs119103280) missense change of MYH14, encoding non-
conventional non-muscle myosin heavy-chain 14, which had been previously categorised as 
pathogenic (Donaudy et al., 2004). The p.Gly384Cys variant was confirmed by Sanger 
sequencing using custom forward and reverse primers for MYH14 exon 11 (Figure 4.8B). 
4.4.13 TOP3A (VUS) – Topoisomerase III-α 
Patient 8 was a 67 year old female presenting with a complex PEO-plus phenotype with onset 
of ptosis at 44 years old. She also manifested with PEO, proximal muscle weakness, ataxia, 
axonal neuropathy, dysphagia, decreased visual acuity and hearing loss. A pacemaker was 
fitted due to a cardiac conduction defect. Interestingly, the patient also had telangiectasia; a 
condition with red lines or other patterns on the skin due to dilated blood vessels near the 
surface of the skin. Muscle histopathology disclosed >10% COX-deficient fibres and >10% 
Figure 4.8 RRM2B MSA and MYH14 p.Gly384Cys Sanger Sequencing Confirmation. 
(A) MSA of the RRM2B Thr161 residue. (B) Sanger sequencing confirmation of the 
heterozygous p.Gly384Cys MYH14 missense change. 
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ragged red fibres. Multiple mtDNA deletions were confirmed by diagnostic long-range PCR 
and Southern blotting. Family history was significant for a female sibling who died during her 
late 20s, apparently due to lupus although there were no further details available.  
WES analysis identified compound heterozygous variants in TOP3A encoding topoisomerase 
III-α; a c.298A>G (p.Met100Val) missense change and a c.403C>T (p.Arg135*) nonsense 
variant. TOP3A (17p11.2) matched the GO-Term ‘topoisomerase’. The variants were 
confirmed by Sanger sequencing with custom forward and reverse primers for TOP3A exons 
3 and 5 (Figure 4.9A). Both variants were absent from in-house exomes. The p.Met100Val 
missense change was reported in 7/120600 alleles (MAF=0.00005804) in ExAC comprising 
five non-Finnish Europeans, one Finn and one Latino, all in heterozygous state. It was also 
reported in 1/13006 heterozygous allele (MAF=0.00007689) in the NHLBI ESP. The 
p.Arg135* nonsense change was reported in 24/121054 alleles (MAF=0.0001983) in ExAC 
comprising 20 non-Finnish Europeans, three Finns and one undisclosed individual, all in 
heterozygous state. It was also reported in 1/13006 heterozygous allele (MAF=0.00007689) in 
the NHLBI ESP. Both variants occurred in the Toprim domain of TOP3A (Figure 4.9B). The 
Met100 residue was poorly conserved; it was a valine residue in D. melanogaster (Figure 
4.9C). Segregation studies performed by Charlotte Alston (Wellcome Trust Centre for 
Mitochondrial Research, Institute of Neuroscience, The Medical School, Newcastle 
University, Newcastle upon Tyne) confirmed that the mother and her daughter were 
heterozygous carriers of the p.Arg135* nonsense mutation.
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Figure 4.9 TOP3A Sanger Sequencing Confirmation, Domain Architecture and MSA. (A) Sanger sequencing confirmation of the TOP3A 
p.Met100Val and p.Arg135* variants harboured by patient 8. (B) TOP3A domain architecture demonstrating the locations of the identified TOP3A 
variants. (C) MSA of the TOP3A Met100 residue. 
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4.4.14 POLRMT (VUS) – Mitochondrial RNA Polymerase 
Patient 15 was a 56 year old male presenting with an indolent PEO phenotype. 
Ophthalmoplegia was noted incidentally on clinical examination at 28 years old, while ptosis 
predated this for an unknown duration. Brain MRI was normal and there had been no disease 
progression since initial examination. Muscle histopathology showed COX-deficient and 
ragged-red fibres (Figure 4.10A and B). Multiple mtDNA deletions were detected by 
diagnostic long-range PCR and quantitative real time PCR assays. The patient had an uncle 
who was also thought to have PEO but this was not clinically confirmed.  
WES filtering identified a heterozygous c.2641-1G>C splice acceptor site variant in intron 10 
of POLRMT encoding the mitochondrial RNA polymerase. The Human Splicing Finder 
predicted that this would lead to a broken splice-acceptor site, with possible skipping of exon 
11. POLRMT (19p13.3) the GO-Terms ‘mitochondr*’, ‘transcription’ and ‘polymerase’. The 
splice-site variant was absent from in-house exomes, the 1000 Genomes Project and NHBLI 
Exome Variant Server databases, but was present in 1/61428 heterozygous allele 
(MAF=0.00001628) in ExAC. The splice-site variant was confirmed by Sanger sequencing 
using custom forward and reverse primers for POLRMT exon 11 (Figure 4.10C). Fibroblast 
RNA was extracted from patient 14 fibroblasts and one control, then cDNA was synthesised 
for sequencing. However, four sets of custom forward and reverse primers failed to amplify 
the cDNA for sequencing due to a high GC-content of the flanking exons. Segregation studies 
were also not possible.   
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The POLRMT splice-site mutation was investigated using available fibroblasts from patient 
14 and two controls. Western blotting with antibodies specific to POLRMT, mitochondrial 
ribosomal protein subunit L12 (MRPL12) and SDHA showed non-specific findings in the 
patient fibroblasts under proliferating and quiescent states (Figure 4.11A). However, there 
was considerable variation between the control samples. Quantitative real time PCR to assess 
mtDNA copy number in proliferating and quiescent fibroblasts revealed no significance 
between patient and control fibroblasts, based upon two repeats (Figure 4.11B). In contrast to 
patient 14 skeletal muscle, long-range PCR of quiescent fibroblasts did not reveal large-scale 
mtDNA rearrangements (Figure 4.11C). 
Figure 4.10 Muscle Histopathology and POLRMT Sanger Sequencing Confirmation for 
Patient 14. Patient 14 skeletal muscle was subjected to (A) sequential COX-SDH 
histochemistry and (B) Gomori trichrome staining. (C) Sanger sequencing confirmation of the 
c.2641-1G>C POLRMT splice-site mutation.   
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4.4.15 MGME1 (VUS) – Mitochondrial Genome Maintenance Exonuclease 1 
Patient 17 was an 80 year old male who presented with PEO, ptosis and mild dysphagia. 
Muscle histochemistry disclosed 30% COX-deficient fibres. Diagnostic long-range PCR also 
detected multiple mtDNA deletions. Family history was significant; his father, sister and 
brother were all reported to have mild PEO. 
WES analysis of heterozygous variants identified a novel c.706C>G (p.Leu236Val) missense 
variant of MGME1 (20p11.23), matching the GO-Term ‘mitochondr*’. The variant was 
absent from in-house exomes and all external databases. Sanger sequencing of all coding 
exons of MGME1 was performed but did not reveal any other significant variants (Figure 
Figure 4.11 Molecular Studies of Patient 14 Fibroblasts. (A) Steady-state POLRMT, 
MRPL12 and SDHA levels in proliferating and quiescent fibroblasts of patient 14 plus two β-
actin was used as a loading control. (B) Relative mtDNA copy number in patient 14 (red) and 
control fibroblasts in proliferating and quiescent state based upon two repeats only. One-way 
ANOVA (Kruskal-Wallis test) and Dunn’s Multiple Comparisons tests were performed to 
compare the mean relative mtDNA copy number between proliferating and quiescent controls 
to patient fibroblasts. (C) Long-range PCR of wild-type blood homogenate, two control 
quiescent fibroblast (C1 and C2), patient 14 (POLRMT) quiescent fibroblast DNA and a no 
template control. Amplification of each sample was performed in triplicate with two sets of 
optimised forward and reverse primers. Red line indicates the wild-type mtDNA product. 
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4.12A). The Leu236 residue was conserved in all tested species except D. rerio (Figure 
4.12B). Furthermore, DNA was unavailable from additional affected family members to 
perform segregation studies. With further studies currently not possible, the p.Leu236Val 
missense change is classed as a VUS. 
4.5 Discussion 
Utilising WES with a custom filtering strategy to prioritise variants in nuclear genes encoding 
mitochondrial, mtDNA maintenance and DNA repair proteins, a genetic diagnosis was 
attained in only 2/19 (10.5%) patients. Likely causative variants were identified in a further 
4/19 (21.1%) patients for mtDNA maintenance disorders (RRM1, VDAC1, GMPR1, SEPT2) 
and resolving the genetic aetiology of a patient with hearing loss only (MYH14). Potential 
significant VUS were also identified in 3/19 (15.8%) patients (ABAT, TOP3A, POLRMT). 
Figure 4.12 MGME1 Sanger Sequencing Confirmation and MGME1 MSA. (A) Sanger 
sequencing confirmation of the p.Leu236Val MGME1 missense change. (B) MSA of MGME1 
Leu236 residue. 
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However, for both novel causative variants and VUS, further studies are necessary to confirm 
the pathogenic nature. A twentieth patient was later found to not have a mtDNA maintenance 
disorder and instead had hearing loss only, due to a likely causative heterozygous MYH14 
mutation, hence this patient was excluded from the study. 
4.5.1 RNASEH1 Mutations are a Rare Cause of Adult-Onset mtDNA Instability 
RNASEH1 encodes ribonuclease H1, a dual nuclear and mitochondrial endonuclease essential 
for the degradation of DNA-RNA hybrids during mtDNA replication (Cerritelli and Crouch, 
1998). Homozygous Rnaseh1 knockout mice were embryonic lethal with significant loss of 
mtDNA copy number, loss of COX activity and abnormal mitochondria morphology 
(Cerritelli et al., 2003). Recessive RNASEH1 mutations were recently implicated in 12 
patients with systemic adult-onset PEO with multiple mtDNA deletions (Reyes et al., 2015; 
Akman et al., 2016). In light of this, all eight coding exons of RNASEH1 were sequenced in 
67 undiagnosed adult-onset PEO with multiple mtDNA deletions patients referred to the NHS 
Highly Specialised Mitochondrial Diagnostic Service Laboratory in Newcastle upon Tyne. 
Unfortunately, no protein coding variants were identified, including the reported pathogenic 
variants. Thus, it was concluded at that RNASEH1 mutations are a rare cause of adult-onset 
PEO with multiple mtDNA deletions. As detailed in 3.4.17, PEO, ptosis, myopathy with 
generalised muscle wasting and respiratory insufficiency are features that could direct 
immediate targeted RNASEH1 sequencing in future patients. 
4.5.2 Adult-Onset PEO and Multiple mtDNA Deletions Associated with TK2-Deficiency 
A homozygous p.Thr108Met TK2 missense variant was identified in patient that had been 
previously associated with clinically heterogeneous phenotypes, which included both severe, 
early-onset mtDNA depletion syndrome and late-onset myopathy with multiple mtDNA 
deletions (Mancuso et al., 2002; Mancuso et al., 2003; Wang et al., 2005; Oskoui et al., 2006; 
Chanprasert et al., 2013; Martin-Hernandez et al., 2016). A study of the natural history of 
TK2-deficiency confirmed the heterogeneous phenotypes associated with the p.Thr108Met 
missense change (Garone et al., submitted). Six patients had adult-onset myopathy with 
multiple mtDNA deletions, 9 had childhood-onset myopathy and six had infantile-onset 
myopathy with mtDNA depletion. Patient 4 was clinically similar to patients with late-onset 
TK2-deficiency, as outlined in 3.4.9.  
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4.5.3 Somatic Mosaicism of a p.Arg374Gln TWNK Mutation 
Somatic mosaicism is the phenomenon of a single mutation occurring in two or more 
populations of soma cells in one individual (Freed et al., 2014). This contrasts with germline 
mosaic mutations, which occur only in the germ (gonadal) cells. Irrespective, mosaicism can 
occur at any point after first cell division of the zygote. On the other hand, a de novo mutation 
is transmitted from a father harbouring a mutation in only a single sperm cell or arises during 
the first cell divisions of a developing zygote and is harboured in all cells. Somatic mosaic 
mutations have been increasingly recognised in Mendelian human disease, including but not 
limited to Duchene Muscular Dystrophy (DMD) (Kesari et al., 2009), Rett syndrome (Topcu 
et al., 2002) and cancer (Fernandez et al., 2016). Recent studies have also implicated low-
level parental somatic mosaicism in a significant proportion of apparent de novo genomic 
disorders in children than had previously been estimated (Campbell et al., 2014b; Beck et al., 
2016). Primary mitochondrial disease shares similarities with somatic mosaicism, in that 
heteroplasmic pathogenic mtDNA mutations can harboured throughout different tissues and 
can sometimes correlate with clinical severity (Tuppen et al., 2010). Clonal expansion of 
somatic mtDNA deletions have also been associated with a spectrum of human disease and 
ageing (Schon et al., 2012). 
WES analysis of patient 18 identified a p.Arg374Gln TWNK missense change that was one of 
the most commonly reported pathogenic variants associated with late-onset PEO and multiple 
mtDNA deletions (Spelbrink et al., 2001; Naimi et al., 2006; Baloh et al., 2007; Massa et al., 
2009; Martin-Negrier et al., 2011; Yu-Wai-Man et al., 2013; Tafakhori et al., 2016) (3.4.5). 
This was unexpected since all coding exons and intronic regions of TWNK had been 
sequenced diagnostically prior to recruitment for WES. Analysis of the original 
electropherogram and re-sequencing of blood and muscle DNA showed that the p.Arg374Gln 
variant was harboured at low level somatic mosaicism but at sufficient levels to cause 
symptoms. Additionally it has not been possible to determine the extent of the mosaicism in 
other tissues, particularly in the germline population. Hence, the implications for offspring 
were uncertain. Probable germline mosaicism of ANT1 and TWNK mutations causing adult-
onset PEO with multiple mtDNA deletions have been previously described (Deschauer et al., 
2005; Hudson et al., 2005). On the other hand, patient 18 is the first known case of somatic 
mosaicism associated with this disease. This finding has significant ramifications in the 
diagnosis of autosomal dominant Mendelian mitochondrial disease. Manual analysis and 
curation of the electropherogram for TWNK exon 1c of patient 18 blood DNA failed to note 
the small peak at the c.1121 site, which raises uncertainty regarding additional ‘undiagnosed’ 
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patients. While careful curation and annotation of Sanger sequencing electropherograms could 
potentially resolve a handful of undiagnosed cases, this is not practical nor is Sanger 
sequencing sensitive to lower levels of mosaicism (Jamuar et al., 2014; Qin et al., 2016). One 
study found that the lowest range of mutant alleles detectable by Sanger sequencing was 
between 15-50% (Rohlin et al., 2009). Rohlin et al. (2009) also demonstrated that massive 
parallel sequencing could detect somatic alleles at a frequency of 1%, although this was 
dependent upon high read coverage. In an era where NGS is becoming less expensive and its 
use more widespread, additional patients could be anticipated to harbour low level, 
pathogenic somatic mutations of known mtDNA maintenance disorder genes. For patient 18, 
WES was demonstrated as sufficient for detection of the p.Arg374Gln mutation at a level of 
27.3% in blood DNA, verifiable in blood and muscle DNA by Sanger sequencing. 
Nonetheless, such investigations are dependent on the availability of a range of patient tissues 
for testing and of course, access to NGS technologies. With few diagnoses attained in this 
group of patients, somatic mosaicism provides a novel, alternative hypothesis for the low 
diagnostic yield in adult-onset PEO with multiple mtDNA deletions. 
4.5.4 Novel mtDNA Maintenance Disorder Candidates Requiring Further Investigation 
Likely causative variants and VUS were identified in RRM1, VDAC1, GMPR1 (Chapter 5), 
SEPT2, ABAT, RRM2B, TOP3A, POLRMT and MGME1. All genes have been associated with 
either mitochondrial functions or DNA repair and maintenance pathways, but require 
additional functional studies to validate pathogenicity.   
 Dominant and Recessive RRM1 Mutations Associated with a Novel Disorder of 
mtDNA Maintenance 
Dominant and recessive mutations of RRM2B encoding the small p53R2 subunits of the 
ribonucleotide reductase (RNR), for the rate-limiting de novo synthesis of 
deoxyribonucleotides from ribonucleotides (Pär and Peter, 2006), have been established as 
causative for early-onset mtDNA depletion syndrome and adult-onset PEO with multiple 
mtDNA deletions (Bourdon et al., 2007; Pontarin et al., 2007). In this study, a heterozygous 
p.Asn427Lys missense change in RRM1 encoding the large catalytic R1 subunit of the RNR 
was identified using the custom WES filtering strategy in patient 3. Mammalian dNTP 
synthesis for nuclear and mtDNA replication is detailed in 5.1.1. To summarise, during S-
phase of the cell cycle, the RNR is a tetramer comprised of homodimeric R1 subunits and 
smaller homodimeric R2 subunits encoded by RRM2. In non-dividing cells, the R2 subunit is 
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replaced by p53R2 (Bourdon et al., 2007; Pontarin et al., 2007). Given the role of RRM2B in 
dominant and recessive mtDNA maintenance disorders, the novel RRM1 variant was 
considered a highly likely candidate for a novel mtDNA maintenance disorder.  
The case for a RRM1-associated mtDNA maintenance disorder is further compelled by the 
identification of patients from two apparently unrelated families harbouring a homozygous 
c.1142G>A (p.Arg381His) RRM1 missense change. The first patient was a 33 year old Saudi 
Arabian man reported at the 2016 American Academy of Neurology Meeting (Juanola-
Falgarona et al., 2016). He had a MNGIE-like phenotype that was comparable to one patient 
with recessive RRM2B missense variants (3.4.8) (Shaibani et al., 2009). He presented with 
recurrent nausea and vomiting at 7 years old, which progressed to severe gastrointestinal 
dysmotility, cachexia, PEO, ptosis, axonal neuropathy and proximal limb myopathy upon 
clinical examination. Muscle histopathology showed COX-deficient fibres, ragged-red fibres 
and the presence of multiple mtDNA deletions. Unfortunately there were no further details on 
the second patient at the time of writing. However, the homozygous p.Arg381His missense 
changes were identified in both patients by WES. 
The pathogenesis of an RRM1-related mtDNA maintenance disorder necessitates functional 
validation and it is of interest to determine whether this acts in a similar manner to dominant 
and recessive RRM2B mutations. Regarding the dominant heterozygous p.Asn427Lys, this 
could act in a dominant-negative manner, competing with the wild-type R1 subunit and 
leading to an inactive RNR, as proposed for dominant RRM2B missense and nonsense 
mutations (Tyynismaa et al., 2009a). Pitceathly et al. (2011) demonstrated defective 
R1/p53R2 assembly by Blue-native polyacrylamide gel electrophoresis (BN-PAGE) in 
recessive RRM2B patient muscle, with no change in steady-state p53R2 levels. Given the role 
of the RNR for nuclear and mtDNA replication, the current prevailing mechanism could be 
defective RNR assembly as a consequence of the RRM1 mutations. Since the homozygous 
p.Arg381His affects all R1 subunits, it is understandable that the phenotype onset appears to 
manifest earlier in life compared to that of patient 3 with the dominant mutation. Hence, the 
p.Asn427Lys and p.Arg381His mutations likely lead to reduced capacity of the RNR for 
dNTP synthesis, although it is essential to confirm this in future studies of patient muscle and 
through detailed analysis of the R1 and p53R2 interactions. 
 A Novel Heterozygous VDAC1 Mutation in an adPEO Family 
VDAC1 encodes one of three voltage dependent anion channels (VDAC1-3) that each form 
homodimers in the OMM for the movement of small molecules up to 10 kilodaltons (kDa) to 
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enter and exit the intermembrane space (Bayrhuber et al., 2008; Shoshan-Barmatz et al., 
2010). Given that the VDACs are highly abundant in the OMM, it serves to highlight their 
importance for mitochondrial function. A novel heterozygous p.Thr80Ile missense change 
was identified in patient 5, who has a family history of ophthalmoparesis, prompting filtering 
for heterozygous variants of interest. Further support for pathogenicity of VDAC1 as a 
dominant locus for human disease is given in ExAC. This shows that the gene is highly 
intolerant to loss-of-function (LOF) variants including nonsense or splice-site changes with a 
LOF probability score of 0.98, since no such VDAC1 variants have been identified to date. 
However, in silico predictions suggested that the missense change was not highly damaging 
despite that the Thr80 residue was conserved almost all tested species. Since the VDACs are 
implicit in the transport of wide range of molecules for mitochondrial functions, it is 
challenging to propose a potential pathological mechanism at such an early-stage. Based on 
the VDAC1 structure elucidated by Geula et al. (2012), Thr80 is not located in either the β1- 
or β19-strands that are essential for oligomerisation of the two VDAC1 monomers and hence, 
formation of the dimer is unlikely to be impaired. Nonetheless, the Thr80 residue is located at 
the edge of a β-strand and hence, its substitution could still alter the secondary structure of the 
channel. This leads to an alternative pathological mechanism involving ROS. Under oxidative 
stress, mitochondria require removal of ROS to prevent damage to mtDNA, macromolecules 
and lipids (Ott et al., 2007). Hence, the VDACs have been proposed to be gateways for the 
transport of ROS across the OMM to the cytosol (Han et al., 2003). Tikunov et al. (2010) 
demonstrated that closing the VDACs prevented the efflux of O2-
. anions, leading to an 
accumulation of this species and oxidative stress. Han et al. (2003) also demonstrated that 
VDAC inhibitors prevented the efflux of O2
. superanions to the cytosol. Thus, the 
accumulation of ROS leads to mtDNA damage. As there is a reduction of ROS release to the 
cytosol, there may also be a reduction in ROS-induced apoptosis since cytochrome c cannot 
be released to the cytosol. Over time, this ROS accumulation and failure to degrade damaged 
mitochondria is thereby catastrophic. For the moment, the p.Thr80Ile variant remains an 
excellent candidate for patient 5, but requires confirmation that it segregates with affected 
family members before functional validation could commence. 
 SEPT2 Mutation Links Mitochondrial Fission with PEO and Multiple mtDNA 
Deletions   
The cytoskeleton component septin 2 has recently been characterised as an essential regulator 
of mitochondrial fission (Pagliuso et al., 2016). Hence, of all candidates identified in this 
study, the novel heterozygous p.Arg330Cys SEPT2 missense variant harboured by patient 19 
   
149 
was the most recent finding. Pagliuso et al. (2016) showed that siRNA depleted SEPT2 in 
HeLa cells led to elongated mitochondria with decreased rates of mitochondrial fission, but 
with no effect on fusion. Authors also demonstrated that SEPT2 interacted directly with Drp1 
and that localisation of Drp1 to mitochondria was dependent upon SEPT2, perhaps taking the 
role that Fis1 plays in recruitment of Drp1 to the OMM in yeast (Lee et al., 2004). Mutations 
of OPA1 (3.4.6) and MFN2 have associated with adult-onset, autosomal dominant mtDNA 
maintenance disorders (Payne et al., 2004; Rouzier et al., 2012). De novo and recessive 
DNM1L mutations have also been reported in early-onset patients with encephalopathy 
(Waterham et al., 2007), although reduced mtDNA copy number has been noted in fibroblasts 
from one patient (Nasca et al., 2016). Hence, this underpins the importance of proper 
regulation of the mitochondrial network. Impaired fusion due to OPA1 and MFN2 mutations 
may prevent the movement or passage of mtDNA replication machinery to damaged mtDNA 
because of inadequate content mixing, as proposed by Vielhaber et al. (2013). Amati-
Bonneau et al. (2008) proposed that for OPA1 defects, the balance of dGTP pools for mtDNA 
maintenance could be affected by impaired GTPase activity or the mtDNA nucleoids in the 
matrix side of the IMM could be destabilised from defective fusion of mitochondria. 
However, SEPT2 is involved in fission and hence, the pathological mechanism differs 
somewhat. Mitochondrial fission has shown to occur in close proximity to the mtDNA 
nucleoids, of which there are fewer but enlarged and clustered in the absence of Drp1 (Ban-
Ishihara et al., 2013). A further study has also confirmed that mtDNA nucleoid dynamics is 
regulated by mitochondria fission, demonstrated by severe impairment of neonatal cardiac 
development and nucleoid clustering in muscle-specific Drp1-knockout mice (Ishihara et al., 
2015). Based on this knowledge, a SEPT2 defect could impair localisation of Drp1 to 
mitochondria leading to an elongated network, thus impairing the segregation and distribution 
of the nucleoids. There could also be failure to remove damaged mitochondria via mitophagy. 
Hence, this necessitates future studies of patient 19 mitochondrial networks including TMRM 
and nucleoid staining of fibroblasts once available. 
 Possible Dominant Inheritance of an MGME1 Missense Mutation 
Of all VUS, only the MGME1 p.Leu236Val missense variant harboured by patient 17 was 
absent from in-house and external exome databases. Even so, there are currently no dominant, 
pathogenic heterozygous MGME1 variants described; all previously reported patients had 
homozygous variants (3.4.12). Furthermore, a rare c.707T>C substitution affecting the 
adjacent nucleotide had also been described in NHLBI ESP (5/13006 heterozygous alleles, 
MAF=0.0003844) and ExAC (5/121196 heterozygous alleles, MAF=0.00004126) databases, 
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leading to a p.Leu236Pro missense change (rs141266045). A proximal homozygous 
p.Tyr233Cys missense change has also been described in a single patient with a systemic 
PEO-plus phenotype and multiple mtDNA deletions (Kornblum et al., 2013). Leu236 is 
moderately conserved and is the second residue of a second key motif of the PD-(D/E)XK 
nuclease family, (G/h)XhD, where h denotes a hydrophobic residue and X denotes any 
residue (Kornblum et al., 2013). Although, the Leu236 residue could be any amino acid it is 
never valine in humans or orthologues. Alternative inheritance of mutations in one gene 
causing same phenotype has also been well characterised in adult-mtDNA maintenance 
disorders, including POLG, RRM2B and SPG7 defects (3.4.4, 3.4.8, 3.4.14). Nonetheless, for 
patient 17 and the affected family members, segregation studies would confirm or exclude 
this heterozygous MGME1 mutation as the causative variant. 
 Dominant Heterozygous ABAT Missense Mutation 
Similarly, there is uncertainty regarding the heterozygous ABAT and RRM2B missense 
variants identified. Like MGME1, mutations of ABAT have only been associated with a 
recessive disorder of mtDNA maintenance to date (Besse et al., 2015). Furthermore, both the 
ABAT and RRM2B variants have been identified in external databases, albeit at low MAFs. 
The p.Thr161Ile RRM2B missense change had also be diagnostically excluded prior to WES. 
Although the variants affect highly conserved residues, there is unfortunately a lack of 
evidence to confirm pathogenicity. Like all other identified variants in this patient cohort, it 
has not been possible to perform segregation studies. 
 POLRMT Splice-Acceptor Site Mutation 
As described in Chapter 1, POLRMT is essential for initiation of mitochondrial transcription 
with the additional transcription initiation factors TFAM and TFB2M, plus the elongation 
factor TEFM. Although the identified POLRMT splice-site variant is an excellent and 
currently only candidate for patient 15, it occurs at a low MAF in ExAC. On the other hand, 
patient 15 presents non-progressive indolent PEO that could be perhaps be undiagnosed in the 
two heterozygous individuals in ExAC. Initial investigations were initiated using patient 15 
fibroblasts to check steady-state levels of POLRMT and MRPL12, which is known to 
stabilise and coordinate mtDNA transcription with POLRMT (Wang et al., 2007; Surovtseva 
et al., 2011). Together with analysis of quiescent fibroblast mtDNA copy number and long-
range PCR assay to check for large-scale rearrangements, the initial data is inconclusive in 
determining what effect, if any, that the POLRMT mutation has on mtDNA transcription in 
fibroblasts. This is further complicated by failure to sequence the cDNA to confirm the 
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splicing effect of c.2641-1C>G change, since the intronic and exonic regions flanking the 
mutation were GC-rich. Performing in vitro studies similar to Kühl et al. (2016) who 
investigated homozygous and heterozygous conditional Polrmt-knockout mice could confirm 
the pathogenic role of POLRMT in adult-onset PEO with multiple mtDNA deletions. Further 
studies that include analysis of TFAM, TFB2M and TEFM expression would provide 
evidence of changes to mtDNA transcription initiation. Also suggested is northern blot 
analysis to assess D-loop strand levels (known as 7S DNA) and mtDNA. At the time of 
writing, patient 15 skeletal muscle became available for research purposes and could provide 
a more substantial phenotype than fibroblasts. 
 Recessive TOP3A Mutations 
Biallelic TOP3A variants were identified in patient 8, who presented a complex PEO-plus 
phenotype with the unusual feature of telangiectasia-like skin lesions. TOP3A encodes 
topoisomerase III-α, which is required for the transient cleavage and ligation of single-
stranded nuclear and mtDNA during replication (Wu et al., 2010; Chen et al., 2012). This 
dual-localised topoisomerase is translated by a single mRNA transcript with the nuclear and 
mitochondrial isoforms distinguished by two initial translation codons (Wang et al., 2002). 
The role of TOP3A in nuclear and mtDNA replication has been well-characterised, with 
knock-out in D. melanogaster causing mtDNA depletion and reduced ATP synthesis (Wu et 
al., 2010). The p.Met100Val and p.Arg135* TOP3A mutations identified in patient 8 both 
occurred in a conserved catalytic topoisomerase-primase (Toprim) domain in the N-terminal 
of the encoded protein, shared with additional topoisomerases (Aravind et al., 1998). 
However, the Met100 residue was poorly conserved in all tested species and was in fact 
valine in D. melanogaster, which led to classification of both variants as VUS. Interestingly, 
TOP3A is known to interact with the bloom syndrome helicase (BLM) for chromosome 
segregation in the nucleus (Chan et al., 2007). BLM mutations cause the extremely rare 
genomic instability disorder of Bloom syndrome that is characterised by erythematous skin 
lesions (Bloom, 1954). Given the high similarity to the patient 8 skin lesions, the biallelic 
TOP3A variants are currently under investigation at the time of writing to validate whether 
these are related to the adult-onset PEO-plus phenotype or if the skin lesions as co-incidental. 
It is worth noting however, that one TK2 patient had skin sarcoidosis (Tyynismaa et al., 2012) 
(3.4.9). 
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4.5.5 Prevalence of Digenic Mendelian Disorders 
 Contiguous 1.4Mb 17p12 Deletion Associated with Axonal Neuropathy 
Analysis of patient 1 CNVs identified a known pathogenic contiguous 1.4Mb 17p12 deletion 
associated with hereditary neuropathy and liability to pressure palsy (HNPP) (Li, 2012; van 
Paassen et al., 2014). This deletion includes all coding exons of PMP22 encoding peripheral 
myelin protein 22, which is essential for nerve myelination and cell proliferation (Adlkofer et 
al., 1995). On the other hand, duplication of the same 1.4Mb 17p12 region including PMP22 
is associated with CMT type 1A (CMT1A). However, patient 1 did not manifest the HNPP 
phenotype and instead had an axonal neuropathy reminiscent of CMT1A. Although 
uncommon, patients harbouring the PMP22 deletion presenting severe axonal neuropathy 
instead of HNPP have been reported (Chance et al., 1993; Bergamin et al., 2014). CMT 
disease due to PMP22 deletion or duplication is one of the most common neurological 
disorders in North East England with an estimated minimum prevalence of 11.8 per 100,000 
(Foley et al., 2012). Given that neuropathy is a common feature of adult-onset Mendelian 
mtDNA maintenance disorders (Chapter 3), digenic disorders of mitochondrial PEO and 
CMT could be under recognised in this cohort of patients. However, this requires the further 
genetic studies of patients with PEO and neuropathy to ascertain any prevalence. 
 Isolated Cystinuria Type A Due to Recessive SLC3A1 Mutations 
The presence of cystinuria together with PEO and multiple mtDNA deletions in patient 19 
was an unusual finding that suggested the presence of a second Mendelian disorder. Since 
patient 19 had received penicillamine to treat the cystinuria, it was presumed that PEO and 
fatigue was penicillamine-induced myasthenia gravis (Drosos et al., 1993). However, this was 
not the case following withdrawal of penicillamine, leading to the diagnosis of mitochondrial 
myopathy. WES of analysis SLC3A1 and SLC7A9 identified the two most common 
pathogenic SLC3A1 variants associated with isolated cystinuria. As of August 2016, over 150 
different SLC3A1 variants have been associated with isolated cystinuria type A (SLC3A1, 
2016). To date, the p.Met467Thr missense change and exon 5-9 duplication are the most 
common pathogenic SLC3A1 variants associated with isolated cystinuria type A in the United 
Kingdom and other Western European countries (Rhodes et al., 2015; Wong et al., 2015), but 
are not as common in South East Europe (Popovska-Jankovic et al., 2013). 
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 MYH14 p.Gly384Cys Variant is Not Associated with Non-Syndromic Hearing 
Loss 
In the patient 6, a heterozygous p.Gly384Cys MYH14 missense change previously reported as 
pathogenic, causing autosomal dominant non-syndromic hearing loss (DFNA4, OMIM 
#600652). The variant had been reported as pathogenic, occurring de novo in a 9 year old 
Italian girl and was annotated as pathogenic due to the evolutionary conservation of the 
Gly384 residue, absence from tested controls and since the girl was the only affected family 
member (Donaudy et al., 2004). This variant could serve to explain the history of hearing loss 
affecting the family of patient 6. However, thanks to NGS and the sharing of variant 
frequency data over the past decade it has been revealed that a number of annotated ‘rare’ and 
‘pathogenic’ variants associated with various Mendelian disorders actually occur at MAFs 
that suggest that these are not rare within the general population. A significant re-assessment 
of previously reported pathogenic variants can be attributed to the ExAC database (Lek et al., 
2016). Re-assessment of ‘pathogenic’ HCM variants in 7,855 cases found that some variants 
were occurring at MAFs too common to cause penetrative Mendelian disease (Walsh et al., 
2016). Assessing the MYH14 p.Gly384Cys missense change, it also occurs more frequently 
than would be expected for a disease-causing mutation. In ExAC, it occurs in 343/119994 
heterozygous alleles (MAF=0.002858, 0.028%) and when further sub-categorised by 
ethnicity, the variant occurs in 275/66322 non-Finnish European alleles (MAF=0.004146, 
0.041%). Similarly, the variant was identified in 36/12712 alleles (MAF=0.0023832, 0.024%) 
from NHLBI ESP and in 12/4996 alleles (MAF=0.002, 0.02%) in the 1000 Genomes Project 
databases. Hence, it the opinion of this study that the MYH14 p.Gly384Cys mutation is not 
associated with hearing loss. Thus, this serves to highlight the importance of variant 
classification and the need to functionally validate candidate variants.  
Although excluded from WES analysis for adult-onset PEO with multiple mtDNA deletions, 
a second heterozygous MYH14 missense change (p.Arg1729Trp) was also identified in patient 
13 through analysis of known autosomal dominant and recessive hearing loss genes. 
Therefore it was concluded that the MYH14 change identified in patient 13 was the most 
likely aetiology for his SNHL since it occurred at a low MAF and affected a conserved 
residue. 
4.5.6 Concluding Remarks 
To summarise, WES of 19 patients presenting with adult-onset PEO and multiple mtDNA 
deletions attained a diagnostic yield of 35%, which comprised causative (10.5%). Based upon 
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the expected predominance of autosomal dominant mutations (Chapter 3), almost all 
proposed likely causative and VUS were heterozygous. Nonetheless, it is important to 
acknowledge that segregation and further functional studies are necessary to validate the 
pathogenicity of identified variants. The identification of a heterozygous somatic mosaic 
TWNK missense change is also suggestive of an under recognised phenomenon of mosaicism 
in autosomal dominant Mendelian mitochondrial disease, that is detectable by WES even at 
low mutational levels. Owing to this, careful curation and annotation of electropherograms 
generated from diagnostic targeted gene sequencing will be needed. This study has also 
identified the only known patient harbouring a dominant RRM1 mutation to date, with further 
contributions to this emerging story anticipated. Irrespective of the custom filtering strategy 
that has been devised and employed, the interactome of mitochondrial function and mtDNA 
maintenance is not yet complete as highlighted by the identification of a novel SEPT2 
mutation. Secondary, actionable mutations causing other Mendelian disorders are also not 
prioritised by the filtering strategy devised here and are instead dependent upon thorough 
clinical phenotyping that can direct this additional variant prioritisation. Segregation studies 
will also greatly improve confidence in likely causative variants and VUS identified, although 
it is accepted that this is difficult when studying a late-onset disorder.
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Chapter 5. GMPR1 Mutation is Associated with Late-Onset PEO and 
Multiple mtDNA Deletions 
5.1 Introduction 
This chapter contains material that includes clinical, diagnostic and research support provided 
from colleagues and external collaborators, who are appropriately acknowledged. 
5.1.1 Deoxyribonucleotide Triphosphate (dNTP) Pools for Nuclear and mtDNA 
Replication 
The replication and maintenance of nuclear and mtDNA is dependent upon a balanced supply 
of all four deoxyribonucleotide triphosphates (dNTPs), the building blocks for DNA 
synthesis, which is intricately controlled through synthesis and degradation (Rampazzo et al., 
2010). An imbalance of dNTP pools, or increased or decreased precursors have been 
associated with human disease. Notably, genomic instability is a hallmark of cancer, which 
can arise due to imbalanced dNTPs leading to replication errors (Mathews, 2015). 
Oncogenesis has been associated with increased de novo synthesis of dNTPs via the 
ribonucleotide reductase (RNR), which is demonstrated to reduce the fidelity of DNA repair 
and increase mutation rates (Aye et al., 2015).    
The supply of dNTPs in mammalians for both nuclear and mtDNA replication is tightly 
coordinated by the cell cycle, involving cytosolic and mitochondrial pathways (Pica-
Mattoccia and Attardi, 1972; Saada, 2009). In dividing (proliferating) cells (Figure 5.1A), 
dNTPs are predominantly generated in the cytosol by de novo synthesis from phosporibosyl 
pyrophosphate (pRpp) through ribonucleotide diphosphate (rNDP) reduction by the RNR, 
comprising the large R1 subunit and small R2 subunit (Pär and Peter, 2006). The active RNR 
is a tetramer composed of two R1 and two R2 (or p53R2) subunits, which are encoded by 
RRM1, RRM2 and RRM2B. A small proportion of dNTPs are also generated by recycling 
through the deoxyribonucleotide (NdR) salvage pathway, which comprises three 
phosphorylation steps and four deoxynucleoside kinases (TK1, dCk, TK2, dGk). First, 
thymidine kinase 1 (TK1) phosphorylates thymidine (dT) and deoxyuridine (dU), whereas 
deoxycytidine kinase (dCk) phosphorylates deoxycytidine (dC), deoxyadenosine (dA) and 
deoxyguanosine (dG). Next, deoxyribonucleoside monophosphate kinases (NMPKs) 
phosphorylate deoxynucleotide monophosphates (dNMPs) to deoxynucleotide diphosphates 
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(dNDPs) and finally, deoxyribonucleoside diphosphate kinases (NDPKs) phosphorylate 
dNDPs to dNTPs. Supply of dNTPs for mitochondrial replication are imported from cytosolic 
pools or are to a lesser extent derived from the mitochondrial NdR salvage pathway with 
thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGk/DGUOK) performing the first 
phosphorylation step within mitochondria. TK2 phosphorylates dT, dC and dU, while dGk 
phosphorylates dA and dG. 
In non-dividing (quiescent) cells (Figure 5.1B), nuclear DNA replication is halted. Hence, 
there is a diminished requirement for dNTPs and therefore synthesis of dNTPs and precursors 
in the cytosol is reduced. This is because the cytosolic enzymes TK1 and to an extent, the 
RNR, are S-phase specific, so are not expressed at G0. Nonetheless, mtDNA replication 
continues and still relies upon a pool of dNTPs. In this quiescent state, mitochondrial dNTP 
synthesis becomes dependent on the rate-limiting enzymes TK2 and dGK (Rampazzo et al., 
2007; Eriksson and Wang, 2008), but also on limited de novo synthesis through the RNR that 
instead comprises R1 and the p53R2 small subunit encoded by RRM2B, instead of the R2 
subunit (Tanaka et al., 2000; Hakansson et al., 2006; Pontarin et al., 2007; Pontarin et al., 
2012). To this end, mitochondria are forced to rely upon its mitochondrial salvage pathway 
for mtDNA replication. There are also catabolic enzymes in the cytosol (NT-1) and 
mitochondria (NT-2) for the degradation of nucleotides, plus thymidine phosphorylase 
(TYMP) and purine nucleoside phosphorylase (PNP) for degrading nucleotides. Pools are also 
maintained by sterile alpha motif (SAM) and histidine-aspartic (HD) domain containing 
dNTP triphosphohydrolase 1 (SAMHD1), which has triphosphatase activity for degradation 
of dNTPs (Goldstone et al., 2011; Beloglazova et al., 2013; Franzolin et al., 2013). The 
activity of SAMHD1 was also recently shown to contribute to the pathology of dGK-
deficiency, with SAMHD1-knockout in patient fibroblasts restoring dNTP pools and mtDNA 
copy number (Franzolin et al., 2015). Although nucleotide synthesis underpins both nuclear 
and mtDNA replication, the RNA content of cells is much higher than DNA and relies on the 
reduction of rNDPs to dNDPs by the RNR for DNA replication. Hence, the majority of 
nucleotides generated are rNTPs (Lane and Fan, 2015).  
In vivo studies have taken advantage of the proliferating and quiescent states of patient cells to 
investigate the underlying pathological mechanisms of mtDNA maintenance disorders 
associated with defects of dNTP supply, including patients with mutations of ABAT, MPV17, 
TK2 and RRM2B (Bianchi et al., 2011; Villarroya et al., 2011; Besse et al., 2015; Dalla Rosa 
et al., 2016). This has typically been achieved by lowering the serum content of culture 
medium from 10% FBS to approximately 0.1%. In some but not all patient cells, mtDNA 
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depletion occurs since non-dividing cells are reliant upon the mitochondrial salvage pathway. 
Owing to the underlying genetic defect of the enzymes involved in dNTP supply, this slows 
or stalls mtDNA replication.  
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Figure 5.1 Maintenance of Cellular dNTP Supply in Dividing and Non-Dividing Cells. Cytosolic and mitochondrial dNTP synthesis in (A) 
dividing and (B) non-dividing cells. In dividing cells, mitochondrial dNTP pools are primarily dependent on import of dNTPs synthesised by the 
cytosolic salvage pathway. In non-dividing cells, cytosolic dNTP synthesis is halted and therefore mitochondrial dNTP synthesis relies on the 
mitochondrial salvage pathway. Figure based on Saada (2009).    
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5.1.2 The Interplay Between dNTP Pool Balance and mtDNA Maintenance Disorders 
Both early- and late-onset mtDNA maintenance disorders have been associated with increased 
or decreased dNTP precursors, or a disturbance in the balance of dNTP pools for mtDNA 
replication (Table 5.1). The first gene to be implicated was TYMP encoding the catabolic 
enzyme thymidine phosphorylase, causing MNGIE with mtDNA depletion and multiple 
mtDNA deletions (3.4.2) due to increased deoxythymidine triphosphate (dTTP) levels 
(Nishino et al., 1999b; Nishigaki et al., 2003). Autosomal recessive mutations of TK2 (3.4.9), 
DGUOK (3.4.10) and MPV17 (3.4.11), dominant and recessive mutations of RRM2B (3.4.8) 
and potentially RRM1 (4.4.7) have also been previously associated with adult-onset PEO with 
multiple mtDNA deletions. However, dNTP pool imbalances or alterations in precursor 
synthesis have been primarily associated with autosomal recessive, early-onset mtDNA 
depletion syndrome due to mutations of ABAT (Besse et al., 2015), DGUOK (Mandel et al., 
2001), MPV17 (Spinazzola et al., 2006), RRM2B (Bourdon et al., 2007), SUCLA2 (Elpeleg et 
al., 2005), SUCLG1 (Ostergaard et al., 2007) and TK2 (Saada et al., 2001). SLC25A4 
mutations have also been proposed to alter dNTP pool balance (Kaukonen et al., 2000; 
Thompson et al., 2016). Similar to additional forms mitochondrial disease, early-onset 
mtDNA depletion syndromes manifest in vast clinical and genetic heterogeneity although 
some patterns have emerged. DGUOK and MPV17 mutations manifest in severe infantile liver 
failure, neurological features and liver-specific mtDNA depletion (Mandel et al., 2001; 
Spinazzola et al., 2006). Interestingly, early-onset hepatocerebal mtDNA syndromes have 
also been described due to recessive mutations of other genes encoding mtDNA replication 
machinery including POLG (Naviaux et al., 1999), POLG2 (Varma et al., 2016) and TFAM 
(Stiles et al., 2016), suggesting that faithful mtDNA replication in the liver is critical during 
early human development. Mutations of SUCLA2, SUCLG1 and ABAT are unusual, since 
their involvement in maintaining dNTP pools is secondary to their primary functions. 
SUCLA2 and SUCLG1 encoded the α- and β-subunits of succinyl CoA synthetase that 
catalyses the conversion of succinate to succinyl-CoA in the TCA cycle. Yet, succinyl CoA 
synthetase has been linked to activity of the mitochondrial nucleoside diphosphate kinase 
(NDPK) known as NME4 and hence, dNTP balance for mtDNA replication (Miller et al., 
2011). Similarly, the GABA-transaminase encoded by ABAT was recently shown to interact 
with SUCLA2, SUCLG1, SUCLG2 and NME4 in the mitochondrial matrix, confirming a 
secondary role in mtDNA maintenance (Besse et al., 2015). 
 
160 
  
Gene Onset Genotype Phenotype Reference(s) 
ABAT Infantile AR Encephalopathy, seizures, DD,  Besse et al. (2015) 
DGUOK Infantile AR Hepatocerebral Syndrome Mandel et al. (2001) 
Adulthood AR PEO, myopathy Ronchi et al. (2012a) 
MPV17 Infantile AR Hepatocerebral Syndrome Spinazzola et al. 
(2006) 
Adulthood AR PEO, myopathy, neuropathy, 
Parkinsonism, enlarged liver 
Garone et al. (2012) 
RRM1a Adulthood AD PEO, OPMD-like n.a. 
Childhood AR PEO, MNGIE-like, axonal 
neuropathy 
Juanola-Falgarona et 
al. (2016) 
RRM2B Adulthood AD and 
AR 
PEO and PEO-plus Tyynismaa et al. 
(2009a) 
Infantile AR Encephalomyopathic, proximal 
renal tubulopathy 
Bourdon et al. (2007) 
SUCLA2 Infantile AR Encephalomyopathic, DD, hearing 
loss 
Elpeleg et al. (2005) 
SUCLG1 Infantile AR Encephalomyopathic, lactic 
acidosis, DD 
Ostergaard et al. 
(2007) 
TK2 Infantile AR Rapidly progressive myopathy, 
respiratory insufficiency  
Saada et al. (2001), 
Garone et al. 
(Submitted) 
Childhood AR Progressive myopathy, SMA-like, 
respiratory insufficiency 
Garone et al. 
(Submitted) 
Adulthood AR Late-onset progressive myopathy, 
PEO, respiratory insufficiency 
Tyynismaa et al. 
(2012), Garone et al. 
(Submitted) 
TYMP Childhood AR MNGIE Nishino et al. (1999b) 
Table 5.1 Nuclear Genes Associated with mtDNA Maintenance Disorders of dNTP Pool 
Balance. DD – developmental delay; MNGIE – mitochondrial neurogastrointestinal 
encephalopathy; OPMD – oculopharyngeal muscular dystrophy; SMA – spinal muscular 
atrophy. n.a. – not applicable. aRRM1 mutations were putatively identified in 4.4.7.  
Several of the essential nucleotide metabolism enzymes with defects associated with mtDNA 
maintenance disorders (RRM2B, TYMP, RRM1) are localised only to the cytosol. This 
supports the assumption that there is a mixing of cytosolic and mitochondrial dNTP pools. 
Indeed, transporters traversing the IMM for the movement of nucleotides have been identified 
including pyrimidine nucleotide carriers 1 and 2 (PNC1, PNC2) that transport uracil, thymine, 
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cytosine deoxyribonucleotide mono-, di- and triphosphates (Franzolin et al., 2012; Di Noia et 
al., 2014). Equilibrative nucleotide transporter 1 (ENT1) is localised to the IMM and the 
plasma membrane for transporting both pyrimidine and purine dNTPs and precursor 
molecules to mitochondria (Lai et al., 2004; Lee et al., 2006a). Analogous to several 
nucleotide metabolism enzymes, expression of the transporters is coupled to the cell cycle. 
PNC1 and PNC2 are expressed in dividing cells but PNC1 is downregulated in non-dividing 
cells, suggesting an essential role in the supply of dNTPs for mtDNA replication from the 
cytosolic pool (Franzolin et al., 2012). In contrast, ENT1 is upregulated in non-dividing cells. 
Since there is mixing of the cytosolic and mitochondrial dNTP pools, a disturbance of either 
pool, or an increase or decrease in nucleotide precursors due to defects of a single nucleotide 
metabolism enzyme could in theory lead to a disorder of mtDNA maintenance. Given the 
significant number of pathways, enzymes and transcription factors needed for fine control of 
dNTP synthesis (Lane and Fan, 2015), it is conceivable that there are unrecognised, novel 
mtDNA maintenance disorders yet to be identified from within this area.   
5.1.3 De Novo Guanosine Nucleotide Synthesis and Guanosine Monophosphate 
Reductase (GMPR)  
The nucleotide bases essential for DNA replication and RNA biosynthesis are distinguished 
into two nitrogenous groups; the purines and the pyrimidines. Purines comprise the 
deoxyribonucleosides dA and dG, plus the ribonucleosides adenosine and guanosine. On the 
other hand, the pyrimidines comprise the deoxyribonucleosides dC and dT, plus the 
ribonucleosides cytidine and uridine. Both purines and pyrimidines can be synthesised by two 
independent pathways; either de novo or salvaged. 
Purine nucleotides are synthesised in the cytosol using the pRpp as the starting nucleobase to 
generate the first nucleotide, inosine monophosphate (IMP), in a series of 10 intermediate 
enzymatic reactions requiring five ATP molecules, H2O, CO2, glucose, glycine, glutamine, 
aspartate, and a carbon unit N10-formyl-TetraHydroFolate (THF) (Lane and Fan, 2015). Using 
IMP as a nucleotide precursor, the major purine nucleotides adenosine monophosphate 
(AMP) and guanosine monophosphate (GMP) can be synthesised de novo via two distinct 
pathways.  
Synthesis of GMP from IMP is performed by two enzymes in the cytosol; inosine 
monophosphate dehydrogenase (IMPDH) and GMP synthetase (GMPS) in reversible two-
step rate-limiting reactions (Figure 5.2). First, IMP undergoes NAD-dependent oxidation to 
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the intermediate nucleotide xanthosine monophosphate (XMP) by one of two catalytically 
indistinguishable IMPDH homologs encoded by two separate genes, IMPDH1 and IMPDH2. 
Both genes are expressed throughout most human tissues, although IMPDH1 appears to be 
less expressed and IMPDH2 is upregulated in dividing cells (Senda and Natsumeda, 1994; 
Zimmermann et al., 1998). The IMPDH reaction is summarised in the following equation:     
IMP + NAD+ + H2O
                 
↔    XMP + NADH + H+ 
Second, XMP undergoes ATP-dependent amination to GMP by GMPS (Nakamura and Lou, 
1995; Tesmer et al., 1996). The GMPS reaction is summarised in the following equation: 
XMP + ATP + L-Glutamine + H2O
                 
↔    GMP + P𝑖 + AMP + L-Glutamate 
GMP synthesised from IMP is next free to undergo conversion to guanosine diphosphate 
(GDP) from the addition of a phosphate group donated from ATP by guanylate kinase 1 
(GUK1) (Brady et al., 1996), followed by reduction to deoxyguanosine diphosphate (dGDP) 
via the RNR. 
Although these de novo guanine synthesis reactions are reversible, there is an additional 
irreversible reaction that converts GMP back to IMP with an ammonium (NH4
+) leaving 
group, thus rapidly sustaining the balance of guanine and adenine nucleotides. This NADPH-
dependent amination reaction is performed by GMP reductase (GMPR) (Spector et al., 1979). 
Currently, this is the only known reaction for the catabolism of guanine nucleotides to the 
IMP precursor. The GMPR reaction is summarised in the following equation: 
GMP + NADPH + 2H+
                
→     IMP + NADP+ + NH4
+ 
However, Patton et al. (2011) also demonstrated that in the presence of sufficient ammonia, 
E. coli GMPR could directly synthesise GMP from IMP, therefore suggesting an expanded 
role in GMP synthesis. 
Similar to IMPDH, there are two GMPR homologs encoded by separate genes humans, 
GMPR1 and GMPR2. The two human homologs are 90% identical and exist as 
homotetramers that form catalytic (β/α) barrels in a square planar formation (Li et al., 2006). 
The intron structure varies between the two genes with the GMPR2 gene, with GMPR2 
encoding three more amino acids in the 10th exon than GMPR1 in the 9th exon. Both GMPR1 
and GMPR2 are highly expressed in the heart, skeletal muscle and kidney with low 
expression in the colon, thymus and blood leukocytes, whereas GMPR2 is expressed at much 
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higher levels in the brain, liver and placenta (Deng et al., 2002). GMPR is highly conserved 
from bacteria to humans (Andrews and Guest, 1988) and was recently characterised in 
parasites (Bessho et al., 2016; Smith et al., 2016). The GMPR and IMPDH enzymes have 
opposing catalytic activities in the de novo guanine synthesis, suggesting that their expression 
is coordinated together. Indeed, during differentiation IMPDH is downregulated and GMPR is 
upregulated, leading to a decrease in the GMP pool (Weber et al., 1992). Henceforth, IMPDH 
increases the guanine nucleotide pool whereas GMPR decreases the pool. Interestingly, due to 
their coupled expression and similar enzymatic reactions both GMPR and IMPDH share 
conserved active sites, a conserved GIGPGSICTT sequence motif, binding the same ligands 
although with different affinities (Hedstrom, 2012). The catalytic residue is conserved, 
corresponding to Cys186 in GMPR and Cys319 in IMPDH with this motif (Li et al., 2006). A 
second important catalytic residue in this motif is a threonine, corresponding to Thr188 in 
GMPR and Thr321 in IMPDH (Hedstrom, 2012). 
While the de novo guanine synthesis pathway is crucial to sustain the balance between 
guanine and adenosine nucleotides for nuclear and mtDNA replication, a direct association of 
GMPR or IMPDH to mitochondria has not been established. Interestingly, transcriptome 
profiling of skeletal muscle in patients with early-onset mtDNA depletion syndrome due to 
TK2 mutations noted that GMPR1 was significantly underexpressed, supporting its role in the 
balance of the guanine nucleotide pool (Kalko et al., 2014).  
In Chapter 4, a novel heterozygous p.Gly183Arg GMPR1 missense change was identified 
using WES with a custom filtering strategy in patient 11, who presented with late-onset PEO 
with multiple mtDNA deletions. In this chapter, the novel GMPR1 mutation is characterised 
to understand the potential pathological mechanism linking a disturbance of nucleotide 
synthesis in the cytosol to a novel mtDNA maintenance disorder. 
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Figure 5.2 Human GMP Biosynthesis from IMP. A simplified schematic of the GMP biosynthesis pathway, beginning with the precursor IMP. 
GMPR is denoted in red with the resolved secondary structure (PDB ID 2BLE). 
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5.2 Aims 
This chapter characterises the pathogenic nature of a novel heterozygous GMPR1 missense 
variant in a patient presenting late-onset PEO and multiple mtDNA deletions.    
5.3 Methods 
5.3.1 GMPR1 Protein Structure Analysis 
The full length 345 amino acid sequence of human homologs GMPR1 (NP_006868), GMPR2 
(NP_001002002), paralogs IMPDH1 (NP_000874) and IMPDH2 (NP_000875), plus the 
secondary structure of human GMPR1 (PDB ID 2BLE) were subjected to bioinformatics 
analyses as outlined in 2.7. Putative mitochondrial localisation of human GMPR1 was 
predicted using MitoMiner 4.0 (Smith and Robinson, 2016). 
5.3.2 Cell Culture 
Cultured fibroblasts were grown for patients 11 (GMPR1), 8 (TOP3A) and 15 (POLRMT) plus 
three appropriate age-matched controls. Subculturing, freezing, harvesting and generation of 
quiescent fibroblasts were performed as described in 2.4. 
5.3.3 Ethidium Bromide mtDNA Depletion and Recovery 
Fibroblasts from patients 11, 8 and 15 plus two controls were seeded into eight T75 flasks 
each. Once confluent (day 0), cells were grown in MEM (10% FCS) containing 50ng ml-1 
ethidium bromide (stock 10mg ml-1) for 7 days. This was then replaced with ‘quiescent’ 
MEM (0.1% DBS) containing 50ng ml-1 ethidium bromide for an additional 7 days. On day 
14, MEM was aspirated and replaced with fresh quiescent MEM without ethidium bromide. 
Quiescent MEM was immediately aspirated and replaced again. This was repeated four times 
for each cell line, then after 2 hours and a further 2 hours later. A single T75 flask for each 
cell line was harvested at days 0, 7, 14, 15, 21 and 28. 
Fibroblast DNA was extracted and relative mtDNA copy number was quantified using real 
time PCR assay, as described in 2.3.10. 
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5.3.4 Long-Range PCR of Quiescent Fibroblast DNA 
DNA was extracted from quiescent fibroblasts of patient 11 and two controls. Long-range 
PCR of quiescent fibroblast DNA plus 1:10 control blood DNA homogenate was performed 
as outlined in 2.3.9.    
5.3.5 Live Cell Imaging and Confocal Microscopy 
Patient 11 and two control fibroblast cell lines were prepared, imaged with fluorescent dyes 
TMRM for the mitochondrial network and PicoGreen for dsDNA using the Nikon A1R Invert 
point scanning confocal microscope and analysed as outlined in 2.6. 
5.3.6 Western Blotting 
Fibroblast lysates were prepared as described in 2.5.1. Frozen skeletal muscle from patient 11 
and two age-matched controls were homogenised for western blot studies as described in 
2.5.2. Fibroblast (50µg) and muscle lysates (25-50µg) were prepared and subjected to 10% or 
12% SDS-page, probed with primary and secondary antibodies (Table 2.4, Table 2.5) then 
detected as outlined in 2.5. Membranes were incubated with primary antibodies specific to 
GMPR1, LONP1, TFAM, AK2, AK3, TK1, TK2, PNC1, PNC2, ENT1, RRM1, RRM2, 
p53R2/RRM2B. Primary antibodies used for OXPHOS subunits were NDUFB8, SDHA, 
UQCRC2, MT-COII and ATP5A. α-Tubulin, VCL and GAPDH were used as loading 
controls.  
5.4 Results 
5.4.1 Case Report 
Patient 11 was a 73 year old female presenting indolent, late-onset PEO. She underwent 
corrective squint surgery in 2004 at 60 years old, but complained of double vision post-
surgery. At 69 years old mild bilateral ptosis was noted. Upon clinical examination at 70 
years old, she had marked PEO with subtle asymmetry, mild bilateral ptosis that affected 
predominantly the right eye, double vision, right exotropia and mild orbicularis oculi 
weakness. No abnormalities were detected on brain MRI scan, but there was no comment on 
the extraocular muscles. There was no reported family history of an eye movement disorder; 
she was an only child and had three asymptomatic adult children. Muscle histopathology 
revealed over 15% COX-deficient and 3% ragged-red fibres. Multiple mtDNA deletions were 
detected in skeletal muscle by long-range PCR. 
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Application of the WES filtering strategy prioritised a heterozygous c.547G>C (p.Gly183Arg) 
missense variant in GMPR1 encoding guanosine monophosphate reductase 1 (4.4.9). GMPR1 
(6p22.3) matched GO-Terms ‘nucleotide’ and ‘purine’. The variant was confirmed by Sanger 
sequencing with custom forward and reverse primers for GMPR1 exon 5 (Figure 5.3A). 
Segregation studies were not possible. Gly183 was fully conserved from humans to E. coli 
(Figure 5.3B). The variant was also absent from in-house and external exome databases. The 
c.547G>C change affected the last nucleotide of exon 5, which corresponded to the first 
nucleotide of the Gly183 residue. The Human Splicing Finder predicted that the c.547G>C 
change could lead to either a broken donor or exonic splicing enhancer site, with potential 
implications for mRNA stability.   
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5.4.2 Quadruple Immunofluorescence Assay 
In addition to COX-SDH histochemistry demonstrating COX-deficient fibres (Figure 5.4A), 
patient 11 skeletal muscle was subjected to a quadruple immunofluorescence assay by 
Mariana Rocha (Wellcome Trust Centre for Mitochondrial Research, Institute of 
Figure 5.3 Identification of a Novel p.Gly183Arg GMPR1 Mutation. (A) Pedigree for 
patient 11 (solid black arrow) and Sanger sequencing confirmation of the heterozygous 
p.Gly183Arg GMPR1 variant. (B) Multiple sequence alignment (MSA) of the GMPR1 
Gly183 residue. 
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Neuroscience, The Medical School, Newcastle University, Newcastle upon Tyne). The 
protein expression profile for patient 11 was in agreement with previously investigated 
patients with multiple mtDNA deletions (Rocha et al., 2015); there were a greater proportion 
of fibres with deficiency of complex I and a population of fibres with equal downregulation of 
both complex I and IV (Figure 5.4B). 
 
 
 
 
    
Figure 5.4 Patient 11 COX-SDH Histochemistry and Mitochondrial Respiratory Chain 
Protein Expression Profile. (A) Diagnostic sequential COX-SDH histochemistry of patient 
11 skeletal muscle. (B) Quadruple immunofluorescence result for patient 11. Each dot 
represents Z-scores for complex I and complex IV protein expression for an individual muscle 
fibre, colour coded according to mitochondrial mass (very low: blue, low: light blue, normal: 
light orange, high: orange and very high: red). Thick blue lines indicate the boundaries the 
standard deviation limitations for classification of the fibres. Thin dashed lines indicate the 
mean expression levels of normal fibres.   
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5.4.3 In Silico Analysis of Human GMPR1 
The secondary protein structure of human GMPR1 (hGMPR1) (PDB ID 2BLE) (Figure 
5.5A) and the amino acid sequence (NP_006868) were obtained for in silico studies. 
InterProScan 5 identified an IMP dehydrogenase/GMP reductase signature from residues 176-
188 of the hGMPR1 protein sequence. Hence, the identified p.Gly183Arg mutation was 
located within this region of the protein (Figure 5.5B), which was fully conserved between its 
paralog hGMPR2. MSA also showed that it was conserved between the two additional 
members of the IMP/GMP protein family, IMPDH1 and IMPDH2 (Figure 5.5C).  
Analysis of the secondary GMPR1 monomer structure showed that the Gly183 residue was an 
α-helix coil within IMP dehydrogenase/GMP reductase signature, which formed a loop 
structure within the core. Consistent with Li et al. (2006), an oxygen atom of the Gly183 
residue was hydrogen bonded to nitrogen atom of Cys186, but at a distance of 3.10Å (Figure 
5.6A). Nonetheless, the ‘loop’ structure interacted with the bound GMP and is therefore the 
likely active site. . Gly183 formed one of two carbon hydrogen bonds, with the fourth oxygen 
atom of bound GMP, at a distance of 3.66Å (Figure 5.6B).
Figure 5.5 Human GMPR1 Structure. (A) The secondary structure of human GMPR1 
monomer (PDB ID 2BLE). (B) The IMP dehydrogenase/GMP reductase domain within 
GMPR1 and the location of the p.Gly183Arg missense change. (C) MSA of the patient 11 
GMPR1, wild-type GMPR1, GMPR2, IMPDH1 and IMPDH2 demonstrating conservation of 
the Gly183 residue. Parentheses indicate the conserved IMP dehydrogenase/GMP reductase 
domain. 
   
171 
    
Figure 5.6 Intramolecular Interactions of hGMPR1 Gly183. hGMPR1 forms two intramolecular interactions. (A) A hydrogen bond (dashed green 
line) between an oxygen atom of Gly183 and a nitrogen atom of Cys186. (B) A carbon hydrogen bond between a carbon atom of Gly183 and oxygen 
atom of bound GMP in the hGMPR1 active site loop. The solid arrow denotes the carbon hydrogen bond.   
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GMP (Figure 5.7A) also formed a number of additional significant intramolecular 
interactions when bound to GMPR1 (Figure 5.7B). This included pi-alkyl interactions, 
hydrogen bonds, carbon hydrogen bonds and pi-sulphur interactions. The second carbon 
hydrogen bond of the fourth oxygen atom of GMP involved Asn220 at a distance of 3.16Å, 
also with the fourth oxygen atom of GMP.   
Substitution of glycine with arginine at position 183 abolished the carbon hydrogen bond with 
bound GMP, although the hydrogen bond with Cys183 remained intact. Nonetheless, a 
number of unfavourable interactions between Arg183 and GMP atoms were introduced as a 
consequence the substitution, suggesting either that binding of GMP to the active site loop is 
significantly impaired during to interference from the bulky arginine or that GMP is 
inefficiently bound to GMPR1 (Figure 5.8).  
 
 
 
 
 
    
Figure 5.7 GMP Ligand Interactions. (A) GMP is the substrate of hGMPR1 and hGMPR2. 
(B) Bound GMP forms several intramolecular bonds with GMPR1 residues, including with 
Gly183. 
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5.4.4 Genetic Variation within the GMPR1 Active Site Loop 
Amino acid variations within the active site loop, residues 176-188, of hGMPR1 and 
hGMPR2 were studied within ExAC (Table 5.2). In hGMPR1, one synonymous and one non-
synonymous change was identified. None of the conserved residues were mutated. On the 
other hand, there were two synonymous, 11 non-synonymous changes and one frameshift 
mutation affecting the hGMPR2 active site loop were listed that included all conserved 
residues. Nonetheless, all changes were rare. 
 
 
 
 
 
   
 
Figure 5.8 Substitution of Gly183 with Arginine. Binding of GMP to hGMPR1 is likely 
impaired due to the introduction of unfavourable interactions (red lines denoted by the solid 
black arrow) and abolishment of a carbon hydrogen bond that existed between Gly183 and 
GMP. However, the hydrogen bond between Cys186 and mutated Arg183 is retained (dashed 
arrow). For clarity, the mutated Arg183 residue is shown in dark blue. 
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 Human GMPR1 Variation Human GMPR2 Variation 
Residue Variant MAF Variant MAF 
Ile176 p.Gly179Gly 0.00001648 p.Ile176Met 0.000008284 
Lys177 p.Val180Ala 0.000008243   
Val178   p.Val178Met 
p.Val178Val 
0.000008284 
0.00003313 
Gly179   p.Gly179Arg 
p.Gly179Glu 
0.00003313 
0.000008283 
Val180     
Gly181   p.Gly181Glu 0.000008283 
Pro182     
Gly183 p.Gly183Arg Ø p.Gly183Ser 0.00001657 
Ser184   p.Ser184Cys 0.00002486 
Val185   p.Val185_Cys186insGlu 
p.Val185Val 
0.000008287 
0.00001658 
Cys186   p.Cys186Gly 
p.Cys186Arg 
p.Cys186Phe 
0.000008288 
0.000008288 
0.000008288 
Thr187     
Thr188   p.Thr188Ile 0.00001658 
Table 5.2 Human GMPR1 and GMPR2 Amino Acid Variation. List of hGMPR1 and 
hGMPR2 variants listed in ExAC and the minor allele frequencies (MAF). Synonymous 
changes are shown in green. The novel GMPR1 missense change identified in patient 11 is 
shown in red. Conserved residues between hGMPR1, hGMPR2, hIMPHD1 and hIMPDH2 
are italicised. Ø denotes absence of the p.Gly183Arg missense change in ExAC. 
5.4.5 Sublocalisation of GMPR1 
In MitoMiner 4.0, GMPR1 was predicted to localise to mitochondria by iPSORT (1.0), but 
was predicted unlikely by TargetP (0.36), MitoProt (0.357) and MitoFates (0.003). To 
investigate localisation of GMPR1, subfractionation and immunoblotting of HEK293 and 
HeLa cells was performed by Francesco Bruni (Wellcome Trust Centre for Mitochondrial 
Research, Newcastle upon Tyne). In both HeLa and HEK293 cells, GMPR1 was detectable in 
total cell lysate and the post-mitotic supernatant but not in isolated mitochondrial 
subfractions. Hence, GMPR1 localised only to the cytosol (Figure 5.9).   
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Figure 5.9 Sublocalisation of GMPR1. Subfractionation of (A) HeLa and (B) HEK293 cells subjected to immunoblotting with a GMPR1 antibody 
and markers for each subfraction: GDH – mitochondrial matrix; AIF – mitochondrial inner membrane space; NDUFB8 – mitochondrial inner 
membrane; EF-Tu – mitochondrial inner membrane; eIF4E – cytosol. All subfractions were prepared from the same HeLa or HEK293 lysate. 
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5.4.6 Relative mtDNA Copy Number in Proliferating and Quiescent GMPR1 Fibroblasts 
From the same passage, relative mtDNA copy number of patient 11 proliferating and 
quiescent fibroblasts were compared by Ilaria Dalla Rosa (MRC Mill Hill Laboratory, 
London, United Kingdom). Based on one replicate, control and patient 11 fibroblast mtDNA 
copy number increased from proliferating to quiescent state (Figure 5.10).  
5.4.7 Ethidium Bromide Depletion and Recovery of mtDNA 
Patient 11 (GMPR1), patient 8 (TOP3A) and patient 15 (POLRMT) fibroblasts were depleted 
of mtDNA with ethidium bromide for 14 days. After removal of ethidium bromide and the 
change of proliferating to quiescent MEM, there was no significant difference in the recovery 
of mtDNA compared to control fibroblasts (Figure 5.11). Both control and patient fibroblasts 
did not recover mtDNA to the relative levels at the start (day 0) of depletion.    
Figure 5.10 Relative mtDNA Copy Number of Patient 11 Proliferating and Quiescent 
Fibroblasts. The relative mtDNA copy number of patient 11 and control fibroblasts from the 
same passage in proliferating and quiescent states, with only one replicate. 
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5.4.8 Long-Range PCR of Quiescent Fibroblast DNA 
In contrast to the skeletal muscle, no mtDNA rearrangements were detected in extracted 
quiescent fibroblast DNA from patient 11 and two controls, using two sets of forward and 
reverse primers for mtDNA amplification (Figure 5.12).   
Figure 5.11 Ethidium Bromide Induced mtDNA Depletion of Multiple mtDNA Deletion 
Patient Fibroblasts. Fibroblasts from three adult-onset PEO with multiple mtDNA deletions 
patients and two controls were depleted of mtDNA with ethidium bromide, followed by 
removal and recovery of copy number. Control 1- solid black line. Control 2 – dashed black 
line. Patient 11 (GMPR) – solid blue line. Patient 8 (TOP3A) – solid purple line. Patient 15 
(POLRMT) – solid red line. 
178 
  
5.4.9 Live Cell Imaging and Confocal Microscopy 
Live cell imaging of proliferating fibroblasts was performed together with Maria-Eleni 
Anagnostou (Wellcome Trust Centre for Mitochondrial Research, Newcastle upon Tyne) 
(Figure 5.13). TMRM staining showed no fragmentation or elongation of the mitochondrial 
dynamic network in patient 11 fibroblasts. PicoGreen staining of dsDNA showed also no 
abnormalities in nucleoid morphology. 
Additional confocal microscopy of fixed quiescent fibroblasts from patient 11 was performed 
by Ilaria Dalla Rosa, using anti-DNA to stain dsDNA and anti-TOM20 to stain the 
mitochondrial network (Figure 5.14). This also showed no fragmentation or elongation of the 
mitochondrial network and no abnormal nucleoid morphology. 
Figure 5.12 Long-Range PCR of Patient 11 Quiescent Fibroblast DNA. Long-range PCR 
of wild-type blood homogenate, two control quiescent fibroblast (C1 and C2), patient 11 
(GMPR) quiescent fibroblast DNA and a no template control. Amplification of each sample 
was performed in triplicate with two sets of optimised forward and reverse primers. Red line 
indicates the wild-type mtDNA product. 
   
179 
     
Figure 5.13 Analysis of the Mitochondrial Network and Nucleoids in Patient 11 Proliferating Fibroblasts. TMRM and PicoGreen staining of 
patient 11 fibroblasts and two controls was performed using the Nikon A1R Confocal microscope. 
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Figure 5.14 Analysis of the Mitochondrial Network and Nucleoid Morphology in Patient 11 Quiescent Fibroblasts. Quiescent patient 11 and 
control fibroblasts were incubated with primary antibodies for anti-DNA and TOM20 overnight, probed with corresponding HRP-conjugated 
secondary antibodies for 2 hours and fixed to glass slides for confocal microscopy. 
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5.4.10 Nucleotide Homeostasis 
Steady-state of OXPHOS subunits, mtDNA replication machinery, dNTPs synthesis enzymes 
and nucleotide transporters were investigated in patient 11 and control fibroblasts. 
There was a minor decrease of steady-state GMPR1 levels in patient 11 fibroblasts under 
proliferating and quiescent states (Figure 5.15A). Nonetheless, the relative expression of 
GMPR1 was decreased in patient and control fibroblasts in quiescence compared to 
proliferating cells. Mild decreases in NDUFB8 (complex I) and MT-COI (complex IV) levels 
were also noted in patient 11 fibroblasts.   
Expression of LONP1 was slightly decreased in patient 11 proliferating and quiescent 
fibroblasts, but there was no change in TFAM levels (Figure 5.15B). 
Next, additional nucleotide metabolism enzymes were analysed (Figure 5.16A). Adenylate 
kinase 2 (AK2) was expressed in both proliferating and quiescent fibroblasts but did not 
appear to be significantly altered patient 11 fibroblasts. On the other hand, adenylate kinase 3 
(AK3) was expressed only in quiescent fibroblasts and appeared to be decreased in patient 11 
fibroblasts. As anticipated, TK1 was expressed in proliferating fibroblasts only, while TK2 
was upregulated in quiescence. However, its expression was decreased compared to quiescent 
controls. 
Expression of steady-state RNR subunits (R1, R2, p53R2) were also analysed (Figure 5.16B). 
R1 was expressed in both proliferating and quiescent fibroblasts. R2 was upregulated in 
proliferating cells and decreased slightly in quiescence. p53R2 expression was low in 
Figure 5.15 Western Blot Analysis of GMPR1, OXPHOS subunits and mtDNA 
Replication Factors LONP1 and TFAM in Fibroblasts. Steady-state levels of (A) GMPR1 
and OXPHOS subunits, plus (B) LONP1 and TFAM. 
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proliferating fibroblasts and increased in quiescence. However, expression of the RNR 
subunits were not significantly altered in patient 11 fibroblasts. Nonetheless, there was 
variation between controls, including apparently decreased R1 levels in C1 and multiple 
bands observed for R2 in quiescence. 
Nucleotide transporters PNC1, PNC2 and ENT1 were also investigated (Figure 5.17). As 
expected, PNC2 was downregulated in quiescent fibroblasts, while PNC1 and ENT1 were 
expressed during both states. Although PNC2 was downregulated in quiescence, there was an 
increase in patient 11 fibroblasts compared to controls. Again, there was variation in the 
controls, with C2 apparently showing decreased steady-state levels of PNC1. 
Initial investigation of patient 11 and control skeletal muscle also commenced. Steady-state 
GMPR1 levels were greatly decreased in patient 11 relative to controls (Figure 5.18A). 
TFAM was also downregulated in the muscle, although LONP1 levels were not significantly 
altered (Figure 5.18B). NDUFB8 (complex I) was also markedly decreased in patient 11 
(Figure 5.18C).    
Figure 5.16 Western Blot Analysis of Nucleotide Metabolism Enzymes and the RNR 
Subunits. Steady-state levels of (A) nucleotide metabolism enzymes and (B) RNR subunits. 
Figure 5.17 Western Blot Analysis of Nucleotide Transporters. Steady-state levels of IMM 
nucleotide transporters PNC1, PNC2 and ENT1. 
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5.4.11 Mitochondrial Protein Synthesis in Fibroblasts 
Mitochondrial translation products in proliferating and quiescent fibroblasts were subjected to 
35S-methionine labelling by Ilaria Dalla Rosa using a well-established protocol (Chomyn, 
1996). This demonstrated an exceptionally subtle decrease of nascent mitochondrial proteins 
in patient 11 proliferating and quiescent fibroblasts compared to controls (Figure 5.19). 
 
 
 
 
 
 
 
 
Figure 5.18 Western Blot Analysis of GMPR1, OXPHOS subunits and mtDNA 
Replication Factors LONP1 and TFAM in Skeletal Muscle. Steady-state levels of (A) 
GMPR1, (B) LONP1 and TFAM, plus (C) OXPHOS subunits NDUFB8 (complex I) and 
SDHA (complex II). 
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5.5 Discussion 
Using the custom WES filtering strategy for adult-onset PEO with multiple mtDNA deletions 
outlined in Chapter 4, a novel heterozygous p.Gly183Arg missense change was identified in 
GMPR1 encoding GMP reductase 1 for the catabolism of the ribonucleotide GMP to the 
guanine and adenine precursor nucleotide IMP and hence, maintaining the balance of the 
purine nucleotides. In this chapter, evidence has been provided to demonstrate GMPR1 as a 
novel candidate adPEO gene, through the combination of in silico analysis, study of patient 
fibroblasts and muscle. Together with TYMP, SLC25A4, RRM2B, DGUOK, MPV17, TK2 and 
RRM1, GMPR1 potentially expands the list of genes involved in dNTP nucleotide 
homeostasis that are associated with adult-onset PEO and multiple mtDNA deletions.  
5.5.1 Impaired GMP Binding Within the GMPR1 Active Site 
With the available human GMPR1 secondary structure (PDB ID 2BLE), it was possible to 
model the effect of the p.Gly183Arg mutation on protein structure and function. As first noted 
by Li et al. (2006), in GMPR1 and GMPR2 Gly183 forms a hydrogen bond with the critical 
Figure 5.19 35Methionine-Labelling of Mitochondrial Proteins in Proliferating and 
Quiescent Fibroblasts. Mitochondrial proteins were separated by 12% PAGE. Radiolabelled 
proteins were detected by PhosphorImaging. Fibroblasts were placed in quiescence for 10 
days. Performed by Ilaria Dalla Rosa.   
   
185 
catalytic Cys186 residue. Both residues are within a conserved IMP/GMP dehydrogenase 
domain shared between all IMP/GMP protein family members that comprises an active site 
binding loop conformation for GMP binding. The conversion of GMP to IMP by GMPR has 
been shown to consist of two chemical transformations; a deamination step and hydride 
transfer step (Patton et al., 2011). In the first deamination step, the crucial Cys186 residue 
‘attacks’ the second carbon atom of GMP, which creates a covalent thiomidate intermediate; 
E-XMP*. In the second step there is a hydride transfer of NADP, which forms IMP. A 
mutation of this conserved cysteine residue has been shown to inactivate GMPR activity in E. 
coli (Li et al., 2006; Min et al., 2008). However, in silico modelling shows that the human 
p.Gly183Arg mutation does not abolish the hydrogen bond with this crucial residue. On the 
other hand, this mutation abolishes a critical intramolecular bond for GMP binding and 
introduces unstable interactions with GMP, perhaps as a consequence of the bulky size of 
arginine. Therefore it is probable that the p.Gly183Arg mutation causes an impairment of 
GMP binding either from blocking the active site or due to unstable binding.  
The evolutionary conservation of the GMPR1 active site region was next investigated further. 
Overall, the GMPR1 amino acid sequence is 90% identical to its homolog GMPR2 (Deng et 
al., 2002), suggesting that the latter arose from duplication of the ancestral GMP reductase 
gene (Becerra and Lazcano, 1998). This includes the IMP dehydrogenase/GMP reductase 
signature shared between the two other IMP/GMP enzymes IMPDH1 and IMPDH2. Given 
the conservation of this region and the Gly183 residue in GMPR1, all identified variants in 
this region were examined from ExAC. Remarkably, the p.Gly183Arg missense change is 
only the second missense variant identified in this region, the first being a p.Val180Ala 
variant at a low MAF. However, Val180 is not conserved between GMPR1 and GMPR2, nor 
with IMPDH1 or IMPDH2. Regarding GMPR2, there is an abundance of missense changes, 
albeit at low MAFs, that affect conserved residues between GMPR1, IMPDH1 and IMPDH2. 
This suggests high evolutionary significance for GMPR1 and supports the notion that GMPR1 
is the ancestral gene that underwent duplication to conceive GMPR2, but also probably 
IMPDH1 and IMPDH2. The evolutionary significance is highlighted by Hedstrom (2012), 
who notes that since life likely emerged from an ammonia-rich environment (Zahnle et al., 
2010), the ancestral gene is likely GMPR with some GMP synthesis activity. Such activity is 
supported by Patton et al. (2011), who demonstrated that E. coli GMPR could synthesis GMP 
from IMP in sufficient ammonia levels. It is also worth noting that there is currently only one 
known protein coding hGMPR1 transcript, whereas there are seven known protein coding 
hGMPR2 transcripts. Thus there is high evolutionary constraint against variance in the 
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IMP/GMP dehydrogenase region in human GMPR1, which supports the view that this is 
dominant human disease gene rather than recessive when compared with GMPR2. However, 
it is uncertain whether reduced activity or binding of GMP with GMPR1 is counteracted with 
increased GMPR2 expression. To investigate this further, a collaboration with Dr Liz 
Hedstrom and Dr Masha Rosenberg (Brandeis University, Massachusetts, USA) to express 
and purify human GMPR2 harbouring the p.Gly183Arg mutation from E. coli to measure the 
catalytic conversion of GMP to IMP is currently underway. 
5.5.2 Nucleotide Homeostasis is Altered in GMPR1 Patient Fibroblasts 
Decreased GMPR1 expression was clearly evident in both patient fibroblasts and significantly 
more so in the skeletal muscle. Additionally, GMPR1 expression was mildly decreased in 
non-dividing control and patient fibroblasts. This study has shown for the first time that 
GMPR1 remains active during quiescence and continues to play an important role in the 
synthesis of guanine ribonucleotides, although this is not surprising since the RNR continues 
to reduce rNDPs in non-dividing cells (Tanaka et al., 2000; Hakansson et al., 2006; Pontarin 
et al., 2007; Pontarin et al., 2012). Nonetheless, it should be noted that there was clear 
variation between the control samples used in both proliferating and quiescent states. 
Since GMPR1 reduces GMP to IMP, the precursor of purine nucleotide synthesis, expression 
of the de novo adenine synthesis enzymes, adenylate kinase 2 and 3 (AK2, AK3), were 
studied. Both kinases catalyse the reversible conversion of AMP to ADP, although AK2 is 
localised to the mitochondrial intermembrane space, whereas AK3 is localised to the matrix 
(Noma, 2005). AK2 was expressed in both patient and control proliferating and quiescent 
cells, while AK3 is upregulated in quiescence suggesting a prominent role in the 
mitochondrial salvage pathway. In quiescent patient fibroblasts though, there was a decrease 
in AK3 suggesting that the mitochondrial purine salvage pathway is downregulated. 
Surprisingly, TK2 was also decreased in quiescence, which indicates that mitochondrial 
pyrimidine salvage is also repressed. There was also no apparent change in the expression of 
the RNR subunits in proliferating and quiescent state, implying that the reduction of rNDPs 
from de novo nucleotide synthesis is not altered. Regarding the nucleotide transporters, PNC2 
was downregulated in quiescent control and patient fibroblasts but was mildly elevated in 
patient cells. No observable changes in PNC1 and ENT1 expression were noted. Taken 
together, this suggests that mitochondria are attempting to re-balance the dNTP pools through 
a combination of mitochondrial purine and pyrimidine salvage repression, while also 
attempting to redress the balance by up-taking de novo synthesised and free purine 
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nucleotides from the cytosolic pools. Interestingly the pattern of purine and pyrimidine 
repression together with the upregulated PNC2 transporter is comparable to that of MPV17-
deficient fibroblasts, which demonstrate an interesting link to guanosine synthesis (Dalla Rosa 
et al., 2016). Given that the precise role of MPV17 in nucleotide homeostasis and mtDNA 
maintenance disorders has yet to be elucidated, further examination of the effect of the 
GMPR1 mutation on MPV17 expression in fibroblasts and skeletal muscle could provide an 
invaluable contribution to the debate.  
In light of the mild changes to nucleotide homeostasis in fibroblasts, studies are currently 
underway to measure the total cellular and mitochondrial dNTP pools in both proliferating 
and quiescent states, as has been performed in MPV17-deficient fibroblasts (Dalla Rosa et al., 
2016). Based on the reduced GMPR1 expression and repressed mitochondrial purine and 
pyrimidine salvage pathways, it is expected that the total cellular and mitochondrial dGTP 
pools will be depleted. Moreover, if GMP is not readily catabolised back to IMP, this to some 
degree could also inhibit de novo adenosine synthesis. Therefore, the putative pathogenic 
mechanism of the GMPR1 mutation could be depleted dGTP pools, impairing mtDNA 
replication. Despite this, uptake of dNTPs from the cytosol through PNC2 would be minimal 
since cytosolic de novo synthesis is low in quiescent fibroblasts.  
Owing to the association of genomic instability with oncogenesis due to nucleotide pool 
imbalances (Mathews, 2015), it is important to take a cautious approach regarding defects of 
these essential enzymes. Concerning GMPR1, Wawrzyniak et al. (2013) demonstrated that its 
activity supressed melanoma cell invasion and the formation of tumorigenic cells, by 
depleting the intracellular GTP pools. Interestingly, there is no known history of melanoma or 
cancer for patient 11 or the immediate family. At the age of 73, no apparent clinical 
manifestations associated with nuclear genomic stability such as cancer have arisen. 
Nonetheless, this has yet to be evaluated at a cellular level.  
5.5.3 mtDNA Replication is Not Stalled in Adult-Onset mtDNA Maintenance Patient 
Fibroblasts 
To determine whether mtDNA replication may be slowed or stalled, the intercalating agent 
ethidium bromide was used to deplete the mtDNA in fibroblasts from three adult patients with 
multiple mtDNA deletions for 14 days. This was then removed to allow copy number to 
recover. Ethidium bromide induced mtDNA depletion has been used previously for the study 
of mtDNA maintenance disorders in fibroblasts (Stewart et al., 2011; Dalla Rosa et al., 2016), 
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since it is known to inhibit mtDNA replication without affecting the nuclear DNA (Leibowitz, 
1971; Seidel-Rogol and Shadel, 2002). This was studied with fibroblasts from three patients 
(patients 8, 11, 15) from the adult-onset PEO with multiple mtDNA deletions WES cohort, 
together with two controls. While there was almost complete restoration of mtDNA after 14 
days of treatment, there was no slowing or stalling of mtDNA replication in all fibroblast 
lines. This was somewhat unsurprising since a previous study that used ethidium bromide to 
deplete mtDNA in fibroblasts from a patient harbouring a homozygous TK2 mutation restored 
mtDNA at a similar rate to controls (Stewart et al., 2011). On the other hand, MPV17-
deficient fibroblasts demonstrated a severe stalling of mtDNA replication following treatment 
(Dalla Rosa et al., 2016). This perhaps suggests that not all defects of dNTP pools affect the 
rate of mtDNA replication, although there are presently limited replicates to confirm this. In 
quiescence, there was no effect on the relative mtDNA copy number compared to control 
cells. Additionally, there was no abnormal morphology, aggregation or depletion of the 
nucleoids. Thus, this confirms that the GMPR1 mutation is a qualitative mtDNA maintenance 
disorder. 
Nonetheless, there was a slight unexpected decrease of LONP1 in proliferating and quiescent 
patient fibroblasts accompanied by no apparent change in the steady-state levels of TFAM. 
LONP1 is known to bind to transcription promoters of the mtDNA (Fu and Markovitz, 1998), 
while also acting synergistically with TFAM to regulate mtDNA maintenance, with Lon-
knockdown in Drosophila melanogaster causing increased TFAM and mtDNA copy number 
(Matsushima et al., 2010). Hence, the decreased steady-state LONP1 levels in the GMPR1 
patient fibroblasts would be suggestive of increased mtDNA proliferation perhaps as a 
compensatory mechanism. Although the apparently unchanged levels of TFAM and mtDNA 
copy number suggest otherwise, the increased expression of PNC2 for uptake of dNTPs for 
mtDNA replication advocates this hypothesis. On the other hand, a marked decrease of 
TFAM was observed in the patient skeletal muscle but without altered LONP1 expression. In 
this instance, the significant loss of TFAM expression is indicative of decreased mtDNA 
replication but the unaltered LONP1 levels perhaps implies limited selective degradation of 
TFAM.  
5.5.4 Late-Onset mtDNA Maintenance Disorders Express Null or Subtle Cellular 
Phenotypes 
Although a reduction of GMPR1 was observed in the patient fibroblasts and muscle, the 
expressed cellular phenotype was otherwise mild or subtle despite taking advantage of the 
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proliferating and quiescent states. Moreover, restoration of mtDNA copy number in patient 
fibroblasts indicated that mtDNA replication was neither slow nor stalled; this was also 
observed in fibroblasts from patients 8 and 15 with VUS in TOP3A and POLRMT. A subtle 
reduction in mitochondrial protein synthesis was also noted in both proliferating and 
quiescent fibroblasts, most likely due to the accumulation of mtDNA deletion species. Even 
in muscle, though decreased TFAM expression is a clear indicator of a mtDNA maintenance 
defect this is not specific to a single nuclear gene defect. Quadruple immunofluorescence 
assay to quantify complex I and IV protein expression in skeletal muscle demonstrated an 
expression pattern that matched that of previously studied multiple mtDNA deletion patients 
(Rocha et al., 2015). While this novel technique is highly valuable in the diagnostic process, 
the expression profile is not indicative for a specific nuclear gene defect. Consequently, 
validating the pathogenicity the novel GMPR1 mutation within these tissues remains a 
challenge. Hence, the use of in silico modelling has been crucial to confirm the pathogenic 
nature of the p.Gly183Arg mutation. This reflects the nature of autosomal dominant, late-
onset mtDNA maintenance disorders. Though candidates including GMPR1 have been 
proposed in this study (Chapter 4), the validation process is immediately compounded by the 
inability to perform segregation studies with unaffected and/or affected relatives. Since 
multiple mtDNA deletions associated with disturbed mtDNA maintenance are skeletal muscle 
restricted, additional study of the GMPR patient 11 muscle including analysis of nucleotide 
homeostasis could reveal a more insightful view of the pathogenic nature of the mutation. 
Nonetheless, it has been demonstrated here that techniques and assays should be specific to 
the gene of interest.   
5.5.5 Concluding Remarks 
To summarise, this study has identified a novel heterozygous GMPR1 p.Gly183Arg missense 
change in a patient presenting indolent, late-onset PEO with multiple mtDNA deletions. The 
phenotype was reminiscent of adPEO since the disease onset was late in life, although it is 
acknowledged that there is no known family history suggestive of dominant inheritance. In 
the absence of additional candidate gene variants, this study proposes that GMPR1 is a novel 
candidate locus for adult-onset PEO and multiple mtDNA deletions. GMPR1 has been 
confirmed as a cytosolic enzyme for the catabolism of GMP to IMP, thus maintaining the 
balance of guanine and adenine nucleotides. The p.Gly183Arg mutant likely acts in a 
dominant-negative manner by competing with wild-type (and potentially GMPR2) for GMP 
binding and activity. Nonetheless, GMPR1-mutant fibroblasts and skeletal muscle are a 
paradigm of late-onset mtDNA maintenance disorders due to the subtle cellular phenotypes 
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that provide challenges in elucidating its pathogenic nature. Measurements of the total cellular 
and mitochondrial dNTP pools in proliferating and quiescent fibroblasts are also currently 
underway that seek to confirm the effect of due to repressed mitochondrial salvage pathways. 
Together with further studies of nucleotide metabolism and mtDNA replication in the skeletal 
muscle, these will provide further insights of the pathological nature of the mutation. Finally, 
identification of a second patient with disturbed mtDNA maintenance and one or more 
GMPR1 mutation would provide further validation of pathogenicity. 
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Chapter 6. WES of Mitochondrial Respiratory Chain Complex Deficiency 
6.1 Introduction 
This chapter contains material published in Journal of Inherited Metabolic Disorders Reports 
(Oliveira and Sommerville, 2016) and American Journal of Human Genetics (Kopajtich et al., 
2014). Additional clinical, diagnostic and research support are provided from colleagues and 
external collaborators who are appropriately acknowledged. 
6.1.1 Mitochondrial Respiratory Chain (RC) Deficiency 
Mitochondrial respiratory chain (RC) disorders are among the most common early-onset 
metabolic disorders with an estimated minimum prevalence of 1 in 5000 live births (Skladal 
et al., 2003). These defects affect one or more of the five multi-subunit enzymes that 
comprise the OXPHOS system, manifesting in vast clinical and genetic heterogeneity. 
Pathogenic mtDNA mutations account for an estimated 15-30% of patients with RC 
deficiency (DiMauro and Davidzon, 2005; Kirby and Thorburn, 2008), hence the remaining 
patients have a suspected nuclear aetiology. 
Attaining a genetic diagnosis is challenging, since approximately 1,200 proteins encoded by 
the nuclear genome (Lopez et al., 2000; Calvo et al., 2006) are required for the coordination 
of mitochondrial processes. Mendelian RC defects can be divided into (i) isolated and (ii) 
combined deficiencies. Isolated RC deficiency is predominantly associated with mutations of 
RC complex subunits or assembly factors (Loeffen et al., 2000; Diaz, 2010; Hoekstra and 
Bayley, 2013; Hejzlarova et al., 2014; Fernández-Vizarra and Zeviani, 2015). On the other 
hand, combined RC deficiencies are typically associated with defects of mtDNA maintenance, 
protein synthesis, OXPHOS cofactors, dynamics and metabolism. This genetic and clinical 
heterogeneity is reflected in approximately 245 nuclear genes currently associated with RC 
deficiency (Mayr et al., 2015). 
6.1.2 NGS Approaches in Mitochondrial RC Disease Diagnosis 
While clinical features, patient muscle histology and biochemical studies may be indicative of 
mitochondrial disease, findings are often non-specific to one genetic aetiology. Unless a clear 
phenotype-genotype correlation has been delineated, targeted screening of a subset of nuclear 
genes have mostly proved ineffective in diagnosing suspected autosomal recessive 
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mitochondrial RC disease, providing diagnostic yields up to 11% (Kemp et al., 2011; 
Neveling et al., 2013).  
Over the past decade, various NGS approaches in the diagnosis of paediatric mitochondrial 
RC deficiency have been described throughout the literature (Vasta et al., 2009; Calvo et al., 
2012; Vasta et al., 2012; DaRe et al., 2013; Lieber et al., 2013; Neveling et al., 2013; Taylor 
et al., 2014; Wortmann et al., 2015; Kohda et al., 2016; Legati et al., 2016; Pronicka et al., 
2016). In contrast to late-onset mtDNA maintenance disorders, the vast majority of early-
onset RC disease patients are expected to harbour autosomal recessive (compound 
heterozygous and homozygous) or X-linked (particularly in males) variants. Hence, the focus 
of the majority of NGS studies of Mendelian mitochondrial disease have been on this cohort 
of patients. 
Nonetheless, NGS approaches have varied between published studies. A so-called 
‘MitoExome’ approach whereby a panel of nuclear genes encoding mitochondrial proteins are 
targeted, ranging from ~400 to 1000 genes, was utilised by DaRe et al. (2013), (Vasta et al., 
2012) and Calvo et al. (2012). Furthermore, Calvo et al. (2012) combined the exome panel of 
~1000 genes with whole mitochondrial genome sequencing. As perhaps expected, the highest 
yield was attained by Calvo et al. (2012) with 55% of patients identified with causative or 
likely causative variants. More recently, large cohort studies have used WES or WGS for 
prioritisation of candidate variants in all nuclear genes, including the ~1,200 genes encoding 
mitochondrial proteins. This has given rise to somewhat higher diagnostic yields compared to 
‘MitoExome’ gene panels, varying between 34.5% and 60%. On the other hand, Legati et al. 
(2016) studied 152 patients by first using a small 132 gene ‘MitoExome’ panel, attaining a 
diagnostic yield of 15.2% before next turning to WES for only 10 patients and identifying 
causative variants in six patients (60%). However, it should be noted that the size of patient 
cohorts varied dramatically between studies, making it difficult to ascertain the true diagnostic 
yield in early-onset mitochondrial disease. Crucially, filtering of called variants could also 
have varied between studies, with more efficient and concise prioritisation leading to an 
improved diagnostic yield. Further to this, there are variations of the criteria and proportion of 
patients with isolated RC versus multiple RC defects who were recruited in previous studies.  
Although autosomal recessive or X-linked variants are expected, challenges still remain due 
to the possible implication of de novo dominant (heterozygous) variants (Harel et al., 2016; 
Thompson et al., 2016) and in the identification and prioritisation of candidate variants in 
genes with no known function. Similar to mtDNA maintenance factors as discussed in 
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Chapter 4, there are likely additional nuclear genes encoding proteins involved in RC 
function that have yet to be functionally validated. This is highlighted by the identification of 
previously unknown RC regulators using mitochondrial protein interaction mapping and gene 
editing combined with proteomics analysis to identify complex I assembly factors (Floyd et 
al., 2016; Stroud et al., 2016). Though ~245 nuclear genes have been associated with 
mitochondrial RC disease, there are likely to be additional genes found that are not currently 
associated with human disease. Secondary RC defects have also been described in muscle 
biopsies from patients with other neuromuscular or neurological disorders with phenotypic 
overlap with mitochondrial disease, due to mutations in genes encoding non-mitochondrial 
proteins including but not limited to SOD1, TARDBP, STXBP1, MECP2, ANO10, CAPN3 and 
COLQ (Crugnola et al., 2010; Keogh et al., 2015; Pyle et al., 2015; Kohda et al., 2016). Thus, 
this can be a misleading finding that complicates variant filtering and prioritisation. 
In light of the diagnostic yields attained, WES is an attractive tool in the diagnosis of early-
onset mitochondrial RC disorders. The previously published WES filtering strategies for this 
group of patients, focusing on nuclear genes encoding mitochondrial proteins with autosomal 
recessive or X-linked inheritance means that establishing similar approaches with appropriate 
custom modifications is possible. In this chapter, a custom filtering strategy for the 
prioritisation of candidate gene variants is designed with previous strategies in mind and 
applied to 20 patients with undiagnosed paediatric mitochondrial RC deficiency and a 
suspected nuclear aetiology. 
6.2 Aims 
This chapter aims to attain genetic diagnoses using WES for 20 patients with clinically 
heterogeneous phenotypes and mitochondrial RC complex deficiency.  
6.3 Methods 
6.3.1 Recruitment of Patients 
Patients were clinically examined at the NHS Highly Specialised Service for Rare 
Mitochondrial Disorders or at separate clinics in the UK or internationally, with diagnostic 
testing performed by the NHS Highly Specialised Mitochondrial Diagnostic Service 
Laboratory in Newcastle upon Tyne. There were 20 unrelated patients (14 male, 6 female) 
with genetically undetermined early-onset RC disease recruited for WES. Diagnostic 
investigations were performed as described in 2.2.3.  
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6.3.2 WES Filtering and Analysis 
The WES filtering strategy for mitochondrial RC deficiency patients was similar to the 
filtering strategy outlined for adult-onset PEO with multiple mtDNA deletions patients in 
4.3.5.  
Called variants that passed quality score filtering were restricted to exonic (coding) or splice-
site variants, with a minor allele frequency (MAF) equal to or less than 0.01 (1%) of in-house 
exomes or external exome databases.  
Next, variants were filtered using GO-Terms associated with mitochondrial-localisation and 
mitochondrial protein synthesis. GO-Terms employed were the wildcard term ‘mitochondr*’, 
‘tRNA’ and ‘translation’. This allowed inclusion of nuclear genes encoding proteins involved 
in mitochondrial translation, but also all mitochondrial-targeted proteins. Hence, this provided 
a means of identifying candidate variants in known nuclear genes associated with 
mitochondrial RC deficiency and the prioritisation of novel candidate genes. Copy number 
variations (CNVs) were also analysed using the same employed GO-Terms. 
Lists of genes and called variants were categorised according to gene role and function, 
expected inheritance and association with human disease (if previously known). For patients 
born to consanguineous parents, homozygous variants were prioritised. For patients born to 
non-consanguineous parents, compound heterozygous variants were prioritised.  
To assess the potential pathogenicity of called variants, a simplified scoring system was used 
(Table 6.1). Since trios comprising the proband and parents were not sequenced, segregation 
of variants was not included in variant prioritisation. The effect of missense on protein 
function were predicted using PolyPhen2, Align-GVGD and SIFT. However, in silico 
predictions were purely advisory and were not used to directly excluded candidates using the 
scoring system. Splice-site or nonsense loss-of-function (LOF) variants were also considered 
but not scored. 
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Mutation(s) Genotype  GO-Terms Mitochondrial Disease 
Gene? 
Sco
re 
Mitochondr*  tRNA  Translation  Y/N  Allele-
1 
Allele-
2 
c.?, 
p.? 
        
Table 6.1 Basic WES Variant Scoring System for Early-Onset RC Deficiency Patients. 
Genotype – 1 point for a heterozygous variant, 2 points for a recessive (homozygous, 
compound heterozygous) or hemizygous variant(s). Since mitochondrial disease was 
confirmed in biochemical and histopathological studies, 2 points were given for mitochondr* 
hits, while 1 point was given each for ‘tRNA’ and ‘translation’. 1 point was given if they gene 
was previously associated with mitochondrial disease. 1 point was given to each known 
pathogenic variant (compound heterozygous) or 2 points for a known pathogenic homozygous 
or hemizygous variant. CNVs were also included in analysis.  
Owing to the scores attained, variants could be classified into categories. Category-1 (≥ 7 
points) comprised the highest level candidates. These variants met the following criteria: 
 Autosomal recessive variant(s) – homozygous, compound heterozygous or 
hemizygous (2 points). 
 GO-Terms matched ‘mitochondr*’ (2 points) and ‘translation’ or ‘tRNA’ (1 point for 
each term). 
 Known causative gene associated with mitochondrial RC deficiency (1 point).  
 One or more previously reported causative mutation(s) (1-2 points). 
Category-2 (5-6 points) was comprised of medium prioritised candidates. These variants met 
the following criteria: 
 Autosomal recessive variant(s) – homozygous, compound heterozygous or 
hemizygous (2 points). 
 GO-Terms matched ‘mitochondr*’ (2 points) or ‘translation’ or ‘tRNA’ (1 point for 
each term). 
 Known causative and previously unreported genes (0-1 point). 
 One or more previously reported causative mutation(s) (1-2 points). 
Variants in category-3 (3-4 points) were considered low priority and met the following 
criteria: 
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 Autosomal recessive variant(s) – homozygous, compound heterozygous or 
hemizygous (2 points). 
 GO-Terms matched ‘mitochondr*’ (2 points) or ‘translation’ or ‘tRNA’ (1 point for 
each term). 
 No known association with mitochondrial RC disease (0 points). 
The final category were variants of unknown significance (VUS) (≤ 3 points). In this instance, 
no appropriate candidate variants in nuclear genes encoding mitochondrial localised proteins 
were identified. Upon this failure, all recessive and dominant VUS were evaluated 
individually. All listed VUS in unsolved cases were reviewed at least every 2-3 months to 
ensure up-to-date findings from the literature were reflected. 
 Autosomal dominant (1 point) or autosomal recessive (homozygous, compound 
heterozygous) or hemizygous (2 point). 
 No GO-Terms matched (0 points). 
 No known association with mitochondrial RC disease or other known human 
pathology (0 points). 
A schematic of WES filtering for mitochondrial RC disease is given in Figure 6.1.
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Figure 6.1 Mitochondrial RC Deficiency WES Filtering Strategy. 
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6.3.3 Sanger Sequencing Confirmation 
Custom primer design for candidate variants (Appendix A), PCR amplification, Sanger 
sequencing confirmation and analysis were performed as described in 2.3. If already 
available, primers designed within the NHS Highly Specialised Mitochondrial Diagnostic 
Service Laboratory were used. 
6.3.4 Cell Culture 
Cultured fibroblasts were grown for patient 21 and three appropriate age-matched controls. 
Subculturing, freezing and harvesting of cells were performed as described in 2.4. 
6.3.5 Western Blotting 
Patient 21 and control fibroblast lysates were prepared and subjected to 12% SDS-page, 
probed with primary and secondary antibodies (Table 2.4, Table 2.5) then detected as 
outlined in 2.5. Membranes were incubated with primary antibodies specific to 
PTPIP51/RMDN3, plus OXPHOS subunits NDUFB8, SDHA, UQCRC2, MT-COI, MT-COII 
and ATP5B. β-actin was used as a loading control. 
6.3.6 TMRM Staining and Live-Cell Imaging 
Patient 21 and two control fibroblast cell lines were prepared, imaged with fluorescent dyes 
TMRM for the mitochondrial network using the Nikon A1R Invert point scanning confocal 
microscope then analysed as outlined in 2.6. 
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6.4 Results 
6.4.1 Clinical and Molecular Features 
The clinical, histochemical and biochemical features of the 20 patients recruited for WES are 
summarised in Table 6.2. Metabolic acidosis including lactic acidosis and elevated blood 
serum lactate (15/20, 60%), HCM (9/20, 45%) and neurological impairment including 
abnormal brain MRI and seizures (9/20, 45%) were the most common features in the cohort. 
Additional features were muscle weakness or exercise intolerance (6/20, 30%), liver 
dysfunction (5/20, 25%), failure to thrive (FTT) (5/20, 25%), developmental delay or 
regression (5/20, 25%) and renal impairment (2/20, 10%). Ataxia, limb spasticity, ptosis, 3-
methylglutatonic and methylglutaric acidosis were confined to single cases. Consanguinity 
was reported for 6/20 (30%). Onset was predominantly from birth (7/20, 35%) and almost 
always during the first year of life (16/20, 80%). Age of onset was not determined for two 
patients. 
Muscle biochemical studies of mitochondrial RC activities were performed for all patients, 
comprising 9/20 (45%) patients with complex I and IV deficiency, 4/20 (20%) with complex 
I, III and IV deficiency, 2/20 (10%) patients with isolated complex I deficiency, 3/20 (15%) 
patients with isolated complex IV deficiency and 1/20 (5%) patient with complex I and II 
deficiency. One patient had normal RC activities. Muscle histopathological studies were 
performed in 16/20 (80%) patients and showed variable findings that included global COX-
deficiency (5/20, 25%), COX-mosaic or some COX-deficient fibres (4/20, 20%), lipid 
accumulation (3/20, 15%) and increased fat content (1/20, 5%).   
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Patient Sex AO Consanguinity Clinical Features 
Muscle Studies 
Histochemistry RC Deficiency 
21 M Birth + 
Progressively worsening muscle weakness, gastrointestinal reflux, Trisomy 
21 (Down’s Syndrome), mild cerebellar atrophy and thinning of corpus 
callosum on brain MRI  
COX-deficient fibres, lipid 
accumulation 
I, IV 
22† F 8 Months - 
Developmental regression, cerebellar atrophy on brain MRI, limb 
spasticity, sunken eyes, thick spindle fingers, elbow and shoulder 
contractures, increased lower limb tone, absent reflexes, scoliosis  
Fibre atrophy, secondary 
myopathic changes, 
denervation atrophy 
I, IV 
23 M Day 2 - 
Hypertonia, profound head lag, bulbar weakness, recurrent apnoeic 
episodes, desaturation, bradycardia 
n.d. IV 
24† M Birth - 
Metabolic acidosis, renal impairment, developmental delay, hearing 
impairment, Wolf Parkinson White Syndrome, seizures, denate nucleus 
abnormalities on brain MRI 
Mosaic COX-deficient fibres I, IV 
25 F Childhood - Motor and speech delay, spastic jerky ataxia, pulmonary hypertension 
Occasional transitional or 
intermediate COX-activity 
I, IV 
26† M Birth - Congenital lactic acidosis 
Global COX-deficiency, lipid 
accumulation, neonatal 
myosin positive fibres 
I, III, IV 
27† M 4 Weeks + HCM, lactic acidosis, FTT, Leigh-like changes on brain MRI Global COX-deficiency I, IV 
28† M Birth - 
IUGR, severe lactic acidosis, renal impairment, hypotonia, central apnoea, 
anaemia, liver disease (coagulopathy), dysmorphic (smooth philtrum, 
hypospadias), VSD, PDA, lissencephaly  
Normal I, IV 
   
201 
Patient Sex AO Consanguinity Clinical Features 
Muscle Studies 
Histochemistry RC Deficiency 
29† F Day 7 - 
Leigh-like syndrome, hypotonia, lactic acidosis, apnoeic episodes, 
encephalopathy, liver dysfunction, hypogenesis of the corpus callosum, 
bulbus, nucleus, cerebellum and subthalmic lesions on brain MRI 
COX-deficient fibres 
Ragged red fibres 
I, IV 
30† M Birth - HCM, severe myopathy, lactic acidosis, respiratory failure 
COX-deficient fibres, lipid 
accumulation 
I, III, IV 
31 F Birth + 
Liver failure (hepatomegaly), hypotonia, growth retardation, FTT, 
abnormal ECG (details unknown), possible high signal in globus pallidus 
Normal I, II 
32 F 6 Months - 
HCM, lactic acidosis, myopathy (exercise intolerance), developmental 
delay, seizures, short stature 
Global COX-deficiency I, IV 
33† M Birth - 
Persistent acidosis, developmental delay and regression, 3-methylglutatonic 
and methylglutaric acidosis, constipation, gastroenteritis, vomiting, FTT 
Increased fat content I, III, IV 
34† M 2 Weeks + Congenital lactic acidosis n.d. IV 
35 M Neonatal - 
Congenital lactic acidosis, muscle weakness, Leigh-like changes on brain 
MRI  
Increased SDH activity I, IV 
36† M Infantile + Congenital lactic acidosis, HCM, encephalopathy Global COX-deficiency IV 
37 M 1 Week + 
Encephalopathy, congenital lactic acidosis, liver disease, FTT, basal 
ganglia injury on brain MRI 
Global COX-deficiency I, III, IV 
38 F n.d. - Myopathy, lactic acidosis n.d. I 
39† M 2 Years - HCM n.d. I 
40 M n.d. - 
Seizures, developmental delay, hypotonia, choreoathetoid movement 
disorder, ptosis, FTT, hepatomegaly, periventricular leukomalacia, white 
Normal Normal 
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Patient Sex AO Consanguinity Clinical Features 
Muscle Studies 
Histochemistry RC Deficiency 
matter loss, thinning of corpus callosum on brain MRI 
Table 6.2 Clinical and Molecular Features of the Mitochondrial RC Deficiency Cohort for WES. AO – Age of onset; ECG – echocardiogram; FTT – 
failure to thrive; HCM – hypertrophic cardiomyopathy; IUGR - intrauterine growth restriction; PDA - patent ductus arteriosus; VSD - ventricular 
septic defect. † - deceased; * - ‘+’ – yes; ‘-‘ – no. ‘n.a.’ – not applicable; ‘n.d.’ – not determined.
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 WES Read Coverage and Depth Statistics 
WES read coverage and depth statistics of the mitochondrial RC deficiency cohort were 
calculated for 32,947,520 exome consensus coding sequence (CCDS) bases (bp) (Appendix 
O). The mean depth per exome consensus coding sequence (CCDS) bases was 69-fold. The 
mean percentage of CCDS bases at 20-fold coverage was 78.69%. 
6.4.2 WES Analysis 
Using the simplified scoring system devised to advise the prioritisation of candidates, 
causative or likely causative variants and VUS are listed in Table 6.3 with MAF data and in 
silico predictions. Causative (7/20, 35%) and likely causative variants (2/20, 10%) were 
identified in 9 patients, providing a diagnostic yield of 45%. VUS were also identified in two 
patients.  
Causative mutations were identified in six nuclear genes previously associated with 
mitochondrial RC deficiency for six patients (24, 27-31 and 34) in MRPS22 (NM_020191), 
PDHA1 (NM_001173454), EARS2 (NM_001083614), AARS2 (NM_020745), TRMU 
(NM_018006) and SCO1 (NM_004589.3). GTPBP3 (NM_001195422) was confirmed as the 
seventh nuclear gene associated with RC deficiency following the identification of additional 
patients. Of these, 10 variants were identified of which eight were novel or had not been 
previously reported as causative. Three patients had homozygous variants, one patient had a 
hemizygous (X-linked) variant and the remaining three patients had compound heterozygous 
variants. All variants were confirmed by Sanger sequencing using custom or diagnostic 
forward and reverse primers. Where possible, segregation studies confirmed parental or 
familial carrier status. After evaluation and confirmation, variants were diagnostically 
reported. 
Likely causative variants were identified in two patients (21 and 22) in PTPIP51 
(NM_018145.1) and CTBP1 (NM_001012614.1). However, these variants require additional 
validation including segregation and molecular studies to confirm pathogenicity. 
VUS were identified in two patients (32 and 35) in MTO1 (NM_012123.3) and LONP1 
(NM_004793). The candidate genes were previously associated with Mendelian 
mitochondrial disease but pathogenicity was uncertain due to the genotype and unusual 
phenotype compared to previously reported patients.  
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Analysis of 9 patients (23, 26, 32, 33 and 36-40) did not identify causative or likely causative 
variants. VUS were listed for these patients (Appendix P) but the functional or potential 
pathological role in human disease is currently uncertain.  
To attain a genetic diagnosis, patient 33 genomic DNA was prepared and sent for WGS to the 
Human Genome Sequencing Center at the Baylor College of Medicine in Houston, Texas. At 
the time of writing, the dataset from WGS was not available for filtering and analysis.  
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Patient Clinical Features Gene Mutations Minor Allele Frequency In Silico Predictions 
cDNA Change Amino Acid Change ExAC  NHLBI 
ESP 
1000G PolyPh
en2 
Align-
GVGD 
SIFT 
Causative Variants 
24† Metabolic acidosis, renal impairment, 
developmental delay, hearing 
impairment, Wolf Parkinson White 
Syndrome, seizures, denate nucleus 
abnormalities on brain MRI 
MRPS22 Homozygous 
c.509G>A 
Homozygous p.Arg170His 
(rs119478059) 
0.00005795 0.0003488 Ø 1.000 Class 25 0.00 
27†,a HCM, lactic acidosis, FTT, Leigh-
like changes on brain MRI 
GTPBP3 Homozygous 
c.424G>A 
Homozygous p.Glu142Lys Ø Ø Ø 1.000 Class 15 0.02 
28† IUGR, severe lactic acidosis, renal 
impairment, hypotonia, central 
apnoea, anaemia, liver disease 
(coagulopathy), dysmorphic (smooth 
philtrum, hypospadias), VSD, PDA, 
lissencephaly 
PDHA1 Hemizygous 
c.1033_1035dup 
Hemizygous p.Glu345dup Ø Ø Ø n.a. n.a. n.a. 
29†,b Leigh-like syndrome, hypotonia, 
lactic acidosis, apnoeic episodes, 
encephalopathy, liver dysfunction, 
hypogenesis of the corpus callosum, 
bulbus, nucleus, cerebellum and 
subthalmic lesions on brain MRI 
EARS2 c.1A>G p.Met1? Ø Ø Ø n.a. n.a. n.a. 
c.184A>T p.Ile62Phe Ø Ø Ø 0.006 Class 0 0.04 
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30† HCM, severe myopathy, lactic 
acidosis, respiratory failure 
AARS2 c.1088dupT p.Asp337* 0.00000851 Ø Ø n.a. n.a. n.a. 
c.1738C>T p.Arg580Trp 0.00002474 Ø Ø 0.996 Class 0 0.02 
31 Liver failure (hepatomegaly), 
hypotonia, growth retardation, FTT, 
abnormal ECG (details unknown), 
possible high signal in globus pallidus 
TRMU c.747_752del p.Asp249_Lys251delinsGlu Ø Ø Ø n.a. n.a. n.a. 
c.827C>T p.Pro276Leu 0.00000825 Ø Ø 0.879 Class 35 0.02 
34† Congenital lactic acidosis SCO1 Homozygous 
c.881T>C 
Homozygous p.Met294Thr Ø Ø Ø 0.989 Class 25 0.04 
           
Likely Causative Variants 
21 Progressively worsening muscle 
weakness, gastrointestinal reflux, 
Trisomy 21 (Down’s Syndrome), 
mild cerebellar atrophy and thinning 
of corpus callosum on brain MRI 
PTPIP51 Homozygous 
c.1352C>T 
Homozygous p.Thr451Met 0.00004942 Ø 0.000197 1.000 Class 0 0.02 
22† Developmental regression, cerebellar 
atrophy on brain MRI, limb 
spasticity, sunken eyes, thick spindle 
fingers, elbow and shoulder 
contractures, increased lower limb 
tone, absent reflexes, scoliosis 
CTBP1 c.991C>T/= p.Arg331Trp, Heterozygous Ø Ø Ø 0.996 Class 15 0.03 
           
Variants of Unknown Significance (VUS) 
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Table 6.3 Causative, Likely Causative Variants and VUS Identified in the Mitochondrial RC Cohort. Prioritised variants following application of 
the WES filtering strategy. FTT – failure to thrive; HCM – hypertrophic cardiomyopathy; IUGR - intrauterine growth restriction; PDA - patent ductus 
arteriosus; VSD - ventricular septic defect. ‘Ø’ denotes that a variant was absent from external databases. n.a. – not applicable. aPublished in 
(Kopajtich et al., 2014). bPublished in (Oliveira and Sommerville, 2016). 
32 HCM, lactic acidosis, myopathy 
(exercise intolerance), developmental 
delay, seizures, short stature 
MTO1 c.292G>A/= p.Gly98Ser, Heterozygous Ø Ø Ø 1.000 Class 55 0.00 
35 Congenital lactic acidosis, muscle 
weakness, Leigh-like changes on 
brain MRI 
LONP1 c.1693T>C p.Tyr565His (rs144125085) 0.00000844 Ø Ø 0.997 Class 0 0.00 
c.2197G>A p.Glu733Lys 0.00001671 Ø Ø 0.006 Class 0 0.36 
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6.4.3 MRPS22 – Mitochondrial Ribosomal Protein S22 
Patient 24 was a boy born to non-consanguineous parents who required peritoneal dialysis to 
treat severe metabolic acidosis shortly after birth. He manifested with Wolf-Parkinson-White 
syndrome, seizures, developmental delay, severe hearing loss and renal involvement. 
Erythropoietin treatment was given for renal anaemia but he developed end-stage renal 
failure. Muscle biochemical studies revealed mild complex I and IV deficiency (Figure 
6.2A). Muscle histochemistry revealed mosaic COX-deficient fibres. RC activity was normal 
in fibroblasts. Family history was significant; an affected female sibling died 3 days after 
birth from severe metabolic acidosis and the mother had three earlier miscarriages.  
WES filtering identified a homozygous c.509G>A, p.Arg170His (rs119478059) missense 
variant in MRPS22 encoding Mitochondrial Ribosomal Protein S22. MRPS22 (3q23) matched 
the GO-Term ‘mitochondr*’. Sanger sequencing using custom forward and reverse primers 
for MRPS22 exon 4 confirmed the variant in both patient 24 and his affected sibling. The 
p.Arg170His missense change was absent from in-house exomes, but was present in 7/120796 
non-Finnish European alleles (MAF=0.00005795) in ExAC and 3/13006 alleles 
(MAF=0.00023007) in the NHLBI ESP, all in heterozygous state. Arg170 was fully 
conserved in all tested species and occurred in a highly conserved region of the protein 
(Figure 6.2B). 
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6.4.4 GTPBP3 - GTP Binding Protein 3 
Patient 27 was a boy born prematurely at 34 weeks gestation to apparently non-
consanguineous Romanian parents. At day 25 of life, he was admitted to hospital with weight-
loss, hypothermia, jaundice and metabolic acidosis. Due to presumed sepsis a course of 
intravenous antibiotics (details not known) was prescribed. Blood serum lactate was also 
elevated (11.0mmol/L; normal <2.5mmol/L). Echocardiography revealed concentric left 
ventricular hypertrophy. Cerebrospinal fluid (CSF) lactate was also markedly elevated 
(12.4mmol/L; normal 0.9-2.4mmol/L). On these findings, bicarbonate treatment was given. 
Brain MRI showed an abnormal T2 signal in the midbrain and basal ganglia bilaterally, plus 
diffusion abnormalities of the subthalamic nuclei extending down to the brain stem. There 
were no dysmorphic features but the patient was thin, jaundiced and had swollen feet. Patient 
27 was fed through a nasogastric feeding tube but was not responsive despite a high calorie 
Figure 6.2 Sanger Sequencing Confirmation and MSA of the Homozygous MRPS22 
Mutation in Patient 24. (A) Sanger sequencing confirmation of the homozygous 
p.Arg170His MRPS22 mutation in (i) patient 24 and (ii) the affected female sibling. (B) MSA 
of the MRPS22 Arg170 residue. 
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intake. At 5 weeks old he presented apnoeic episodes and subsequently died. Muscle 
biochemical studies revealed complex I (12%) and IV (12%) deficiency compared to controls 
(Figure 6.3A). Patient 27 was the fourth pregnancy and the third child born. The first 
pregnancy ended in miscarriage, while two older male siblings were unaffected.   
WES filtering revealed a homozygous c.424G>A (p.Glu142Lys) missense variant of GTPBP3 
encoding GTP Binding Protein 3. GTPBP3 (19p13.11) matched the GO-Terms ‘mitochondr*’ 
and ‘tRNA’. The variant was absent from in-house exomes and external databases. Sanger 
sequencing with custom forward and reverse primers for GTPBP3 exons 4+5 confirmed that 
patient 27 was homozygous for the novel p.Glu142Lys missense change, while the mother 
Figure 6.3 Biochemical and Genetic Features of Patient 27. Measurements of 
mitochondrial RC activities normalised to citrate synthase (CS) of complex I (CI/CS), 
complex II (CII/CS), CII and CIII (CII+CIII/CS) and CIV (CIV/CS) from patient 27 (orange) 
compared to controls (red). Complex I and IV defects are denoted with an asterisk (‘*’). (B) 
Family pedigree and Sanger sequencing confirmation of the homozygous p.Glu142Lys 
GTPBP3 mutation. (C) MSA of the GTPBP3 Glu142 residue. 
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was a heterozygous carrier (Figure 6.3B). Paternal DNA was not available but due to the 
maternal carrier status, it was expected that the father was also a heterozygous carrier. Glu142 
was conserved in all species except Saccharomyces cerevisiae (Figure 6.3C). 
At the time of identification, a further 10 patients from eight pedigrees with autosomal 
recessive GTPBP3 mutations from diagnostic centres in Germany, Belgium, Italy, France, 
Israel and Japan were identified independently of this study. Mutations were identified using 
WES for 9 patients, while targeted sequencing found mutations in the tenth patient. All 
patients presented within the first decade of life, although usually within the first year of life, 
with a core phenotype of HCM, encephalopathy and lactic acidosis. However, two patients 
apparently did not have HCM. Six patients died before the age of one, while almost all 
patients who survived beyond the first year of life had delayed development or intellectual 
disability. Including patient 27, brain MRI in four patients showed signal abnormalities in the 
brainstem and basal ganglia comparable with Leigh syndrome. Combined complex I and IV 
deficiency were found in skeletal muscle of eight patients; one patient had normal RC 
activity. Muscle histochemistry also revealed COX-deficient fibres in all tested patients. A 
total of 13 different GTPBP3 variants were identified, including missense, in-frame and 
frameshift variants. Only patient 27 harboured the p.Glu142Lys variant.  
Following the identification of GTPBP3 mutations as a novel disorder of mitochondrial tRNA 
modification, a second patient presenting severe lactic acidosis and HCM with multiple 
OXPHOS defects was referred to the NHS Highly Specialised Mitochondrial Diagnostic 
Service Laboratory in Newcastle upon Tyne. All 9 GTPBP3 coding exons were sequenced 
with custom forward and reverse primers in this patient, but no causative or likely causative 
variants were identified.   
6.4.5 PDHA1 - Pyruvate Dehydrogenase E1 Subunit 
Patient 23 was a boy born at 32 weeks gestation to non-consanguineous parents. Antenatal 
ultrasound showed intrauterine growth restriction (IUGR), echogenic foetal bowel and 
decreased movements. The patient presented from birth with severe lactic acidosis, renal 
impairment, hypotonia, central apnoea, anemia, liver dysfunction (coagulopathy) and died at 2 
days old. He was dysmorphic with a smooth philtrum and hypospadias. He had a ventricular 
septic defect (VSD) and patent ductus arteriosus (PDA) resulting in congestive heart failure. 
He also had lissencephaly and grey matter abnormalities of the brain. Serum lactate was also 
significantly elevated (22.9mmol/L, normal <2.5mmol/L). He was an only child. However, 
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there was apparently a family history of cardiomyopathy; his maternal grandmother was 
affected. However, it was not known if this was HCM or dilated cardiomyopathy. Muscle 
biochemistry revealed mild complex I and IV deficiency (Figure 6.4A). Quantitative real-
time PCR assay also detected severe mtDNA depletion. Targeted screening of NDUFS1, 
NDUFS2, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFAB1, NDUFV1, NDUFV2, TWNK, 
POLG, RRM2B, TK2, DGUOK and MPV17 were negative for causative mutations. 
WES filtering revealed a hemizygous in-frame c.1033_1035dup (p.Glu345dup) duplication of 
PDHA1 encoding the Pyruvate Dehydrogenase E1-α Subunit. PDHA1 (Xp22.12) matched the 
GO-Term ‘mitochondr*’. The variant was absent from in-house exomes and external 
databases. Sanger sequencing with custom forward and reverse primers for PDHA1 exon 12 
confirmed the in-frame duplication. Segregation studies showed that the variant was absent 
from both parents (Figure 6.4B), although possible maternal germline mosaicism could not 
be excluded. Additionally, comparative genomic hybridisation (CGH) array had not been 
performed, in light of the dysmorphic features.   
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Figure 6.4 Biochemical and Genetic Features of Patient 23. (A) Measurements of mitochondrial RC activities normalised to citrate synthase of 
complex I (CI/CS), complex II (CII/CS), complex III (CIII/CS) and complex IV (CIV/CS) from patient 23 (blue) skeletal muscle compared to controls 
(red). Complex I and IV defects are denoted with an asterisk (‘*’). (B) Family pedigree and Sanger sequencing confirmation of the de novo 
p.Glu345dup PDHA1 duplication. 
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6.4.6 EARS2 – Mitochondrial Glutamyl tRNA Synthetase 
Application of the WES strategy for patient 29 revealed biallelic variants of EARS2 encoding 
mitochondrial glutamyl-tRNA synthetase (mt-GluRS). The clinical, genetic and molecular 
features of patient 29 are outlined in 7.4.2 together with additional patients harbouring 
mutations of the mt-aaRS. 
6.4.7 AARS2 – Mitochondrial Alanyl tRNA Synthetase 
Application of the WES strategy for patient 30 revealed biallelic variants of AARS2 encoding 
mitochondrial alanyl-tRNA synthetase (mt-AlaRS). The clinical, genetic and molecular 
features of patient 30 are outlined in 7.4.1, together with additional patients harbouring 
mutations of the mt-aaRS.  
6.4.8 TRMU - tRNA 5-Methylaminomethyl-2-Thiouridylate Methyltransferase 
Patient 31 was a girl born to consanguineous parents who presented from birth with 
significant liver failure, FTT, hypotonia and had growth retardation. Echocardiogram (ECG) 
was abnormal but no details were given. Brain MRI revealed high signal in the globus 
pallidus. Serum lactate was elevated (4.4mmol/L; normal <2.5mmol/L), as was CSF lactate 
(4.4mmol/L; normal 0.9-2.4mmol/L). At 18 months old, the overseeing clinician noted a 
remarkable recovery in weight and satisfactory developmental progress. Muscle 
histochemistry was normal, but biochemical studies revealed a severe complex II (4%) and 
mild complex I (40%) defect compared to controls (Figure 6.5A). Targeted screening of 
SDHA, SDHB, SDHC, SDHD, SDHAF1 and SDHAF2 were negative for causative mutations.  
WES filtering identified compound heterozygous variants in TRMU encoding tRNA 5-
Methylaminomethyl-2-Thiouridylate Methyltransferase (MTU1); a frameshift c.747_752del 
(p.Asp249_Lys251delinsGlu) indel and a c.827C>T (p.Pro276Leu) missense variant. TRMU 
(22q13.31) matched the GO-Terms ‘mitochondr*’ and ‘tRNA’. Sanger sequencing with 
diagnostic forward and reverse primers for TRMU exons 6+7 and 8 confirmed both variants 
(Figure 6.5B). Segregation studies were not possible. The p.Asp249_Lys251delinsGlu 
variant was absent from in-house exomes and external databases. The p.Pro276Leu missense 
change was also absent from in-house exomes, but had been reported in 1/121172 
heterozygous South Asian allele (MAF= 0.000008253) in ExAC. Pro276 was moderately 
conserved and occurred in a moderately conserved region of the protein (Figure 6.5C).
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Figure 6.5 Biochemical and Genetic Features of Patient 31. (A) Measurements of mitochondrial RC activities normalised to citrate synthase (CS) of 
complex I (CI/CS), complex II (CII/CS), complex II and complex III (CII+CIII/CS) and complex IV (CIV/CS) from patient 31 (purple) skeletal 
muscle compared to controls (red). Complex I, II and II+III defects are denoted with an asterisk (‘*’). (B) Sanger sequencing confirmation of TRMU 
variants (i) p.Asp249_Lys251delinsGlu and (ii) p.Pro276Leu. (C) MSA of the MTU1 Pro276 residue. 
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6.4.9 SCO1 - SCO1 Cytochrome C Oxidase Assembly Protein 
Patient 34 was a boy born to consanguineous British-Pakistani parents who had severe early-
onset lactic acidemia and died at 2 weeks old. Muscle biochemical studies showed isolated 
COX deficiency. There was a significant history of mitochondrial disease in additional 
branches of this highly consanguineous family. Previous WES and diagnostic targeted 
screening identified two affected members of one branch who harboured a homozygous 
c.1349G>C (p.*450Serext*32) (rs115079861) extension variant of RMND1 (NM_017909) 
encoding Required for Meiotic Nuclear Division Protein 1, which may be essential for 
assembly or stability of the mitoribosome (Janer et al., 2012; Janer et al., 2015). In another 
branch, one affected member was homozygous for a c.431A>G (p.Tyr144Cys) (rs397514610) 
missense change in FARS2 (NM_006567) encoding mitochondrial phenyl-tRNA synthetase 
(mt-PheRS), which aminoacylates phenylalanine with its cognate mitochondrial tRNAPhe for 
mitochondrial protein synthesis. Patient 34 was neither homozygous nor heterozygous for 
either causative RMND1 or FARS2 variant.  
WES filtering for patient 34 revealed a homozygous c.881T>C (p.Met294Thr) missense 
variant in SCO1 encoding SCO1 Cytochrome c Oxidase Assembly Protein. SCO1 (17p13.1) 
matched the GO-Term ‘mitochondr*’. Sanger sequencing using custom forward and reverse 
primers for SCO1 exon 6 confirmed the missense change (Figure 6.6A). The parents of 
patient 34 were also diagnostically confirmed as heterozygous carriers. The p.Met294Thr 
missense change was absent from in-house exomes including affected family members who 
underwent WES or diagnostic targeted screening and were homozygous for either the 
RMND1 or FARS2 variant. The missense variant was also absent from external databases. 
Met294 was highly conserved except in Caenorhabditis elegans and S. cerevisiae, occurring 
in a moderately conserved region of the protein (Figure 6.6B).   
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Figure 6.6 Family Pedigree for Patient 34, Sanger Sequencing Confirmation and MSA of the Homozygous SCO1 Mutation. (A) Family pedigree 
and Sanger sequencing confirmation of the homozygous p.Met294Thr SCO1 mutation in patient 34. (B) MSA of the SCO1 Met294 residue. 
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6.4.10 PTPIP51 - Protein Tyrosine Phosphatase-Interacting Protein 51  
Patient 21 was a boy born to consanguineous parents who had Trisomy 21 (Down’s 
syndrome), was floppy from birth and had progressively worsening muscle weakness. 
Following respiratory infection and subsequent sepsis at 3 weeks old, he became continuous 
positive airway pressure (CPAP) dependent. He also suffered from severe gastrointestinal 
reflux, had poor diaphragmatic movement and some distal antigravity movement of the distal 
limbs. Brain MRI revealed mild cerebellar atrophy and thinning of the corpus callosum 
consistent with Down’s syndrome. Muscle histochemistry revealed COX-deficient fibres and 
lipid accumulation. Muscle biochemical studies showed severe complex I and IV defect 
(Figure 6.7A). Targeted screening of TRMU mutations was negative for causative mutations.  
Figure 6.7 Biochemical and Genetic Features of Patient 21. (A) Measurements of 
mitochondrial RC activities normalised to citrate synthase of complex I (CI/CS), complex II 
(CII/CS), complex III (CIII/CS) and complex IV (CIV/CS) from patient 21 (orange) skeletal 
muscle compared to controls (red). Complex I and IV defects are denoted with an asterisk 
(‘*’). (B) Sanger sequencing confirmation of the homozygous p.Thr451Met PTPIP51 
missense variant. (C) MSA of the PTPIP51 Thr451 residue. 
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WES filtering revealed a homozygous c.1352C>T (p.Thr451Met) missense variant in 
PTPIP51 encoding Protein Tyrosine Phosphatase-Interacting Protein 51, also referred to as 
Regulator Of Microtubule Dynamics 3 (RMND3). PTPIP51 (15q15.1) matched the GO-Term 
‘mitochondr*’. CNV analysis showed a partial duplication of chromosome 21 
(chr21:10,475,517-48,084,864), confirming the diagnosis of Trisomy 21. Sanger sequencing 
with custom forward and reverse primers for PTPIP51 exon 12 confirmed the p.Thr451Met 
variant (Figure 6.7B). Segregation studies were not possible. The p.Thr451Met missense 
change was present at a MAF of 0.002392344 from in-house exomes and in 6/121412 alleles 
(MAF=0.00004942) in ExAC, comprising five South Asians and one non-Finnish European, 
all in heterozygous state. Thr451 was conserved in all tested species except Danio rerio 
(Figure 6.7C).  
Western blot analysis of patient 21 fibroblasts did not reveal changes in steady-state PTPIP51 
levels compared to controls (Figure 6.8A). However, porin/VDAC1 was significantly 
increased compared to controls. Furthermore, there were no changes in steady-state OXPHOS 
subunits levels (Figure 6.8B). Skeletal muscle was not available for analysis.    
TMRM staining of the mitochondrial network in patient 21 fibroblasts was also performed but 
this did not show elongation or fragmentation compared to controls (Figure 6.9).     
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Figure 6.8 Western Blot Analysis of Patient 21 Fibroblasts. Western blot analysis of (A) steady-state PTPIP51 and Porin/VDAC1, plus (B) 
OXPHOS subunit protein levels in patient 21 fibroblasts.   
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Figure 6.9 Analysis of the Mitochondrial Network in Patient 21 Fibroblasts. (A) TMRM staining of patient 21 fibroblasts and two controls was 
performed using the Nikon A1R Confocal microscope. Mitochondrial morphological features were quantified by (B) aspect ratio (AR) and (C) form 
factor (FF). Student’s t test and Dunn’s Multiple Comparison tests were performed to compare the median AR and FF between patient 21 fibroblasts 
and controls.  
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6.4.11 CTBP1 – C-Terminal Binding Protein 1 
Patient 22 was a girl born at term to non-consanguineous parents who presented a complex 
phenotype and died at 16 years old due to acute respiratory failure. Initial development was 
normal for the first 8 months of life but she then manifested with a delay in walking. Rapid 
progressive scoliosis developed by 10 years old that necessitated corrective surgery. She 
suffered a respiratory tract infection at 14 years old that required resuscitation, following 
which she was weaker, became dependent on a percutaneous endoscopic gastrostomy (PEG) 
tube for feeding and was noted to subsequently develop contractures of the wrists and elbows. 
Clinical examination showed bradykinesia, unusually cold lower limbs with raised papular 
skin texture, marked spinal scoliosis and increased tone at the elbows, wrists, knees and 
ankles. Muscle mass was generally decreased. The patient also had slightly sunken eyes and 
thin spindle fingers. Brain MRI at 13 years old revealed mild cerebellar and brain stem 
atrophy. Muscle biochemical studies at 6 years old revealed complex I and IV deficiency 
(Figure 6.10A). Muscle histopathology disclosed fibre atrophy, secondary myopathic changes 
and evidence of denervation atrophy. Diagnostic targeted gene screening of PLA2G6 and 
APTX were negative for causative mutations.  
WES filtering failed to identify likely autosomal recessive candidate variants and hence, 
single heterozygous variants were then prioritised. A rare heterozygous c.452A>G 
(p.Lys151Arg) EARS2 missense change was identified. All coding and intronic regions of 
EARS2 were sequenced but no second likely causative variant was identified. There were no 
additional heterozygous variants in nuclear genes encoding mitochondrial proteins of interest 
identified. Hence, all rare recessive and dominant variants were listed for future evaluation. 
Beck et al. (2016) reported four patients with severe developmental delay, intellectual 
disability, hypotonia, ataxia, problems with weight gain and tooth enamel defects who all 
shared a de novo heterozygous c.991C>T (p.Arg331Trp) missense variant in CTBP1, 
encoding C-terminal binding protein 1 (CtBP1). Re-analysis of candidate variants for patient 
22 identified the p.Arg331Trp CTBP1 variant. Sanger sequencing with custom forward and 
reverse primers for CTBP1 exon 9 confirmed the variant (Figure 6.10B). CTBP1 (4p16.3) did 
not match the prioritised GO-Terms. The missense change was absent from in-house and 
external databases. The p.Arg331Trp variant occurred in the PLDLS C-terminal binding 
domain (Figure 6.10C), with Arg331 fully conserved in all tested species except S. cerevisiae 
(Figure 6.10D). Segregation studies were not possible. 
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Following identification of the p.Arg331Trp missense change in patient 22, all in-house WES 
datasets were analysed for additional CTBP1 variants. A total of 19 rare (MAF≤0.01) were 
identified from all in-house exomes, including the novel p.Arg331Trp variant. It was 
confirmed that the p.Arg331Trp was harboured only by patient 22. Additional missense 
variants were evaluated but were not deemed causative for other cases.
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Figure 6.10 Biochemical and Genetic Features of Patient 22. (A) Measurements of mitochondrial RC activities normalised to citrate synthase of 
complex I (CI/CS), complex II (CII /CS), complex III (CIII/CS) and complex IV (CIV/CS) from patient 22 (green) skeletal muscle compared to 
controls (red). Complex I and IV defects are denoted with an asterisk (‘*’). (B) Family pedigree with sequencing confirmation of a heterozygous 
p.Arg331Trp missense change in patient 22. (C) CtBP1 domain architecture with the p.Arg331Trp variant denoted (red) in the PLDLS C-terminal 
binding domain. (C) MSA showing conservation of the CtBP1 Arg331 residue. 
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6.4.12 MTO1 (VUS) – Mitochondrial tRNA Translation Optimisation 1 
Patient 32 was a 35 year old female and a long-standing, unresolved case first referred to NHS 
Highly Specialised Service for Rare Mitochondrial Disorders in the late 1980s. From 6 
months old she apparently had difficulty raising her head. At 8 years old, HCM was 
diagnosed. She also had exercise intolerance, persistent lactic acidosis, developmental delay, 
suffered from headaches and had seizures. At 10 years old, serum lactate was also elevated 
(3.3mmol/L; normal <2.5mmol/L). Muscle histochemistry showed striking global COX-
deficiency. Muscle biochemical studies revealed severe complex I and IV defects, but also a 
significant increase of complex II, III and V (Figure 6.11A). Quantitative real time PCR of 
skeletal muscle DNA also showed a significant increase in mtDNA copy number. 
Intriguingly, her mother also reported some muscle fatigue since childhood and in her 50s 
reported difficulty opening her eyes during the night and occasionally in the morning. Clinical 
examination revealed slight jerky eye movements, but no PEO or ptosis. She had neck muscle 
weakness (Medical Research Council (MRC) muscle strength grade 4/5) and mild shoulder 
and hip weakness; she was unable to stand from a crouched position. She also had HCM. 
Interestingly, the proband’s maternal aunt (her mother’s sister) had marked PEO and ptosis 
but did not have muscle weakness. Histochemical studies of muscle from the proband’s 
mother were performed externally and apparently showed COX-deficient fibres, but no 
specific details were available. Patient 32 also had a sister who had problems with depression 
but was otherwise asymptomatic.   
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Utilising the WES filtering strategy to prioritise both recessive and dominant variants, a novel 
heterozygous c.292G>A, p.Gly98Ser missense variant was identified in MTO1 encoding 
mitochondrial tRNA translation optimisation 1. MTO1 (6q13) matched the GO-Terms 
‘mitochondr*’ and ‘tRNA’. Using diagnostic forward and reverse primers for MTO1 exons 
2+3, the variant was confirmed in both patient 32 and her mother (Figure 6.11B). Genomic 
DNA was not available from the asymptomatic sister or father. The missense change was 
absent from in-house exomes and external databases. It affected a fully conserved residue in a 
moderately conserved region of the protein (Figure 6.11C). In the absence of a second 
causative variant the read coverage of MTO1 was examined, revealing three coding regions 
with no bases at 20-fold coverage. Targeted sequencing of all 14 MTO1 exons using 
Figure 6.11 Biochemical and Genetic Features of Patient 32. (A) Measurements of 
mitochondrial RC activities normalised to citrate synthase of complex I (CI/CS), complex 
II+III (CII+III/CS), complex IV (CIV/CS) and complex V (CV/CS) from patient 27 (blue) 
skeletal muscle compared to controls (red). Complex I and IV defects are denoted with an 
asterisk (‘*’). (B) Sanger sequencing confirmation of the novel heterozygous p.Gly98Ser 
MTO1 missense variant in patient 32 and her mother. (C) MSA of the MTO1 Gly98 residue. 
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diagnostic forward and reverse primers did not reveal a second likely causative variant in 
either patient 32 or her mother.  
6.4.13 LONP1 (VUS) – Lon Peptidase 1 
Patient 35 was a male born to non-consanguineous parents who presented from birth with 
congenital lactic acidosis and muscle weakness. Brain MRI showed a Leigh-like Syndrome 
pattern. Muscle histochemistry showed increased SDH activity but no COX-deficient fibres. 
Muscle biochemical studies revealed complex I and IV defects (Figure 6.12A). Severe 
mtDNA depletion was also detected by quantitative real time PCR. Targeted screening of 
SLC25A4, MPV17, SUCLG1, SUCLA2, TK2 and RRM2B were negative for causative 
mutations. 
WES filtering identified compound heterozygous missense variants in LONP1 encoding Lon 
peptidase 1; c.1693T>C (p.Tyr565His) (rs144125085) and c.2197G>A (p.Glu733Lys). Both 
variants were sequenced and confirmed diagnostically. The p.Tyr565His variant was present 
in 1/118492 non-Finnish European allele (MAF=0.000008439) in ExAC, while the 
p.Glu733Lys variant was present in 2/119658 alleles (MAF=0.00001671), a South Asian and 
non-Finnish European in ExAC, all in heterozygous state. Both variants were absent from in-
house exomes and external databases. The p.Tyr565His missense change occurred within the 
AAA+ ATPase domain, whereas the p.Glu733Lys variant occurred within the peptidase C-
terminal domain near the boundary of the ATPase domain (Figure 6.12B). Tyr565 was also 
fully conserved in all tested species. On the other hand, Glu733 was poorly conserved, 
occurring in a moderately conserved region of the protein (Figure 6.12C). Autosomal 
recessive LONP1 mutations had been previously associated with a multisystem syndrome of 
cerebral, ocular, dental, auricular and skeletal abnormalities, known as CODAS syndrome 
(Dikoglu et al., 2015; Strauss et al., 2015). As this did not fit the phenotype, the missense 
changes were classed as VUS. 
At the time of writing, patient 35 and the LONP1 missense variants were under investigation 
by Christie Waddington (Wellcome Trust Centre for Mitochondrial Research, Institute of 
Neuroscience, The Medical School, Newcastle University, Newcastle upon Tyne).
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Figure 6.12 Biochemical Features of Patient 35, LONP1 Domain Architecture and MSA. (A) Measurements of mitochondrial RC activities 
normalised to citrate synthase of complex I (CI/CS), complex II+III (CII+III/CS) and complex IV (CIV/CS) from patient 35 (orange) skeletal muscle 
compared to controls (red). Complex I and IV defects are denoted with an asterisk (‘*’). (B) Domain architecture of LONP1 with the p.Tyr565His and 
p.Glu733Lys missense changes noted (red). (C) MSA of LONP1 Tyr565 and Glu733Lys residues. ‘……‘ denotes the space between the regions where 
Tyr565 and Glu733 are located. 
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6.5 Discussion 
Utilising WES and a custom filtering strategy to prioritise variants in nuclear gene encoded 
mitochondrial proteins, genetic diagnoses were attained in 7/20 (35%) patients. Additionally, 
2/20 (10%) patients had likely, novel causative nuclear genes (CTBP1, PTPIP51) associated 
with RC deficiency. Potential significant VUS were identified in 2/20 (10%) patients (MTO1, 
LONP1). This is comparable to the diagnostic yield attained by Wortmann et al. (2015), but 
not as high as 60% attained by Calvo et al. (2012), Taylor et al. (2014), Pronicka et al. (2016) 
and Legati et al. (2016).  
6.5.1 Disorders of Mitochondrial Translation 
Of the seven patients confirmed genetic diagnoses attained, five had mutations in nuclear 
genes encoding factors in mitochondrial protein synthesis involved in mitoribosome structure 
(MRPS22), mt-tRNA aminoacylation (EARS2, AARS2) and tRNA modification (TRMU, 
GTPBP3). In Chapter 7, the two patients with EARS2 and AARS2 mutations plus the 
pathological mechanisms are described. 
 A Homozygous MRPS22 Mutation Affecting Mitoribosome Assembly and 
Stability 
MRPS22 mutations had previously been reported in five patients, including three siblings who 
were also homozygous for the p.Arg170His missense change identified in patient 24 (Saada et 
al., 2007; Smits et al., 2011b; Baertling et al., 2015). HCM was shared in all patients but the 
phenotypic spectrum was broad. Three siblings reported by Saada et al. (2007) harbouring the 
homozygous p.Arg170His mutation presented with neonatal skin oedema, hypotonia and had 
a tubulopathy. The patient reported by Baertling et al. (2015) with a homozygous 
c.1032_1035dup (p.Leu346Asnfs*21) also presented a severe neonatal phenotype with 
multiple organ system failure leading to death at 3 days old. Contrastingly, the patient 
reported by Smits et al. (2011b) with a homozygous c.644T>C (p.Leu216Pro) missense 
variant presented with mild, Cornelia de Lange-like dysmorphic features and brain 
abnormalities manifesting as corpus callosum hypoplasia. Hypogenesis of the corpus 
callosum was also shared with the patient reported by Baertling et al. (2015). 
MRPS22 encodes a small 28S subunit of the mitoribosome but its exact location within the 
structure had been unknown and it had no bacterial, eukaryotic cytoplasmic or yeast 
mitochondrial homolog. Recently, Amunts et al. (2015) and Greber et al. (2015) resolved the 
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mitoribosome structure using cryo-electron microscopy, which demonstrated S22 of the 28S 
subunit was located in the lower body domain on the solvent side. Both publications also 
modelled the p.Arg170His mutation, suggesting that it impaired assembly of the 28S subunit. 
Functional analysis of p.Arg170His patient fibroblasts showed a substantial decrease in 12S 
rRNA levels and decreased S11 and S16 levels in mitochondria, suggesting the 28S subunit 
cannot assemble in the absence of S22 (Emdadul Haque et al., 2008). Despite the broad 
phenotypes, when taken together with the resolved structure of the mitoribosome, the S22 
subunit is confirmed as a critical component of 28S subunit stability, assembly or both and 
hence, mitochondrial translation. Additional mitoribosome subunit mutations have also been 
reported in MRPL3 (Galmiche et al., 2011), MRPL12 (Serre et al., 2013), MRPL44 (Carroll et 
al., 2013), MRPS16 (Miller et al., 2004) and MRPS23 (Kohda et al., 2016), highlighting the 
importance of mitoribosome assembly and stability for mitochondrial protein synthesis. 
 Mutations of Mitochondrial tRNA Modification Factors 
Mutations were also identified in three mt-tRNA modification factors; autosomal recessive 
mutations in TRMU (patient 31) and GTPBP3 (patient 27) (6.5.1.3), plus a potential causative 
heterozygous MTO1 (patient 32) mutation. Interestingly, all three mt-tRNA modification 
factors are involved in modifying the uridine 34 (U34) wobble-base of mitochondrial 
tRNALeu(UUR), tRNATrp, tRNALys, tRNAGln or tRNAGlu. Modification of the U34 wobble-base 
in mitochondria is evolutionarily conserved, with both yeast and bacteria possessing 
homologs of MTU1 (MnmA in bacteria), MTO1 (GidA in bacteria) and GTPBP3 (Mss1 in 
yeast, MnmE in bacteria) (Elseviers et al., 1984; Colby et al., 1998; Cabedo et al., 1999; 
Scrima et al., 2005; Villarroya et al., 2008). The first modification is 5-taurinomethyluridine 
(τm5U) at position 5 of U34 of tRNALeu(UUR), tRNATrp, tRNALys, tRNAGln or tRNAGlu that is 
proposed to be synthesised by a GTPBP3-MTO1 complex (Colby et al., 1998). However in 
yeast and bacteria, MTO1-Mss1 (yeast) and GidA-MnmE (bacteria) synthesise a 5-
carboxymethylaminomethyluridine (cmnm5U) modification of U34 instead of τm5U 
(Elseviers et al., 1984). A second modification of τm5U, 2-thiouridine (τm5s2U) is also 
synthesised at the second position of the U34 wobble-base of tRNALys, tRNAGln and tRNAGlu 
by MTU1 (Umeda et al., 2005). Regarding mt-tRNA mutations and the U34 wobble-base, 
cybrid cells from patients harbouring the mt-tRNALeu(UUR) m.3243A>G and m.3271T>C 
MELAS mutations lacked τm5U modification (Yasukawa et al., 2000). In contrast, tissue 
from patients harbouring different mt-tRNALeu(UUR) mutations had normal taurinomethylation 
of U34 (Kirino et al., 2005), which correlates the MELAS phenotype with the specific lack of 
τm5U modification. 
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TRMU mutations have been previously reported in patients presenting acute infantile-onset 
liver failure (AILF) and RC deficiency, with onset between birth and 6 months of life 
(Zeharia et al., 2009; Kemp et al., 2011; Schara et al., 2011; Uusimaa et al., 2011; Gaignard 
et al., 2013; Taylor et al., 2014; Grover et al., 2015). Consistent with previous cases, patient 
31 had severe acute liver failure and hepatomegaly from birth, with cardiac involvement and 
possible signal changes in the globus pallidus, which were rare manifestations of TRMU 
patients. Normal muscle histology was also true in previous cases. The 
p.Asp249_Lys251delinsGlu and p.Pro276Leu variants harboured by patient 31 had not been 
previously described in affected patients. However, the p.Pro276Leu missense change was 
proximal to previously reported c.815G>A (p.Gly272Asp) and c.835G>A (p.Val279Met) 
variants. Although further details were not available, patient 31 appeared to have some 
recovery at around 18 months of age, as seen in other patients who survived beyond the first 
year of life.  
Since its activity is thiouridylase and not methyltransferase, MTU1 is the accepted term for 
the encoded enzyme by TRMU. The pathological nature of TRMU mutations may be due to 
loss of MTU1 thiouridylation activity causing failure to modify the U34 wobble-base in 
mitochondrial tRNALys, tRNAGln and tRNAGlu, and hence impaired mitochondrial translation. 
Accumulation of non-thiourylated tRNALys, tRNAGln and tRNAGlu in patient fibroblasts has 
been found (Zeharia et al., 2009), but defective mitochondrial translation associated with 
MTU1-deficiency was not demonstrated in patient fibroblasts, MTU1-knockout HEK293 
cells or myoblasts and there were non-specific decreases in mt-tRNAs (Sasarman et al., 
2011). Sasarman et al. (2011) proposed that although MTU1 is essential for 2-thiouridylation 
of the U34 wobble-base for mitochondrial tRNALys, tRNAGln and tRNAGlu, it is dispensable 
since mitochondrial protein synthesis was normal. Furthermore, knockout of TRMU in 
MELAS and MERRF patient fibroblasts, for which the translation defects are ascribed to 
failed modification of the mt-tRNALeu(UUR) (MELAS) and mt-tRNALys (MERRF) U34 wobble-
base, did not cause further impairment of mitochondrial protein synthesis. To explain this, it 
was hypothesised that only loss of steady-state mt-tRNA levels for thiouridylation together 
with deficient MTU1 could impair translation. When steady-state levels of mt-tRNAs are 
normal, MTU1 is not required for mitochondrial translation. This has yet to be studied and 
confirmed in TRMU patient liver, which could provide further evidence to support this 
hypothesis and the tissue-specific nature of this disease. 
Unexpectedly, patient 31 had a severe complex II defect (4% activity compared to controls) in 
skeletal muscle, despite all complex II subunits being encoded by the nuclear genome. A 
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complex II defect was also noted in one patient with compound heterozygous TRMU 
mutations; p.Val279Met and a splice-site c.248+1G>A variant (Gaignard et al., 2013). In 
agreement with Gaignard et al. (2013), this unusual finding indicates a secondary role for 
MTU1 that is independent of mitochondrial protein synthesis. In bacteria and yeast homologs, 
2-thiouridylation of the U34 wobble-base is dependent on a sulphur relay system to provide 
sulphur, encoded by five genes unconserved between the species (Kambampati and Lauhon, 
2003; Noma et al., 2009). In humans, bacteria and yeast the essential sulphur donor for 2-
thiouridylation is the amino acid L-cysteine, which is critical for early human development. 
During the neonatal period, the availability of L-cysteine is reduced because its synthesis 
from methionine is restricted by the rate-limiting enzyme cystathionase, which is expressed at 
low levels from birth and increases slowly during the first few months of life (Zlotkin and 
Anderson, 1982; Levonen et al., 2000). The low availability of L-cysteine as a sulphur donor 
together with TRMU mutations has been proposed as a pathological mechanism for severe 
liver failure and recovery or stabilisation in several patients over time (Zeharia et al., 2009). 
Concerning the complex II defect, Sasarman et al. (2011) noted that MTU1-deficient 
HEK293 cells and TRMU patient fibroblasts had a subcomplex of complex II appearing as a 
‘doublet’ when using an antibody for the 70kDa subunit SDHA, which was consistent in all 
knockdowns and patient fibroblasts. In MTU1-deficient HEK293 cells the 30kDa subunit 
SDHB that contained the iron-sulphur (Fe-S) clusters was absent. Authors proposed that 
addition of the Fe-S clusters to this complex II subunit was compromised due to MTU1 
deficiency, resulting in an unassembled subcomplex containing only the 70kDa subunit. 
Hence, MTU1 may have a secondary role in obtaining the sulphur it requires for 2-
thiouridylation and for the addition of Fe-S clusters to the complex II 30kDa subunit. Why 
only two TRMU patients have been noted to have a complex II defect however remains 
intriguing, particularly as the clinical course of the patient reported by Gaignard et al. (2013) 
was fatal, unlike that of patient 31, warranting further investigation of the secondary function 
of MTU1.   
 A Novel Disorder of Defective mt-tRNA Modification Due to GTPBP3 Mutations 
The third nuclear gene associated with mt-tRNA modification and with mutations in patients 
with multiple RC deficiency was GTPBP3. The homozygous GTPBP3 mutation harboured by 
patient 27 was identified independently by this study on patients with early-onset RC 
deficiency. Although the parents reported no consanguinity, the possibility of a founder effect 
within Romania could not be excluded but no further details on the family were available. 
Following the sharing of WES results with diagnostic centres worldwide, a cohort of 11 
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patients from 9 pedigrees with autosomal recessive GTPBP3 mutations was collated, 
including patient 27, suggesting that GTPBP3 mutations are an important cause of 
mitochondrial RC disease. All patients including patient 27 (corresponding to patient #81471) 
have been published in Kopajtich et al. (2014), all presenting a core phenotype of HCM, 
encephalopathy and lactic acidosis. When performed, brain MRI revealed abnormalities of the 
brainstem and basal ganglia suggestive of Leigh syndrome that included patient 27. Based on 
these core features, targeted GTPBP3 sequencing was performed in an additional undiagnosed 
patient referred to the NHS Highly Specialised Mitochondrial Diagnostic Service Laboratory 
in Newcastle upon Tyne but did not reveal any likely causative variants.  
Although it has been proposed that the τm5U modification at position 5 of U34 of 
mitochondrial tRNALeu(UUR), tRNATrp, tRNALys, tRNAGln or tRNAGlu is synthesised by 
cooperation of GTPBP3 and MTO1 (Colby et al., 1998), there is currently no functional 
confirmation of this. While GTPBP3 patient fibroblasts demonstrate a mitochondrial 
translation defect and multiple RC deficiency that could be rescued by lentiviral transfection, 
there were no changes in the steady-state mt-tRNA levels, including mitochondrial 
tRNALeu(UUR), tRNATrp, tRNALys, tRNAGln or tRNAGlu to validate the role of GTPBP3 in τm5U 
modification. On the other hand, analysis of mt-tRNAs in MTO1 patient fibroblasts showed 
altered mt-tRNAGlu modification but not mt-tRNALys or mt-tRNAGln (Tischner et al., 2015), 
providing evidence for a pathological mechanism due to defective τm5U modification. This 
could also be a shared mechanism in GTPBP3 patients but this has yet to be examined. 
Activity of the proposed MTO1-GTPBP3 complex is also coupled to the 2-thiouridylation 
activity of MTU1 (Umeda et al., 2005). Patients with TRMU and MTO1 mutations manifest 
liver failure or HCM. On the other hand, patients with GTPBP3 and MTO1 mutations present 
striking similarities of HCM, lactic acidosis and multiple RC defects (Ghezzi et al., 2012; 
Kopajtich et al., 2014), which provides some support for the shared mechanism of τm5U 
modification.  
6.5.2 A Novel SCO1 Mutation Causing Isolated COX Deficiency in a Consanguineous 
Family with ‘Triple Threat’ Mitochondrial Disease 
Isolated COX deficiency is a prevalent form of mitochondrial disease that can occur due to 
mutations of any of the three mtDNA encoded structural subunits and some nuclear encoded 
structural subunits, or COX assembly factors (DiMauro et al., 2012). In a highly 
consanguineous British Pakistani family with mitochondrial disease affecting several 
branches of the pedigree, a novel homozygous SCO1 mutation was identified in a single 
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affected patient with fatal congenital lactic acidosis and isolated COX deficiency. Causative 
homozygous RMND1 and FARS2 mutations were identified in the other branches of this 
family. The RMND1 p.*450Serext*32 extension variant had been previously reported 
homozygous in several affected patients of Pakistani origin (Taylor et al., 2014; Ng et al., 
2016). The p.Tyr144Cys FARS2 missense change was previously reported in homozygous in 
a Saudi girl presenting with mitochondrial encephalopathy (Shamseldin et al., 2012). 
Consanguineous families are at a greater risk of Mendelian disease due to common founder 
mutation within the family or local population (Hamamy, 2012). Nonetheless, the presence of 
three segregating forms of Mendelian mitochondrial disease in one consanguineous family is 
exceptional. 
SCO1 and its paralog SCO2 encode copper chaperones, with autosomal recessive mutations in 
either gene causing isolated COX deficiency (Papadopoulou et al., 1999; Jaksch et al., 2000; 
Valnot et al., 2000; Salviati et al., 2002; Tarnopolsky et al., 2004; Verdijk et al., 2008; 
Stiburek et al., 2009; Leary et al., 2013a), though SCO1 mutations have been previously 
reported in only three pedigrees. Both SCO proteins have high sequence identity, particularly 
in the C-terminal and share a CxxxC motif and histidine residue that are indispensable for 
copper binding, which is also shared with the yeast sco1 homolog (Balatri et al., 2003; Horng 
et al., 2005). Although yeast has conserved sco1 and sco2 homologs, only yeast sco1 is 
essential for COX assembly (Glerum et al., 1996). In humans, together in cooperation with 
SCO2 and additional copper chaperones that include recently characterised COX20 and 
COA6 (Bourens et al., 2014; Stroud et al., 2015), SCO1 is required for the delivery of two 
copper ions to the catalytic core of COX and metalation of the CuA copper site of MT-COII 
during the early stage of COX assembly, forming a complex that facilitates MT-COII 
insertion, maturation and assembly into the COX holoenzyme (Leary et al., 2004). Therefore 
failure to maturate and incorporate MT-COII leads to its degradation and ultimately, COX 
deficiency. Significant tissue- and cell-specific copper deficiency due to an inability to retain 
cellular copper content and improper mitochondrial redox signalling have also been 
demonstrated in affected SCO1 and SCO2 patient tissue, highlighting a critical role for the 
SCO proteins in cellular copper homeostasis (Leary et al., 2007; Leary et al., 2013b). 
Furthermore, a fraction of SCO1 is physically associated with fully assembled COX in human 
muscle mitochondria, suggesting a link between COX and cellular copper homeostasis 
(Stiburek et al., 2009).  
SCO1 and SCO2 mutations appear to show tissue- and cell-specificity despite ubiquitous 
expression. SCO2 mutations have been associated with fatal cardioencephalomyopathy with 
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heart and muscle tissues demonstrating severe COX-deficiency in comparison to other tissues 
(Papadopoulou et al., 1999). The SCO1 patient reported by Leary et al. (2013a) who had fatal 
lactic acidosis and harboured compound heterozygous SCO1 (p.Met294Val and c.425+6T>C) 
is comparable to patient 34 who also had fatal infantile lactic acidosis and harboured a novel 
missense variant affecting the same residue, p.Met294Thr. In contrast, previously reported 
SCO1 patients had neonatal liver failure or HCM (Valnot et al., 2000; Stiburek et al., 2009). 
The pathological mechanisms to explain the distinct tissue specific phenotypes were 
investigated by Leary et al. (2013a), who compared fibroblasts from the patient with the 
p.Met294Val variant to a patient with a c.520C>T (p.Pro174Leu) variant. Fibroblasts 
expressing the p.Met294Val variant had a milder COX-defect, more stable MT-COII and an 
absent intermediate S2 subcomplex previously observed in SCO1 patient fibroblasts as a 
consequence of stalled COX assembly. Despite lower expression of SCO1, this evidence 
suggests that SCO1 expressing the p.Met294Val variant retained residual ability for COX 
assembly. Authors proved this by overexpressing the p.Met294Val mutation, which resulted 
in fully recoverable COX activity. Nonetheless, the copper deficiency of patient fibroblasts 
harbouring the p.Met294Val mutation was similar to second SCO1 patient. Overall, Leary et 
al. (2013a) proposed that the defect caused by p.Met294Val is due to the cellular copper 
deficiency, instead of impaired COX assembly as demonstrated in SCO1 patients with 
different mutations. Hence, tissue specificity of SCO1 mutations is dependent upon the 
particular function that is impaired, either COX assembly or cellular copper homeostasis. 
Although the amino acid substitution of patient 34 is different, from methionine to threonine, 
the proposed mechanism likely stands true as both patients presented fatal lactic acidosis and 
isolated COX deficiency. 
6.5.3 Pyruvate Dehydrogenase Deficiency Due to a De Novo PDHA1 Mutation 
A novel de novo p.Glu345dup PDHA1 mutation was identified in patient 23, who presented 
severe neonatal metabolic acidosis, renal impairment, hypotonia, central apnoea, anemia, liver 
disease and a coagulopathy. Mutations of PDHA1, which encodes the E1-α subunit of the 
pyruvate dehydrogenase complex (PDHc), are a common cause of mitochondrial disease and 
that are typically characterised by neonatal- or infantile-onset lactic acidosis and pyruvate 
dehydrogenase deficiency with a poor outcome, although it is known to have a broad 
phenotypic spectrum (DeBrosse et al., 2012). Diagnosis of PDHc deficiency is typically made 
using an assay for measuring activity, normally with patient fibroblasts but can also include 
skeletal muscle, liver or lymphocytes (Kerr et al., 1987; Kerr et al., 2012).   
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The pyruvate dehydrogenase complex (PDHc) is an approximately 9.5 megadalton (MDa), 
nuclear encoded mitochondrial matrix multi-enzyme complex required for the irreversible 
conversion of pyruvate to acetyl co-enzyme A (CoA) (Patel and Korotchkina, 2006). Hence, 
the PDHc provides this vital link with glycolysis (Harris et al., 2002; Patel and Korotchkina, 
2006). It is comprised of five essential enzymes, one of which is pyruvate dehydrogenase (E1) 
that is composed of 20-30 E1 units. Each unit is a heterotetrameric complex comprising two 
E1-α subunits encoded by PDHA1 and two E1-β subunits encoded by PDHB (Patel and 
Korotchkina, 2006). PDHB mutations have also been implicated in pyruvate dehydrogenase 
deficiency but are uncommon compared to PDHA1 (Okajima et al., 2008; DeBrosse et al., 
2012). The active site of the E1 subunit is within a deep cleft at the interface of the α- and β-
subunits (Gray et al., 2014).  
Missense, in-frame and frameshift PDHA1 mutations have been identified in patients with 
pyruvate dehydrogenase deficiency, which have been proposed to affect either (i) targeting to 
mitochondria, (ii) binding to thiamine pyrophosphate co-factor or (iii) assembly of the 
pyruvate dehydrogenase complex (Gray et al., 2014). As the p.Glu345dup in patient 23 did 
not introduce a frameshift, it is unclear how this impacts the PDHc activity or function. 
Furthermore, patient 23 PDHc activity was not measured, perhaps due to early demise. 
Nonetheless since the p.Glu345dup variant apparently occurred de novo or was germline 
mosaic and that in-frame PDHA1 mutations have been previously reported, it is highly likely 
to be the definitive diagnosis. Given the critical role of the PDHc in generating acetyl CoA for 
the TCA cycle in mitochondria and hence, the dependency for OXPHOS this would explain 
the low complex I and IV activities in patient muscle. Severe mtDNA depletion in patient 23 
muscle was also an intriguing finding. This could be linked to the activity of succinyl-CoA in 
the TCA cycle, given its association with early-onset mtDNA depletion syndrome (Carrozzo 
et al., 2007; Ostergaard et al., 2007). In patient 23, mtDNA depletion may be secondary to a 
disturbance of the PDHc leading to deficiency of acetyl CoA feeding into TCA cycle, 
therefore affecting pathways downstream, disrupting the interaction between succinyl CoA 
synthetase and NDPK. Currently, patient 23 is currently the only known PDHA1 patient 
known to have mtDNA depletion and therefore it is not clear if this is a rare phenomenon or if 
it is an under recognised feature of PDHc deficiency.  
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6.5.4 CTBP1 Mutation and the Emergence of De Novo Dominant Mitochondrial RC 
Disease 
Surprisingly, two novel heterozygous missense variants were identified in two early-onset 
patients; p.Arg331Trp CTBP1 in patient 22 and p.Gly98Ser MTO1 in patient 32. Of the two 
variants, the CTBP1 missense change is the most likely causative variant due to the 
identification of four patients who were also de novo for the same missense change with 
similar phenotypes (Beck et al., 2016). All patients including patient 22 had hypotonia, 
developmental delay and varying muscle weakness. Cerebellar atrophy was noted in patient 
22 and two reported patients.  
Contrastingly, patient 22 had limb spasticity, whereas the reported patients had difficulty 
walking due to ataxia. Muscle biopsies also showed non-specific findings in the four reported 
patients. Additionally, RC defects were not reported but it is unclear whether skeletal muscle 
was analysed given the neurological phenotypes presented by the four patients were not 
dissimilar to some early-onset patients with mitochondrial disease. One patient was 
apparently investigated for mitochondrial mutations, but no further details were given. The 
four reported patients had enamel hypoplasia or discolouration. According to the clinical 
notes, patient 22 had normal teeth but there was no description on the enamel. It is not clear 
though when these defects manifested, or if it was the deciduous or permanent teeth that were 
affected. Finally, it was not possible to determine whether the p.Arg331Trp missense change 
occurred de novo in patient 22. At the time of writing, segregation studies had not been 
performed. Interestingly, the mother of one of the four reported patients was low-level 
somatic mosaic for the p.Arg331Trp variant, but did not present any neurological impairment.  
To date, CtBP1 is not a known mitochondrial protein nor predicted to possess a MTS. It was 
first identified as an E1A oncogene binding protein (Schaeper et al., 1995), but has since been 
characterised as a transcriptional co-repressor that associates with DNA-specific repressors 
during human development and tumorigenesis (Bergman and Blaydes, 2006; Chinnadurai, 
2007). Hence it regulates gene expression and DNA repair. Mammalian CtBP1 has 
overlapping gene expression roles with its paralog CtBP2, whereby knockout of CtBP1 
resulted in smaller offspring and 25% lethality by day 20 of life in CtBP1-mutator mice and 
knockout of CtBP2 is embryonic lethal (Hildebrand and Soriano, 2002). Despite no 
mitochondrial targeting, CtBP1 has been identified as a key regulator of mitochondrial 
morphology and function. Knockout of CtBP1 in mouse embryonic fibroblasts (MEFs) results 
in elongated mitochondria, swollen cristae, decreased cellular ATP, decreased oxygen 
consumption and decreased mitochondrial membrane potential (Kim and Youn, 2009). 
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Altered mitochondrial morphology and function were attributed to the regulation of the Bax 
(Bcl-2-associated X protein) gene by CtBP1. BAX promotes mitochondrial apoptosis and has 
been proposed to associate with mitochondrial fission and fusion sites (Wu et al., 2011). Kim 
and Youn (2009) demonstrated that mitochondrial-dependent apoptosis in response to glucose 
deprivation was regulated by the Bax gene, for which expression was modulated by the 
association of CtBP1 to the Bax promotor. This association was proven when both Bax and 
Ctbp1 were knocked out together in MEFs, which led to an increase in ATP production, 
oxygen consumption rate and membrane potential. RC deficiency demonstrated in patient 22 
skeletal muscle suggests that mitochondrial morphology has been disrupted due to impaired 
regulation of Bax. Without the proper fusion and fission of mitochondria there is a failure to 
target and clear damaged mitochondria via mitophagy, including factors involved in 
mitochondrial protein synthesis or assembly of the RC complexes. Further investigation of 
RC activities in the muscle of the four reported patients could provide further insights. Given 
the neurological phenotypes and the function of CtBP1, it is likely that the p.Arg331Trp 
mutation acts in a dominant-negative manner on Bax expression. 
The role of CtBP1 in the regulation of gene expression is reflected in the spectrum of clinical 
features. The tooth enamel defects in the four reported patients are the most unusual yet 
specific feature of this disorder. Development of teeth and enamel is dependent on tight gene 
regulation (Paine et al., 2001; Balic and Thesleff, 2015). Non-syndromic and syndromic 
forms of Mendelian orodental disorders affecting tooth development and the oral cavity have 
described with a significant proportion of nuclear encoding transcriptional regulators with 
some phenotypic overlap between the CTBP1 patients (Bergendal et al., 2011; Prasad et al., 
2016; Shahid et al., 2016). This suggests a key role of CtBP1 in regulating enamel structure. 
Since the p.Arg331Trp missense change likely acts in a dominant-negative manner, the 
expression of genes critical for mineralisation or formation of the enamel could be 
significantly downregulated.  
De novo heterozygous mutations are widely associated with early onset autism and epileptic 
encephalopathies (Epi and Epilepsy Phenome/Genome, 2013; Iossifov et al., 2014). In 
contrast, de novo mutations of nuclear encoded mitochondrial proteins causing mitochondrial 
disease are limited. Recently, five patients with global developmental delay, hypotonia, optic 
atrophy, axonal neuropathy and HCM sharing a de novo c.1582C>T (p.Arg528Trp) ATAD3A 
mutation were reported (Harel et al., 2016). De novo c.239G>A (p.Arg80His) and c.703C>G 
(p.Arg235Gly) SLC25A4 mutations were also reported in seven patients with neonatal-onset 
respiratory insufficiency and severe mtDNA depletion in skeletal muscle (Thompson et al., 
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2016). Dominant SLC25A4 mutations are further complicated though by patients with late-
onset PEO and multiple mtDNA deletions, as described in 3.4.3. These recent publications 
suggest that de novo nuclear gene mutations in early-onset mitochondrial disease patients 
could be considerably underrepresented. Hence, full re-evaluation of candidate variants in 
unsolved cases may increase diagnostic yield.  
6.5.5 Novel Mitochondrial RC Disease Candidates Requiring Further Investigation 
Likely causative variants and VUS were identified in PTPIP51, MTO1 and LONP1. Although 
all three genes encode mitochondrial proteins that have been characterised to varying extents, 
the potential mechanisms associated with RC deficiency are currently unclear. 
 A Homozygous PTPIP51 Missense Mutation 
A novel homozygous p.Thr451Met missense variant in PTPIP51 was identified in a boy with 
progressive muscle weakness, complex I and IV defects who was born to consanguineous 
parents. Given consanguinity, the homozygous PTPIP51 variant was a strong candidate as the 
causative variant in this case. PTPIP51 is a scaffold protein that localises in different cellular 
locations has been associated with several cellular processes including regulation of the 
microtubule cytoskeleton, photoreceptor differentiation, cell morphology and mitosis (Yu et 
al., 2008; Brobeil et al., 2012). Regarding mitochondrial function, Lv et al. (2006) first 
demonstrated localisation of PTPIP51 to mitochondria by identifying a putative N-terminal 
MTS and showing that overexpression in HEK293 and HeLa cells induced apoptosis, the 
release of cytochrome c and a decrease in mitochondrial membrane potential. De Vos et al. 
(2012) further demonstrated that PTPIP51 localises to the OMM and interacts with the 
endoplasmic reticulum (ER) membrane protein VAPB to regulate calcium exchange between 
the two organelles. Knockout of either PTPIP51 or VAPB caused increased cytosolic and 
decreased mitochondrial calcium levels that was comparable to knockout of mitofusin-2 
(MFN2), which is also proposed to tether mitochondria to the endoplasmic reticulum (de 
Brito and Scorrano, 2008), although it was recently proposed that MFN2 acts antagonistically 
in mitochondria-ER contacts (Filadi et al., 2015). OMM proteins including MFN1, MFN2, 
OPA1 and Drp1 are also critical for mitochondrial fusion or fission (Pitts et al., 1999; Chen et 
al., 2003; Cipolat et al., 2004). To determine if PTPIP51 had any role in mitochondrial 
morphology, TMRM staining of patient fibroblasts was performed but this did not reveal any 
elongation or fragmentation of the network. Steady-state PTPIP51 levels were also 
unchanged, demonstrating the difficulty of functional investigations in fibroblasts. Curiously 
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there was a significant upregulation in VDAC1/porin, which is also an OMM channel protein 
that allows the movement of metabolites, cations, adenine nucleotides and calcium into the 
intermembrane space (Bayrhuber et al., 2008; Shoshan-Barmatz et al., 2010). This 
upregulation suggests a possible compensatory mechanism, although whether this is related to 
disturbed mitochondrial calcium homeostasis is not clear. Unfortunately, skeletal muscle is 
unavailable and no second patient has yet been identified with PTPIP51 mutations to allow 
for further investigations.  
 An Atypical Phenotype with Severe mtDNA Depletion Due to Compound 
Heterozygous LONP1 Mutations 
Compound heterozygous LONP1 mutations were identified in patient 35 who had congenital 
lactic acidosis, muscle weakness, a Leigh-like imaging pattern on brain MRI and severe 
mtDNA depletion. The Lon protease is known to be involved in the protein quality control by 
degrading proteins damaged by oxidative stress (Venkatesh et al., 2012). Lon also binds to 
mtDNA to regulate expression but it also binds and degrades TFAM to control the ratio of 
TFAM-mtDNA, hence regulating mtDNA transcription (Venkatesh et al., 2012; Lu et al., 
2013). Given the severe mtDNA depletion in patient 35 muscle, an autosomal recessive 
mtDNA depletion disorder was suspected and hence, LONP1 strongly fitted the criteria due to 
its role in mtDNA maintenance. Despite this, recessive LONP1 mutations have been 
previously associated with a multisystem syndrome of cerebral, ocular, dental, auricular and 
skeletal abnormalities, known as CODAS syndrome (Dikoglu et al., 2015; Strauss et al., 
2015). CODAS syndrome did not fit the phenotype for patient 35. Furthermore, there was no 
evidence of mtDNA depletion in muscle of affected CODAS syndrome patients. On the other 
hand, the clinical and genetic heterogeneity of mitochondrial disease suggest that multiple 
phenotypes associated with causative mutations of the same nuclear gene are to be expected, 
due to independent pathological mechanisms. The p.Tyr565His and p.Glu733Lys missense 
changes were also proximal to previous reported causative LONP1 variants, but require 
further investigation. 
 An Autosomal Dominant MTO1 Mutation with Reduced Penetrance? 
Finally, a novel heterozygous MTO1 p.Gly98Ser mutation was identified in a family with 
possible autosomal dominant inheritance of a mitochondrial disorder. Both patient 32 and her 
affected mother harboured the p.Gly98Ser missense change with no second likely causative 
MTO1 variant identified in either patient. Clinically, patient 32 fits the previously described 
MTO1 phenotype well. On the other hand, her mother is not affected to the same degree, 
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although muscle histochemistry performed externally apparently confirmed a mitochondrial 
myopathy. To date, all patients harbouring MTO1 mutations have homozygous or compound 
heterozygous variants, hence not only would this be the first causative dominant inherited 
MTO1 variant, but also the first dominant mitochondrial translation disorder. Quite how this 
mutation acts requires investigation into the τm5U modification of mt-tRNAs. The p.Gly98Ser 
mutation could be acting in a dominant-negative manner with reduced penetrance in the 
affected mother. Phenotypic variability between affected family members with dominant 
heterozygous PEO with multiple mtDNA deletions mutations are not uncommon (Chapter 
3). In the absence of other possible candidates, the MTO1 variant remains the best candidate. 
Further segregation studies, particularly of the apparently unaffected sibling could support the 
likelihood of this novel MTO1 mutation. 
6.5.6 Concluding Remarks 
To summarise, WES of 20 early-onset patients with mitochondrial RC deficiency provided a 
higher diagnostic yield for causative and likely causative variants (45%) than the adult-onset 
PEO with multiple mtDNA deletions cohort (35%). This is due to the undeniable prominence 
of causative autosomal recessive variants, versus the prevalence of dominant variants in adult-
onset mtDNA maintenance disorders. However, diagnostic targeted gene screening from the 
early-onset RC cohort was limited to one or two genes before recruitment to WES 
increasingly the likelihood of a diagnosis and identifying variants in known disease genes, 
whereas all common nuclear genes associated with PEO and multiple mtDNA deletions were 
excluded in the late-onset cohort. Furthermore, the identification of a heterozygous CTBP1 
mutation associated with combined RC defects suggests a growing significance for 
(presumed) de novo or germline mosaic variants in early-onset Mendelian mitochondrial 
disease. The clinical and genetic heterogeneity of mitochondrial RC disease is highlighted in 
that only single cases for each gene were identified. This study advocates (i) reporting of all 
recessive and heterozygous candidate variants in unsolved cases and (ii) periodic re-
evaluation, which may ultimately lead to an increase in diagnostic yield. The identification of 
variants in genes predominantly involved in mitochondrial translation indicate that 
prioritisation of these genes is appropriate but nonetheless still allow for additional factors in 
complex assembly, dynamics and metabolism to be listed. Finally, attaining diagnoses in 
paediatric cases is paramount for the parents and families, that will help inform future 
reproductive options to include pre-natal or pre-implantation diagnosis.
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Chapter 7. Expanding the Clinical, Genetic and Molecular Features of 
Mitochondrial Amino-Acyl tRNA Synthetase Mutations 
7.1 Introduction 
This chapter contains material published in Journal of Inherited Metabolic Disorders Reports 
(Oliveira and Sommerville, 2016) and JAMA Neurology (Sommerville et al., 2017). The 
expansion of the clinical, molecular and genetic features of mitochondrial amino-acyl tRNA 
synthetase (mt-aaRS) mutations is a large on-going collaborative study. Additional clinical, 
diagnostic and research support are provided from colleagues and external collaborators who 
are appropriately acknowledged. 
7.1.1 The mt-aaRS and Mitochondrial Translation 
Integrity of mitochondria is dependent upon accurate and efficient translation of the genetic 
code in the form of mRNA to produce the correct, corresponding amino acid sequence. 
Following post-transcriptional modification, it is vital that amino acids are aminoacylated 
(attached) with their specific cognate tRNA, as dictated by the codon sequence of the mRNA. 
This attachment is catalysed by the mt-aaRS, an essential set of enzymes encoded by the 
nuclear genome and imported to mitochondria. These are distinguished from the cytosolic 
‘aaRS’ by the prefix ‘mt-‘ or the suffix ‘2’. For example, AlaRS refers to the cytosolic alanyl-
tRNA synthetase, whereas mt-AlaRS or AlaRS2 refers to mitochondrial alanyl-tRNA 
synthetase. On the other hand, the nuclear genes are referred to as ‘aaRS’ for aaRS or ‘aaRS2’ 
for mt-aaRS. 
There are 19 mt-aaRS each encoded by a single nuclear gene distinct from the aaRS with the 
exceptions of GARS and KARS, which encode dual-localised cytosolic and mitochondrial 
synthetases (Suzuki et al., 2011). The cytosolic and mitochondrial GlyRS isoforms are 
encoded by a single mRNA transcript with alternate translation initiation sites (Shiba et al., 
1994; Mudge et al., 1998). The LysRS isoforms are generated by alternative splicing of exons 
1, 2 and 3 (Tolkunova et al., 2000). Cytosolic LysRS is generated by splicing of exons 1 and 
3, while the mitochondrial LysRS is generated from inclusion of all three exons. Additionally, 
there is no mammalian mitochondrial homolog of GlnRS. Instead, Nagao et al. (2009) 
discovered that mt-GluRS efficiently misaminoacylates tRNAGln to form Glu-tRNAGln in 
mitochondria.  
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Each mt-aaRS catalyses the attachment of an amino acid to its specific cognate tRNA by a 
two-step reaction (Ibba and Söll, 2000) (Figure 7.1). First, the amino acid is activated with 
ATP at the mt-aaRS active site to form an intermediate aminoacyl-adenlyate species, with an 
inorganic pyrophosphate leaving group. Second, the amino-acyl group is transferred to the 3’ 
acceptor stem of the cognate tRNA by 3’-esterification, generating an AMP leaving group. To 
discriminate between the mt-aaRS, mt-tRNAs contain structural elements that are often 
unique, ensuring that aminoacylation occurs with its correct mt-aaRS (Ibba and Söll, 2000). 
Low levels of misaminoacylated tRNAs have been shown to be lethal in bacteria and led to 
cerebellar Purkinje cell loss, ataxia and tremors in mice (Beebe et al., 2003; Lee et al., 
2006b). However, the mischarging of tRNAs with incorrect amino acids can occasionally 
occur due to discrete structural differences in the active site. For example, PheRS can 
mischarge tyrosine to generate an incorrect Tyr-tRNAPhe species (Ling et al., 2007) and IleRS 
can mischarge valine to generate Val-tRNAIle (Fukai et al., 2000). Maintenance of 
mitochondrial translation fidelity from the mischarging of amino acids is provided by an 
editing domain acquired by several mt-aaRS or by the mitochondrial elongation factor mtEF-
Tu, which forms a complex with the aminoacylated tRNA and GTP following 
aminoacylation. Mischarged mammalian Ser-tRNAGln was demonstrated to have a lower 
affinity for mt-EFTu than Glu-tRNAGln and Ser-tRNASer (Nagao et al., 2007), confirming a 
mechanism for ensuring accuracy of mitochondrial protein synthesis. 
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Figure 7.1 Aminoacylation of Cognate mt-tRNAs with their Specific Amino Acid. Aminoacylation of mt-tRNAs is a two-step reaction whereby 
(1) the amino acid is activated to form an intermediate amino-adenylate species and (2) the charged amino acid is attached to the 3’ acceptor stem of 
its corresponding tRNA by 3’-esterification. 
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The mt-aaRS are structurally diverse but typically possess a catalytic domain for the two-step 
aminoacylation reaction and an anti-codon binding domain for binding of the cognate tRNA. 
Several aaRS and mt-aaRS have also acquired a second active site referred to as the editing 
domain for proofreading of mischarged amino acids. This includes mt-AlaRS since glycine 
and serine are also able to bind to the synthetase, hence requiring correcting (Beebe et al., 
2008; Guo et al., 2009). Much like their cytosolic counterparts, mt-aaRS are also divided into 
two distinct, unrelated classes; Class I synthetases (mt-ArgRS, mt-CysRS, mt-GluRS, mt-
IleRS, mt-LeuRS, mt-MetRS, mt-TrpARS, mtValRS) function as either monomeric or 
dimeric structures and Class II synthetases (mt-AlaRS, mt-AsnRS, mt-AspRS, GlyRS, mt-
HisRS, LysRS, mt-PheRS, mt-ProRS, mt-SerRS, mt-ThrRS, mt-TyrRS) function as either 
dimeric or tetrameric structures. Class I and II synthetases are distinguished by structural 
differences of the active site and by the presence of distinct sequence motifs. Class I 
synthetases have a Rossmann fold for the binding of co-factors such as nucleotides, whereas 
class II synthetases have an anti-parallel β-fold and three characteristic motif sequences (Ibba 
and Söll, 2000). Due to the structural differences in the active sites, ATP binds in an extended 
form in class I synthetases and in a bent formation in class II synthetases (Arnez and Moras, 
1997). Nonetheless, the charging of cognate amino acids is performed by virtually the same 
two-step reaction in all mt-aaRS. 
7.1.2 The mt-aaRS and Human Disease 
All genes encoding the mt-aaRSs except WARS2 have been associated with an autosomal 
recessive disorder of mitochondrial translation with multiple respiratory chain complex 
activity deficiency (Table 7.1). Of the dual-localised synthetases, recessive GARS mutations 
have been reported in two patients with systemic mitochondrial disease (McMillan et al., 
2014; Taylor et al., 2014). Recessive KARS mutations have been associated with hearing 
impairment or peripheral neuropathy (McLaughlin et al., 2010; Santos-Cortez et al., 2013). 
However, the potential pathological mechanisms of the dual-localised synthetases with 
mitochondrial defects has not be fully explored. Mt-aaRS mutations typically manifest in 
early-onset phenotypes with clinical, genetic and molecular heterogeneity. However, notable 
tissue and cell-type specific phenotypes have been described for some mt-aaRS associated 
disorders (Table 7.1), with the nervous system (NS) most frequently affected. Although 
mtDNA disease can present some degree of tissue specificity due to varying heteroplasmy in 
cells, mt-aaRS defects are intriguing since mutations are expressed in all cells. Furthermore, 
mutations of the mt-aaRS cause phenotypes that do not correspond with mutations of their 
corresponding cognate mtDNA-encoded tRNA.
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 OMIM # Genotype Affected Tissue(s) Onset Phenotype Reference 
Mitochondrial Amino-Acyl tRNA Synthetases 
AARS2 614096 AR Heart Infantile HCM Götz et al. (2011) 
615889 AR NS, Reproductive Childhood Leukoencephalopathy, POF 
(females) 
Dallabona et al. (2014) 
CARS2 616672 AR NS Infantile EIEE Hallmann et al. (2014) 
DARS2 611105 AR NS Variable LBSL Scheper et al. (2007) 
EARS2 614924 AR NS Antenatal-Infantile LTBL Steenweg et al. (2012) 
FARS2 614946 AR NS Infantile EIEE Almalki et al. (2014) 
n.a. AR NS, Liver Infantile Alpers-like Elo et al. (2012) 
617046 AR NS Childhood SPG77 Yang et al. (2016) 
n.a. AR NS Infantile DD Vernon et al. (2015) 
HARS2 614926 AR Inner Ear, Reproductive Childhood Perrault Syndrome-2 Pierce et al. (2011) 
IARS2 616007 AR NS, Endocrine Infantile CAGSSS Schwartzentruber et al. (2014) 
 n.a. AR NS, Muscle Neonatal Leigh Syndrome Schwartzentruber et al. (2014) 
LARS2 615300 AR Inner Ear, Reproductive Childhood Perrault Syndrome-4 Pierce et al. (2013) 
617021 AR Blood, Liver Neonatal HLASA Riley et al. (2015) 
MARS2 611390 AR NS Variable SPAX3 Bayat et al. (2012) 
 616430 AR NS, Endocrine Neonatal DD, Growth Retardation, 
Hearing Loss 
Webb et al. (2015) 
NARS2 616239 AR NS Infantile Alpers-like Sofou et al. (2015) 
616239 AR NS Childhood ID, Seizures Vanlander et al. (2015) 
616239 AR Muscle Childhood Myopathy, Fatigue, CPEO Vanlander et al. (2015) 
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 OMIM # Genotype Affected Tissue(s) Onset Phenotype Reference 
n.a. AR Inner Ear Infantile DFNB94 Simon et al. (2015) 
n.a. AR NS Infantile Leigh Syndrome Simon et al. (2015) 
PARS2 n.a. AR NS, Liver Infantile Alpers-like Sofou et al. (2015) 
RARS2 611523 AR NS Infantile PCH6 Edvardson et al. (2007) 
SARS2 613845 AR Renal, Pulmonary Infantile HUPRA Belostotsky et al. (2011) 
 n.a. AR NS Infantile Spastic Paresis Linnankivi et al. (2016) 
TARS2 615918 AR NS Neonatal Encephalopathy Diodato et al. (2014) 
VARS2 615917 AR NS Infantile Encephalopathy, Myopathy, 
CPEO 
Diodato et al. (2014) 
YARS2 613561 AR Muscle, Blood Variable MLASA Riley et al. (2010) 
       
Dual-Localised Amino-Acyl tRNA Synthetases 
GARS n.a. AR NS Neonatal-
Childhood 
Cardiomyopathy, 
Leukoencephalopathy, 
Myalgia 
McMillan et al. (2014) 
601472 AD NS Variable CMT2D Antonellis et al. (2003) 
600794 AD NS Variable HMN5A Antonellis et al. (2003) 
KARS 613641 AR NS n.a. CMTRIB McLaughlin et al. (2010) 
613916 AR Inner Ear Infantile DFNB89 Santos-Cortez et al. (2013) 
       
Cytosolic Mitochondrial Amino-Acyl tRNA Synthetases 
AARS 613287 AD NS, Inner Ear Childhood- CMT2N Latour et al. (2010) 
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 OMIM # Genotype Affected Tissue(s) Onset Phenotype Reference 
Adulthood 
616339 AR NS Infantile EIEE Simons et al. (2015) 
DARS 615281 AR NS Infantile HBSL Taft et al. (2013) 
HARS 616625 AD NS Variable CMT2W Vester et al. (2013) 
614504 AR Inner Ear, Ocular Childhood USH3B Puffenberger et al. (2012) 
IARS 617093 AR NS, Endocrine, Liver Childhood GRIDHH Kopajtich et al. (2016) 
LARS 615438 AR Liver Infantile-Childhood IFLS1 Casey et al. (2012) 
MARS 616280 AD NS Adulthood CMT2U Gonzalez et al. (2013) 
615486 AR Liver, Pulmonary Infantile-Childhood ILLD van Meel et al. (2013) 
QARS 615760 AR NS Neonatal-Infantile MSCCA Zhang et al. (2014) 
RARS 616140 AR NS Infantile HLD9 Wolf et al. (2014) 
VARS n.a. AR NS Infantile Microcephaly, Cortical 
Atrophy 
Karaca et al. (2015) 
YARS 608323 AD NS Childhood-
Adulthood 
CMTDIC Jordanova et al. (2006) 
 n.a. AR NS, Liver Infantile Leukoencephalopathy Nowaczyk et al. (2016) 
Table 7.1 The Amino-Acyl tRNA Synthetases and Human Disease. Summary of the mt-aaRS and aaRS associated with human disease. CAGSSS - 
Cataracts, Growth Hormone Deficiency, Sensory Neuropathy, Sensorineural Hearing Loss and Skeletal Dysplasia; CMT – Charcot-Marie-Tooth; 
CMTDIC – CMT Dominant Intermediate Type C; CMTRIB - Charcot-Marie-Tooth Recessive Intermediate, B; DD – Developmental Delay; DFNB89 
- Deafness, Autosomal Recessive 89; EIEE – Early Infantile-Onset Epileptic Encephalopathy; GRIDHH - Growth Retardation, Intellectual 
Developmental Disorder, Hypotonia and Hepatopathy; HBSL - Hypomyelination with Brainstem and Spinal Cord Involvement and Lactate Elevation; 
HCM – hypertrophic cardiomyopathy; HLASA – Hydrops, Lactic Acidosis and Sideroblastic Anaemia; HLD9 - Hypomyelinating Leukodystrophy-9; 
HMN5A - Neuropathy, Distal Hereditary Motor, Type VA; HUPRA - Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis; IFLS1 - 
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Infantile Liver Failure Syndrome 1; ILLD - Interstitial Lung and Liver Disease; LBSL - Leukoencephalopathy with brainstem and spinal cord 
involvement and lactate elevation; LTBL - leukoencephalopathy with thalamus and brainstem involvement and high lactate; MLASA – myopathy, 
lactic acidosis and sideroblastic anaemia; MSCCA - Microcephaly, Progressive Seizures and Cerebral and Cerebellar Atrophy; PCH – Pontocerebellar 
Hypoplasia; POF – Premature Ovarian Failure; SPAX3 – Spastic Ataxia 3; SPG77 - Spastic Paraplegia 77, Autosomal Recessive; USH3B – Usher 
Syndrome Type 3B. AD – Autosomal Dominant; AR – Autosomal Recessive. ‘n.a.’ – not available.
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Regarding cytosolic aaRS defects, there are some similarities and differences between the mt-
aaRS. In contrast to the mt-aaRS, some aaRS have been associated with autosomal dominant 
Charcot-Marie Tooth (CMT) disease (Antonellis et al., 2003; Jordanova et al., 2006). 
Autosomal recessive mutations have also been described with overlapping phenotypes or 
features due to mt-aaRS mutations without biochemical evidence of mitochondrial 
dysfunction, which includes overlap between some specific aaRS and mt-aaRS. Despite the 
specific brain imaging pattern, leukoencephalopathy is a shared feature between recessive 
DARS2 and DARS mutations (Taft et al., 2013), suggesting a possible shared pathological 
mechanism. However, this is not strictly established between all mt-aaRS and their 
corresponding aaRS.   
Several mt-aaRS mutations have been identified in only a few or isolated patients, therefore 
delineating the genotype-phenotype correlations is challenging. The use of WES and NGS 
have further broadened the phenotypic spectrum to include patients with differential tissue 
specificity. A homozygous SARS2 c.1347G>A splicing variant was identified in a patient with 
progressive spastic paresis other than HUPRA syndrome (Linnankivi et al., 2016). Authors 
demonstrated that mt-tRNASer(AGY) was significantly more destabilised than in HUPRA 
patients and mt-tRNASer(UCN) largely unaffected in both types of patients, suggesting a 
possible influence for the differential tissue specificity. Additionally, FARS2 variants have 
now been associated with many overlapping phenotypes; Alpers-like (Elo et al., 2012; 
Shamseldin et al., 2012), epileptic encephalopathy (Almalki et al., 2014; Raviglione et al., 
2016; Walker et al., 2016), developmental delay (Vernon et al., 2015) and HSP (Yang et al., 
2016). Several hypotheses have been proposed in attempting to explain the tissue- and cell-
specific manifestations. Complete loss of a single mt-aaRS is likely to be incompatible with 
life. However, a decrease in the steady-state levels of a single mt-aaRS, severe or partial loss 
of aminoacylation activity may not be immediately lethal and could modulate the phenotype. 
Loss of aminoacylation activity for a single mt-aaRS in some tissue or cell types may be 
insufficient to cause defective mitochondrial translation. Mt-aaRS could also have secondary, 
non-translational functions similar to the aaRS that could contribute to the apparent cell 
specificity (Yao and Fox, 2013). For example, the yeast homolog of the dual-localised human 
LysRS has been shown to import a small proportion of cytosolic tRNALys into mitochondria 
(Martin et al., 1979). Nonetheless, the identification of additional patients is needed to further 
investigate these proposed these hypotheses.   
As described in 6.4.7 and 6.4.8, two patients with biallelic AARS2 (patient 30) and EARS2 
(patient 29) variants were identified by WES, utilising the variant filtering strategy for 
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multiple respiratory chain deficiency. Together with six adult patients with childhood-onset 
mitochondrial myopathy referred to the NHS Highly Specialised Mitochondrial Diagnostic 
Service for Rare Mitochondrial Disorders in Newcastle upon Tyne harbouring YARS2 variants 
identified previously by WES or targeted YARS2 gene screening, this chapter depicts and 
expands the clinical, genetic and molecular features of mt-aaRS mutations and defective 
mitochondrial translation. 
7.1.3 Mitochondrial Alanyl-tRNA Synthetase (AARS2) 
Mutations of AARS2 encoding the class II mitochondrial alanyl-tRNA synthetase (mt-AlaRS) 
are a notable example of two different phenotypes and differential tissue effects associated 
with one aaRS2 gene. Unlike other class II synthetases, mt-AlaRS is monomeric. The first 
patients described presented HCM leading to death within the first year of life (Götz et al., 
2011). A second distinct phenotype of childhood- to adult-onset leukoencephalopathy with 
premature ovarian failure (POF) in females was also described in several patients with 
conspicuous absence of cardiac involvement (Dallabona et al., 2014; Hamatani et al., 2016; 
Lynch et al., 2016; Szpisjak et al., 2016). Interestingly, all patients presenting with fatal 
infantile HCM harboured a recurrent c.1774C>T (p.Arg592Trp) missense variant, either 
homozygous or in compound with a second variant, that was absent in patients with 
leukoencephalopathy. Leukoencephalopathy was also described in patients harbouring 
recessive variants of the cytosolic homolog AARS manifesting as deficient myelination on 
MRI, although accompanied by severe infantile-onset epileptic encephalopathy (Simons et al., 
2015). This possibly suggests a similar pathological mechanism, especially since cardiac 
involvement was also absent from these patients. Euro et al. (2015) proposed that the two 
distinct phenotypes and tissue specificity could be explained by the location of the mutations 
within the mt-AlaRS structure with differential effects on the alanyl-aminoacylation activity 
due to the possible combinations of mutations. AARS2 missense variants were classified as 
moderate, severe or loss of function. Missense changes occurring in the mt-AlaRS editing 
domain including the recurrent p.Arg592Trp variant were restricted to patients with fatal 
infantile HCM due to loss of aminoacylation activity, impaired tRNA binding or 
misaminoacylation with serine or glycine. In contrast, missense changes associated with 
childhood- to adult-onset leukoencephalopathies led to only partial reduction in 
aminoacylation activity.  
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7.1.4 Mitochondrial Glutamyl-tRNA Synthetase (EARS2) 
Mutations of EARS2 encoding the class I mitochondrial glutamyl-tRNA synthetase (mt-
GluRS) cause a unique neonatal- or childhood-onset neurological phenotype known as 
Leukoencephalopathy with Thalamus and Brainstem involvement and high Lactate (LTBL) 
(Steenweg et al., 2012). Previous clinical and genetic diagnoses of EARS2 patients have relied 
upon a distinct brain MRI pattern of leukoencephalopathy, abnormal signal changes in the 
thalamus and brainstem with magnetic resonance (MR) spectroscopy disclosing a lactate 
peak. Although brain imaging of EARS2 patients shows remarkable consistency, Steenweg et 
al. (2012) noted two bi-phasic courses; (i) a mild or intermediate phenotype with 
developmental delay preceding severe regression within the first year of life, followed by 
some stabilisation that is evident by improved brain magnetic resonance imaging (MRI); (ii) a 
severe phenotype with neurological impairment from birth (or shortly after) and clinical 
stabilisation over time, dependent on the initial neurological damage. Since the initial report, 
patients harbouring EARS2 mutations have consistently grouped into one of these two bi-
phasic courses. 
7.1.5 Mitochondrial Tyrosyl-tRNA Synthetase (YARS2) 
Mutations of YARS2 encoding the class II mitochondrial tyrosyl-tRNA synthetase (mt-TyrRS) 
have been associated with childhood-onset myopathy, lactic acidosis and sideroblastic 
anaemia, known as MLASA syndrome (Riley et al., 2010; Sasarman et al., 2012; Riley et al., 
2013; Shahni et al., 2013; Nakajima et al., 2014; Ardissone et al., 2015b). Sideroblastic 
anaemia is a conspicuously rare feature of mitochondrial disease more commonly associated 
with Pearson’s syndrome due to single large-scale mtDNA deletions (Pearson et al., 1979; 
McShane et al., 1991). Prior to YARS2, mutations of PUS1 encoding pseudouridylate synthase 
1 were associated with a phenotypically similar mitochondrial translation disorder 
(Bykhovskaya et al., 2004; Fernandez-Vizarra et al., 2009; Cao et al., 2015). Therefore, 
MLASA syndrome has been useful in guiding diagnostic investigations. On the other hand, 
this has been complicated by the recent identification of similar presentations in patients with 
different genetic aetiologies (Table 7.2). 
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Gene Mutation(s) Onset Phenotype Reference(s) 
MtDNA Mutations 
Single Large-Scale Deletion Infantile Pearson’s Syndrome Pearson et al. (1979), 
McShane et al. (1991) 
MT-ATP6 m.8969G>A Neonatal MLASA Syndrome, DD, 
Hearing Loss, Epilepsy 
Burrage et al. (2014) 
     
Nuclear-Encoded Genes 
NDUFB11 c.276_278del, 
p.Phe93del 
Neonatal-
infantile 
X-Linked Congenital 
Sideroblastic Anaemia 
Lichtenstein et al. (2016), 
Torraco et al. (2016) 
PUS1 Variable Variable MLASA Syndrome Bykhovskaya et al. (2004), 
Patton et al. (2005), Zeharia 
et al. (2005), Fernandez-
Vizarra et al. (2009), Cao et 
al. (2015), Metodiev et al. 
(2015) 
TRNT1 Variable Variable Sideroblastic anaemia, 
Immunodeficiency, DD 
Chakraborty et al. (2014), 
Sasarman et al. (2015), 
Wedatilake et al. (2016) 
YARS2 Variable Variable MLASA Syndrome Riley et al. (2010), Sasarman 
et al. (2012), Riley et al. 
(2013), Shahni et al. (2013), 
Nakajima et al. (2014), 
Ardissone et al. (2015b),  
Sommerville et al. (2017) 
Table 7.2 Sideroblastic Anaemia in Mitochondrial Disease. A list of mt-DNA and nuclear 
genes currently associated with sideroblastic anaemia.  
To date, YARS2 mutations have predominantly been identified in patients from Lebanon with 
either a homozygous c.137G>A (p.Gly46Asp) or c.156C>G (p.Phe52Leu) missense change. 
Despite harbouring the same missense change, patients presented variable phenotypes 
including childhood- to adult-onset and the absence of some clinical features, including 
sideroblastic anaemia. Taken together, this suggests that YARS2-associated mitochondrial 
disease could be underdiagnosed outside of the Middle East. 
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7.2 Aims 
This chapter expands the clinical, genetic and molecular features of patients harbouring 
AARS2, EARS2 or YARS2 mutations. 
7.3 Methods 
7.3.1 Patients 
This study comprised 10 patients (29, 30 and 41-46.2) referred to the NHS Highly Specialised 
Service for Rare Mitochondrial Disorders or to external clinics. 
7.3.2 Diagnostic Histochemical, Biochemical and Molecular Studies 
Histochemical, biochemical and molecular studies of patient skeletal muscle were performed 
by the NHS Highly Specialised Mitochondrial Diagnostic Service in Newcastle upon Tyne or 
externally, as described in 2.2.3.  
7.3.3 YARS2 mtDNA Haplogroups 
Haplogroups of YARS2 patients (43.1 and 44-46.1) were defined from all mtDNA 
polymorphisms using HaploGrep2 (Kloss-Brandstätter et al., 2011).  
7.3.4 Genetic Studies 
Patients 29 (EARS2) and 30 (AARS2) were diagnosed using WES by this research (6.4.7 and 
6.4.8) utilising the WES filtering strategy for the mitochondrial respiratory chain complex 
deficiency cohort. Identified EARS2 (NM_001083614) and AARS2 (NM_020745.2) variants 
were confirmed by Sanger sequencing using forward and reverse primers for the respective 
exons (Appendix A). Patients 41 and 42 (AARS2) were diagnosed previously using WES, 
corresponding to patients #11 and #7 from Taylor et al. (2014).  
YARS2 (NM_001040436.2) variants were identified previously in patients 43.1, 44-46.1 using 
WES or targeted screening of all exons and intronic regions of YARS2. Patient 46.1 was 
diagnosed first by WES and corresponded to patient 22 from Taylor et al. (2014). Patients 44 
and 45 were also diagnosed previously using WES, analysed using a different WES 
bioinformatics pipeline (Haack et al., 2012). Patient 43.1 was diagnosed by targeted YARS2 
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screening and had been initially described in 1974 together with his sibling, patient 43.2 
(Rawles and Weller, 1974). 
7.3.5 Cell Culture 
The subculturing, freezing and harvesting of cells was performed as described in 2.4. Cultured 
fibroblasts were grown for patients 30, 41, 42 (AARS2), patient 29 (EARS2) and patient 45 
(YARS2), together with at least two appropriate age-matched controls. Cultured myoblasts for 
patient 45 (YARS2) and two age-matched controls were also grown.  
7.3.6 Western Blotting 
Fibroblast and myoblast lysates were prepared as described in 2.5.1. Frozen skeletal muscle 
from patient 29 and two age-matched controls were homogenised as described in 2.5.2. All 
fibroblast (50µg), myoblast (50µg) and muscle lysates (25µg) subjected to 12% SDS-page, 
probed with primary and secondary antibodies (Table 2.4, Table 2.5) then detected as 
outlined in 2.5. Membranes were incubated with primary antibodies specific to mt-AlaRS, mt-
GluRS or mt-TyrRS, plus OXPHOS subunits NDUFB8, SDHA, UQCRC2, MT-COI, MT-
COII and ATP5B. α-Tubulin, β-Actin and VDAC1/Porin were used as loading controls. 
7.4 Results 
7.4.1 A Novel AARS2 Editing Domain Mutation Causing Fatal Infantile HCM and 
Respiratory Failure 
Clinical data for patient 30 were obtained and diagnostic investigations were performed by 
Andrew A. M. Morris (Willink Biochemical Genetics Unit, Manchester Centre for Genomic 
Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester), 
Robert McFarland, and Robert W. Taylor (Wellcome Trust Centre for Mitochondrial 
Research, Institute of Neuroscience, The Medical School, Newcastle University, Newcastle 
upon Tyne). In silico and functional studies were performed in collaboration with Liliya Euro 
and Svetlana Konovalova, Henna Tyynismaa (Research Programs Unit, Molecular 
Neurology, Biomedicum Helsinki and Department of Medical Genetics, Haartman Institute, 
University of Helsinki, Helsinki, Finland). 
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 Case Report 
Patient 30 was a boy born to non-consanguineous British parents who presented with severe 
myopathy, metabolic acidosis, respiratory insufficiency that required non-invasive ventilation 
(NIV) from birth and died at 7 weeks of age. Initially absent, cardiomyopathy developed by 5 
weeks of age, manifesting as mild biventricular hypertrophy and a significant conduction 
defect. Whole mitochondrial genome sequencing did not identify any pathogenic or likely 
pathogenic mutations. Muscle biochemical studies revealed decreased complex I, III and IV 
activities compared to controls (Figure 7.2A), while muscle histopathology disclosed over 
50% COX-deficient fibres and increased lipid. Patient 30 was the fifth pregnancy of the 
parents and the third child born (Figure 7.2B). The first-born child (female) died 24 hours 
after birth from severe lactic acidemia and coagulopathy, with post mortem showing 
pulmonary hypoplasia. The second born child (male) was healthy but the third and fourth 
pregnancies resulted in miscarriages. 
The clinical, molecular and genetic features of the AARS2 patients (30, 41 and 42) included in 
this study are provided in Table 7.3. To summarise, all three patients presented with fatal 
HCM within the first year of life. Patients 30 and 42 also had myopathy and lactic acidosis. 
Respiratory involvement was confined to patient 30 and central nervous system (CNS) 
involvement to patient 42 only. All patients had COX-deficient fibres and multiple respiratory 
chain complex deficiency. 
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Patient 30 41 42  
Sex M F M 
Age of Onset Birth 6 months Birth 
Death 7 weeks 11 months 6 weeks 
Ethnicity White White White 
Consanguinity No No No 
Family History Yes (one sibling) No No 
    
Clinical Signs    
HCM + + + 
Myopathy + (severe) - + 
Lactic acidosis + - + 
Other Features Respiratory insufficiency  - CNS involvement 
    
Muscle Studies    
Histochemistry >50% COX-deficient 
fibres, increased lipid 
COX-mosaic COX-mosaic 
RC Deficiency I, III, IV I, IV I, III, IV 
    
AARS2 
Variants 
   
cDNA Change c.1088dupT/c.1738C>T Homozygous 
c.1774C>T 
c.1774C>T/c.2882C>T 
Amino Acid 
Change 
p.Asp337*/p.Arg580Trp Homozygous 
p.Arg592Trp 
p.Arg592Trp/p.Ala961Val 
Table 7.3 Clinical, Molecular and Genetic Features of Studied AARS2 Patients. ‘+’ – 
present; ‘-‘ – absent; RC – mitochondrial respiratory chain.   
 WES Analysis 
Implementation of the WES filtering strategy (6.4.8) in patient 30 revealed biallelic variants 
in AARS2; c.1008dupT, p.Asp337* and c.1738C>T, p.Arg580Trp (Figure 7.2B) as the only 
recessive variants in genes encoding mitochondrial-targeted proteins. AARS2 (6p21.1) 
matched the GO-Terms ‘mitochondr*’, ‘tRNA’ and ‘translation’. Sanger sequencing with 
diagnostic primers for AARS2 exons 6+7 and 11+12 confirmed both variants. However, 
segregation studies were not possible. Both variants were absent from in-house exomes. The 
p.Asp337* nonsense variant was present in 1/117540 heterozygous non-Finnish European 
allele (MAF=0.000008508) in ExAC but was absent in other external exome databases. The 
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p.Arg580Trp missense variant was present in 3/121260 heterozygous alleles 
(MAF=0.00002474), two South Asians and one non-Finnish European, in ExAC but was 
absent in other external databases. The Arg580 residue was highly conserved in vertebrate 
species, but not in invertebrate species Drosophila melanogaster, Caenorhabditis elegans and 
Saccharomyces cerevisiae (Figure 7.2C). It was predicted to be damaging by both PolyPhen 
2 (0.996) and SIFT (0.02) but not by Align-GVGD (Class 0).  
Figure 7.2 Biochemical and Genetic Features of Patient 30. (A) Measurements of 
mitochondrial respiratory chain activities normalised to citrate synthase of complex I (CI/CS), 
II (CII/CS), III (CIII/CS) and IV (CIV/CS) from patient 30 (red) skeletal muscle compared to 
controls (green). (B) Family pedigree and Sanger sequencing confirmation of the p.Asp337* 
and p.Arg580Trp AARS2 variants. (C) Multiple sequence alignment (MSA) of the mt-AlaRS 
Arg580 residue. 
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From Taylor et al. (2014), patient 41 was homozygous for the recurrent p.Arg592Trp 
missense change and patient 42 had compound heterozygous p.Arg592Trp and c.2882C>T, 
p.Ala916Val AARS2 missense variants. 
 In Silico Structural Modelling of p.Arg580Trp 
In silico modelling of the p.Arg580Trp missense change on human mt-AlaRS was performed 
by Liliya Euro (Research Programs Unit, Molecular Neurology, Biomedicum Helsinki and 
Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, 
Finland) to predict possible effects on structure and aminoacylation activity. Modelling was 
performed using the resolved human mt-AlaRS structure as described previously (Euro et al., 
2015). 
In human mt-AlaRS, Arg580 is a surface exposed residue at the top of the β-barrel in the 
editing domain. Other exposed residues of the editing domain mutated in patients presenting 
fatal infantile cardiomyopathy were Tyr539 and Arg592. However, Arg580 was localised 
nearer the top of the β-barrel structure (Figure 7.3A). Given the position of Arg580 and the 
side chains of possible residues, it was suggested that Arg580 would have a role in the 
enzyme structure. Substitution with tryptophan was predicted to affect either enzyme stability, 
the surface of the β-barrel or both (Figure 7.3B). Previous modelling of human mt-AlaRS 
demonstrated the presence of a linker between the aminoacylation and editing domains 
referred to as the ‘safety belt’, with the editing domain acting as a ‘buckle’ when tRNAAla is 
bound to the aminoacylation domain (Euro et al., 2015). Side chains of tryptophan may 
propagate along the entire β-barrel surface, affecting areas in direct contact with the ‘safety 
belt’. The Arg580 residue was predicted to be associated in electrostatic, hydrophobic and 
hydrogen bonds (Figure 7.3C), though it was not predicted to interact directly with the 
‘safety belt’. Substitution with tryptophan was predicted to abolish approximately half of the 
interactions (Figure 7.3D). Several of these interactions were predicted to be involved the 
stability of the β-barrel domain, which may affect both folding of the β-barrel domain and 
stability of the whole protein structure. Furthermore, absence of several side chain 
interactions, including one required for when tRNA is bound for aminoacylation was 
predicted to be abolished, possibly affecting the rate of tRNA aminoacylation. 
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Figure 7.3 In silico Modelling of the Human mt-AlaRS p.Arg580Trp Missense Change. (A) Location of the Arg580 residue within the β-barrel of 
the human mt-AlaRS editing domain, together with additional residues mutated in AARS2 patients. The ‘safety belt’ is shown in green, denoted by the 
solid arrow. The dashed arrow denotes the direction of propagation due to p.Arg580Trp variant. (B) Comparison of the possible side chains with 
Arg580 or Trp580. (C) Intramolecular interactions of the Arg580 residue. (D) Changes in intramolecular interactions due to the p.Arg580Trp missense 
variant. Hydrogen bonds – green dashed lines; electrostatic bonds – orange dashed lines; hydrophobic bonds – magenta dashed lines.   
   
261 
 Western Blot Analysis 
Fibroblasts from all three studied AARS2 patients showed a marked decrease in steady-state 
mt-AlaRS levels, as predicted by the in silico modelling of the p.Arg580Trp variant and 
previous modelling of the p.Arg592Trp and p.Ala961Val missense variants. However, levels 
of OXPHOS subunits were not decreased in all patients compared to controls (Figure 7.4).   
 Northern Blot and Aminoacylated tRNA Analysis 
Northern blot analysis of tRNAs were performed by Svetlana Konovalova (Research 
Programs Unit, Molecular Neurology, Biomedicum Helsinki and Department of Medical 
Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland), with total RNA 
extracted from fibroblasts of patient 30 and a second patient homozygous for the recurrent 
p.Arg592Trp variant. RNA was hybridised with probes for tRNAAla and tRNAArg (loading 
control) species. However, this did not show changes in the abundance of either species 
(Figure 7.5A and B). Analysis of aminoacylated tRNAAla showed the presence of charged 
Ala-tRNAAla and Arg-tRNAArg with no uncharged tRNAs (Figure 7.5C). 
Figure 7.4 Western Blot Analysis of AARS2 Patient Fibroblasts. Steady-state mt-AlaRS 
and OXPHOS subunit protein levels in fibroblasts of patients 30, 41 and 42. 
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7.4.2 Lethal Neonatal Leukoencephalopathy with Thalamus and Brainstem Involvement 
with High Lactate (LTBL) Caused by EARS2 mutations 
Clinical data for patient 29 were obtained and diagnostic investigations were performed by 
Renata Oliveira (Human Genetics Department, Centro Hospitalar de São João, Porto, 
Portugal), Joana Nunes (Imaging Department, Centro Hospitalar Vila Nova de Gaia/Espinho, 
Vila Nova de Gaia, Portugal), Manuela Grazina (CNC - Center for Neuroscience and Cell 
Biology, Laboratory of Biochemical Genetics, University of Coimbra, Coimbra, Portugal; 
Faculty of Medicine, University of Coimbra, Coimbra, Portugal), Luísa Diogo, Paula Garcia 
(Metabolics Unit - Child Development Center, Hospital Pediátrico, Centro Hospitalar e 
Universitário de Coimbra (CHUC), Coimbra, Portugal), Kyle Thompson and Robert W. 
Taylor (Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, The 
Medical School, Newcastle University, Newcastle upon Tyne).  
 Case Report 
Patient 29 was a female born at term to non-consanguineous Portuguese parents. Mild 
ventriculomegaly was noted on ultrasound at 21 weeks of gestation. This was confirmed by 
brain MR at 22 weeks, but a further brain MR at 24 weeks was normal. Birth weight, length 
Figure 7.5 Northern Blot Analysis of AARS2 Patient Fibroblasts. (A) Northern blot 
analysis of mt-tRNAAla levels in fibroblasts from patient 30 and a patient homozygous for the 
recurrent p.Arg592Trp AARS2 missense change, using mt-tRNAArg as a loading control. (B) 
Quantification of tRNAAla normalised to tRNAArg. (C) Northern blot analysis of charged 
(aminoacylated) Ala-tRNAAla and Arg-tRNAArg with uncharged (deacylated) tRNAs. The 
lower bands in the dAC lanes denote uncharged tRNA species. 
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and occipital frontal circumference were normal. Her first admission was 7 days after birth 
because of FTT, severe feeding problems and hypotonia. On further admissions she had signs 
of undernutrition and subsequently developed encephalopathy. She had persistent lactic 
acidosis and liver dysfunction, but no respiratory or cardiac involvement. Newborn screening 
was also normal. Brain MRI was performed at 2 months of age, which showed delayed 
myelination and symmetrical lesions of the brainstem, cerebellum and thalami (Figure 7.6A-
G). Elevated lactate peak was observed on brain MRI. Blood plasma ammonia levels were 
normal and there was no ketonuria. Muscle histochemistry demonstrated COX-deficient 
(Figure 7.7A) and ragged-red fibres. Mitochondrial respiratory chain complex activities were 
measured in muscle and liver, showing decreased complex I (19%) and complex IV (11%) 
activity in the muscle compared to controls (Figure 7.7B). Respiratory chain activity in the 
liver was within normal ranges. Histopathology of the liver demonstrated sinusoid distension, 
mixed steatosis of the peri-centrilobulbar and hemosiderosis. Whole mitochondrial genome 
sequencing of patient blood, muscle and liver DNA excluded mtDNA mutations. 
Additionally, mtDNA depletion and rearrangements were excluded by quantitative real time 
PCR and long range PCR assays. Sanger sequencing and Multi Ligation Probe Amplification 
(MLPA) also excluded SURF1 and POLG variants.    
264 
  
     
Figure 7.6 Brain MRI of Patient 29. Brain MRI was performed at 2 months old. T2-weighted images showed abnormally high bilateral and 
symmetrical signals in (A) (i) posterior part of the medulla oblongata and (ii) cerebellar white matter and dentate nucleus, (B) posterior part of the 
pons, (C) cerebral penducles and (D, E) subthalamus and thalamus. (F) Delayed myelination in pericentral regions. (G) Hypogenesis of the corpus 
callosum. Adopted and amended from (Oliveira and Sommerville, 2016). 
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 WES Analysis 
Implementation of the WES filtering strategy (6.4.7) identified biallelic EARS2 variants; a 
c.1A>G (p.Met1?) start-loss variant and a c.184A>T (p.Ile62Phe) missense variant. EARS2 
(16p12.2) matched the GO-Terms ‘mitochondr*’, ‘tRNA’ and ‘translation’. Both variants 
were confirmed by Sanger sequencing using primers for EARS2 exons 1 and 2. Segregation 
studies confirmed that p.Met1? was inherited from the mother and p.Ile62Phe from the father 
(Figure 7.7C). Both p.Met1? and p.Ile62Phe were absent from in-house exomes and external 
databases. However, p.Met1? was previously identified in a patient of Portuguese ancestry 
harbouring biallelic EARS2 variants (Steenweg et al., 2012), suggesting a possible founder 
effect in this population. Since the first nucleotide of the EARS2 start codon was substituted, 
this was predicted to eliminate translation of the protein on one allele. The novel p.Ile62Phe 
missense variant affected a moderately conserved residue in a highly conserved region of mt-
GluRS (Figure 7.7D). It was predicted benign by PolyPhen2 (0.006) and Align-GVGD (Class 
0), but was predicted to affect protein function by SIFT. 
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Figure 7.7 Histochemical, Biochemical and Genetic Features of Patient 29. (A) Sequential COX-SDH histochemistry of patient 29 skeletal muscle. 
(B) Biochemical analysis of mitochondrial respiratory chain activities in skeletal muscle of patient 29 (blue) compared to controls (red), normalised to 
citrate synthase of complex I (CI/CS), II (CII/CS), III (CIII/CS), IV (CIV/CS) and V (CV/CS). (C) Family pedigree and Sanger sequencing 
confirmation of parental carrier status of the p.Met1? and p.Ile62Phe EARS2 variants. (D) MSA of the Ile62 mt-GluRS residue. Adopted from (Oliveira 
and Sommerville, 2016). 
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 Western Blot Analysis 
Fibroblasts and muscle homogenate were studied to inspect mt-GluRS protein levels and 
OXPHOS subunits. Kyle Thompson (Wellcome Trust Centre for Mitochondrial Research, 
Institute of Neuroscience, The Medical School, Newcastle University, Newcastle upon Tyne) 
performed western blotting of control and patient muscle homogenates. Both patient 
fibroblasts and muscle homogenate showed marked decreases in steady-state mt-GluRS levels 
(Figure 7.8), confirming elimination of the translation initiation site due the p.Met1? start-
loss variant and suggesting that p.Ile62Phe leads to unstable mt-GluRS protein structure. A 
reduction in the abundance of steady-state mt-GluRS levels had been previously demonstrated 
in fibroblasts of a patients harbouring compound heterozygous EARS2 variants (Danhauser et 
al., 2016). Decreased levels of MT-COI, MT-COII (complex IV) and NDUFB8 (complex I) 
were observed only in patient muscle homogenate, which correlated with the complex I and 
IV activity deficiencies (Figure 7.8B).  
7.4.3 Adults with YARS2-Associated Mitochondrial Myopathy 
Clinical data for six patients with YARS2 mutations were obtained, diagnostic investigations 
and functional studies were performed by Yi Ng, Charlotte L. Alston, Langping He, Charlotte 
Knowles, Sophie L. Chin, Andrew M. Schaefer, Gavin Falkous, Robert McFarland, Douglass 
Figure 7.8 Western Blot Analysis of Patient 29 Fibroblasts and Muscle Homogenate. 
Steady-state mt-GluRS and OXPHOS subunit protein levels in patient 29 (A) fibroblasts and 
(B) muscle homogenate. Adopted and amended from (Oliveira and Sommerville, 2016). 
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Turnbull, Robert W. Taylor, Gráinne S. Gorman (Wellcome Trust Centre for Mitochondrial 
Research, Institute of Neuroscience, The Medical School, Newcastle University, Newcastle 
upon Tyne), Cristina Dallabona, Micol Gilberti, Claudia Donnini (Department of Life 
Sciences, University of Palma, Italy), David Murdoch (Department of Cardiology, Queen 
Elizabeth University Hospital, Glasgow), Cheryl Longman (West of Scotland Regional 
Genetics Service, Queen Elizabeth University Hospital, Glasgow), Marianne de Visser 
(Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands), Laurence 
A. Bindoff (Department of Clinical Medicine (K1), University of Bergen, Norway; 
Department of Neurology, Haukeland University Hospital, Bergen, Norway), John M. Rawles 
(Formerly Department of Medicine, University of Aberdeen, Aberdeen), John C. S. Dean 
(Department of Medical Genetics, Medical School Building, University of Aberdeen, 
Aberdeen), Richard K. Petty, Maria E. Farrugia (Institute of Neurological Sciences, Queen 
Elizabeth University Hospital, Glasgow), Tobias B. Haack and Holger Prokisch (Institute of 
Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany; Institute of Human 
Genetics, Technische Universität München, Munich, Germany).  
 Case Reports 
The clinical, genetic and molecular features of six patients diagnosed with YARS2-associated 
mitochondrial myopathy are summarised in Table 7.4. This was comprised of four pedigrees 
with two sets of affected siblings (43.1 and 43.2, 46.1 and 46.2). Patients 43.1 and 43.2 were 
first reported in Rawles and Weller (1974). Patient 46.1 was reported in Taylor et al. (2014), 
corresponding to patient #22.   
All six studied patients presented during childhood and had varying degrees of myopathy, but 
only four patients had lactic acidosis. Three patients had sideroblastic anaemia, but only 
patient 46.1 was transfusion dependent. All patients survived into adulthood. However, three 
patients were deceased (43.1, 43.2 and 46.1); they had respiratory insufficiency that required 
NIV and/or HCM that preceded death. Patient 44 was the oldest surviving patient, who at 73 
years old is currently alive having presented progressive myopathy without lactic acidosis and 
sideroblastic anaemia.  
All patients had striking global-COX deficiency (Figure 7.9), while patient 45 also had 
ragged-red fibres. Biochemical analysis of muscle respiratory chain activities in patients 43.1, 
44-46.1 revealed multiple respiratory chain deficiency; patients 44 and 46.1 had decreased 
complex I and IV activities, while patients 43.1 and 45 had decreased complex I, III and IV 
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activities. Additionally, mtDNA copy number was substantially increased in patient 45, while 
a modest increase was also seen in patient 46.1. 
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Patient 43.1 43.2 44 45 46.1 46.2 
Sex M M F M M M 
Age of Onset 12 2 Childhood 4 <10 <10 
Course 52† 45† Alive, 73 Alive, 23 33† Alive, 35 
Ethnicity White White White White Arab Arab 
Consanguinity No No Yes No No No 
Family History Yes (43.2) Yes (43.1) No No Yes (46.2) Yes (46.1) 
       
Clinical Signs 
Myopathy 
(MRC) 
+ (4/5) + + ( 4-/5, wheel chair at 
age 59) 
+ (4/5) + (4/5) + (3/5) 
Lactic Acidosis + + - + + + 
SA + + - - + n.d. 
Transfusion 
Dependent 
- - - - + n.d. 
Respiratory 
Insufficiency 
n.a. n.a. + (NIV at age 55) + (severe restrictive 
pattern) 
+ + (NIV at age 33) 
HCM + + - + + - 
Other Features - - Facial weakness - - Scapular winging 
       
Muscle Studies 
Histochemistry Global COX n.a. Global COX Global COX Global COX Ragged Red Fibres 
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Table 7.4 Clinical, Molecular and Genetic Features of Studied YARS2 Patients. † – deceased; ‘+’ – present; ‘-‘ – absent; HCM – hypertrophic 
cardiomyopathy; MRC - Medical Research Council scale for muscle strength; SA – sideroblastic anaemia. ‘n.a.’ – not available; ‘n.d.’ – not 
determined. Adopted and amended from (Sommerville et al., 2017).  
 
 
 
 
deficiency deficiency deficiency, Ragged 
Red Fibres 
deficiency 
RC Deficiency I, III, IV n.a. I, IV I, III, IV I, IV n.d. 
       
YARS2 Variant 
cDNA Change Homozygous 
c.1175T>C 
n.d. Homozygous 
c.1175T>C 
c.1106G>A/ 
c.1147_1164dup 
Homozygous 
c.137G>A 
n.d. 
Amino Acid 
Change 
Homozygous 
p.Leu392Ser 
n.d. Homozygous 
p.Leu392Ser 
p.Cys369Tyr/ 
p.Val383_Glu388d
up 
Homozygous 
p.Gly46Asp 
n.d. 
       
mtDNA 
Haplogroup 
H1m1 n.d. G2a3a T2e1a HV13 n.d. 
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Figure 7.9 Sequential COX-SDH Muscle Histochemistry of YARS2 Patients. Sequential COX-SDH histochemistry of skeletal muscle from (A) a 
healthy control adult, (B) patient 44 and (C) patient 46.1. Adopted from (Sommerville et al., 2017). 
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 Identification of YARS2 Mutations 
Patients 43.1 and 44 both harboured the same homozygous p.Leu392Ser missense change and 
were apparently from two unrelated families of Scottish ancestry. It was not possible to 
confirm the missense change the affected sibling, patient 43.2. However, his unaffected 
sibling did not harbour the missense change. Patient 44 was born to first cousin parents. The 
p.Leu392Ser missense variant was reported in 1/121354 non-Finnish European allele 
(MAF=0.000008240) in ExAC. The Leu392 residue was a highly conserved residue in all 
species except D. melanogaster and occurred in a moderately conserved region of mt-TyrRS 
(Figure 7.10A). Patient 45, who was also of Scottish ancestry, harboured compound 
heterozygous p.Cys369Tyr and p.Val383_Glu388dup variants. The p.Cys369Tyr variant was 
absent from all external exome databases. The Cys369 residue was also highly conserved 
except in D. melanogaster and S. cerevisiae, occurring in the same moderately conserved 
region of mt-TyrRS as the Leu392 residue (Figure 7.10A). The p.Val383_Glu388dup in-
frame duplication was reported in 2/121360 non-Finnish European alleles 
(MAF=0.00001648) in ExAC. Patient 46.1 was Jordanian who was homozygous for the 
previously reported p.Gly46Asp missense change (Sasarman et al., 2012). He had an affected 
sibling (patient 46.2), but segregation studies were not possible. 
 Microsatellite Genotyping of the p.Leu392Ser Missense Change 
To determine a possible founder effect between patient 43.1 and 44 who shared the 
homozygous p.Leu392Ser missense change, microsatellite genotyping of dinucleotide repeat 
regions flanking the YARS2 gene (Figure 7.10B) was performed by Charlotte Alston 
(Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, The Medical 
School, Newcastle University, Newcastle upon Tyne). This confirmed a founder effect, with 
both patients 43.1 and 44 sharing a T-1-2-3 haplotype that consisted of the p.Leu392Ser 
variant and three markers (Figure 7.10C). Analysis of an unaffected sibling of patient 43.1 
confirmed inheritance of wild-type alleles i.e. not harbouring the p.Leu392Ser missense 
change. Family pedigrees for the YARS2 patients are also given (Figure 7.10C).
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Figure 7.10 YARS2 MSA, Microsatellite Genotyping and Pedigrees. (A) MSA of mt-TyrRS demonstrating conservation of the human Cys369 and 
Leu392 amino acids. (B) Locations of dinucleotide regions flanking YARS2 used for microsatellite genotyping. (C) Pedigrees of the six YARS2 with 
microsatellite genotyping results for families 1 and 2 with the shared haplotype (blue) and the novel Scottish p.Leu392Ser founder mutation (red). 
Adopted and amended from (Sommerville et al., 2017). 
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 mtDNA Haplogroups 
MtDNA haplogroups had been previously proposed to influence the clinical heterogeneity of 
patients with YARS2-related mitochondrial disease (Riley et al., 2013). Using the full list of 
mtDNA polymorphisms from whole mitochondrial genome sequencing of YARS2 patients 
43.1, 44-46.1 (Appendix Q), mtDNA haplogroups were investigated. All patients were found 
to belong to different mtDNA haplogroups. Patient 43.1 was H1m1; patient 44 was G2a3a; 
patient 45 was T2e1a and patient 46.1 was HV13 (Table 7.4). 
 Western Blot Analysis 
Fibroblasts and myoblasts from patient 45 were investigated for steady-state mt-TyrRS levels 
and OXPHOS subunits (Figure 7.11). Both fibroblasts and myoblasts showed no decrease in 
steady-state mt-TyrRS protein levels, despite the in-frame duplication and a possible splicing 
defect due to the p.Cys369Tyr missense variant. There was a mild reduction of MT-COI 
(complex IV) in fibroblasts and myoblasts. However, NDUFB8 (complex I) was markedly 
decreased in the myoblasts only.  
 In Silico Analysis of mt-TyrRS Protein Structure 
The human mt-TyrRS protein structure (PDB ID 2PID) was analysed to observe the 
p.Cys369Tyr missense variant, as resolved by (Bonnefond et al., 2007). However, this was 
not the full length mt-TyrRS as it did not include the S4-like domain where the Leu392 
Figure 7.11 Western Blot Analysis of Patient 45 Fibroblasts and Myoblasts. Steady-state 
mt-TyrRS and OXPHOS subunit protein levels in patient 45 (A) fibroblasts and (B) 
myoblasts. Adopted and amended from (Sommerville et al., 2017). 
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residue is located, due to previous difficulties of modelling this domain in other species. 
Therefore, the p.Leu392Ser missense change was not analysed. 
The structure of human mt-TyrRS has been examined in detail by (Bonnefond et al., 2007). 
Mt-TyrRS is the only class II mt-aaRS that exists as a dimer. The Cys369 residue is located in 
the α15 helix of the anti-codon binding region (Figure 7.12), comprising five α-helices at the 
distal regions of the synthetase. Substitution with tyrosine does not affect the secondary helix 
structure. Given the residue conservation and position, binding of mt-TyrRS to the anticodon 
loop of tRNATyr, recognition or both may be affected by the p.Cys369Tyr substitution. 
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Figure 7.12 Human mt-TyrRS Protein Structure and Spatial Location of p.Cys369Tyr Missense Variant. The resolved dimeric structure of 
human mt-TyrRS (Bonnefond et al., 2007). The anticodon binding domain comprising the five α-helices (α11-15) are indicated in orange at the distal 
end of one mt-TyrRS monomer. The Cys369 residue located with the anticodon binding domain is indicated. The resolved structure does not contain 
the S4-like domain where the Leu392 residue is located. Adopted and amended from PDB ID 2PID.   
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 Yeast Modelling of YARS2 Missense Variants 
Yeast modelling of the unreported YARS2 missense variants (p.Cys369Tyr and p.Leu392Ser) 
with S. cerevisiae was performed by Cristina Dallabona, Micol Gilberti and Claudia Donnini 
(Department of Life Sciences, University of Palma, Italy) to demonstrate pathogenicity. Yeast 
strains were generated to express mutant alleles that corresponded to Cys369Tyr and 
Leu392Ser, using previously described methods (Ho et al., 1989; Bonneaud et al., 1991; 
Wach et al., 1994; Gietz and Schiestl, 2007; Baruffini et al., 2010). The Leu392 amino acid 
was conserved, corresponding to Leu411 in yeast (msyL411S) (Figure 7.13A). However the 
human Cys369 residue was not conserved in yeast (Figure 7.13A). Therefore, a humanised 
mutant was generated (msyhL391C) with the corresponding yeast leucine amino acid substituted 
with cysteine. The mutant human allele, a substitution with tyrosine, was then also generated 
(msyL391Y). Oxidative growth and consumption of yeast strains expressing mutant alleles were 
compared to the wild-type strain at 28OC and 36OC, as previously described (Ardissone et al., 
2015b). Strains expressing the msyL411S and humanised msyhL391C alleles had oxidative growth 
that was similar to the wild-type strain. On the other hand, the mutant msyL391Y strain had 
reduced growth that was more evident at 36OC (Figure 7.13B). All mutant strains also 
showed a reduction in oxygen consumption compared to the wild-type (Figure 7.13C). The 
humanised msyhL391C strain was similar to the wild-type, whereas the mutant msyL391Y strain 
showed a 27% reduction in respiration. The mutant msyL411S showed a slightly milder 21% 
reduction in respiration.  
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7.5 Discussion 
Here, the clinical, genetic and molecular features of AARS2, EARS2 and YARS2 mutations are 
expanded by delineating two patients presenting fatal, neonatal mitochondrial disease and six 
adult patients with childhood-onset YARS2-associated mitochondrial myopathy. Although the 
clinical phenotypes of the AARS2 and EARS2 patients were consistent with previously 
reported cases (Götz et al., 2011; Steenweg et al., 2012), YARS2 patients presented striking 
phenotypic variability that included three patients who did not have sideroblastic anaemia. 
Figure 7.13 Yeast Modelling of YARS2 Missense Variants. The unreported YARS2 
p.Cys369Tyr and p.Leu392Ser missense variants were modelled in S. cerevisiae. MSY1 
corresponds to the wild-type strain. (A) MSA showing conservation of Leu392 residue 
between human and yeast (blue), but not the Cys369 residue (red). (B) Oxidative growth of 
the wild-type, empty vector, msyhL391C, msyL391Y and msyL411S strains at 28OC and 36OC. (C) 
Oxygen consumption of strains relative to the wild-type MSY1 strain. Two-paired student’s t 
test was used to compare strains using 0.05 or less as the value of statistical significance. 
Adopted and amended from (Sommerville et al., 2017). 
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The use of in silico models, yeast modelling and functional studies of fibroblasts and muscle 
were invaluable in demonstrating the pathological nature of novel mutations. While it is clear 
that the mechanisms surrounding the tissue and cell specificity of the mt-aaRS remain 
unresolved, this data provides a further contribution to the hypotheses surrounding this 
intriguing conundrum. 
7.5.1 A Novel AARS2 Editing Domain Mutation Leads to Misaminoacylation of mt-
tRNAAla 
Autosomal recessive AARS2 mutations were first associated with fatal infantile HCM (Götz et 
al., 2011). However, patients with childhood- to adult-onset leukoencephalopathy are now 
equally prominent (Dallabona et al., 2014; Hamatani et al., 2016; Lynch et al., 2016; Szpisjak 
et al., 2016). Currently, patient 30 is the 11th patient reported with a fatal infantile HCM 
phenotype. However, he is the first known patient not to harbour the recurrent p.Arg592Trp 
editing domain founder mutation and instead had a different editing domain missense change, 
p.Arg580Trp. In silico modelling of p.Arg580Trp predicted that aminoacylation would be 
severely compromised, as would potentially the entire protein structure. Western blot analysis 
of steady-state mt-AlaRS levels in fibroblasts, together with two patients harbouring the 
p.Arg592Trp variant on at least one allele, was in agreement with previous in silico modelling 
(Euro et al., 2015) and of p.Arg580Trp. Patients 30 and 42 demonstrated slightly more 
decreased mt-AlaRS compared to patient 41, likely due to the combination of the nonsense 
p.Asp337* (patient 30) and a p.Ala961Val (patient 42) missense change predicted to result in 
an unstable protein (Euro et al., 2015). OXPHOS was apparently unaffected. Similarly, 
northern blot analysis of patient fibroblasts did not demonstrate loss of aminoacylation 
activity, suggesting a lower requirement for OXPHOS and hence, lower aminoacylation 
activity of mt-AlaRS is typical regardless of the AARS2 mutations. Taken together, the 
unreported p.Arg580Trp editing domain variant fits into the ‘severe’ AARS2 missense change 
category with other editing domain variants p.Arg592Trp and p.Tyr539Cys proposed by Euro 
et al. (2015), due to (i) the position in the β-barrel of the editing domain, (ii) the predicted 
significant loss of aminoacylation activity and (iii) proofreading errors due to increased 
misaminoacylation of tRNAAla with serine or glycine. Further to the p.Arg592Trp and 
p.Tyr539Cys variants, p.Arg580Trp also may lead to misfolding of the β-barrel subdomain 
and hence, stability of the entire protein structure. This continues to support the proposal that 
the two distinct AARS2-associated phenotypes are due to the differential effects on 
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aminocylation activity and that cardiac cells during early development are especially 
susceptible to the dramatic loss of mt-AlaRS activity. 
7.5.2 Lethal Neonatal LTBL Due to EARS2 Mutations 
Similar to AARS2, biallelic EARS2 mutations harboured by patient 29 caused a lethal 
mitochondrial translation disorder that was phenotypically consistent with previously reported 
cases. The presence of a specific brain imaging pattern is comparable to that DARS2 (Scheper 
et al., 2007), although even with CNS involvement specific neuronal cells appear to be more 
receptive to loss of mt-GluRS or mt-AspRS aminoacylation activities. Unlike previously 
published EARS2 patients however, brain imaging of patient 29 at 2 months of age revealed 
an atypical pattern. There were 26 published patients (including patient 29) harbouring EARS2 
variants (Steenweg et al., 2012; Talim et al., 2013; Biancheri et al., 2015; Danhauser et al., 
2016; Gungor et al., 2016; Kevelam et al., 2016; Kohda et al., 2016; Oliveira and 
Sommerville, 2016; Pronicka et al., 2016; Sahin et al., 2016; Taskin et al., 2016). Of these, 
brain MR imaging was available from 11 patients for comparison with phenotypes varying 
from the severe to mild and intermediate forms of LTBL. Patient 29 presented the severe form 
that was similar to patients described by Danhauser et al. (2016) and Talim et al. (2013). 
However, there was no brain imaging available from these patients to compare. Although 
bilateral and symmetrical lesions that predominantly affected the grey structures and 
brainstem were indicative of Leigh syndrome, it was insufficient to indicate LTBL. An 
important determinant for this was the patient’s age, which at 2 months old the brain would 
not be fully developed. The rapid, fatal disease course and delayed myelination also prevented 
further delineation of the brain MR changes. Therefore, the cerebral white matter lesions were 
not as apparent compared to published patients and leukoencephalopathy or additional white 
matter changes may not have been evident, but in spite of this there was sparing of the 
periventricular rim as reported previously (Steenweg et al., 2012; Biancheri et al., 2015; 
Gungor et al., 2016; Kevelam et al., 2016; Sahin et al., 2016; Taskin et al., 2016). Despite her 
age, the brainstem, thalami and cerebral lesions were features typical of LTBL. Hypogenesis 
of the corpus callosum was also evident as described previously (Steenweg et al., 2012; 
Biancheri et al., 2015; Gungor et al., 2016; Kevelam et al., 2016), including the severely 
affected patients reported by Danhauser et al. (2016) and Talim et al. (2013). WES of patient 
29 was performed shortly after the first report of patients with biallelic EARS2 mutations 
(Steenweg et al., 2012). Given the clinical, histochemical and biochemical features together 
with the brain imaging, irrespective of the inconspicuous white matter lesions, this would 
prompt targeted EARS2 gene screening. Regarding EARS2 variants, there was no correlation 
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with location or whether variants were homozygous or compound heterozygous (Oliveira and 
Sommerville, 2016), which contrasted with AARS2 mutations. The complete loss of mt-
GluRS activity due to the near or complete loss of steady-state mt-GluRS levels demonstrated 
in by western blotting in fibroblasts and muscle show that this incompatible for life. 
Differential effects due to other EARS2 mutations may also lead to complete or partial loss of 
mt-GluRS, loss of aminoacylation activity or both. Currently though, no correlation between 
the effects of mutations and the clinical phenotypes have been ascertained, although Sahin 
(2016) proposed that the combination of a mild and a severe EARS2 mutation could contribute 
to the milder phenotypes.   
7.5.3 Phenotypic Spectrum of YARS2 Mutations Due to Differential Effects on mt-
TyrRS Activity 
YARS2-related mitochondrial disease has been associated with MLASA that includes the 
distinct presence of sideroblastic anaemia; a rare manifestation of mitochondrial disease more 
commonly associated in Pearson’s Syndrome due to single, large scale mtDNA deletions 
(Pearson et al., 1979; McShane et al., 1991). All six YARS2 patients identified through WES 
or targeted YARS2 gene screening presented during childhood with myopathy, commonly 
manifesting as exercise intolerance with survival into adulthood. However, disease 
progression varied from complete MLASA syndrome to slowly progressive mitochondrial 
myopathy. Additionally, four patients of Scottish ancestry were identified including two 
pedigrees sharing a novel YARS2 Scottish p.Leu392Ser founder mutation. To date, YARS2-
related mitochondrial disease have predominantly been described in patients from the Middle 
East presenting severe early-onset phenotypes, harbouring either a homozygous p.Phe52Leu 
or p.Gly46Asp missense change (Riley et al., 2010; Sasarman et al., 2012; Riley et al., 2013; 
Shahni et al., 2013). Given the broad phenotypes observed between the six adult patients, this 
indicates that YARS2-related mitochondrial myopathy may be underdiagnosed outside of the 
Middle East, especially in Western populations who do not harbour the known, frequently 
reported variants. 
Despite varied clinical severity between the six YARS2 patients, impressive global COX-
deficiency in skeletal muscle was demonstrated in all tested patients that may be diagnostic 
for adults with YARS2-related myopathy. This was examined further by immunoblotting of 
fibroblasts and myoblasts from patient 45, which revealed minimal decreases in MT-COI and 
MT-COII (complex IV) in both tissues, but a significant decrease of NDUFB8 (complex I) in 
the myoblasts. This was an intriguing finding due to the profound COX-deficiency 
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demonstrated histochemically and biochemically, which may reflect the tissue specificity of 
mt-TyrRS since mitochondrial protein synthesis differs between tissues and may also explain 
the stable expression of OXPHOS subunits in the AARS2 patient fibroblasts. Furthermore, no 
changes in steady-state mt-TyrRS levels were detected. Prior immunoblotting of fibroblasts, 
myoblasts or MyoD-forced myotubes from two patients also did not disclose any loss of mt-
TyrRS (Riley et al., 2010; Riley et al., 2013). In contrast, mt-TyrRS was undetectable in 
myoblasts and myotubes from a third patient, but increased with differentiation of healthy 
cultured muscle cells from myoblasts to myotubes (Sasarman et al., 2012). Mitochondrial 
proliferation during myogenesis resulting in increased respiratory chain complex subunits was 
demonstrated between healthy control myotubes and myofibres, but not in YARS2 patient 
muscle cells (Riley et al., 2013). Furthermore, upregulation of mtDNA proliferation was also 
observed between control myoblasts and myotubes. In contrast, a substantial increase in 
mtDNA copy number was observed in patient 45 skeletal muscle and a modest increase in 
patient 46.1. Taken together, this suggests an increased requirement for YARS2 during muscle 
proliferation and that increased mitochondrial proliferation is a response to overcome the 
respiratory chain defects in muscle cells, providing a link between mt-TyrRS requirement in 
muscle cells and the myopathy and exercise tolerance presented in affected patients. Despite 
mt-TyRS requirement in the muscle the phenotypic variability between patients is stark, 
suggesting additional contributing mechanisms. Riley et al. (2013) hypothesised that mtDNA 
haplogroups of YARS2 patients could be one explanation. Haplogroup T appeared to align 
with a severe fatal infantile form of the disease due to HCM and haplogroup H aligning with a 
mild clinical phenotype. Haplogroup T has been previously associated with increased 
susceptibility of HCM in the Spanish population (Castro et al., 2006), but has not been 
verifiable in the Danish population (Hagen et al., 2013). Using HaploGrep2 to define 
haplogroups (Kloss-Brandstätter et al., 2011), patient 45 was found to belong to haplogroup T 
and also developed HCM, but presented with a milder phenotype. Additionally, patient 43.1 
belonged to haplotype H and similarly presented with a mild disease course. Cybrids with 
haplogroup H were shown to have increased mitochondrial protein synthesis compared to 
cybrids of haplogroups J and U (Gómez-Durán et al., 2010; Gómez-Durán et al., 2012). 
Interestingly, cybrids of haplotype T have been shown to have higher mtDNA copy number 
and be less susceptible to oxidative stress than haplotype H cybrids (Mueller et al., 2012). 
However, this did not correlate with patient phenotypes; patient 44 presented with the mildest 
phenotype of all six YARS2 patients and belonged to haplogroup G. Together with the 
previous assessment of YARS2 patient mtDNA haplogroups (Riley et al., 2013), the 
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heterogeneous phenotypes including the presence of absence of sideroblastic anaemia are 
likely due to additional genetic factors that are yet to be disclosed.  
Yeast modelling of the unreported YARS2 missense changes (p.Cys369Tyr and p.Leu392Ser) 
was performed to demonstrate pathogenicity. A previously reported p.Asp311Glu YARS2 
variant was modelled in yeast (msyD333E) and shown to have a severe OXPHOS defect 
(Ardissone et al., 2015b). Oxidative growth and respiration of mutant strains expressing the 
p.Cys369Tyr (msyL391Y) and p.Leu392Ser (msyL411S) both had milder OXPHOS defects, 
though msyL391Y was slightly more severe. Comparing OXPHOS defects of all mutant yeast 
strains including msyD333E showed a direct correlation with the severity of YARS2 human 
patient phenotypes. Finally, to better understand the relationship between the secondary 
structure and missense variants, the available human mt-TyrRS protein structure was used to 
analyse the p.Cys369Tyr variant (Bonnefond et al., 2007). The p.Cys369Tyr change occurred 
in the α-15 helix of the distal anti-codon binding domain, but this substitution did not affect 
the overall secondary structure. Although it was not possible to analyse the p.Leu392Ser 
change using the resolved secondary mt-TyrRS structure, it was proximal to p.Cys369Tyr and 
could also potentially be associated with tRNATyr anti-codon binding. Furthermore, missense 
changes within this region of mt-TyrRS were not previously reported. One hypothesis could 
be that patients harbouring either p.Cys369Tyr or p.Leu392Ser have a stable mt-TyrRS with 
partial reduction in aminoacylation activity due to impaired binding, recognition or both of 
the tRNATyr anti-codon loop. The unchanged steady-state levels of mt-TyrRS in patient 45 
fibroblasts and myoblasts lends support this hypothesis. However, how sideroblastic anaemia 
in two of four patients harbouring either p.Cys369Tyr or p.Leu392Ser remains unclear. Also, 
it is not possible to be absolutely certain regarding the differences between the S4-like domain 
variants p.Leu392Ser with survival into adulthood and a homozygous YARS2 p.Ser435Gly 
missense change that led to a severe MLASA phenotype with death within the 6 months of 
life (Nakajima et al., 2014). 
7.5.4 Tissue and Cell Specificity of mt-aaRS Defects  
Mt-aaRS mutations associated with defective translation are a paradigm of mitochondrial 
disease, reflected in the vast clinical heterogeneity manifested in affected patients and 
intriguing tissue and cell specificity. Absence of one or more features, such as sideroblastic 
anaemia in YARS2-related mitochondrial myopathy, abnormal brain imaging in LTBL due to 
EARS2 mutations or two different phenotypes due to AARS2 mutations provides challenges in 
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attaining a genetic diagnosis and understanding the pathological mechanisms underpinning 
tissue specific phenotypes.  
Varying thresholds in each tissue- or cell-type whereby levels of misaminoacylated tRNAs or 
uncharged mt-tRNAs are intolerable or toxic, thus having a greater degree of impact on 
mitochondrial protein synthesis could account for the high level of apparent specificity. Due 
to the significant number of mt-aaRS defects associated with NS and brain involvement, it 
appears that specific neuronal cells types are significantly affected. Together with other 
developing tissues in early life such as cardiac cells, these could be highly susceptible to 
either a severe reduction of mt-aaRS activity and are sensitive to misaminoacylated mt-tRNAs 
or uncharged mt-tRNAs. Tissue- or cell-type thresholds are not are unknown in mitochondrial 
disease; mtDNA mutations manifest in tissue-specific phenotypes when the mutational load 
reaches a particular level, known as the ‘phenotypic threshold effect’ (Rossignol et al., 2003). 
Variation in the threshold of misaminoacylated or uncharged mt-tRNAs between individuals 
could account for some of this phenotypic and tissue specific variability. Furthermore, the 
variability of mt-tRNA expression in specific tissues or cells will perhaps impact the 
aminoacylation activity of mt-aaRS. Interestingly, the brain has been found to express higher 
levels of mt-tRNAs than any other tested tissue (Dittmar et al., 2006), emphasising a greater 
need for mitochondrial translation fidelity. Levels of misaminoacylated or uncharged tRNAs 
in tissues and cells appear to be intrinsically linked to the differential effects of the synthetase 
mutations. As demonstrated for mt-AlaRS, editing domain mutations including the novel 
p.Arg580Trp missense variant likely cause tRNAAla to be misaminoacylated with serine or 
glycine, together with a severe reduction of aminoacylation activity. On the face of it 
however, EARS2 mutations do not appear to show a genotype and phenotype correlation. 
Indeed, both homozygous and compound heterozygous mutations contribute to both the 
severe and mild or intermediate phenotypes. As noted though by Sahin et al. (2016), the 
combination of a mild and a severe EARS2 mutation led to a milder clinical course for their 
patient. On the other hand, complete loss of mt-GluRS expression on one allele together with 
a severe mutation contributed to a severe, lethal course. This was true for patient 29, who 
harboured a start-loss p.Met1? variant together with p.Ile62Phe missense change, which is 
likely detrimental to mt-GluRS stability as evidenced by loss of mt-GluRS expression in 
patient 29 fibroblasts and muscle on western blotting. Initial investigations of YARS2 
missense variants including the p.Cys369Tyr variant appear to show some structural 
correlation with the vast phenotypic variability observed in patients, like that of AARS2 
mutations. The p.Phe52Leu and p.Gly46Asp mutations are located near the binding site for 
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the mt-tRNATyr acceptor stem, with both variants associating with a more severe phenotype 
that was strongly associated sideroblastic anaemia requiring transfusion, suggesting a 
decreased binding affinity with mt-tRNATyr. On the other hand a p.Cys369Tyr variant 
associated with a milder phenotype and investigated in this study is located within the anti-
codon binding domain, suggesting impairment on mt-tRNATyr due to impaired recognition of 
the anti-codon loop instead. However, there are no additional in silico or functional studies of 
EARS2 or YARS2 missense changes to the extent that AARS2 missense changes have been 
investigated (Euro et al., 2015). Thresholds in tissues could also change over time and with or 
without differential effects of mt-aaRS mutations, may lead to broadened phenotypes between 
individuals, as seen with AARS2 mutations. Nonetheless, findings from this study and 
previous suggest that a reduction of mt-GluRS activity is a key mediator of the LTBL 
phenotype in neuronal cells of the brainstem and thalamus.  
It is also conceivable that mt-aaRS have secondary functions in addition to their 
aminoacylation activities like the aaRS (Yao and Fox, 2013). Several nuclear encoded 
regulators of mitochondrial function have been associated with possible secondary roles, 
including MTU1 in sulphur trafficking (Sasarman et al., 2011) and SCO1 in cellular copper 
homeostasis (Leary et al., 2007). Given the presence of sideroblastic anemia in a significant 
proportion of YARS2 patients, there may be an as yet undisclosed role for mt-TyrRS in 
haematopoiesis; the production of all blood cell types in each individual throughout their 
entire lifetime. Inhibition of mitochondrial translation as a therapeutic strategy for treatment 
of acute myeloid leukaemia highlights the importance of mitochondria for blood cell 
production in haematopoietic stem cells in the bone marrow (Škrtić et al., 2011). Currently, 
potential secondary functions of the mt-aaRS are not well characterised compared to their 
cytosolic counterparts, with the exception of dual-localised LysRS (Martin et al., 1979). 
7.5.5 Concluding Remarks 
To summarise, there are likely to be varying and multiple pathological mechanisms between 
each mt-aaRS defect that explain tissue and cell specificity. Although AARS2 mutations have 
a clear link between differential mutations and aminoacylation activity, the same proposed 
mechanism does not fit for EARS2 and YARS2, or indeed other mt-aaRS defects. Further 
studies of mt-aaRS mutations on aminoacylation activity, secondary roles of mt-aaRS and of 
their cytoplasmic aaRS counterparts could provide insights. In spite of this, in silico and yeast 
modelling of missense changes were demonstrated as powerful tools to confirm 
pathogenicity, with an impressive correlation demonstrated between YARS2 variants and 
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clinical severity. When considering the clinical, histochemical and biochemical features 
together, it may be possible to direct targeted gene screening. Identification of additional 
patients using this approach and NGS will also likely further expand the phenotypic spectrum 
of mt-aaRS defects.
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Chapter 8. Final Discussion 
The past decade has ushered in an exciting era of targeted NGS technologies that includes 
WES and WGS, which have sought to enhance the diagnosis and understanding of complex 
genetic disorders. Mitochondrial disease poses a particular challenge for both clinicians and 
researchers in the laboratory, due to vast clinical and genetic heterogeneity. This is 
compounded by a potential defect in either mtDNA or one of approximately 1,200 nuclear 
encoded proteins that are essential for mitochondrial functions (Lopez et al., 2000; Calvo et 
al., 2006). Establishing a genetic diagnosis is essential for expanding our understanding of the 
pathological nature of mitochondrial disease, which is seminal for the development of 
therapeutic strategies to mitigate the devastating symptoms that impact on health-related 
quality of life. For parents and families of paediatric patients, a genetic diagnosis informs 
reproductive options for future pregnancies, including pre-natal or pre-implantation diagnosis. 
The foundation of all studies in my thesis centred on the use of WES as a cost-effective tool 
for the diagnosis of suspected Mendelian mitochondrial disease, while building upon 
previously described approaches to enhance the diagnostic yield. 
8.1 Whole Exome Sequencing (WES) in Mitochondrial Disease 
The fundamental challenge of WES is to discriminate pathogenic or causative variants from 
thousands of called variants, which include common, benign or neutral polymorphisms. To 
this end, it is essential to devise and employ filtering strategies to sift through and prioritise 
the most likely candidate causal variants. In seeking to advance WES filtering strategies, 40 
undiagnosed deep-phenotyped mitochondrial disease patients presenting extreme genotypic 
and phenotypic heterogeneity were recruited. These were sub-grouped into (i) adult-onset 
PEO with multiple mtDNA deletions (n=19) and (ii) early-onset mitochondrial RC deficiency 
(n=20). 
Adult-onset Mendelian PEO with secondary, clonally expanded skeletal muscle restricted 
multiple mtDNA deletions (Zeviani et al., 1989) is a well-recognised disorder of mtDNA 
maintenance. Mutations of 16 nuclear genes have now been associated with Mendelian PEO 
with mtDNA instability (Sommerville et al., 2014). In general, more than 50% of these 
patients could receive a genetic diagnosis if all known genes are investigated. Nuclear genes 
associated with this disorder predominantly encode proteins involved in mtDNA 
maintenance. 
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Anticipating the potential difficulties of WES in this particular patient cohort, I 
comprehensively reviewed all published patients (Chapter 3), confirming the considerable 
heterogeneity of disorder. The review also noted that autosomal dominant mutations were the 
most common inheritance pattern in adult-onset mtDNA maintenance disorders and hence, 
this knowledge was applied to the WES strategy. Utilising a custom filtering strategy 
(Chapter 4), a confirmed diagnostic yield of just 10.5% was achieved. Nonetheless, primarily 
heterozygous candidate variants and VUS (as anticipated) were also identified in nuclear 
genes encoding mitochondrial proteins involved in a range of functions that included mtDNA 
replication (POLRMT, TOP3A), mitochondrial fission (SEPT2), nucleotide homeostasis 
(ABAT, GMPR1, RRM1, RRM2B) and metabolite transport (VDAC1). 
On the other hand, early-onset mitochondrial RC disorders arise due to defects affecting one 
or more of the five multi-subunit enzymes comprising the OXPHOS system and are among 
the most common early-onset metabolic disorders with an estimated minimum prevalence of 
1 in 5,000 live births (Skladal et al., 2003), compared to adult-onset mtDNA maintenance 
disorders, early-onset RC deficiency has been extensively studied using NGS approaches and 
is associated with defects in approximately 245 nuclear genes encoding proteins involved in 
mtDNA maintenance, but also protein synthesis, OXPHOS cofactors, dynamics and 
metabolism (Mayr et al., 2015). With a second custom filtering strategy specific to this cohort 
(Chapter 6), I identified causative mutations in known and novel mitochondrial disease genes 
plus one putative non-mitochondrial nuclear gene, giving a causative and likely causative 
diagnostic yield of 45%. Significantly, I identified mostly autosomal recessive mutations in 
nuclear genes encoding mitochondrial protein synthesis machinery (AARS2, EARS2, 
GTPBP3, MRPS22, MTO1, TRMU), indicating that biased filtering for this group of genes in 
early-onset RC deficiency is appropriate, while still prioritising other genes encoding 
mitochondrial proteins. 
Prioritisation of candidate variants was also dependent on deep phenotyping of patients with 
suspected mitochondrial disease. Biochemical or histochemical evidence of mitochondrial 
dysfunction ensured that variant filtering and prioritisation of candidate variants was focused 
on nuclear genes encoding mitochondrial proteins. This had a profound impact within my 
WES cohorts, particularly emphasised in patients with early-onset RC deficiency. Of the five 
patients with isolated deficiency, a definitive diagnosis made was in only one case. On the 
other hand, of the 14 patients with multiple RC deficiency, causative or likely causative 
variants were identified in eight; a diagnostic yield of 57%; higher than 45% yield attained for 
the full early-onset RC cohort. 
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However, I accept that my filtering strategies are limited to nuclear genes encoding known 
mitochondrial proteins. Despite advances in NGS technological capabilities, functional 
examination of the human proteome is on-going. I was unable to prioritise the novel 
heterozygous SEPT2 mutation without knowledge of its recently published involvement in 
mitochondrial fission (Pagliuso et al., 2016). Therefore, there remain uncharacterised proteins 
that could be essential for mitochondrial function and associated with mitochondrial disease, 
yet cannot be prioritised without functional knowledge. This advocates the need for continued 
re-evaluation of apparently unsolved and future exomes as the human proteome continues to 
be characterised. 
8.1.1 De Novo and Dominant Mutations 
Prior studies of undiagnosed early-onset mitochondrial disease cohorts using NGS have 
warned that the inheritance pattern could sometimes wrongly be assumed to be recessive, as 
Kohda et al. (2016) most recently acknowledged. This was accentuated by the recent 
identification of de novo ATAD3A and SLC25A4 mutations in early-onset mitochondrial 
disease patients (Harel et al., 2016; Thompson et al., 2016). Hence, substantial emphasis was 
placed on the potential prominence of causative dominant or de novo heterozygous mutations, 
despite expectations that the majority of inheritance would be recessive and that no trios 
underwent WES. I was exonerated by the identification of a possible de novo CTBP1 
mutation (Beck et al., 2016) and the first prospective dominant inherited MTO1 mutation 
within this cohort. While RC deficiency due to the CTBP1 mutation is probably secondary, it 
by no means precludes the identification of other patients with RC deficiency due to a 
mutation(s) of a non-mitochondrial disease gene. My observations further serve to reinforce 
the need for continued re-evaluation of heterozygous variants in unsolved and future exomes, 
since these are likely to be under recognised in mitochondrial disease. 
8.1.2 Is Somatic Mosaicism an Under-Recognised Phenomenon? 
To my knowledge, I identified the first case of somatic mosaicism associated with adult-onset 
PEO and multiple mtDNA deletions in a single patient harbouring a known heterozygous 
pathogenic TWNK p.Arg374Gln mutation (Spelbrink et al., 2001; Naimi et al., 2006; Baloh et 
al., 2007; Massa et al., 2009; Martin-Negrier et al., 2011; Yu-Wai-Man et al., 2013; 
Tafakhori et al., 2016). This demonstrated the efficiency of WES to detect low level 
mosaicism. Significantly, somatic mosaicism may provide an explanation for the failure to 
attain a diagnosis in a small proportion of patients with mtDNA maintenance disorders. 
   
 291 
However, difficulties could arise from the availability of tissues for testing or failure to 
amplify DNA in one or more tissues. Sanger sequencing is also insufficient to detect mutation 
loads of less than 15% (Rohlin et al., 2009). Until NGS is established as routine in the 
diagnosis of prospective mitochondrial disorders, the impact of somatic mosaicism remains an 
open question. In the interim, this requires careful curation and annotation of 
electropherograms generated from diagnostic targeted screening of mtDNA maintenance 
disorder-associated genes. 
8.1.3 Guanosine Monophosphate Reductase 1 (GMPR1) 
I pursued investigations of a novel heterozygous GMPR1 p.Gly183Arg missense change 
harboured by patient 11 to determine if it was the causal mutation leading to PEO and 
multiple mtDNA deletions (Chapter 5). Despite the known role of GMPR1 in de novo 
guanosine synthesis, it had not been previously associated with human disease nor was there 
evidence demonstrating a direct link to mtDNA maintenance. Collaborating with Dr 
Antonella Spinazzola and Dr Ilaria Dalla Rosa (MRC Mill Hill Laboratory, London), altered 
nucleotide homeostasis in proliferating and quiescent patient fibroblasts was noted, 
emphasised by decreased steady-state GMPR1 protein expression and further underpinned by 
a decrease in patient skeletal muscle. However, the subtle cellular phenotype was not specific 
to directly implicate the GMPR1 mutation, underscoring the difficulties in understanding the 
pathological mechanisms of dominant, late-onset mtDNA maintenance disorders. 
Nonetheless, continued investigation of the GMPR1 mutation is on-going. Expression and 
purification of mutant GMPR harbouring the p.Gly183Arg mutation from Escherichia coli for 
measuring enzymatic activity is to be performed by Dr Liz Hedstrom and Dr Masha 
Rosenberg (Brandeis University, Massachusetts, USA). Simultaneously, Dr Spinazzola and 
Dr Dalla Rosa are extracting and measuring the dNTP pools from patient fibroblasts. 
8.1.4 Tissue Specificity in Mitochondrial Disease 
Tissue- and cell-specificity was a significant theme throughout my thesis. It was especially 
prominent in mutations of the mt-aaRS (Chapter 7), although tissue-specificity was also 
noted in the SCO1 patient with fatal lactic acidosis (Valnot et al., 2000; Stiburek et al., 2009), 
plus the TRMU patient with acute infantile-onset liver failure (AILF) (Zeharia et al., 2009; 
Kemp et al., 2011; Schara et al., 2011; Uusimaa et al., 2011; Gaignard et al., 2013; Taylor et 
al., 2014; Grover et al., 2015). It is also reasonable to consign mtDNA maintenance disorders 
in this classification, since mtDNA instability is restricted to the skeletal muscle. 
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This thesis expanded the clinical, molecular and genetic spectrum of mt-aaRS defects 
(Chapter 7). Once thought to be key to directing targeted gene screening, the absence of one 
or more clinical features in mt-aaRS defects provides new challenges in diagnosing early-
onset RC deficiency. Between the three mt-aaRS defects studied in this thesis and likely for 
all other mt-aaRS, the rules governing tissue- and cell-specificity differ. Secondary roles of 
the mt-aaRS also offer explanations, as proposed for MTU1 and SCO1 (Leary et al., 2007; 
Sasarman et al., 2011). Nevertheless, further examination and the identification of additional 
patients is necessary to provide more detailed insights.     
8.2 Genetic Diagnoses to Therapeutic Strategies 
Attaining genetic diagnoses and understanding disease mechanisms can allow for the 
development of treatments and therapeutic strategies for mitochondrial disease, although these 
are currently in the early-stages (Nightingale et al., 2016). Indeed, I identified mutations in 
genes that are potential targets for treatments. Notably, dTMP and dCMP supplementation has 
been trialled in Tk2 p.His126Asn knock-in mouse models as a means to overcome pool 
imbalances causing mtDNA depletion (Garone et al., 2014). Given the emergence of 
nucleotide metabolism defects associated with mtDNA maintenance disorders in this cohort, 
dNTP supplementation therapy is emerging as a significant avenue of further study. 
Supplementation could be beneficial in GMPR1 patient fibroblasts. However, it is too early to 
evaluate the potential of this strategy until dNTP measurements are completed. Given the 
subtle cellular phenotype observed so far, the effect of supplementation may not be valuable. 
Another significant finding was the identification of defects in the modification or processing 
of mt-tRNAGlu; EARS2, TRMU, MTO1 and GTPBP3. Reversible infantile RC deficiency 
(RIRCD) is associated with a homoplasmic m.14674T>C or m.14674T>G mutation in the mt-
tRNAGlu gene, manifesting as severe encephalomyopathy in the first months of life followed 
by spontaneous recovery (Horvath et al., 2009; Mimaki et al., 2010; Uusimaa et al., 2011). 
Strikingly, spontaneous recovery of some patients harbouring EARS2 and TRMU mutations 
have been noted (Steenweg et al., 2012), while partial recovery of patients with MTO1 
mutations has also been described (Ghezzi et al., 2012). This was not true for patient 29 
(EARS2), but the clinical course for patients 31 (TRMU) and 32 (MTO1) indeed appeared to 
stabilise. Recovery has been linked to the availability of L-cysteine, expressed at low levels 
from birth and slowly increase throughout the first few months of life (Zlotkin and Anderson, 
1982; Levonen et al., 2000). Thus, in vitro supplementation of L-cysteine or N-acetyl-
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cysteine in fibroblasts from patients with TRMU and MTO1 mutations show incredible 
restoration of RC activities (Boczonadi et al., 2013; Bartsakoulia et al., 2016). 
8.3 WES or WGS? 
Regrettably, I was unable to identify causative or likely causative variants in 17/40 (42.5%) of 
patients in this thesis. Though this was significant proportion, failure to identify causative 
mutations is a common outcome in WES studies throughout the literature. This poses the 
question of how to proceed these cases. It could be that the causative mutation(s) were missed 
by WES or lie in non-coding regions of the genome, such as the deep-intronic or untranslated 
regions. Thus, WGS signifies a potential solution for both problems and has some significant 
advantages over WES in the diagnostic setting (Belkadi et al., 2015; Meienberg et al., 2016). 
WES throughout this study relied upon amplicon-based library preparation for adequate 
coverage of the human genome. Poor or uneven read coverage from WES likely stems from 
the PCR-amplification steps (Kebschull and Zador, 2015), which could be attributed to GC-
rich regions and the use of short read lengths (Kozarewa et al., 2009; Veal et al., 2012). 
Therefore, inadequate and uneven read coverage of the genome could have led to causative 
variants being missed, as has been proposed previously (Calvo et al., 2012). Detection of 
CNVs is also challenging in WES, again due to uneven coverage and the use of short reads 
that are insufficient to cover large rearrangements (Tattini et al., 2015). This includes 
expanded and triplet repeats, which are associated with several neurological conditions 
including Huntington’s disease, Friedreich’s ataxia and spinocerebellar ataxia (Orr et al., 
1993; Campuzano et al., 1996; Walker, 2007). On the other hand, PCR-free WGS has been 
demonstrated to provide more uniform coverage of the human genome since it is less 
sensitive to GC-rich regions (Meienberg et al., 2016). Owing to greater read lengths, this also 
allows more accurate identification of large genomic structural rearrangements (Belkadi et al., 
2015).  
Non-coding mutations are increasingly reported throughout the literature in neuromuscular 
and neurological diseases (Ruggieri et al., 2015; Elsaid et al., 2016; Gonorazky et al., 2016; 
Kremer et al., 2016), which would not be called by WES. However, if the genetic aetiology of 
a mitochondrial disease patient is potentially non-coding, how does one interpret 
pathogenicity from a list of thousands of non-coding changes called by WGS? Recently, 
RNA-based transcript analysis (RNAseq) has been used in tandem with PCR-free WGS to 
evaluate RNA expression or processing for patients who have not received a genetic diagnosis 
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via WES (Ku et al., 2012). RNAseq has only been applied to mitochondrial disease once so 
far; Kremer et al. (2016) identified three families with an intronic exon-creating variant in 
TIMMDC1 associated with complex I deficiency. On these early studies, RNAseq appears to 
be more beneficial only when combined with PCR-free WGS.  
Irrespective of the additional, essential bioinformatics processing that would be required for 
PCR-free WGS and RNAseq analysis, these technologies will remain out of reach for many 
public-funded diagnostic centres owing to the costs involved. While sequencing of the human 
genome continues to become rapidly less expensive, it has yet to reach a level that can be 
widely afforded. While I whole-heartedly agree that PCR-free WGS with RNAseq should and 
will ultimately be the first-tier choice of genetic investigation in the diagnosis of Mendelian 
disease, the current costs remain out of reach. Meanwhile, WES currently remains the most 
viable and cost-efficient tool for diagnostic services, including the NHS Highly Specialised 
Mitochondrial Diagnostic Service Laboratory. Thus, PCR-free WGS and RNAseq are 
currently options of last-resort.  
8.4 Concluding Remarks 
To summarise, my thesis has demonstrated the power of WES for the identification of 
causative and likely causative variants in two cohorts of suspected Mendelian mitochondrial 
disease manifesting broad clinical and genetic heterogeneity. The clinical, molecular and 
genetic spectrum of known mitochondrial disease genes were expanded, while novel 
candidates were proposed. Alas, I concede that further functional validation of the novel 
genes is essential and on-going. As NGS technologies including WES, PCR-free WGS and 
RNAseq become less expensive and more accessible for diagnostic purposes, we are entering 
a new age of ‘Now-Generation Sequencing’ in mitochondrial disease diagnosis.
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Appendix 
Appendix A – Sanger Sequencing Primers 
Primer Sequence Fragment 
size (bp) 
Position of 
primer 
Optimal 
conditions 
AARS2_Ex6+7 F-ttctggatgtggttggcttt 
R-atttagggtggggacctctg 
694 Chr6:44274548-
44275241 
 
AARS2_Ex11+12 F-cgaggctgaagtcccact 
R-agcctttccctccccttg 
705 Chr6:44272301-
44273005 
 
ABAT_Ex13 F-aattcagcgagattgggtgt 
R-gaatgggatggagggatagg 
506 Chr16:8870041- 
8870546 
 
APEX1_Ex5 F-gcctgaactcttcaaaaccaa 
R-tcccaggctcaaagtgattt 
655 Chr14:2092504
3- 20925697 
 
BCL2L13_Ex7a F-tttgctttccagattgatgttt 
R-agggctggatttctcaactg 
591 Chr22:1820936
8- 18209958 
 
BCL2L13_Ex7b F-agctcccttgcttccacata 
R-gctgctggaggttcaaattc 
508 Chr22:1820986
8- 18210375 
 
C10orf2_Ex1c F-acaatctgtttggattaccactg 
R-aacccacttgcttttgtcacc 
578 Chr10:1027487
01-102749278 
 
CTBP1_Ex9 F-agtgcccagagagacaggac 
R-cttccaagaggccctggt 
456 Chr4:1206524-
1206979 
62OC 
EXD2_Ex7 F-tggttaggccccagttagaa 
R-tgagggttaatgtccctggt 
504 Chr14:6970419
2- 69704695 
 
FDXR_Ex4 F-ggtttggagactttggtcaag 
R-tcagcaccagcactgatagg 
477 Chr17:7286240
2- 72862878 
 
EARS2_Ex1 F-tgtgactttaaggggcaagg 
R-aacacaagaaactcctggcaat 
447 Chr16:2356832
6-23568772 
DMSO 
EARS2_Ex2 F-gtgagccaatgtgtcctgct 
R-ccagtcttggagctgtgtttc 
483 Chr16:2356327
1-23563753 
 
EARS2_Ex3 F-ggacattgtactaatgccaacc 
R-ttgcttgtggctttgagaga 
497 Chr16:2355566
1-23556157 
 
EARS2_Ex4 F-ggtcacacagctatgacagagg 
R-aggactgtctgagccaaagc 
631 Chr16:2354613
4-23546764 
 
EARS2_Ex5 F-gaagacaggctggaggattg 
R-tgtgccagggctatacaaga 
536 Chr16:2354372
8-23544263 
 
EARS2_Ex6+7 F-tttccctgggggagagac 
R-ccagccctgaaggaaagag 
551 Chr16:2354074
1- 23541291 
 
EARS2_Ex8 F-gtcccttggtggtttttcct 
R-cctaacacaatgcttgcaca 
516 Chr16:2353638
0-23536895 
 
EARS2_Ex9 F-ggctcttaggacccatcctt 
R-cccagccaattgacaaaaac 
442 Chr16:2353550
3-23535944 
 
GMPR1_Ex5 F-ttctcatgccaacagctcac 
R-acttttcatcaggggcttcc 
451 Chr6:16274451- 
16274901 
DMSO 
GNL3L_Ex11 F-tcacccctcctccaactcta 
R-ttcttcttcttccccaaacg 
499 ChrX:54577852
- 54578350 
 
GTPBP3_Ex1 F-cagccaatggaagcgagtat 
R-gactgtgaggccagaaggag 
409 Chr19:1744824
6-17448654 
 
GTPBP3_Ex2 F-gtctccttctggcctcacag 
R-gaagggggaaactgagtcat 
489 Chr19:1744863
3-17449121 
 
GTPBP3_Ex3 F-tctggttcccaggtgagg 
R-gtcaggttcagcttcccatt 
374 Chr19:1744905
3- 17449426 
 
GTPBP3_Ex4+5 F-catgactcagtttcccccttc 501 Chr19:1744910 64OC 
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Primer Sequence Fragment 
size (bp) 
Position of 
primer 
Optimal 
conditions 
R-gttgcacagatggggtctct 1-17449601 
GTPBP3_Ex6+7 F-cacctcatatcagccctcaaa 
R-cagggagaaaaggcagagaa 
605 Chr19:1744986
6-17450470 
 
GTPBP3_Ex8 F-taactgtccctccacccagt 
R-atggtctctcccgacctttt 
488 Chr19:1745178
1-17452268 
 
GTPBP3_Ex9 F-tccctcaacttcaatttctgaac 
R-cctgcagggatctcactacc 
489 Chr19:1745218
3-17452671 
 
GUF1_Ex12 F-tgattacagctggagggatttt 
R-tcagtatgctcagcagaaagaaa 
344 Chr4:44692636- 
44692979 
 
LETM2_Ex5a F-aaaatgaaacaagacagggttttt 
R-gagaaattgggatggggttg 
359 Chr8:38251518- 
38251876 
 
LETM2_Ex6 F-ggcttctttttacttgctctgg 
R-aagacaggcttttctgcaaac 
497 Chr8:38257617- 
38258113 
 
MGME1_Ex2 F-ataaaggccttcgaccgttg 
R-cattcttttgacaccgttgc 
633 Chr20:1795045
4-17951086 
62OC, 
DMSO 
MGME1_Ex3 F-ttgtattgtttcagggcgttt 
R-tggctcttctccttgtacctg 
479 Chr20:1795623
4-17956712 
 
MGME1_Ex4 F-tggtgaataagagcaatggtca 
R-ggcccggagttatagttttaag 
322 Chr20:1796868
5-17969006 
 
MGME1_Ex5 F-tcttgtgtcctggtgcagtc 
R-gggcttttcagtctttttgg 
504 Chr20:1797041
9-17970922 
 
MYH14_Ex11 F-ccacacgtgacctctgtcc 
R-ggaagggggatgctctctac 
226 Chr19:5074746
8- 50747693 
 
MYH14_Ex35 F-agaggtgagcacaggtcagg 
R-gtgccttgcctcacactaca 
475 Chr19:5079629
5- 50796769 
 
MIEF2_Ex2 F-ggtgtcctcccctgtggat 
R-cagggcaaagcagaccag 
492 Chr17:1816585
0- 18166341 
64OC 
MRPL9_Ex1 F-attctaggcgtccgtcacc 
R-gcgcctccagaaacaatact 
395 Chr1:15173574
5- 151736139 
62OC 
MRPL9_Ex3 F-agcagtctcttaaatcttgttcct 
R-ggcttctgcattcctgttct 
412 Chr1:15173472
3- 151735134 
 
MRPS12_Ex2 F-cggagggactttctgttagc 
R-acacgcagtagccctccat 
406 Chr19:3942176
1- 39422166 
 
MRPS12_Ex3 F-tgcctaaaacaccaaaattga 
R-agcatcggaggaccctgt 
527 Chr19:3942289
4- 39423420 
 
MRPS22_Ex4 F-gcacagcagtgattagtgaagg 
R-atcaaggcacaaagccaact 
415 Chr3:13906882
8-139069242 
 
MTO1_Ex1 F-gccctgcagattgtctcttg 
R-cctgatccttgcgagacact  
459 Chr6:74171494- 
74171952 
HS PCR 
MTO1_Ex2+3 F-attgggtctttgggattttctt 
R-tccaggtagagaaaatgcaaca  
682 Chr6:74175774- 
74176455 
HS PCR 
MTO1_Ex4 F-ctggcgatagagtgagacttca 
R-cagtacttcctgctgtgaatagc  
466 Chr6:74182975- 
74183440 
HS PCR 
MTO1_Ex5+6 F-cgtatcatgtggaatttatttgga 
R-gctaaggcctcctcactgac  
547 Chr6:74189374- 
74189374 
HS PCR 
MTO1_Ex8 F-gccactgctcctgacctaaata  
R-atctccaaacaccctgaaacat  
396 Chr6:74190277- 
74190672 
HS PCR 
MTO1_Ex9 F-tttctccttttaatgtctgttgtg  
R-atcctattattggctgggcaa  
409 Chr6:74190579- 
74190987 
HS PCR 
MTO1_Ex10 F-ggcaatacttgctttcttcctg 
R-gggaagggagaaagagaatataatg  
519 Chr6:74191650- 
74192168 
HS PCR 
MTO1_Ex11 F-taatccaagcaatttgagagacca 
R-ccaaaaacaagctacattcatttg  
449 Chr6:74192020- 
74192468 
HS PCR 
MTO1_Ex12 F-tacagttgatgggcgacaga 
R-gcccagccaagattctgtat  
467 Chr6:74201792- 
74202258 
HS PCR 
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Primer Sequence Fragment 
size (bp) 
Position of 
primer 
Optimal 
conditions 
MTO1_Ex13 F-tgaaatgagtgttgaatgagatga 
R-cccatgctggaagtttcttattac  
417 Chr6:74207332- 
74207748 
HS PCR 
MTO1_Ex14 F-ttcccatttgtaaaatgaagacat 
R-ttaatggcaaacccatagtaacct 
487 Chr6:74210097- 
74210583 
HS PCR 
OXR1_Ex4 F-ttttcaaagatgacaataccagttg 
R-tttctgcctttctgtttaatgtttc 
296 Chr8:10769529
6- 107695591 
 
PDHA1_Ex12 F-ttacaccagcaacaggtcctc 
R-cactcaataattcatcttttaatgcac 
447 ChrX:19377516
-19377962 
 
POLRMT_Ex11 F-catccgtggctatggagaac 
R-cacctccagagaataccacga 
409 Chr19:620258-
620666 
HS PCR, 
62OC, 
DMSO 
PPIF_Ex4 F-ttggatgtttattgaccccttt 
R-caacaagccagaaatgctga 
394 Chr10:8111110
7- 81111500 
 
PTPIP51_Ex12 F-caggattttccaaagcagga 
R-ggattcaagcgattctccag 
379 Chr15:4102914
5-41029523 
 
RNASEH1_Ex1 F-ccagacgtgcgtcatcttc 
R-gccgagcaggaaaacgag 
398 Chr2:3605566-
3605963 
DMSO 
RNASEH1_Ex2 F-cctggaatcagtctccctca 
R-acacgaggttccctacatgc 
346 Chr2:3604269-
3604614 
 
RNASEH1_Ex3 F-attccctcgtttccctcgt 
R-ccatcaagtgggaaacacct 
397 Chr2:3599654-
3600050 
 
RNASEH1_Ex4 F-ctgcagcgttgtaaaataccc 
R-aacacgaaccaaagctgctc 
367 Chr2:3597815-
3598181 
 
RNASEH1_Ex5 F-ctgctctctgctgggagtct 
R-cgaaattgaaacatcccctct 
468 Chr2:3596388-
3596855 
 
RNASEH1_Ex6 F-gaggggatgtttcaatttcg 
R-cctgccctgttacaacacct 
258 Chr2:3596150-
3596407 
 
RNASEH1_Ex7 F-ccaaaggccaaagcaactaa 
R-actacgcccagcctcaaata 
437 Chr2:3595364-
3595800 
 
RNASEH1_Ex8 F-catgtgttgcttatgtaaagatga 
R-acatgtcacagaaggccact 
300 Chr2:3593219-
3593518 
 
RRM1_Ex12 F-ctgcctcattttcccctatg 
R-ttccttcctttgctctctgc 
541 Chr11:4144230- 
4144770 
 
SCO1_Ex6 F-gacaatttttgttaggaatttgc 
R-aattttggttgaacgcaagg 
483 Chr17:1058426
4- 10584746 
 
SEPT2_Ex11 F-tgattttctctttagctgttgcttt 
R-gcttctgtttttcaggagcaa 
469 Chr2:24228931
1- 242289779 
 
SETX_Ex23 F-agcctcttggagtcactgct 
R-tgtctacccaggagccacac 
496 Chr9:13515046
4- 135150959 
 
SLC3A1_Ex8 F-ctgtgtatacagctgtgttc 
R-atagctgtgatgaatagtc 
246 Chr2:44539684- 
44539929 
 
THNSL1_Ex1b F-ggatgttggtaatgagcaatttt 
R-tgaatgtttccgagtccaca 
383 Chr10:2531246
4- 25312846 
 
TK2_Ex5 F-tcctgcagatgccactttg 
R-ccccaagtctgaagaaaacg 
194 Chr16:6656522
8-66565421 
 
TOP3A_Ex3 F-tcaacatgcctcaaaattcct 
R-gaagctcctccctctcatttt 
237 Chr17:1821158
7- 18211823 
58OC 
TOP3A_Ex5 F-gcagcacttaccagccttaca 
R-gtcacactccaagagcagca 
232 Chr17:1820841
5- 18208646 
 
TOP3B_Ex6 F-aggtgcaggaaaggggatag 
R-ccttcttcagggttggtgaa 
496 Chr22:2232444
0- 22324935 
 
TRMU_Ex6+7 F-gaagcaaagtgtggggtgag 
R-gccccacagagccttctac 
454 Chr22:4674790
4- 46748357 
 
TRMU_Ex8 F-tttggtggttggagaatcgt 
R-tgctggaggccttctcaag 
342 Chr22:4674951
3- 46749854 
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Primer Sequence Fragment 
size (bp) 
Position of 
primer 
Optimal 
conditions 
USP8_Ex2 F-accactcatcgtctgctgtg 
R-tgtacgagttcacacattatacacatt 
510 Chr15:5073337
4- 50733883 
 
VDAC1_Ex3 F-cattcagggtcttgcctctt 
R-ccacctgcaacatcagagaa 
460 Chr5:13332649
3- 133326952 
 
List of custom or diagnostic forward and reverse primers used in this thesis for Sanger 
Sequencing. Forward and reverse primer sequences, fragment size (bp), amplified region and 
optimal PCR conditions are given. HS PCR – Hot Start PCR
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Appendix B – Scopus Electronic Search Term Strategy 
Scopus electronic search terms used and the number of relevant articles identified. ‘#’ – number. 
 Search Terms # Entries 
#1 progressive external ophthalmoplegia OR cpeo OR peo 974 
#2 #1 AND (adult-onset OR adult) 608 
#3 #1 AND (polg OR polg1) 107 
#4 #2 AND (polg OR polg1) 67 
#5 #1 AND (polg2) 13 
#6 #1 AND (rrm2b) 10 
#7 #1 AND (tymp OR thymidine phosphorylase) 20 
#8 #7 OR (mngie) 56 
#9 #1 AND (peo1 OR twinkle OR c10orf2) 81 
#10 #1 AND (slc25a4 OR ANT1) 46 
#11 #1 AND (dguok OR deoxyguanosine kinase) 8 
#12 #1 AND (tk2 OR thymidine kinase) 11 
#13 #1 AND opa1 13 
#14 #1 AND (mgme1 OR c20orf72) 0 
#15 mgme1 OR c20orf72 2 
#16 #1 AND dna2 1 
#17 #1 AND mpv17 4 
#18 mpv17 AND ophthalmoplegia 5 
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Appendix C – Medline via PubMed Electronic Search Term Strategy 
 Search Terms # Entries 
#1 (progressive external ophthalmoplegia[MeSH Terms]) AND adult[MeSH Terms] 434 
#2 progressive external ophthalmoplegia[Text Word] OR PEO[Text Word] OR CPEO[Text Word] 1131 
#3 #2 AND adult*[Text Word] 624 
#4 progressive external ophthalmoplegia OR ophthalmoplegia OR ophthalmoparesis OR PEO OR CPEO 8853 
#5 #1 AND polg[Text Word] OR polg1[Text Word] 139 
#6 #4 AND (polg OR polg1) 194 
#7 #1 AND polg2[Text Word] 5 
#8 #4 AND polg2[Text Word] 14 
#9 #1 AND rrm2b[Text Word] 2 
#10 #4 AND rrm2b[Text Word] 9 
#11 #2 AND (tymp[Text Word] OR thymidine phosphorylase[Text Word]) 17 
#12 #2 AND mngie[Text Word] 20 
#13 mngie[Text Word] 115 
#14 #1 AND peo1[Text Word] OR twinkle[Text Word] OR c10orf2[Text Word] 140 
#15 #4 AND (slc25a4[Text Word] OR ant1[Text Word]) 118 
#16 #2 AND (dguok[Text Word] OR deoxyguanosine kinase[Text Word]) 7 
#17 #2 AND (tk2[Text Word] OR thymidine kinase[Text Word]) 14 
#18 #1 AND opa1[Text Word] 4 
#19 ophthalmop*[Text Word] AND opa1[Text Word] 14 
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Medline via PubMed electronic search terms used and the number of relevant articles identified. ‘#’ – number. 
 
 
 
 
 
 
 
 
 
 
 
#20 (mgme1[Text Word] OR c20orf72[Text Word]) 1 
#21 ophthalmop* AND dna2[Text Word] 1 
#22 ophthalmop*[Text Word] AND mpv17[Text Word]  3 
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Appendix D – Genetics Abstracts Electronic Search Term Strategy 
Medline via PubMed electronic search terms used and the number of relevant articles identified. ‘#’ – number. 
 
 Search Terms # Entries 
#1 ophthalmoplegia  147 
#2 #1 AND (polg1 OR polg) 31 
#3 #1 AND (slc25a4 OR ant1) 17 
#4 #1 AND (peo1 OR twinkle OR c10orf2) 29 
#5 #1 AND polg2 6 
#6 #1 AND rrm2b 3 
#7 #1 AND opa1 4 
#8 #1 AND dguok 2 
#9 #1 AND (tk2 OR thymidine kinase) 4 
#10 #1 AND dna2 1 
#11 #1 AND mpv17 1 
#12 #1 AND (tymp OR thymidine phosphorylase) 4 
#13 #12 AND mngie 4 
#14 mngie 26 
#15 #1 AND mgme1 1 
#16 #1 AND #16 10 
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Appendix E – UniProt Electronic Search Term Strategy 
UniProt electronic search terms used and the number of relevant articles identified. ‘#’ – number. 
 
 
 
 Search Terms # Entries 
#1 peo1 16 
#2 polg 26 
#3 polg2 2 
#4 rrm2b 4 
#5 tymp 2 
#6 slc25a4 6 
#7 dguok 2 
#8 tk2 4 
#9 opa1 17 
#10 mgme1 1 
#11 dna2 1 
#12 mpv17 3 
#13 afg3l2 4 
#14 spg7 4 
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Appendix F – Clinical, Molecular and Genetic Data of RRM2B, POLG2, SLC25A4, DGUOK, TK2, OPA1, MPV17, MGME1, DNA2, SPG7, 
AFG3L2, DNM2 and RNASEH1 Mutations Associated with Adult-Onset PEO and Multiple mtDNA Deletions 
Gene cDNA Change Amino Acid Change Associated Phenotypes/Symptoms Effect on mtDNA # Patients Reference(s) 
RRM2B       
 c.48G>A p.(Glu16=) PEO, ptosis, proximal muscle weakness, ataxia, 
fatigue, sensorineural hearing loss, tinnitus, 
hypothyroidism, stroke-like episodes, renal 
disturbance (colics) 
Multiple deletions 3 (Pitceathly et al., 2012) 
 c.97C>T p.(Pro33Ser) PEO, ptosis, hearing loss, muscle weakness, 
depression, anxiety, gonadal atrophy, pigmentary 
retinopathy 
Multiple deletions 1 (Takata et al., 2011) 
 c.121C>T p.(Arg41Trp) PEO, ptosis, migraine, mild neck flexion 
weakness, proximal muscle weakness 
Multiple deletions 1 (Pitceathly et al., 2012) 
 c.122G>A p.(Arg41Gln) PEO, encephalopathy, stroke-like episodes, 
hearing loss, cognitive impairment 
Multiple deletions 1 
 c.208G>A p.(Asp70Asn) PEO, ptosis, ataxia, proximal muscle weakness, 
bulbar involvement, facial muscle weakness, 
ischaemic heart disease, sleep disorder 
Multiple deletions 1 
 c.253_255del p.(Glu85del) PEO, ptosis, mild proximal muscle wasting, 
fatigue 
Multiple deletions 1 (Pitceathly et al., 2011) 
 c.329G>A p.(Arg110His) PEO, ptosis, sensorineural hearing loss, Depletion 1 (Shaibani et al., 2009) 
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Gene cDNA Change Amino Acid Change Associated Phenotypes/Symptoms Effect on mtDNA # Patients Reference(s) 
 c.362G>A p.(Arg121His) peripheral neuropathy, ataxia, dysarthria, 
gastrointestinal dysmotility, cachexia 
 c.583G>A p.(Gly195Arg) PEO, ptosis, proximal muscle weakness, hearing 
loss, dysphonia, ataxia, glaucoma, cataracts 
Multiple deletions 2 (Fratter et al., 2011; 
Pitceathly et al., 2012) 
 c.632G>A p.(Arg211Lys) PEO, ptosis Multiple deletions 1 (Pitceathly et al., 2012) 
 c.671T>G p.(Ile224Ser) PEO, diplopia, proximal muscle weakness, 
cataracts, migraine 
Multiple deletions 1 
 c.950del p.(Leu317*) PEO, ptosis, dysphagia, dysarthria, ataxia, 
proximal myopathy, fatigue, glaucoma 
Multiple deletions 3 (Fratter et al., 2011) 
 c.952G>T p.(Glu318*) PEO, ptosis, dysarthria, dysphagia, fatigue Multiple deletions 1 
 c.965dup p.(Asn322Lysfs*4) PEO, ptosis, dysphagia, ataxia, proximal 
myopathy, fatigue, dysphonia, gastrointestinal 
dysmotility, irritable bowel syndrome, respiratory 
failure 
Multiple deletions 5 (Fratter et al., 2011; 
Pitceathly et al., 2012) 
 c.979C>T p.(Arg327*) PEO, ptosis, exercise intolerance, fatigue, 
reduced reflexes, ataxia, hypoacusis, mood 
disturbance, cognitive dysfunction, diplopia 
Multiple deletions 19 (Tyynismaa et al., 2009a; 
Pitceathly et al., 2012) 
 c.1046C>G p.(Ala349Gly) PEO, ptosis, proximal muscle weakness, fatigue, 
tremor, impaired memory, breast carcinoma 
Multiple deletions 1 (Pitceathly et al., 2012) 
       
POLG2       
 c.1105A>G p.(Arg369Gly) PEO, ptosis, proximal muscle weakness, absent Multiple deletions 2 (Young et al., 2011; Craig 
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Gene cDNA Change Amino Acid Change Associated Phenotypes/Symptoms Effect on mtDNA # Patients Reference(s) 
knee jerks, slurred speech, ataxia, exercise 
intolerance, fatigue, gastrointestinal reflux, 
delayed gastric emptying, respiratory 
deficiency/failure, failure to thrive, apnea, lactic 
acidosis 
et al., 2012) 
 c.1352G>A p.(Gly451Glu) PEO, exercise intolerance, muscle pain, ptosis, 
facial and limb muscle atrophy 
Multiple deletions 1 (Longley et al., 2006) 
       
SLC25A4       
 c.269C>A p.(Ala90Asp) PEO, ptosis, exercise intolerance, limb muscle 
weakness, retinopathy, schizoaffective disorder 
Multiple deletions 3 (Deschauer et al., 2005) 
 c.293T>C p.(Leu98Pro) PEO, ptosis, bipolar affective disorder, facial 
hypokinesia, temporal wasting, ataxic gait, 
peripheral neuropathy, hearing loss, migraines, 
memory lapses, temporoparietal cortex atrophy, 
diabetes mellitus 
Multiple deletions 4 (Napoli et al., 2001; 
Siciliano et al., 2003) 
 c.311A>G p.(Asp104Gly) PEO, ptosis, generalised muscle weakness and 
wasting 
Multiple deletions 4 (Komaki et al., 2002) 
 c.340G>C p.(Ala114Pro) PEO, ptosis, sensorineural hearing loss, 
generalised muscle weakness, hypo- or 
hyperthyroidism, dementia 
Multiple deletions 27 (Kaukonen et al., 2000) 
 c.865G>A p.(Val289Met) PEO, neck and proximal limb muscle weakness, Multiple deletions 1 (Galassi et al., 2008) 
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Gene cDNA Change Amino Acid Change Associated Phenotypes/Symptoms Effect on mtDNA # Patients Reference(s) 
bradykinesia, cogwheel rigidity, slurred speech, 
dysphagia, dysmetria, Romberg sign, postural 
tremor, absent deep tendon reflexes, severe 
depression, insomnia, nocturnal panic attacks 
       
DGUOK       
 c.130G>A  p.(Glu44Lys) PEO, ptosis, limb girdle weakness, dysphagia, 
cramps 
Multiple deletions 1 (Ronchi et al., 2012c) 
 c.462T>A p.(Asn154Lys) Multiple deletions 1 
 c.605_606del  p.(Arg202Tyrfs*12) PEO Multiple deletions 1 
       
TK2       
 c.103C>T p.(Gln32*) PEO, ptosis, sensorineural hearing loss, facial 
muscle weakness, proximal muscle wasting, 
respiratory failure 
Multiple deletions 1 (Alston et al., 2013) 
 c.156+6T>G Splice site PEO, ptosis, dysphagia, facial diplegia, neck 
muscle weakness, EMG myopathic 
Multiple deletions 1 (Garone et al., submitted) 
 c.323C>T p.Thr108Met PEO, dysarthria, dysphagia, respiratory 
insufficiency, EMG myopathic 
Multiple deletions 1 (Garone et al., submitted) 
 c.415G>A p.(Ala139Thr) PEO, ptosis, respiratory insufficiency Multiple deletions 1 Garone et al., submitted) 
 u.k. p.(Asp157Valfs*11) PEO, ptosis, dysphagia, facial diplegia, neck 
muscle weakness, EMG myopathic 
Multiple deletions 1 (Garone et al., submitted) 
 c.547C>T p.(Arg183Trp) PEO, progressive proximal muscle weakness and Multiple deletions 3 (Tyynismaa et al., 2012), 
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Gene cDNA Change Amino Acid Change Associated Phenotypes/Symptoms Effect on mtDNA # Patients Reference(s) 
atrophy, dysphagia, dysarthria, respiratory 
insufficiency 
Garone et al., submitted) 
 c.562A>G p.(Thr188Ala) PEO, progressive proximal muscle weakness and 
atrophy, dysphagia, dysarthria 
Multiple deletions 2 (Tyynismaa et al., 2012) 
 c.582G>T p.(Lys194Asn) PEO, ptosis, sensorineural hearing loss, facial 
muscle weakness, proximal muscle wasting, 
respiratory failure 
Multiple deletions 1 (Alston et al., 2013) 
 c.604_606del p.(Lys202del) PEO, severe ptosis, limb girdle muscle weakness, 
dysphagia, facial diplegia, dysarthria, respiratory 
insufficiency 
Multiple deletions 2 (Camara et al., 2015), 
Garone et al., submitted) 
       
OPA1       
 c.113_130del p.(Arg38_Ser43del) PEO, ptosis, proximal and facial muscle 
weakness, sensorineural hearing loss, migraines, 
anxiety, depression, gastrointestinal dysmobility 
Multiple deletions 1 (Milone et al., 2009) 
 c.610+364G>A Splice acceptor site PEO, optic atrophy, ptosis, cerebellar ataxia, 
muscle atrophy, spasticity, peripheral axonal 
neuropathy, decreased vibratory sense 
n.d. 3 (Bonifert et al., 2014) 
 c.1053T>A p.(Asp351Glu) PEO, ptosis, visual loss, sensorimotor 
neuropathy, proximal muscle weakness, ataxia, 
absent deep tendon reflexes, wide based gait 
n.d. 5 (Ahmad et al., 2015) 
 c.1069G>A p.(Ala357Thr) PEO, optic atrophy, ptosis, sensorineural hearing Multiple deletions 1 (Amati-Bonneau et al., 
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loss, muscle weakness, peripheral axonal 
neuropathy 
2008) 
 c.1198C>T p.(Pro400Ser) PEO, optic atrophy, sensorineural hearing loss Multiple deletions 1 (Yu-Wai-Man et al., 
2010a) 
 c.1294A>G p.(Ile432Val) PEO, optic atrophy, ptosis, fatigue, muscle pain, 
cerebellar ataxia, peripheral axonal neuropathy 
Multiple deletions 1 (Stewart et al., 2008) 
 c.1316G>T p.(Gly439Val) PEO, optic atrophy, sensorineural hearing loss, 
ataxia, Romberg sign, peripheral axonal 
neuropathy 
Multiple deletions 1 (Amati-Bonneau et al., 
2008) 
 c.1334G>A p.(Arg455His) PEO, optic atrophy, ptosis, sensorineural hearing 
loss, exercise intolerance, peripheral axonal 
neuropathy 
Multiple deletions 12 (Payne et al., 2004; Amati-
Bonneau et al., 2008; 
Stewart et al., 2008) 
 c.1345A>C p.(Thr449Pro) PEO, optic atrophy, ataxia, peripheral axonal 
neuropathy, sensorineural hearing loss, 
migraines, nystagmus, pes cavus 
n.d. 4 (Liskova et al., 2013) 
 c.1462G>A p.(Gly488Arg) PEO, optic atrophy, sensorineural hearing loss, 
muscle weakness, gait unsteadiness, peripheral 
axonal neuropathy, ataxia, dementia, migraines, 
epilepsy, Romberg sign, reduced vibration sense, 
weak/absent deep tendon reflexes, bradykinesia, 
rigidity, tremor, cognitive impairment, apnoea, 
Parkinsonism, cardiomyopathy 
Multiple deletions 9 (Yu-Wai-Man et al., 
2010a; Carelli et al., 2015) 
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Gene cDNA Change Amino Acid Change Associated Phenotypes/Symptoms Effect on mtDNA # Patients Reference(s) 
 c.1484C>T p.(Ala495Val) PEO, optic atrophy, sensorineural hearing loss, 
muscle weakness, peripheral axonal neuropathy, 
gait unsteadiness, ataxia, Romberg sign, reduced 
vibration sense, weak/absent deep tendon 
reflexes, bradykinesia, tremor, Parkinsonism  
Multiple deletions 5 (Yu-Wai-Man et al., 
2010a; Carelli et al., 2015) 
 c.1635C>G p.(Ser545Arg) PEO, optic atrophy, ptosis, sensorineural hearing 
loss, ataxia, Romberg sign, diffuse myalgia, 
peripheral axonal neuropathy, gait disturbance 
facial muscle weakness, proximal muscle 
weakness, distal muscle weakness and atrophy, 
spasticity 
Multiple deletions 7 (Amati-Bonneau et al., 
2008; Hudson et al., 2008; 
Yu-Wai-Man et al., 2010a) 
 c.1741A>G p.(Tyr582Cys) PEO, sensorineural hearing loss, macrocytic 
anemia, hypogonadism, central vision loss, mild 
ataxia  
Multiple deletions 1 (Ferraris et al., 2008) 
 c.2708_2711del p.(Val903fs*3) PEO, optic atrophy, sensorineural hearing loss Multiple deletions 1 (Yu-Wai-Man et al., 
2010a) 
 c.2819-1_2821del p.(Lys940_Val942delinsI
) 
PEO, optic atrophy, ptosis, fatigue, pes cavus Multiple deletions 1 (Ranieri et al., 2012) 
       
MPV17       
 c.263A>T p.(Lys88Met) PEO, ptosis, progressive distal and proximal 
muscle weakness, exercise intolerance, axonal 
Multiple deletions 1 (Garone et al., 2012) 
 c.265A>T p.(Met89Leu) 1 
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 c.428T>G p.(Leu143*) sensorimotor peripheral neuropathy, hearing loss, 
gastrointestinal dysmobility, depression, 
parkinsonism, diabetes mellitus, steatohepatitis  
1 
       
MGME1       
 c.456G>A p.(Trp152*) PEO, proximal muscle weakness, generalised 
muscle atrophy, emaciation, respiratory failure, 
mild spinal deformities, renal colics 
Multiple deletions 2 (Kornblum et al., 2013) 
 c.698A>G p.(Tyr233Cys) PEO, proximal muscle weakness, respiratory 
failure, emaciation, cardiac arrhythmias, 
depression, memory loss 
1 
       
DNA2       
 c.2167G>A p.(Val723Ile) PEO, proximal muscle weakness in lower limbs, 
diplopia, myalgia 
Multiple deletions 1 (Ronchi et al., 2013) 
       
SPG7       
 c.233T>A p.(Leu78*) PEO, ptosis, ataxia, spasticity, proximal 
myopathy, moderate dysarthria, bladder 
symptoms 
n.d 2 (Pfeffer et al., 2014) 
 c.861dup p.(Asn288*) PEO, ptosis, proximal myopathy, mild dysphagia, 
ataxia, spasticity 
Multiple deletions 1 
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Gene cDNA Change Amino Acid Change Associated Phenotypes/Symptoms Effect on mtDNA # Patients Reference(s) 
 c.1046insC p.(Gly352Argfs*44) PEO, ptosis, ataxia, spastic ataxia, optic atrophy, 
mild myopathy, cerebellar atrophy 
Multiple deletions 1 
 c.1192C>T p.(Arg398*) PEO, ptosis, ataxia, spasticity, dysphagia, bladder 
symptoms, cerebellar atrophy 
Multiple deletions 2 
 c.1454_1462del p.(Arg485_Glu487del) PEO, ptosis, ataxia, spasticity, dysarthria, upper 
and lower limb hyperreflexia, upper and lower 
limb weakness, bladder symptoms, decreased 
vibratory sense, nystagmus, cognitive impairment   
Multiple deletions 2 (Pfeffer et al., 2014; 
Wedding et al., 2014) 
 c.1529C>T p.(Ala510Val) PEO, ptosis, proximal myopathy, mild dysphagia, 
ataxia, spasticity, bladder symptoms, cerebellar 
atrophy, lower limb proximal weakness, mild 
cognitive impairment, optic atrophy 
Multiple deletions 7 (Pfeffer et al., 2014) 
 c.1672A>T p.(Lys558*) PEO, ptosis, proximal myopathy, mild dysphagia, 
ataxia, spasticity, bladder symptoms, cerebellar 
atrophy 
Multiple deletions 2 (Pfeffer et al., 2014) 
 c.2102A>C p.(His701Pro) PEO, ptosis, dysarthria, upper and lower limb 
hyperreflexia, upper and lower limb weakness, 
spasticity, ataxia, bladder symptoms, decreased 
vibratory sense, nystagmus, cognitive impairment  
n.d. 1 (Wedding et al., 2014) 
 c.2221G>A p.(Glu741Lys) PEO, ptosis, proximal myopathy, ataxia, 
spasticity, dysphagia, dysphonia, dysarthria, optic 
atrophy, cerebellar atrophy 
Multiple deletions 1 (Pfeffer et al., 2014) 
 c.2224G>A p.(Asp742Asn) 1 
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 c.2228T>C p.(Ile743Thr) PEO, ptosis, ataxia, spasticity, dysarthria Multiple deletions 1 
       
AFG3L2       
 c.2011G>T p.(Gly671Trp) PEO, ptosis, lower limb proximal muscle 
weakness, brisk tendon reflexes, flexor plantar 
reflexes, mild dysarthria, dysmetria, ataxic gait, 
slurred speech 
Multiple deletions 1 (Gorman et al., 2015a) 
 c.2065T>C p.(Tyr689His) PEO, ptosis, lower limb proximal weakness, 
brisk tendon reflexes, flexor plantar reflexes, 
mild dysmetria, ataxic gait, cerebellar atrophy  
Multiple deletions 1 
       
DNM2       
 c.1105C>T p.(Arg369Trp) PEO, ptosis, left bundle branch block, blurred 
vision, diplopia, proximal and distal muscle 
weakness, decreased deep tendon reflexes, 
pallhypesthesia, axonal neuropathy, depression, 
paranoia, cognitive decline, EMG myopathic  
Multiple deletions 1 (Gal et al., 2015) 
       
RNASEH1      
 c.424G>A p.(Val142Ile) PEO, ptosis, ataxia, muscle pain, dysphagia, 
speech difficulties, dysarthria, dysphonia, wide-
based gait, exercise intolerance, muscle cramps, 
Multiple deletions 10 (Reyes et al., 2015; 
Akman et al., 2016) 
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lower muscle weakness, respiratory 
insufficiency, cerebellar and brainstem atrophy, 
mild motor demyelinating neuropathy, distal 
clonus, fatigue, right bundle branch block 
 c.469C>T p.(Arg157*) PEO, ptosis, muscle pain, dysphagia, speech 
difficulties, dysarthria, dysphonia, wide-based 
gait, exercise intolerance, muscle cramps, lower 
muscle weakness, respiratory insufficiency, 
cerebellar and brainstem atrophy, mild motor 
demyelinating neuropathy 
Multiple deletions 1 (Reyes et al., 2015) 
 c.554C>T p.(Ala185Val) PEO, ptosis, distal clonus, fatigue, right bundle 
branch block 
Multiple deletions 1 
n.d. – not determined; u.k. – unknown. ‘#’ – number. 
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Appendix G – TYMP Mutations Associated with Adult-Onset PEO and Multiple mtDNA Deletions 
cDNA Change Amino Acid change Effect on mtDNA Reference(s) 
c.131G>A p.(Arg44Gln) n.d. (Gamez et al., 2002) 
c.261G>T p.(Glu87Asp) n.d. (Zimmer et al., 2009) 
c.317G>C p.(Glu106Gln) n.d. (Nakhro et al., 2011) 
c.340G>A p.(Asp114Asn) n.d. (Zimmer et al., 2009) 
u.k. p.(Asp123*) n.d. (Kintarak et al., 2007) 
c.433G>A p.(Gly145Arg) Multiple deletions and depletion (Giordano et al., 2008) 
c.457G>A p.(Gly153Ser) n.d. (Marti et al., 2005) 
c.467A>G p.(Asn156Gly) n.d. (Said et al., 2005) 
c.530T>C p.(Leu177Pro) n.d. (Said et al., 2005) 
c.605G>A p.(Arg202Lys) n.d. (Feddersen et al., 2009) 
c.605G>C p.(Arg202Thr) n.d. (Marti et al., 2005) 
c.622G>A p.(Val208Met) n.d. (Marti et al., 2005) 
c.766G>T p.(Val256Phe) n.d. (Etienne et al., 2012) 
c.854T>C p.(Leu285Pro) n.d. (Marti et al., 2005; Hirano et al., 2006) 
c.856A>C p.(Glu286Lys) n.d. (Amiot et al., 2009) 
c.866A>C p.(Glu289Ala) Multiple deletions and depletion (Blondon et al., 2005b; Said et al., 2005; Giordano et al., 2008; 
Amiot et al., 2009; Filosto et al., 2011; Scarpelli et al., 2013) 
c.928+1G>A Splice mutation n.d. (Amiot et al., 2009) 
c.931G>C p.(Gly311Arg) n.d. (Marti et al., 2005) 
c.1112T>C p.(Leu371Pro) Depletion (Kocaefe et al., 2003; Oztas et al., 2010) 
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c.1135G>A p.(Glu379Lys) Depletion (Massa et al., 2009) 
c.1142T>G p.(Leu381Arg) n.d. (Etienne et al., 2012) 
c.1160-1G>A Splice mutation n.d. (Scarpelli et al., 2013) 
c.1160G>A p.(Gly387Asn) n.d. (Said et al., 2005) 
c.1160-1G>A Splice mutation Depletion (Amiot et al., 2009; Massa et al., 2009; Filosto et al., 2011) 
c.1231_1243del u.k. n.d. (Filosto et al., 2011; Scarpelli et al., 2013) 
c.1412C>T p.(Ala474Val) n.d. (Tan et al., 2012) 
c.1460_1479del u.k. Multiple deletions (Blazquez et al., 2005) 
u.k. u.k. Depletion (Kocaefe et al., 2003) 
u.k. u.k. n.d. (Bedlack et al., 2004) 
u.k. Splice mutation Depletion (Kocaefe et al., 2003) 
u.k. Splice mutation Depletion (Kocaefe et al., 2003) 
IVS1-1G>C Splice mutation n.d. (Szigeti et al., 2004) 
IVS9-1G>C Splice mutation Multiple deletions and depletion (Giordano et al., 2008; Kalkan et al., 2012) 
IVS5+1G>A Splice mutation n.d. (Laforce et al., 2009) 
u.k. u.k. n.d. (Tan et al., 2012) 
n.d. – not determined; u.k. – unknown. 
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Appendix H – POLG Clinical Manifestations in Adult-Onset PEO and Multiple mtDNA Deletion Patients from the Literature 
Finding Manifestation Reference(s) 
Psychiatric Illness Depression (Lamantea et al., 2002; Van Goethem et al., 2003a; Luoma et al., 2004; Mancuso et al., 2004a; Kollberg 
et al., 2005; Hudson et al., 2007; Galassi et al., 2008; Schulte et al., 2009; Echaniz-Laguna et al., 2010b; 
Synofzik et al., 2010a; Gurgel-Giannetti et al., 2012; Palin et al., 2012; Dolhun et al., 2013) 
 Psychosis (Hakonen et al., 2005; Horvath et al., 2006a; Schulte et al., 2009; Kinghorn et al., 2013) 
 Cognitive Decline (Mancuso et al., 2004a; Van Goethem et al., 2004; Hakonen et al., 2005; Luoma et al., 2005; Naimi et 
al., 2006; Invernizzi et al., 2008; Milone et al., 2008; Paus et al., 2008; Betts-Henderson et al., 2009; 
Schulte et al., 2009; Echaniz-Laguna et al., 2010b; Martikainen et al., 2010; McHugh et al., 2010; 
Synofzik et al., 2010b; Smits et al., 2011a; Gurgel-Giannetti et al., 2012; Hansen et al., 2012; Tang et 
al., 2012; Roos et al., 2013b; Yu-Wai-Man et al., 2013; Hanisch et al., 2014; Horga et al., 2014; 
Delgado-Alvarado et al., 2015) 
 Dementia (Van Goethem et al., 2004; Horvath et al., 2006a; Komulainen et al., 2010; Martikainen et al., 2010; 
Dolhun et al., 2013; Roos et al., 2013b) 
 Intellectual Disability (Kollberg et al., 2005; Blok et al., 2009) 
Seizure Disorder Status Epilepticus (Van Goethem et al., 2004; Hakonen et al., 2005; Winterthun et al., 2005; Naimi et al., 2006; Tzoulis et 
al., 2006; Paus et al., 2008; Schulte et al., 2009; Hansen et al., 2012; Lax et al., 2012; Neeve et al., 2012; 
Palin et al., 2012; Woodbridge et al., 2013; Yu-Wai-Man et al., 2013) 
 Grand Mal Epilepsy (Neeve et al., 2012) 
 Myoclonus (Van Goethem et al., 2004; Hakonen et al., 2005; Winterthun et al., 2005; Horvath et al., 2006a; Tzoulis 
et al., 2006; Johansen et al., 2008; Remes et al., 2008; Neeve et al., 2012; Horga et al., 2014) 
 Focal Motor Seizures (Tzoulis et al., 2006; Neeve et al., 2012) 
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 Generalised Seizure (Winterthun et al., 2005; Stewart et al., 2009; Synofzik et al., 2010b; Kinghorn et al., 2013; Hanisch et 
al., 2014; Rajakulendran et al., 2016)       
Extrapyramidal Movement 
Disorder 
Parkinsonism (Lamantea et al., 2002; Van Goethem et al., 2003a; Luoma et al., 2004; Mancuso et al., 2004b; Hisama 
et al., 2005; Pagnamenta et al., 2006; Hudson et al., 2007; Galassi et al., 2008; Invernizzi et al., 2008; 
Johansen et al., 2008; Remes et al., 2008; Betts-Henderson et al., 2009; Synofzik et al., 2010a; Ferreira 
et al., 2011a; Milone et al., 2011; Sato et al., 2011; Gurgel-Giannetti et al., 2012; Brandon et al., 2013; 
Dolhun et al., 2013; Mukai et al., 2013; Horga et al., 2014; Miguel et al., 2014; Delgado-Alvarado et al., 
2015; Martikainen et al., 2016) 
 Chorea (Hakonen et al., 2005) 
 Dystonia (Paus et al., 2008; Remes et al., 2008; Horga et al., 2014; Rajakulendran et al., 2016) 
Cerebellar Involvement Ataxia (Lamantea et al., 2002; Filosto et al., 2003; Van Goethem et al., 2003b; Mancuso et al., 2004a; Hakonen 
et al., 2005; Hisama et al., 2005; Kollberg et al., 2005; Winterthun et al., 2005; Horvath et al., 2006a; 
Hudson et al., 2006; Naimi et al., 2006; Tzoulis et al., 2006; Hudson et al., 2007; Johansen et al., 2008; 
Milone et al., 2008; Paus et al., 2008; Remes et al., 2008; Wong et al., 2008; Blok et al., 2009; Schulte et 
al., 2009; Stewart et al., 2009; Echaniz-Laguna et al., 2010b; McHugh et al., 2010; Synofzik et al., 
2010b; Gati et al., 2011; Smits et al., 2011a; Bostan et al., 2012; Gurgel-Giannetti et al., 2012; Hansen et 
al., 2012; Lax et al., 2012; Neeve et al., 2012; Palin et al., 2012; Tang et al., 2012; Brandon et al., 2013; 
Degos et al., 2013; Kinghorn et al., 2013; Mukai et al., 2013; Woodbridge et al., 2013; Yu-Wai-Man et 
al., 2013; Hanisch et al., 2014; Horga et al., 2014; Henao et al., 2016; Martikainen et al., 2016; Mongin 
et al., 2016; Rajakulendran et al., 2016)   
“Cerebrovascular” 
Involvement 
Migraine (Winterthun et al., 2005; Tzoulis et al., 2006; Paus et al., 2008; Tang et al., 2012; Brandon et al., 2013; 
Woodbridge et al., 2013) 
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Finding Manifestation Reference(s) 
 Relapsing/Remitting 
Neurological Events 
(Degos et al., 2013) 
 Stroke-like Episodes (Neeve et al., 2012; Rajakulendran et al., 2016) 
 Hypertrophic Olivary 
Degeneration 
(Kinghorn et al., 2013) 
Special Sensory Sensorineural Hearing Loss (Di Fonzo et al., 2003; Van Goethem et al., 2003b; Mancuso et al., 2004a; Gonzalez-Vioque et al., 2006; 
Horvath et al., 2006a; Hudson et al., 2007; Milone et al., 2008; Wong et al., 2008; Stewart et al., 2009; 
Tzoulis et al., 2009; Echaniz-Laguna et al., 2010b; Komulainen et al., 2010; Milone et al., 2011; Tang et 
al., 2012; Brandon et al., 2013; Cheldi et al., 2013; Kinghorn et al., 2013; Woodbridge et al., 2013; 
Martikainen et al., 2016) 
 Retinitis Pigmentosa (Del Bo et al., 2003; Di Fonzo et al., 2003; Blok et al., 2009) 
Myopathy Proximal Myopathy (Lamantea et al., 2002; Di Fonzo et al., 2003; Filosto et al., 2003; Van Goethem et al., 2003a; Luoma et 
al., 2004; Mancuso et al., 2004b; Luoma et al., 2005; Gonzalez-Vioque et al., 2006; Horvath et al., 
2006a; Hudson et al., 2006; Santoro et al., 2006; Hudson et al., 2007; Galassi et al., 2008; Invernizzi et 
al., 2008; Milone et al., 2008; Betts-Henderson et al., 2009; Blok et al., 2009; Stewart et al., 2009; 
Echaniz-Laguna et al., 2010b; Martikainen et al., 2010; McHugh et al., 2010; Schicks et al., 2010; 
Baruffini et al., 2011; Ferreira et al., 2011a; Smits et al., 2011a; Bostan et al., 2012; Gurgel-Giannetti et 
al., 2012; Lax et al., 2012; Neeve et al., 2012; Tang et al., 2012; Roos et al., 2013b; Woodbridge et al., 
2013; Yu-Wai-Man et al., 2013; Horga et al., 2014; Martikainen et al., 2016) 
 Distal Myopathy (Lamantea et al., 2002; Di Fonzo et al., 2003; Mancuso et al., 2004a; Gago et al., 2006; Hudson et al., 
2006; Santoro et al., 2006; Schulte et al., 2009; McHugh et al., 2010; Mukai et al., 2013; Horga et al., 
2014; Miguel et al., 2014; Rajakulendran et al., 2016) 
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Finding Manifestation Reference(s) 
 Exercise Intolerance (Di Fonzo et al., 2003; Filosto et al., 2003; Luoma et al., 2004; Mancuso et al., 2004a; Mancuso et al., 
2004b; Hakonen et al., 2005; Milone et al., 2008; Wong et al., 2008; Blok et al., 2009; Milone et al., 
2011; Tang et al., 2012; Woodbridge et al., 2013) 
Peripheral Neuropathy Sensory 
Neuronopathy/Ganglionopathy 
(Del Bo et al., 2003; Di Fonzo et al., 2003; Filosto et al., 2003; Van Goethem et al., 2003b; Mancuso et 
al., 2004a; Mancuso et al., 2004b; Hakonen et al., 2005; Hisama et al., 2005; Luoma et al., 2005; 
Gonzalez-Vioque et al., 2006; Santoro et al., 2006; Johansen et al., 2008; Milone et al., 2008; Schulte et 
al., 2009; Stewart et al., 2009; Tzoulis et al., 2009; Komulainen et al., 2010; McHugh et al., 2010; 
Schicks et al., 2010; Synofzik et al., 2010b; Gati et al., 2011; Smits et al., 2011a; Bostan et al., 2012; 
Gurgel-Giannetti et al., 2012; Lax et al., 2012; Neeve et al., 2012; Tang et al., 2012; Dolhun et al., 2013; 
Kinghorn et al., 2013; Woodbridge et al., 2013; Mongin et al., 2016) 
 Axonal Sensorimotor 
Neuropathy 
(Di Fonzo et al., 2003; Mancuso et al., 2004a; Mancuso et al., 2004b; Hisama et al., 2005; Horvath et al., 
2006a; Milone et al., 2008; Remes et al., 2008; Stewart et al., 2009; Tzoulis et al., 2009; Gati et al., 
2011; Bostan et al., 2012; Hansen et al., 2012; Lax et al., 2012; Neeve et al., 2012; Tang et al., 2012; 
Degos et al., 2013; Mukai et al., 2013; Hanisch et al., 2014; Horga et al., 2014; Miguel et al., 2014; 
Bindu et al., 2016; Henao et al., 2016; Rajakulendran et al., 2016) 
Endocrine/Gonadal system Diabetes Mellitus (Horvath et al., 2006a; Blok et al., 2009; Komulainen et al., 2010; Roos et al., 2013b; Hanisch et al., 
2014) 
 Primary Ovarian Failure (Pagnamenta et al., 2006; Hudson et al., 2007; Blok et al., 2009; Baruffini et al., 2011) 
 Hypothyroidism (Tzoulis et al., 2009; Gurgel-Giannetti et al., 2012) 
 Hypogonadism (Kollberg et al., 2005; Milone et al., 2008) 
Gastrointestinal System Gastrointestinal Dysmotility; 
Constipation/Diarrhoea; 
(Filosto et al., 2003; Van Goethem et al., 2003a; Bostan et al., 2012; Tang et al., 2012; Woodbridge et 
al., 2013; Horga et al., 2014) 
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Finding Manifestation Reference(s) 
Gastroparesis; Bowel 
Obstruction; Cachexia 
 Liver Failure (Neeve et al., 2012) 
Heart Cardiomyopathy (Van Goethem et al., 2003b; Gonzalez-Vioque et al., 2006; Horvath et al., 2006a; Komulainen et al., 
2010; Palin et al., 2012; Brandon et al., 2013; Mukai et al., 2013) 
Ocular Cataract (Filosto et al., 2003; Kollberg et al., 2005; Milone et al., 2011; Gurgel-Giannetti et al., 2012; Brandon et 
al., 2013) 
 Diplopia (Mancuso et al., 2004b; Gago et al., 2006; Tzoulis et al., 2009; Ferreira et al., 2011a; Sato et al., 2011; 
Palin et al., 2012; Degos et al., 2013; Kinghorn et al., 2013; Yu-Wai-Man et al., 2013; Miguel et al., 
2014; Rajakulendran et al., 2016) 
Other Dysarthria (Van Goethem et al., 2003b; Mancuso et al., 2004a; Hakonen et al., 2005; Luoma et al., 2005; Gago et 
al., 2006; Johansen et al., 2008; Milone et al., 2008; Paus et al., 2008; Betts-Henderson et al., 2009; Blok 
et al., 2009; Schulte et al., 2009; McHugh et al., 2010; Schicks et al., 2010; Gati et al., 2011; Bostan et 
al., 2012; Hansen et al., 2012; Lax et al., 2012; Neeve et al., 2012; Palin et al., 2012; Brandon et al., 
2013; Cheldi et al., 2013; Kinghorn et al., 2013; Roos et al., 2013b; Woodbridge et al., 2013; Horga et 
al., 2014; Miguel et al., 2014; Mongin et al., 2016; Rajakulendran et al., 2016) 
 Dysphagia (Lamantea et al., 2002; Del Bo et al., 2003; Di Fonzo et al., 2003; Hakonen et al., 2005; Gago et al., 
2006; Horvath et al., 2006a; Hudson et al., 2006; Santoro et al., 2006; Invernizzi et al., 2008; Milone et 
al., 2008; Betts-Henderson et al., 2009; Schulte et al., 2009; Stewart et al., 2009; Echaniz-Laguna et al., 
2010b; Komulainen et al., 2010; Ferreira et al., 2011a; Gati et al., 2011; Milone et al., 2011; Brandon et 
al., 2013; Cheldi et al., 2013; Roos et al., 2013b; Horga et al., 2014; Miguel et al., 2014; Da Pozzo et al., 
2015; Rajakulendran et al., 2016) 
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Finding Manifestation Reference(s) 
 Dysphonia (Lamantea et al., 2002; Santoro et al., 2006; Invernizzi et al., 2008; Betts-Henderson et al., 2009; 
Ferreira et al., 2011a; Delgado-Alvarado et al., 2015) 
 Hypoacusis (Di Fonzo et al., 2003; Schicks et al., 2010) 
 Asthma (Gurgel-Giannetti et al., 2012) 
 Pes Cavus (Hakonen et al., 2005; Santoro et al., 2006) 
 Developmental Delay (Wong et al., 2008) 
 Short Stature (Da Pozzo et al., 2015) 
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Appendix I – POLG Mutations Associated with Adult-Onset PEO and Multiple mtDNA Deletions 
cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.8G>C p.(Arg3Pro) Multiple deletions (Van Goethem et al., 2001) 
c.82A>T p.(Ser28Cys) n.d. (Tang et al., 2012) 
c.487C>T p.(Pro163Ser) n.d. (Woodbridge et al., 2013) 
c.679C>T p.(Arg227Trp) Multiple deletions (Lamantea et al., 2002; Agostino et al., 2003; Horvath et al., 2006a; Horga et al., 
2014) 
c.752C>T p.(Thr251Ile) Multiple deletions and depletion (Lamantea et al., 2002; Agostino et al., 2003; Del Bo et al., 2003; Di Fonzo et al., 
2003; Lamantea and Zeviani, 2004; Kollberg et al., 2005; Gonzalez-Vioque et al., 
2006; Horvath et al., 2006a; Blok et al., 2009; Stewart et al., 2009; Tzoulis et al., 
2009; Gati et al., 2011; Cheldi et al., 2013; Hanisch et al., 2014; Miguel et al., 2014) 
c.803>C p.(Gly268Ala) Multiple deletions (Del Bo et al., 2003; Di Fonzo et al., 2003; Gonzalez-Vioque et al., 2006) 
c.823C>T p.(Arg275*) n.d. (Blok et al., 2009) 
c.824G>A p.(Arg275Gln) Multiple deletions (Echaniz-Laguna et al., 2010b) 
c.830A>T p.(His277Leu) n.d. (Sato et al., 2011) 
c.911T>G p.(Leu304Arg) Multiple deletions (Van Goethem et al., 2001; Horvath et al., 2006a; Naimi et al., 2006; Bindu et al., 
2016) 
c.926G>T p.(Arg309Leu) n.d. (Lamantea et al., 2002) 
c.934T>C p.(Trp312Arg) Multiple deletions (Agostino et al., 2003; Del Bo et al., 2003; Horvath et al., 2006a) 
c.1139G>A p.(Gly380Asp) Multiple deletions (Naimi et al., 2006) 
c.1190C>T p.(Ala397Val) Multiple deletions and depletion (Degos et al., 2013) 
c.1250+5G>C Splice-site variant n.d. (Martikainen et al., 2016) 
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cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.1270_1271del p.(Leu424Glyfs*28) Multiple deletions (Agostino et al., 2003) 
c.1288A>T p.(Met430Leu) Multiple deletions (Invernizzi et al., 2008; Ferreira et al., 2011a) 
c.1292G>T p.(Gly431Val) Multiple deletions (Agostino et al., 2003) 
c.1298C>G p.(Ser433Cys) Multiple deletions (Horvath et al., 2006a; Hudson et al., 2006) 
c.1356T>G p.(Tyr452*) Multiple deletions (Hudson et al., 2006; Echaniz-Laguna et al., 2010b) 
c.1389G>T p.(Leu463Phe) Multiple deletions (Hudson et al., 2007) 
c.1399G>A p.(Ala467Thr) Multiple deletions and depletion (Van Goethem et al., 2001; Agostino et al., 2003; Di Fonzo et al., 2003; Van Goethem 
et al., 2003b; Luoma et al., 2005; Winterthun et al., 2005; Gonzalez-Vioque et al., 
2006; Horvath et al., 2006a; Naimi et al., 2006; Tzoulis et al., 2006; Milone et al., 
2008; Paus et al., 2008; Blok et al., 2009; Schulte et al., 2009; Stewart et al., 2009; 
Echaniz-Laguna et al., 2010b; McHugh et al., 2010; Schicks et al., 2010; Gati et al., 
2011; Smits et al., 2011a; Hansen et al., 2012; Lax et al., 2012; Neeve et al., 2012; 
Tang et al., 2012; Kinghorn et al., 2013; Yu-Wai-Man et al., 2013; Hanisch et al., 
2014; Horga et al., 2014; Martikainen et al., 2016; Rajakulendran et al., 2016) 
c.1402A>G p.(Asn468Asp) Multiple deletions (Luoma et al., 2004; Gonzalez-Vioque et al., 2006; Schulte et al., 2009) 
c.1457G>A p.(Trp486*) n.d. (Miguel et al., 2014) 
c.1534G>A p.(Ser511Asn) Multiple deletions (Hudson et al., 2007) 
c.1535A>T p.(Lys512Met) n.d. (Dolhun et al., 2013) 
c.1550G>T p.(Gly517Val) Multiple deletions (Schulte et al., 2009; Ferreira et al., 2011a; Woodbridge et al., 2013) 
c.1676T>C p.(Leu559Pro) n.d. (Horga et al., 2014) 
c.1685G>A p.(Arg562Gln) Multiple deletions (Di Fonzo et al., 2003) 
c.1720C>T p.(Arg574Trp) Multiple deletions (Horvath et al., 2006a) 
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cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.1735C>T p.(Arg579Trp) Multiple deletions (Filosto et al., 2003) 
c.1754G>A p.(Trp585*) Multiple deletions (Ferreira et al., 2011a) 
c.1760C>T p.(Pro587Leu) Multiple deletions and depletion (Lamantea et al., 2002; Di Fonzo et al., 2003; Filosto et al., 2003; Lamantea and 
Zeviani, 2004; Kollberg et al., 2005; Gonzalez-Vioque et al., 2006; Horvath et al., 
2006a; Blok et al., 2009; Stewart et al., 2009; Tzoulis et al., 2009; Cheldi et al., 2013; 
Hanisch et al., 2014; Horga et al., 2014; Miguel et al., 2014) 
c.1807A>T p.(Met603Leu) Multiple deletions (Gonzalez-Vioque et al., 2006) 
c.1879C>T p.(Arg627Trp) Multiple deletions (Van Goethem et al., 2003b; Horvath et al., 2006a) 
c.1880G>A p.(Arg627Gln) Multiple deletions (Schicks et al., 2010) (Luoma et al., 2005; Horvath et al., 2006a; Schulte et al., 2009) 
c.1943C>G p.(Pro648Arg) Multiple deletions (Gago et al., 2006; Horvath et al., 2006a; Remes et al., 2008; Miguel et al., 2014) 
c.2125C>T p.(Arg709*) Multiple deletions (Del Bo et al., 2003; Di Fonzo et al., 2003) 
c.2447G>A p.(Arg722His) Multiple deletions (Komulainen et al., 2010) 
c.2209G>C p.(Gly737Arg) Multiple deletions (Milone et al., 2008; Tzoulis et al., 2009) 
c.2236G>A p.(Gly746Ser) Multiple deletions (Stewart et al., 2009; Lax et al., 2012) 
c.2243G>C p.(Trp748Ser) Multiple deletions and depletion (Van Goethem et al., 2004; Hakonen et al., 2005; Winterthun et al., 2005; Horvath et 
al., 2006a; Naimi et al., 2006; Tzoulis et al., 2006; Johansen et al., 2008; Milone et 
al., 2008; Paus et al., 2008; Remes et al., 2008; Blok et al., 2009; Schulte et al., 2009; 
Stewart et al., 2009; Tzoulis et al., 2009; Schicks et al., 2010; Synofzik et al., 2010b; 
Gati et al., 2011; Smits et al., 2011a; Hansen et al., 2012; Lax et al., 2012; Palin et al., 
2012; Tang et al., 2012; Kinghorn et al., 2013; Yu-Wai-Man et al., 2013; Hanisch et 
al., 2014; Horga et al., 2014; Henao et al., 2016; Mongin et al., 2016) 
c.2287G>C p.(Gly763Arg) Multiple deletions (Santoro et al., 2006) 
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cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.2293C>A p.(Pro765Thr) n.d. (Bostan et al., 2012) 
c.2354ins p.(Gly785fs21*) n.d. (Lamantea et al., 2002) 
c.2419C>T p.(Arg807Cys) Multiple deletions (Gago et al., 2006; Ferreira et al., 2011a; Miguel et al., 2014) 
c.2420G>C p.(Arg807Pro) Multiple deletions (Del Bo et al., 2003; Di Fonzo et al., 2003) 
c.2492A>G p.(Tyr831Cys) Multiple deletions (Mancuso et al., 2004b; Wong et al., 2008; Woodbridge et al., 2013) 
c.2542G>A p.(Gly848Ser) Multiple deletions (Lamantea et al., 2002; Van Goethem et al., 2003a; Kollberg et al., 2005; Betts-
Henderson et al., 2009; Schulte et al., 2009; Schicks et al., 2010; Ferreira et al., 
2011a; Gati et al., 2011; Lax et al., 2012) 
c.2551A>G p.(Thr851Ala) n.d. (Woodbridge et al., 2013) 
c.2557C>T p.(Arg853Trp) Multiple deletions (Gonzalez-Vioque et al., 2006) 
c.2564T>C p.(Val855Ala) Multiple deletions and depletion (Degos et al., 2013) 
c.2584G>A p.(Ala862Thr) Multiple deletions (Stewart et al., 2009; Lax et al., 2012) 
c.2606G>A p.(Arg869Gln) Multiple deletions (Hanisch et al., 2014) 
c.2665G>A p.(Ala889Thr) Multiple deletions (Filosto et al., 2003; Hisama et al., 2005) 
c.2740A>C p.(Thr914Pro) Multiple deletions and depletion (Wong et al., 2008; Roos et al., 2013b) 
c.2740A>G p.(Thr914Ala) Multiple deletions (Echaniz-Laguna et al., 2010b) 
c.2752T>C p.(Trp918Arg) Multiple deletions (Invernizzi et al., 2008; Ferreira et al., 2011a) 
c.2768G>A p.(Gly923Asp) n.d. (Lamantea et al., 2002) 
c.2794C>T p.(His932Tyr) Multiple deletions (Di Fonzo et al., 2003; Mancuso et al., 2004a) 
c.2827C>T p.(Arg943Cys) n.d. (Sato et al., 2011) 
c.2828G>A p.(Arg943His) Multiple deletions (Lamantea et al., 2002; Blok et al., 2009; Brandon et al., 2013) 
c.2831A>G p.(Glu944Gly) Multiple deletions (Da Pozzo et al., 2015) 
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cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.2834A>T p.(His945Leu) Multiple deletions (Delgado-Alvarado et al., 2015) 
c.2840G>A p.(Lys947Arg) n.d. (Baruffini et al., 2011) 
c.2857C>T p.(Arg953Cys) Multiple deletions and depletion (Gurgel-Giannetti et al., 2012; Tang et al., 2012) 
c.2864A>G p.(Tyr955Cys) Multiple deletions and depletion (Van Goethem et al., 2001; Lamantea et al., 2002; Luoma et al., 2004; Kollberg et al., 
2005; Pagnamenta et al., 2006; Ferreira et al., 2011a; Mukai et al., 2013; Horga et al., 
2014; Martikainen et al., 2016) 
c.2869G>T p.(Ala957Ser) n.d. (Lamantea et al., 2002) 
c.2894T>G p.(Leu965*) Multiple deletions (Horvath et al., 2006a) 
c.2993C>T p.(Ser998Leu) Multiple deletions (Martikainen et al., 2010) 
c.3104 + 3A>T Splice mutation Multiple deletions and depletion (Milone et al., 2011; Roos et al., 2013b) 
c.3139C>T p.(Arg1047Trp) Multiple deletions (Stewart et al., 2009; Lax et al., 2012) 
c.3140G>A p.(Arg1047Gln) Multiple deletions (Agostino et al., 2003) 
c.3151G>C p.(Gly1051Arg) n.d. (Mancuso et al., 2004a) 
c.3235A>C p.(Ile1079Leu) n.d. (Wong et al., 2008) 
c.3240_3242dup p.(Arg1081dup) Multiple deletions (Horga et al., 2014) 
c.3285C>G p.(Ser1095Arg) n.d. (Wong et al., 2008) 
c.3286C>T p.(Arg1096Cys) Multiple deletions (Agostino et al., 2003; Horvath et al., 2006a; Lax et al., 2012; Yu-Wai-Man et al., 
2013) 
c.3287G>A p.(Arg1096His) n.d. (Schulte et al., 2009; Schicks et al., 2010) 
c.3311C>G p.(Ser1104Cys) Multiple deletions (Agostino et al., 2003; Betts-Henderson et al., 2009) 
c.3313G>A p.(Ala1105Thr) Multiple deletions (Luoma et al., 2004) 
c.3316G>A p.(Val1106Ile) n.d. (Lamantea and Zeviani, 2004) 
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cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.3412C>T p.(Arg1138Cys) Multiple deletions and depletion (Milone et al., 2008) 
c.3428A>G p.(Glu1143Gly) Multiple deletions and depletion (Di Fonzo et al., 2003; Van Goethem et al., 2004; Hisama et al., 2005; Horvath et al., 
2006a; Hudson et al., 2006; Milone et al., 2008; Paus et al., 2008; Remes et al., 2008; 
Palin et al., 2012) 
c.3527C>T p.(Ser1176Leu) n.d. (Lamantea et al., 2002) 
c.3550G>A p.(Asp1184Asn) Multiple deletions (Gonzalez-Vioque et al., 2006) 
c.3550G>C p.(Asp1184His) Multiple deletions (Martikainen et al., 2010) 
c.3556G>C p.(Asp1186His) Multiple deletions (Cheldi et al., 2013) 
c.3594ins p.(Thr1199fs1215*) n.d. (Schulte et al., 2009; Schicks et al., 2010) 
c.3708G>T p.(Gln1236His) Multiple deletions (Di Fonzo et al., 2003; Luoma et al., 2005; Horvath et al., 2006a) 
c.3715T>C p.(*1240Glnins35) Multiple deletions (Lax et al., 2012; Yu-Wai-Man et al., 2013; Horga et al., 2014) 
n.d. – not determined. 
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Appendix J – TWNK Clinical Manifestations in Adult-Onset PEO and Multiple mtDNA Deletion Patients from the Literature 
Finding Manifestation # Patients Reference(s) 
Psychiatric Illness Depression 7 (Spelbrink et al., 2001; Van Goethem et al., 2003a; Baloh et al., 2007; Virgilio et al., 
2008; Bohlega et al., 2009; Van Hove et al., 2009) 
 Cognitive Decline 1 (Van Hove et al., 2009) 
 Dementia 4 (Hudson et al., 2005; Echaniz-Laguna et al., 2010a) 
Seizure Disorder Status Epilepticus 1 (Hudson et al., 2005) 
Extrapyramidal Movement 
Disorder 
Parkinsonism 6 (Van Goethem et al., 2003a; Baloh et al., 2007; Liu et al., 2008; Vandenberghe et al., 
2009; Brandon et al., 2013; Kiferle et al., 2013) 
 Orthostatic Tremor 1 (Milone et al., 2013) 
Cerebellar Involvement Ataxia 5 (Hudson et al., 2005; Van Hove et al., 2009; Echaniz-Laguna et al., 2010a) 
“Cerebrovascular” 
Involvement 
Migraine 1 (Virgilio et al., 2008) 
Special Sensory Sensorineural Hearing Loss 10 (Kiechl et al., 2004; Houshmand et al., 2006; Van Hove et al., 2009; Echaniz-Laguna et 
al., 2010a; Fratter et al., 2010; Park et al., 2011) 
Myopathy Proximal Myopathy 56 (Spelbrink et al., 2001; Lewis et al., 2002; Agostino et al., 2003; Van Goethem et al., 
2003a; Kiechl et al., 2004; Wanrooij et al., 2004; Hudson et al., 2005; Houshmand et 
al., 2006; Naimi et al., 2006; Baloh et al., 2007; Rivera et al., 2007; Jeppesen et al., 
2008; Virgilio et al., 2008; Massa et al., 2009; Negro et al., 2009; Van Hove et al., 
2009; Echaniz-Laguna et al., 2010a; Fratter et al., 2010; Hong et al., 2010; Park et al., 
2011; Ronchi et al., 2011; Brandon et al., 2013; Yu-Wai-Man et al., 2013; Ji et al., 
2014; Paramasivam et al., 2016) 
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Finding Manifestation # Patients Reference(s) 
 Distal Myopathy 2 (Martin-Negrier et al., 2011; Ji et al., 2014) 
 Exercise Intolerance 4 (Kiechl et al., 2004; Jeppesen et al., 2008; Bohlega et al., 2009; Paramasivam et al., 
2016) 
Peripheral Neuropathy Sensory 
Neuronopathy/Ganglionopathy 
8 (Hudson et al., 2005; Van Hove et al., 2009; Echaniz-Laguna et al., 2010a; Fratter et 
al., 2010; Park et al., 2011) 
 Axonal Sensorimotor 
Neuropathy 
5 (Kiechl et al., 2004; Baloh et al., 2007; Park et al., 2011; Kiferle et al., 2013; Milone et 
al., 2013)   
Endocrine/Gonadal System Diabetes Mellitus 5 (Kiechl et al., 2004; Hudson et al., 2005; Houshmand et al., 2006; Bohlega et al., 2009; 
Van Hove et al., 2009) 
 Primary Ovarian Failure 2 (Virgilio et al., 2008; Fratter et al., 2010) 
 Hypothyroidism 9 (Houshmand et al., 2006; Virgilio et al., 2008; Bohlega et al., 2009; Milone et al., 
2013) 
 Thyroid-Resistance Syndrome 1 (Ronchi et al., 2011) 
Gastrointestinal system Gastrointestinal Dysmotility 1 (Nakhro et al., 2011) 
 Constipation/Diarrhoea 2 (Houshmand et al., 2006; Fratter et al., 2010) 
 Cachexia 2 (Van Goethem et al., 2003a; Nakhro et al., 2011) 
Heart Cardiomyopathy 11 (Spelbrink et al., 2001; Lewis et al., 2002; Houshmand et al., 2006; Bohlega et al., 
2009; Negro et al., 2009; Fratter et al., 2010; Hong et al., 2010; Milone et al., 2013) 
Ocular Cataract 5 (Houshmand et al., 2006; Virgilio et al., 2008; Van Hove et al., 2009; Fratter et al., 
2010) 
 Diplopia 8 (Houshmand et al., 2006; Liu et al., 2008; Virgilio et al., 2008; Ronchi et al., 2011; 
Kiferle et al., 2013) 
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Other Short Stature 1 (Da Pozzo et al., 2015) 
‘#’ – number. 
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Appendix K – TWNK Mutations Associated with Adult-Onset PEO and Multiple mtDNA Deletions 
cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.907C>T p.(Arg303Trp) Multiple deletions (Agostino et al., 2003; Houshmand et al., 2006; Virgilio et al., 2008; Negro et al., 2009; 
Fratter et al., 2010; Brandon et al., 2013) 
c.908G>A  p.(Arg303Gln) Multiple deletions (Van Hove et al., 2009) 
c.944G>T p.(Trp315Leu) Multiple deletions (Spelbrink et al., 2001) 
c.944G>C p.(Trp315Ser) Multiple deletions (Virgilio et al., 2008) 
c.955A>G p.(Lys319Glu) Multiple deletions (Hudson et al., 2005) 
c.956A>C p.(Lys319Thr) Multiple deletions (Deschauer et al., 2003) 
c.1001G>C p.(Arg334Pro) Multiple deletions (Virgilio et al., 2008) 
c.1001G>A p.(Arg334Gln) Multiple deletions (Agostino et al., 2003; Houshmand et al., 2006; Vandenberghe et al., 2009; Fratter et al., 
2010; Yu-Wai-Man et al., 2013) 
c.1061G>C p.(Arg354Pro) Multiple deletions (Spelbrink et al., 2001; Ji et al., 2014) 
c.1071G>C p.(Arg357Pro) Multiple deletions (Rivera et al., 2007) 
c.1075G>A p.(Ala359Thr) Multiple deletions (Spelbrink et al., 2001; Kiferle et al., 2013) 
c.1078C>G 
c.1079T>G 
p.(Leu360Gly) Multiple deletions (Bohlega et al., 2009) 
c.1053_1092dup (p.Asn352_Trp364dup) Multiple deletions (Spelbrink et al., 2001; Wanrooij et al., 2004) 
c.1088G>T p.(Trp363Thr) Multiple deletions (Fratter et al., 2010) 
c.1100T>C p.(Ile367Thr) Multiple deletions (Spelbrink et al., 2001) 
c.1105T>C p.(Ser369Pro) Multiple deletions (Spelbrink et al., 2001) 
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cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.1106C>A p.(Ser369Tyr) Multiple deletions (Lewis et al., 2002) 
c.1110C>A p.(Phe370Leu) Multiple deletions and 
depletion 
(Jeppesen et al., 2008) 
c.1120C>T p.(Arg374Trp) Multiple deletions (Echaniz-Laguna et al., 2010a) 
c.1121G>A p.(Arg374Gln) Multiple deletions (Spelbrink et al., 2001; Naimi et al., 2006; Baloh et al., 2007; Massa et al., 2009; Martin-
Negrier et al., 2011; Yu-Wai-Man et al., 2013; Tafakhori et al., 2016) 
c.1133T>C p.(Leu378Pro) Multiple deletions (Ronchi et al., 2011) 
c.1142T>C p.(Leu381Pro) Multiple deletions (Spelbrink et al., 2001; Da Pozzo et al., 2015) 
c.1277G>A p.(Ser426Asn) Multiple deletions (Virgilio et al., 2008) 
c.1342A>G p.(Asn448Asp) Multiple deletions (Hong et al., 2010) 
c.1364T>C p.(Met455Thr) Multiple deletions (Milone et al., 2013) 
c.1374G>T p.(Gln458His) Multiple deletions (Fratter et al., 2010) 
c.1378G>C p.(Ala460Pro) Multiple deletions (Fratter et al., 2010) 
c.1379C>G p.(Ala460Gly) n.d (Fratter et al., 2010) 
c.1421G>C p.(Trp474Ser) Multiple deletions (Virgilio et al., 2008) 
c.1422G>T p.(Trp474Cys) Multiple deletions (Spelbrink et al., 2001) 
c.1423G>C p.(Ala475Pro) Multiple deletions  (Spelbrink et al., 2001; Ji et al., 2014) 
c.1423G>A p.(Ala475Thr) Multiple deletions (Liu et al., 2008) 
c.1424C>A p.(Ala475Asp) Multiple deletions (Fratter et al., 2010) 
c.1432T>A p.(Phe478Ile) Multiple deletions (Virgilio et al., 2008) 
c.1435G>A p.(Glu479Lys) Multiple deletions (Virgilio et al., 2008; Park et al., 2011) 
c.1640G>A p.(Phe485Leu) Multiple deletions (Kiechl et al., 2004) 
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cDNA change Amino Acid change Effect on mtDNA Reference(s) 
c.1609T>C p.(Tyr537His) Multiple deletions (Ronchi et al., 2011) 
c.1964G>A p.(Gly655Asp) Multiple deletions (Paramasivam et al., 2016) 
n.d. – not determined. 
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Appendix L – RNASEH1 Sanger Sequencing Results for 66 Adult-onset PEO with Multiple mtDNA Deletions Patients 
Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
I NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[498A>G],
p.Pro166Pro 
(rs10186193) 
NMD NMD NMD NMD 
II NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[498A>G],
p.Pro166Pro 
(rs10186193) 
NMD NMD NMD NMD 
III NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
IV NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
V NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD (Fw only) NMD NMD (Fw 
only) 
NMD (Rv only) 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
VI NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD (Rv only) 
VII NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
VIII NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[498A>G],
p.Pro166Pro 
(rs10186193) 
NMD NMD NMD NMD 
IX NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402), 
c[409+34C>A]+[409
+34C>A] 
(rs75663960) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
X NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402), 
c.[498A>G]+[498A>G],
p.Pro166Pro 
(rs10186193) 
NMD NMD NMD NMD 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
c[409+34C>A]+[409
+34C>A] 
(rs75663960) (Rv 
only due to fs) 
XI NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402), 
c[409+34C>A]+[409
+34C>A] 
(rs75663960) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD (Rv only) NMD NMD NMD 
XII NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402), 
c[409+34C>A]+[409
+34C>A] 
(rs75663960) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
XIII NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402), 
c[409+34C>A]+[409
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
+34C>A] 
(rs75663960) (Rv 
only due to fs) 
XIV NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402), 
c[409+34C>A]+[409
+34C>A] 
(rs75663960) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD c.[649+13A>G]+[
=] (rs75789502) 
c.[774+132
A>T]+[=] 
(rs11608390
9) 
NMD 
XV NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XVI NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XVII NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
XVIII NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XIX NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
XX NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD c.564+16C>T]+[=] 
(rs375447388) 
NMD NMD NMD 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
XXI NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XXII NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
XXIII NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XXIV NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD NMD NMD c.[702A>G]
+[=],p.Ala2
34Ala 
(rs14351032
9) 
NMD 
XXV NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
XXVI NMD (Rv only) NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
XXVII NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD c.[649+13A>G]+[
=] (rs75789502) 
c.[774+132
A>T]+[=] 
(rs11608390
9) 
NMD 
XXVIII NMD NMD c[409+34C>A]+[409 NMD NMD NMD NMD NMD 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
+34C>A] 
(rs75663960) 
XXIX NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XXX NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XXXI NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD (Fw only) NMD NMD 
XXXII NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XXXIII NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XXXIV NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD (Fw only) NMD NMD 
XXXV NMD NMD c[409+34C>A]+[409
+34C>A] 
NMD NMD NMD NMD NMD 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
(rs75663960) 
XXXVI NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XXXVII NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD (Fw only) NMD NMD 
XXXVIII NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
NMD NMD NMD NMD NMD 
XXXIX NMD NMD NMD NMD (Fw only) NMD NMD NMD (Rv 
only) 
NMD 
XL NMD NMD NMD NMD NMD NMD NMD NMD 
XLI NMD NMD NMD NMD NMD NMD NMD NMD 
XLII NMD NMD NMD NMD NMD NMD NMD NMD 
XLIII NMD NMD NMD c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
XLIV NMD NMD NMD c.[474A>G]+[=],p.Ala1
58Ala (rs61738918) 
NMD NMD NMD NMD 
XLV NMD NMD NMD NMD NMD NMD NMD NMD 
XLVI NMD NMD NMD NMD (Fw only) NMD (Rv only) NMD NMD NMD (Rv only) 
XLVII NMD NMD NMD (Rv only) c.[498A>G]+[=],p.Pro16NMD NMD NMD NMD 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
6Pro (rs10186193) 
         
1 NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
2 NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
NMD NMD NMD NMD NMD 
3 NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
NMD NMD NMD NMD NMD 
4 NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
c.[509+44C>G]+[=] NMD NMD NMD NMD 
5 NMD NMD NMD NMD NMD NMD NMD NMD 
6 NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD NMD NMD NMD NMD 
7 NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
8 NMD NMD c[409+34C>A]+[409
+34C>A] 
c.[498A>G]+[498A>G],
p.Pro166Pro 
NMD NMD NMD NMD 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
(rs75663960) (rs10186193) 
9 NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
10 c.[128+44G>A]+[
=]  
NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[498A>G],
p.Pro166Pro 
(rs10186193) 
c.564+16C>T]+[=] 
(rs375447388) 
NMD NMD NMD 
11 NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
12 NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
13 NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
14 NMD NMD c[409+34C>A]+[409
+34C>A] 
(rs75663960) 
c.[498A>G]+[498A>G],
p.Pro166Pro 
(rs10186193) 
NMD NMD NMD NMD 
15 NMD NMD c.245-118_245- c.[498A>G]+[=],p.Pro16NMD NMD NMD NMD 
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Patient Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8 
115het_delAGAG 
(rs151141402), 
c[409+34C>A]+[409
+34C>A] 
(rs75663960) (Rv 
only due to fs) 
6Pro (rs10186193) 
16 NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
17 NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
NMD NMD NMD c.[702A>G]
+[=],p.Ala2
34Ala 
(rs14351032
9) 
NMD 
18 NMD NMD c.245-118_245-
115het_delAGAG 
(rs151141402) (Rv 
only due to fs) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
19 NMD NMD NMD NMD NMD NMD NMD NMD 
20 NMD NMD c[409+34C>A]+[=] 
(rs75663960) 
c.[498A>G]+[=],p.Pro16
6Pro (rs10186193) 
NMD NMD NMD NMD 
Patients excluded from the WES are listed using Roman numerals. Patient 1-20 who underwent WES are listed at the bottom of the table. Novel 
variants are highlighted in red. NMD – no mutation detected. Rv – reverse. Fw – forward. 
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Appendix M – WES Read Coverage and Depth Statistics of the Adult-Onset PEO with Multiple mtDNA Deletions Cohort 
Patient Mean Depth 
per CCDS 
(bp) 
Min 
Depth 
Max 
Depth 
# CCDS 
Bases 
Covered 
30-fold 
% CCDS 
Bases 
Covered 
30-fold 
% CCDS 
Bases 
Covered 
20-fold 
% CCDS 
Bases 
Covered 
20-fold 
% CCDS 
Bases 
Covered 
10-fold 
% CCDS 
Bases 
Covered 
10-fold 
% CCDS 
Bases 
Covered 5-
fold 
% CCDS 
Bases 
Covered 5-
fold 
% CCDS 
Bases 
Covered 1-
fold 
% CCDS 
Bases 
Covered 1-
fold 
1 46.79 0 1516 17928267 54.41 22039667 66.89 26656034 80.90 29102175 88.33 31095238 94.38 
2 80.88 0 5875 27423246 83.23 29026231 88.10 30033915 91.16 30414434 92.31 30903151 93.80 
3 46.19 0 2107 20158197 61.18 24042480 72.97 27156273 82.42 28718437 87.16 30566762 92.77 
4 47.35 0 1840 18089146 54.90 22162163 67.27 26710156 81.07 29125522 88.40 31093549 94.37 
5 43.77 0 1116 17519213 53.17 21873989 66.39 26641180 80.86 29110976 88.36 31097774 94.39 
6 46.79 0 1586 20665823 62.72 24447320 74.20 27427183 83.25 28936342 87.83 30672655 93.10 
7 67.47 0 5211 26052706 79.07 28357620 86.07 29804518 90.46 30306973 91.99 30848858 93.63 
8 51.78 0 2415 21431786 65.05 24682166 74.91 27360019 83.04 28781235 87.35 30571544 92.79 
9 75.20 0 5052 26942407 81.77 28779489 87.35 29933682 90.85 30359506 92.15 30864617 93.68 
10 47.88 0 1177 18450525 56.00 22495422 68.28 26924631 81.72 29244713 88.76 31096901 94.38 
11 60.77 0 4669 22231774 67.48 25665082 77.90 28920959 87.78 30330774 92.06 31299626 95.00 
12 70.52 0 4710 26577450 80.67 28628332 86.89 29861392 90.63 30295824 91.95 30818822 93.54 
13 70.34 0 4621 26449272 80.28 28558602 86.68 29861501 90.63 30327236 92.05 30849881 93.63 
14 52.31 0 1314 19224564 58.35 23016914 69.86 27195573 82.54 29395031 89.22 31151592 94.55 
15 77.42 0 5274 27124871 82.33 28865777 87.61 29975917 90.98 30384487 92.22 30876609 93.71 
16 50.70 0 2417 21288660 64.61 24693067 74.95 27452272 83.32 28882866 87.66 30636573 92.99 
17 54.80 0 2217 22220223 67.44 25207075 76.51 27683737 84.02 29055086 88.19 30716923 93.23 
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Patient Mean Depth 
per CCDS 
(bp) 
Min 
Depth 
Max 
Depth 
# CCDS 
Bases 
Covered 
30-fold 
% CCDS 
Bases 
Covered 
30-fold 
% CCDS 
Bases 
Covered 
20-fold 
% CCDS 
Bases 
Covered 
20-fold 
% CCDS 
Bases 
Covered 
10-fold 
% CCDS 
Bases 
Covered 
10-fold 
% CCDS 
Bases 
Covered 5-
fold 
% CCDS 
Bases 
Covered 5-
fold 
% CCDS 
Bases 
Covered 1-
fold 
% CCDS 
Bases 
Covered 1-
fold 
18 71.20 0 6477 26588827 80.70 28668001 87.01 29903743 90.76 30338801 92.08 30841613 93.61 
19 50.99 0 1770 19015765 57.72 22894983 69.49 27150352 82.40 29379418 89.17 31157142 94.57 
20 75.61 0 6264 26899440 81.64 28766484 87.31 29933470 90.85 30365108 92.16 30874692 93.71 
‘#’ – number. CCDS – exome consensus coding sequence. 
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Appendix N – VUS Identified by WES in the Adult-Onset PEO with Multiple mtDNA Deletions Cohort 
Patient Gene Mutations Minor Allele Frequency GO-Terms Matched 
cDNA Change Amino Acid Change ExAC  NHLBI ESP 1000G 
2 TICRR c.2990T>G/= p.Val997Gly, Heterozygous Ø Ø Ø DNA repair, replication 
 TOP3B c.524C>T/= p.Ala175Val, Heterozygous Ø Ø Ø Topoisomerase 
 MARK2 c.894C>G/= p.Ile298Met, Heterozygous Ø Ø Ø n.a. 
 POLR2A c.5789A>C/=  p.Tyr1930Ser, Heterozygous Ø Ø Ø Transcription, nucleotide, polymerase, 
DNA repair 
 FDXR c.349G>A/= p.Val117Met, Heterozygous 0.00000861 Ø Ø Mitochondr* 
6 PPIF c.382G>A/= p.Glu128Lys, Heterozygous 0.00001661 Ø Ø Mitochondr* 
7 USP8 c.179A>G/= p.Tyr60Cys, Heterozygous Ø Ø Ø n.a. 
 SETX c.6941A>G/= p.Tyr2314Cys, Heterozygous 0.00000895 Ø Ø Polymerase, transcription, helicase 
8 APEX1 c.467G>A/= p.Arg156Gln, Heterozygous 0.00003341 Ø Ø Mitochondr*, DNA repair, transcription, 
exonuclease 
9 BCL2L13 c.658G>T/= p.Asp220Tyr, Heterozygous 0.00000824 Ø Ø Mitochondr* 
 THNSL1 c.524G>A/=  p.Gly175Asp, Heterozygous Ø Ø Ø n.a. 
 PTCHD2 c.2264G>A p.Arg755Gln 0.0001015 Ø Ø n.a. 
  c.3450_3451insGCT p.Gln1150delinsGlnAla Ø Ø Ø 
12 GART c.2323delC/= p.Arg775Valfs*2, Heterozygous Ø Ø Ø Purine, ligase  
 RIF1 c.113C>T p.Thr38Ile, Heterozygous 0.00001654 Ø Ø n.a. 
14 EXD2^ c.1547C>G/= p.Pro516Arg, Heterozygous Ø Ø Ø Exonuclease 
16 DCP2 c.427A>G/=  p.Arg143Gly, Heterozygous Ø Ø Ø n.a. 
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 XRCC6 c.645G>C/= p.Leu215Phe, Heterozygous 0.00001112 Ø Ø DNA repair, transcription 
 OAS2 c.2152_2300del/= p.Asn718_*720del, Heterozygous Ø Ø Ø Mitochondr*, nucleotide, purine 
 OGDH c.20G>A/= p.Cys7Tyr, Heterozygous Ø Ø Ø Mitochondr* 
 OXR1 c.328A>G/= p.Thr110Ala, Heterozygous 0.00000826 Ø Ø Mitochondr* 
20 DDHD2 c.1973G>A/=  p.Arg658His, Heterozygous 0.00000824 Ø Ø n.a. 
 CLPX c.1891G>A/= p.Ala631Thr, Heterozygous 0.00000825 Ø Ø Transcription, mitochondr*, nucleotide 
 ACSM1 c.915delA/= p.Thr305fs, Heterozygous Ø Ø Ø Mitochondr* 
Variants of unknown significance (VUS) that were identified by WES in the adult-onset PEO with multiple mtDNA deletions cohort. Variants are 
listed due based upon the GO-Terms matched or in silico predictions. ‘Ø’ denotes that a variant absent from external databases. ‘^’ denotes variants 
that were false positives or did not segregate in Sanger sequencing studies. 
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Appendix O – WES Read Coverage and Depth Statistics of the Mitochondrial RC Deficiency Cohort 
Patient Mean Depth 
per CCDS 
(bp) 
Min 
Depth 
Max 
Depth 
# CCDS 
Bases 
Covered 
30-fold 
% CCDS 
Bases 
Covered 
30-fold 
# CCDS 
Bases 
Covered 
20-fold 
% CCDS 
Bases 
Covered 
20-fold 
# CCDS 
Bases 
Covered 
10-fold 
% CCDS 
Bases 
Covered 
10-fold 
# CCDS 
Bases 
Covered 5-
fold 
% CCDS 
Bases 
Covered 5-
fold 
# CCDS 
Bases 
Covered 1-
fold 
% CCDS 
Bases 
Covered 1-
fold 
21 73.65 0 6197 26838572 81.46 28720597 87.17 29875411 90.68 30289024 91.93 30760299 93.36 
22 72.56 0 5673 26846045 81.48 28716822 87.16 29856967 90.62 30274093 91.89 30745928 93.32 
23 142.36 0 4899 29389138 89.20 29978180 90.99 30378846 92.20 30582382 92.82 30993567 94.07 
24 52.62 0 2301 21380705 64.89 25489798 77.36 29147855 88.47 30556260 92.74 31411912 95.34 
25 49.15 0 1765 19600852 59.49 23212490 70.45 26648976 80.88 28134599 85.39 29165927 88.52 
26 61.16 0 3629 25340123 76.91 28018731 85.04 29666439 90.04 30211698 91.70 30735134 93.29 
27 183.78 0 7710 29853739 90.61 30191548 91.64 30465693 92.47 30632803 92.97 31016761 94.14 
28 66.37 0 5088 26089119 79.18 28367628 86.10 29768244 90.35 30251849 91.82 30752736 93.34 
29 43.22 0 1712 18526126 56.23 23482136 71.27 28199914 85.59 30134026 91.46 31342028 95.13 
30 50.33 0 2433 20721434 62.89 25120924 76.25 29041531 88.14 30527038 92.65 31415167 95.35 
31 33.41 0 861 13639045 41.40 18600490 56.45 24756815 75.14 28244491 85.73 31051275 94.24 
32 73.70 0 4358 26831926 81.44 28733560 87.21 29884853 90.70 30292343 91.94 30750505 93.33 
33 39.36 0 7208 16901296 51.30 22376077 67.91 27825651 84.45 30035534 91.16 31330079 95.09 
34 48.99 0 2936 20462335 62.11 24936914 75.69 28928150 87.80 30468589 92.48 31402486 95.31 
35 76.44 0 2775 24193731 73.43 26853761 81.50 29373382 89.15 30482327 92.52 31292064 94.98 
36 60.76 0 7390 22068259 66.98 25432908 77.19 28711509 87.14 30194657 91.64 31247149 94.84 
37 84.25 0 3709 25091992 76.16 27482271 83.41 29688410 90.11 30642284 93.00 31331222 95.09 
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Patient Mean Depth 
per CCDS 
(bp) 
Min 
Depth 
Max 
Depth 
# CCDS 
Bases 
Covered 
30-fold 
% CCDS 
Bases 
Covered 
30-fold 
# CCDS 
Bases 
Covered 
20-fold 
% CCDS 
Bases 
Covered 
20-fold 
# CCDS 
Bases 
Covered 
10-fold 
% CCDS 
Bases 
Covered 
10-fold 
# CCDS 
Bases 
Covered 5-
fold 
% CCDS 
Bases 
Covered 5-
fold 
# CCDS 
Bases 
Covered 1-
fold 
% CCDS 
Bases 
Covered 1-
fold 
38 68.99 0 2225 23425033 71.10 26330834 79.92 29102469 88.33 30337744 92.08 31240118 94.82 
39 65.14 0 7269 22783203 69.15 25930697 78.70 28964979 87.91 30325065 92.04 31272723 94.92 
40 34.58 0 7035 15303006 46.45 20569456 62.43 26494514 80.41 29328182 89.01 31161053 94.58 
‘#’ – number. CCDS – exome consensus coding sequence. 
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Appendix P – VUS Identified By WES in the Early-Onset RC Deficiency Cohort 
Patient Gene Mutations Minor Allele Frequency GO-Terms Matched 
cDNA Change Amino Acid Change ExAC  NHLBI ESP 1000G 
23 ALKBH8 Homozygous c.886T>G p.Cys296Gly (rs61743188), 
Homozygous  
0.001245 Ø 0.004 tRNA 
 NXPE4 c.1456A>G p.Arg486Gly 0.00004145 Ø Ø n.a. 
 c.1484A>T p.Gln495Leu 0.00004145 Ø Ø 
 POLRMT c.3541C>T/=  p.Gln1181*, Heterozygous Ø Ø Ø Mitochondr* 
25 MIEF2^ c.115G>T  p.Ala39Ser Ø Ø Ø Mitochondr* 
 c.124G>T  p.Val42Leu 0.000009174 Ø Ø 
 MRPL9^ c.13G>T p.Val5Phe Ø Ø Ø Mitochondr*, translation 
 c.365G>A p.Arg122Gln (rs371659600) 0.003148 0.000116279 0.006 
 DNAJB4 c.790G>C/= p.Gly264Arg, Heterozygous Ø Ø Ø n.a. 
26 MRPS12 c.23A>G p.His8Arg (rs33988199) 0.005288 0.038 0.017 Translation, mitochondr*  
  c.244C>T p.Arg82* 0.000008320 Ø Ø 
 MRPL14 c.305dupC/= p.Ser102fs, Heterozygous Ø Ø Ø Translation, mitochondr* 
33 TEP1 Homozygous c.3476C>A
  
p.Pro1159His (rs145944940), 
Homozygous 
0.0001657 0.000153775 Ø n.a. 
 FGFR4 Homozygous c.215G>C p.Arg72Pro, Homozygous Ø Ø Ø n.a. 
 GNL3L^ Hemizygous c.883C>A Hemizygous p.Leu295Met Ø Ø Ø Mitochondr* 
 LETM2^ c.496T>C p.Ser166Pro 0.0001731 Ø Ø Mitochondr* 
 c.629C>G p.Ser210Cys (rs147828005) 0.0002891 0.000615 0.0005 
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36 TICRR c.2254G>A p.Asp752Asn Ø Ø Ø Translation 
c.5354G>A p.Arg1785His (rs141989878) 0.001172 0.000692414 0.000199681 
37 NUP210 Homozygous c.5423A>G p.Gln1808Arg (rs548431600), 
Homozygous 
0.0005065 Ø 0.001 Translation, tRNA 
38 TRMT61B Homozygous c.1109T>C p.Leu370Ser (rs150890124), 
Homozygous 
0.001921 0.000399361 0.0029 Translation, mitochondr* 
 COQ2 c.286C>T/= p.Pro96Ser, Heterozygous Ø Ø Ø Mitochondr* 
 TMEM126A c.364G>C/= p.Ala122Pro, Heterozygous Ø Ø Ø Mitochondr* 
39 PTCD3 c.1366T>C/= p.Phe456Leu (rs200807149), 
Heterozygous 
0.00008263 0.000230663 Ø Translation, mitochondr* 
Variants of unknown significance (VUS) that were identified by WES in the early-onset RC deficiency cohort. Variants are listed due based upon the 
GO-Terms matched or in silico predictions. ‘Ø’ denotes that a variant absent from external databases. ‘^’ denotes genes or variants that were false 
positives or did not segregate in Sanger sequencing studies. 
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Appendix Q – List of mtDNA Polymorphisms of YARS2 Patients for mtDNA 
Haplogrouping 
Patient 43.1 - H1m1 Patient 44 - G2a3a Patient 45 - T2e1a Patient 46.1 - HV13 
m.93A>G m.73A>G m.41C>T m.199T>C 
m.146T>C m.152T>C m.73A>G m.263A>G 
m.263A>G m.185G>A (het) m.150C>T m.309insCC 
m.310insTC  (het) m.263A>G m.263A>G m.750A>G 
m.750A>G m.310insCC (het) m.309insC (het) m.1438A>G 
m.1438A>G m.315insC m.315insC m.2706A>G 
m.3010G>A m.489T>C m.709G>A m.3106delC 
m.3107delC m.709G>A m.750A>G m.4769A>G 
m.4171C>T m.750A>G m.1438A>G m.7028C>T 
m.4769A>G m.1438A>G m.1888G>A m.7256C>T 
m.8860A>G m.2706A>G m.2706A>G m.8860A>G 
m.9468A>G m.3107delC m.3107delC m.9305G>A 
m.15323G>A m.3882G>A m.4216T>C m.10382A>G 
m.15326A>G m.4769A>G m.4769A>G m.12879T>C 
m.16519T>C m.4833A>G m.4917A>G m.13708G>A 
 m.5108T>C m.7028C>T m.15326A>G 
 m.5601C>T m.7828A>G m.16357T>C 
 m.6152T>C m.8697G>A  
 m.7028C>T m.8790G>A  
 m.7600G>A m.8860A>G  
 m.8701A>G m.10463T>C  
 m.8860A>G m.11251A>G  
 m.9377A>G m.11719G>A  
 m.9540T>C m.11812A>G  
 m.9575G>A m.13368G>A  
 m.10398A>G m.14233A>G  
 m.10400C>T m.14766C>T  
 m.10873T>C m.14905G>A  
 m.11719G>A m.15244A>G  
 m.12705C>T m.15326A>G  
 m.13563A>G m.15452C>A  
 m.14569G>A m.15607A>G  
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Patient 43.1 - H1m1 Patient 44 - G2a3a Patient 45 - T2e1a Patient 46.1 - HV13 
 m.14766C>T m.15928G>A  
 m.14783T>C m.16093T>C (het)  
 m.15043G>A m.16126T>C  
 m.15301G>A m.16153G>A  
 m.15326A>G m.16294C>T  
 m.16169C>T m.16301C>T  
 m.16189T>C (low level het) m.16519T>C  
 m.16223C>T   
 m.16227A>G   
 m.16262C>T   
 m.16278T>C   
 m.16294C>T   
 m.16318A>G   
 m.16526G>A   
D-loop control region polymorphisms are highlighted in red.
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